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THE CELLULAR IMPACT OF DIMINISHED DNA ORIGIN LICENSING 
CAPACITY AND ITS POTENTIAL THERAPEUTIC EXPLOITATION 
SUMMARY 
Genomic instability underlies various diseases including cancer. The maintenance of 
genomic stability requires accurate replication of the genome, proper segregation of 
duplicated DNA to progeny cells, and the capacity to respond effectively to DNA 
damage. Early sections of this thesis focus on the response to DNA double-strand 
breaks (DSBs) within compact regions of chromatin (heterochromatin). Here, 
methodology was optimised for monitoring the repair of site-specific DSBs within 
regions likely to be enriched for heterochromatin. This system was exploited to examine 
the function of the Artemis endonuclease in heterochromatic DSB repair. Later sections 
focus on factors involved in DNA replication and the response to replication stress. 
Among the various mechanisms involved in the DNA damage response (DDR) to 
replication stress, the licensing of excess origins of replication has been proposed to 
safeguard against replication failure. Here, the impact of diminished origin licensing 
capacity on the response to replication stress was compared in tumour and non-tumour 
cell lines. I present findings demonstrating that depletion of origin licensing factors 
causes hypersensitisation of tumour-derived but not non-tumour cell lines to replication 
stress-inducing agents. Further, combining diminished origin licensing capacity with 
depletion of the tumour suppressor, p53, or overexpression of the c-Myc oncogene 
impairs viability under conditions of replication stress in non-tumour fibroblasts. These 
findings suggest that tumour cells have a greater reliance on origin licensing capacity, 
raising the possibility that licensing factors might represent suitable targets for drug-
based cancer therapy. Factors involved in replication origin licensing have also been 
implicated in the establishment of heterochromatin. Here, I examined higher-order 
chromatin structure and the ionizing radiation (IR)-induced DDR in cells from patients 
harbouring mutations in origin licensing factors. Findings from these studies provide 
evidence for the first time that origin licensing complex (ORC)-deficient Meier-Gorlin 
Syndrome (MGS) may be classified as a disordered chromatin syndrome. 
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I Introduction 
I.1 Genomic instability and cancer 
Cancer is currently one of the greatest health risks known to man, with an estimated 7.6 million 
worldwide cancer deaths reported in the year 2008 (Ferlay et al. 2010). In part as a result of 
longer life expectancy and increased cancer detection, cancer incidence is still on the rise in 
countries such as the United Kingdom (Maddams et al. 2009). However, significant progress in 
research, prevention, and clinical strategies has contributed to a decrease in the rate of cancer 
caused deaths in the United States (Maddams et al. 2009; Eheman et al. 2012). Given the 
enormous scope and impact of this life-altering disease, continued progress in research into 
therapeutic interventions is critically needed to improve the prognosis and quality of life of 
patients with cancer.  
The term “cancer” encompasses an incredibly complex range of neoplastic diseases 
which involve a variety of alterations in the genome. Several hallmarks of cancer have been 
described, including the ability to evade cell death, sustained angiogenesis, metastatic capacity, 
insensitivity to anti-growth signals, self-sufficiency in growth signals, and finally, a limitless 
replicative potential (Hanahan et al. 2000). In addition, nearly all human cancers display 
genome instability which can encompass chromosomal instability, microsatellite instability, 
epigenetic changes, and increased rates of spontaneous mutations (Negrini et al. 2010).  
The genome instability characteristic of cancer cells may be propagated by genetic 
alterations which impact the deoxyribonucleic acid (DNA) damage response (DDR), an 
elaborate series of biological pathways which function to protect genome integrity. The DDR, 
which acts as an anti-cancer barrier (Bartek et al. 2007b), encompasses various mechanisms 
involved in the arrest of the cell cycle, repair of DNA damage, and in some contexts, cell death 
(Hoeijmakers 2009). Depending on the type of damage occurring, the repair of DNA lesions can 
occur through pathways such as mismatch repair (MMR), base excision repair (BER), 
nucleotide excision repair (NER), single-strand break (SSB) repair, double-strand break (DSB) 
repair (Section I.3.1), or direct reversal of damage (Lord et al. 2012).  
Reflecting the role of the DDR in preventing tumourigenesis, mutations in DDR genes 
have been identified in various types of hereditary cancers. For example, mutations in MMR 
genes such as mutL homolog 1 (MLH1) and mutS homolog 2 (MSH2) underlie hereditary non-
polyposis colon cancer (HNPCC), also known as Lynch syndrome (Aaltonen et al. 1994; 
Peltomaki et al. 1997; Pedroni et al. 2001; Heinen et al. 2002).  In addition, an estimated 80-
90% of familial breast cancer cases are associated with mutations in the breast cancer 
susceptibility 1 (BRCA1) and breast cancer susceptibility 2 (BRCA2) genes (Ford et al. 1998; 
Stratton et al. 2008), both of which are involved in DSB repair (Liu et al. 2002) (Section I.3). 
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Further, germline mutations in tumour protein p53 (TP53), a tumour suppressor involved in 
DDR mechanisms such as cell cycle arrest and apoptosis, cause Li-Fraumeni syndrome, a 
disease characterised by the development of various forms of cancer from as early as childhood 
(Varley 2003; Hanel et al. 2012).   
In addition to these examples of hereditary mutations, spontaneous alterations in DDR 
genes are thought to propagate tumour development and growth (Negrini et al. 2010).  One 
model for tumourigenesis proposes that the genomic instability arising from changes in pre-
cancerous cells induces replication-associated DNA damage (replication stress) (Section I.2.3), 
potentially contributing to the spontaneous mutagenesis of “caretaker genes” such as the DDR 
genes and to tumour propagation (Negrini et al. 2010).  Hereditary alterations in DDR genes 
may also, in part, drive cancer development by further increasing mutagenesis (Bartek et al. 
2007a; Murga et al. 2007). One potential source of replication stress in cancer is the aberrant 
expression of an oncogene (Halazonetis et al. 2008), one of the earliest lesions that may occur 
during tumourigenesis (Petermann et al. 2007). As described in Section I.2.4, the increased 
expression of an oncogene such as avian myelocytomatosis viral oncogenes homolog (Myc) can 
induce many cellular changes including the induction of DNA damage (ie. replication stress), 
changes in transcription, escalation of cellular growth, and the unscheduled activation of DNA 
replication origins (defined in Section I.2.4) (Vafa et al. 2002; Dominguez-Sola et al. 2007; 
Herold et al. 2009a). Activation of the DDR, as observed at early cancer-associated lesions 
(Bartkova et al. 2005), is in part attributed to oncogene-induced  replication stress (Di Micco et 
al. 2006) and is thought to act as a barrier to tumour development by inducing cellular 
senescence (a state in which growth is permanently arrested) and/or cell death (Bartkova et al. 
2006; Bartek et al. 2007a). Consequently, alterations in DDR genes may allow pre-cancerous 
cells (which harbour genome instability) to evade senescence and cell death, ultimately 
contributing to cancer development (Bartkova et al. 2005). 
Our increased understanding of the molecular alterations which distinguish tumour cells 
from healthy tissue is vital in developing and improving therapeutic strategies for cancer 
patients. Therapeutic interventions in oncology have traditionally exploited the changes in 
replication observed in cancer cells. Since the discovery in the 1940’s by Sidney Farber that 
antifolates (inhibitors of DNA replication) reduce remission in acute lymphoblastic leukaemia 
(AML) patients, a vast number of replication-targeting chemotherapies have been developed 
(Farber et al. 1948; Helleday et al. 2008). However, these agents do not discriminate between 
tumour cells and rapidly dividing cells in healthy tissue. As a result, clinical side effects are 
frequently observed with administration of replication inhibitors (Helleday et al. 2008). 
Strategies which selectively target alterations that distinguish tumour cells from healthy tissue 
have shown great promise in cancer therapy (Aggarwal 2010). This is exemplified by the 
success of the Breakpoint cluster region fused with V-abl Abelson murine leukaemia viral 
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oncogene homolog 1 (BRC-ABL) inhibitor Imantinib in the treatment of chronic myeloid 
leukaemia (CML), the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor 
Vemurafenib/Zelboraf  in the treatment of melanoma, the epidermal growth factor receptor 
(EGFR) oncogene inhibitor Cetuximab/Erbitux in head and neck carcinoma and colorectal 
cancer, the human epidermal growth factor receptor 2 (HER2)-inhibiting antibody 
Trastuzumab/Herceptin in the treatment of breast cancer, and finally the vascular endothelial 
growth factor (VEGF) inhibiting antibody Bevacizumab/Avastin in a variety of tumour types 
(Aggarwal 2010; Yap et al. 2012).  
Both the development of therapeutic interventions which target DDR proteins and an 
increased understanding of the impact of tumour-associated DDR alterations on drug 
cytotoxicity have shown promise in guiding clinical strategies for the treatment of cancer 
(Helleday et al. 2008; de Bono et al. 2010; Lord et al. 2012). Tumour cells deficient in one DNA 
repair pathway are thought to rely more heavily on other DDR pathways for survival; therefore, 
DDR protein inhibitors are proposed to enhance cytotoxicity specifically in these tumours (a 
concept known as synthetic lethality) (Helleday et al. 2008; de Bono et al. 2010; Lord et al. 
2012). In support of this model, single agent treatment with inhibitors of the poly adenine 
diphosphate (ADP)-ribose polymerase (PARP) DNA damage signalling proteins may be 
beneficial specifically to patients with mutations in DNA repair genes such as BRCA1 or 
BRCA2 (Bryant et al. 2005; Farmer et al. 2005). As a further example, inhibitors of the DDR 
protein checkpoint kinase 1 (Chk1) are particularly lethal in tumour cells deficient in the p53 
and p21 proteins (involved in DNA damage-induced cell cycle arrest and death  pathways) 
(Origanti et al. 2012),  Fanconi Anemia DNA repair proteins (Chen et al. 2009), or BRCA2 
(Hattori et al. 2011).  
The combined administration of DDR inhibitors with DNA damage-inducing agents 
may also improve the so-called “therapeutic index,” a measure used to determine the dose range 
in which an agent will induce beneficial therapeutic outcome with minimal side effects. For 
example, PARP inhibition combined with the DNA damage-inducing chemotherapeutic agent 
Temozolomide is reported to enhance anti-tumour activity of Temozolomide alone (Palma et al. 
2008). Further, PARP inhibition has been demonstrated to enhance sensitivity to radiation-
induced DNA damage particularly in cells deficient in DNA repair proteins (Loser et al. 2010) 
and the combined administration of a PARP inhibitor with radiation is reported to reduce 
tumour growth in a model for lung cancer (Albert et al. 2007). Consequently, beneficial effects 
may be observed at lower doses of Temozolomide or radiation under conditions of PARP 
inhibition, therefore improving therapeutic index.  
Overall, the development of DDR-targeted therapeutics, administration of 
combinational drug therapy with DDR inhibitors, and exploitation of synthetic lethality have 
proven promising in improving clinical outcome (de Bono et al. 2010) and remain the subject of 
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ongoing medical research.  Further understanding of the DDR will also provide insight to guide 
these developments.  
I.2 The cellular threat of DNA damage 
As previously introduced, DDR pathway activation occurs in a manner dependent on the type of 
damage induced.  Many distinct forms of DNA damage may arise from a variety of sources. For 
the purpose of this thesis, specific forms of DNA damage arising from oxidative stress, IR, 
replication stress, and oncogenic expression will be emphasized in the context of cancer. 
On a daily basis, each cell in our body must contend with tens of thousands of 
potentially harmful DNA lesions (Hoeijmakers 2009; Ciccia et al. 2010). Spontaneous DNA 
aberrations may arise from redox-cycling events such as oxidative respiration which generates 
DNA base damage, mis-incorporation of DNA bases during replication, deamination of cytosine  
which results in the transition to uracil, alteration of DNA following depurination, and DNA 
base modification by alkylation (Ciccia et al. 2010). DSBs are generated during cellular 
processes such as meiosis, variable, diversity, and joining genes (V(D)J) recombination, and 
immunoglobulin (Ig) class switch recombination (CSR) (Szostak et al. 1983; Alt et al. 1992; 
Soulas-Sprauel et al. 2007). DNA damage may also arise from environmental sources including 
ultraviolet (UV) radiation from sunlight, ionizing radiation (IR), as well as DNA damage-
inducing chemicals such as tobacco-based products, pesticides, and various chemotherapeutic 
drugs (Jackson et al. 2009) (Table I.1). As introduced in Section I.1, the aberrant expression of 
oncogenes can induce cellular changes resulting in various types of DNA lesions (Halazonetis et 
al. 2008).  
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  Damaging 
agent/process  Example of aberration  Sources/purpose 
Endogenous damage 
Base oxidation 8-oxo-dG  ROS  
Base deamination Hydrolysis of cytosine to uracil Spontaneous 
Depurination  Apurinic site Spontaneous, BER glycosylase 
Base alkylation 3-methyladenine, 7-methylguanine, 06-methylguanine 
Endogenous alkylating 
agents 
Base mis-incorporation  Base transition/transversion Replication errors 
Cellular Processes 
Meiosis DSBs Production of gametes 
V(D)J recombination DSBs Production of Ig and T cell receptors 
CSR DSBs Switch of antibody class 
Exogenous Damage 
UV 6-4 photoproducts, thymine dimers Sunlight (UVA,B) 
IR 8-oxo-dG, SSBs, DSBs Cosmic radiation, radiotherapy 
 HU, Gemcitabine SSBs, one-ended DSBs (replication fork stalling/collapse) Chemotherapy 
H2O2 
8-oxo-dG, SSBs, one-ended DSBs 
(replication fork stalling/collapse) 
Disinfectant, byproduct 
from aerobic respiration 
Topoisomerase 
inhibitors 
Intercalation with DNA, SSBs,  
DSBs Chemotherapy 
Cisplatin DNA crosslinks Chemotherapy 
Table I.1 Sources of DNA damage. See main text for abbreviations. 
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I.2.1 Oxidative stress-induced base damage 
Oxidative stress from excessive levels of reactive oxygen species (ROS) may result from 
endogenous sources such as aerobic respiration in mitochondria or from exogenous agents such 
as IR, hydrogen peroxide (H2O2), and chemotherapy (Cooke et al. 2003; Conklin 2004). The 
DNA damage induced by oxidative stress results from the ability of ROS, such as the hydroxyl 
radical and superoxide anion, to physically interact with DNA and promote the modification of 
DNA bases (Cooke et al. 2003). To date, the most extensively studied ROS-induced lesion is 
the oxidation of the deoxyguanosine nucleoside to 8-oxo-2’-deoxyguanosine (8-oxo-dG) 
(Figure I.1). In normal human cells, 8-oxo-dG is estimated to occur at a steady state level of 2-3 
lesions per 106 guanine bases (Cadet et al. 1997; Cooke et al. 2003; Gedik et al. 2005; Ohno et 
al. 2006). This base modification can become incorporated into DNA, leading to error-prone 
DNA replication, replication stress, and ultimately mutagenesis (Hanes et al. 2006; David et al. 
2007). In addition to the modification of DNA bases, oxidative stress leads to the induction of 
DNA strand breaks (Bertoncini et al. 1995), which will be introduced in Section I.2.2.  
Most cancer cells can be characterised by an increase in  levels of cellular ROS and 
oxidative stress is thought to contribute to genomic instability during tumourigenesis (Maiti 
2012). The majority of chemotherapeutic agents induce further increases in ROS levels in 
tumour cells which can result in apoptotic cell death, presumably as a result of excess damage. 
However, over time, treatment with the same drug may result in a reduction in ROS levels in 
surviving tumour cells and chemoresistance. Therefore, maintaining high levels of ROS in 
tumour cells throughout therapeutic treatment may be important in clinical outcome (Maiti 
2012).  
In addition to contributing to carcinogenesis, the accumulation of 8-oxo-dG has also 
been observed during aging. In fact the free radical theory of aging, first proposed in the 1950’s, 
postulates that ageing results from the accumulation of oxidative damage over time (Harman 
1956; Kaneko et al. 2001).  
I.2.2 IR-induced DNA strand breaks 
DNA stand breaks, which disrupt the sugar-phosphate backbone of the DNA molecule, are 
potentially hazardous events and may arise from various sources. An accumulation of breaks in 
either a single strand or both strands of the DNA duplex may threaten chromosomal stability 
and, ultimately, the survival of cells.  
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I.2.2.a Single-strand breaks (SSBs) 
SSBs are characterised by the severing of one of the two strands of DNA and are usually 
accompanied by damage to 5’ or 3’ DNA termini at the break (Figure I.1). These breaks can 
arise from sources of damage which generate ROS such as cellular respiration (Section I.2.1) or 
from exposure to exogenous agents such as H2O2 or IR. Direct SSB induction from ROS occurs 
when a sugar moiety of the DNA backbone becomes oxidized and subsequently disintegrates 
(Caldecott 2008).  SSBs induced by damaging agents generally occur much more frequently 
than DSBs. For example, treatment with H2O2 generates roughly 2,000 SSBs for every DSB and 
IR induces 20 SSB for every DSB (Bradley et al. 1979). SSBs may also result in DSBs, as 
evidenced by the fact that closely located SSBs may result in DSBs with single-stranded DNA 
(ssDNA) overhangs  (Chadwick et al. 1994) and that SSBs persisting during DNA replication 
lead to blockage or collapse of replication forks, thereby generating one-ended DSBs 
(Kuzminov 2001) (see Section I.2.3). 
In addition to the direct induction of SSBs by IR and ROS, direct SSB induction can 
also occur from BER and as a result of aborted activity of topoisomerases. BER is a process 
initiated by DNA glycosylases which remove damaged bases and generates 
apurinic/apyrimidine (AP) sites. AP endonuclease 1 (APE1) may then cleave DNA at AP sites, 
generating SSBs (Singer et al. 1981). Topoisomerases such as topoisomerase I (TopoI), relieve 
torsional strain in DNA during transcription and replication by generating nicks in DNA. The 
collision of unsealed nicks with polymerases or close proximity to other lesions may result in 
SSBs covalently linked to the topoisomerase (Pommier et al. 2003).  
While defects in SSB repair can result in cerebellar ataxia and neurodegeneration, as 
observed in disorders such as Ataxia-oculomoter apraxia I (AOAI) and spinocerebellar ataxia 
with axonal neuropathy 1 (SCAN1), these disorders are not marked by genomic instability and 
cancer, potentially as a result of alternative factors compensating for defective repair (Caldecott 
2008). 
I.2.2.b Double-strand breaks (DSBs) 
The DSB, which occurs when both strands of the DNA helix are severed, is considered to be 
one of the most toxic DNA lesions that cells encounter (Helleday et al. 2007). DSBs may 
consist of a blunt cut across the double helix or, more commonly, of two SSBs on opposite 
strands within several base pairs (bp) of one another (Van Der Schans 1978) (Figure I.1). 
Additionally DSBs can arise when replication forks collapse, generating a structurally distinct 
type of break. If left unrepaired or if repaired inaccurately, DSBs can result in genomic 
translocations, loss of genetic material, and cell death (Ferguson et al. 2001).  
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I.2.2.b.1 IR-induced DSBs 
Since the discovery of radiation, the process in which energy particles or waves travel through 
space, in the 1800’s, radiation has been exploited  therapeutically in the diagnosis and treatment 
of human diseases such as cancer (Rontgen 1896). The penetrative properties of IR allow for 
technologies used in medical imaging but also induce DNA damage via the production of 
excited and ionised molecules. IR both directly deposits energy in cells to generate excited and 
ionized molecules and also indirectly generates damage via the ionization of water molecules 
(Ward 1988). As a result, multiple types of DNA damage, ranging from modification of DNA 
bases to DNA strand breaks, can occur. Of all energy deposited by IR, greater than 90% 
generates ROS resulting in DNA damage (Section I.2.1) (Ward 1988). Both direct and indirect 
damage from IR can result in a variety of DNA lesions including SSBs and DSBs, with a ratio 
of roughly 20 SSBs for every 1 DSB generated (Lobrich et al. 2010).  As depicted in Figure I.1, 
IR-induced DSBs usually consist of two SSBs on opposite strands within 10-20 bp of one 
another (Van Der Schans 1978), and therefore also contain 3’ and 5’ overhangs which may 
require processing prior to repair (Mahaney et al. 2009).  
Several forms of IR exist including γ rays, which are produced by radioactive decay, 
particle accelerators generating X-rays and carbon ions, and radiation found in cosmic rays, 
such as iron ions (Charles 2001). The amount of energy transferred to a substance as an ionizing 
particle travels through is referred to as linear energy transfer (LET). While X-rays and γ rays 
are considered to be sparsely ionizing sources, and therefore have low LET, heavy ions such as 
carbon and iron ions are densely ionizing, have high LET, and result in greater cell death in 
human cells (Niemantsverdriet et al. 2012).  
The induction of clustered DNA lesions, resulting from multiple forms of damage in 
close vicinity on the DNA, increases with increased LET and poses a challenge for the cell 
(Ward 1981). Results from predictive studies have demonstrated that roughly 30% of DSBs 
induced by a source such as γ-rays or X-rays contain clustered damage with up to 10 lesions per 
cluster, while roughly 70% of DSBs induced by high LET radiation have been predicted to 
contain clustered damage with up to 25 lesions per cluster (Nikjoo et al. 1997; Semenenko et al. 
2004). 
The DDR mechanisms which respond to IR-induced DSBs will be further discussed in 
Section I.3. 
 
I.2.3 Replication stress and one-ended DSBs 
 
The maintenance of stability of the replication fork, a dynamic structure which forms when two 
strands of DNA separate during DNA synthesis, is crucial in the prevention of genomic 
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aberrations.  Replication stress, a term encompassing many different types of strains put on the 
progression of the fork, may arise from a variety of sources. For example, progression of 
replication forks may be delayed or completely inhibited by a variety of obstacles including 
protein-DNA complexes, regions that are difficult to unwind, and secondary structures arising 
from A-T dinucleotide-rich flexibility islands in genomic fragile sites (Burhans et al. 2007; 
Branzei et al. 2010; Burrow et al. 2010). The approach of a replication fork to a region of 
damaged DNA (for example, containing modified bases or SSBs) may also preclude further 
progression of replication. Alterations in the replication machinery and/or timing of replication 
(Section I.4) have been reported in various forms of cancer (Lau et al. 2007b; Fritz et al. 2012) 
and may lead to either over- or under-replication, putting strain on replication forks. Finally, 
exposure to replication inhibiting agents, as in the context of cancer therapy, may limit 
nucleotide pools or DNA polymerase activity, leading to slowed replication fork progression 
and the induction of replication-associated damage. 
Upon stalling of a replication fork, regions of single-stranded DNA become exposed, 
generating unstable structures which generally require stabilization (Branzei et al. 2010). 
Various DDR proteins function in the stabilization of stalled forks, allowing for the preservation 
of genome integrity while the obstruction is resolved (Section I.4.2). However, under conditions 
which challenge stability of these stalled forks and after extended times of stalling, forks can 
collapse into structures known as “one-ended DSBs” (Figure 1.1) (Helleday et al. 2007). The 
MUS81-EME nuclease may also directly cleave replication forks resulting in this distinct type 
of DSB (Ciccia et al. 2010).  
If unresolved, replication stress may result in inefficient DNA synthesis and DNA 
damage accumulation. Ultimately, tumourigenic genomic rearrangements or cell lethality may 
result. The DDR mechanisms which respond to replication stress will discussed in detail in 
Section I.4.  
 
I.2.4 The various lesions induced by oncogenic stress 
The aberrant expression of oncogenes such as Myc has pleiotropic cellular effects, resulting 
from changes in both transcriptional and non-transcriptional control of cellular processes.  
Using an inducible system of Myc expression in normal human fibroblasts, Vafa, Wade et al.  
demonstrated in 2002 that Myc overexpression results in an increase in ROS to a level similar to 
that generated from short treatment with H2O2. Consequently, an elevation in the frequency of 
8-oxo-dG base modifications has been reported under conditions of Myc overexpression (KC et 
al. 2006). This increase in the production of ROS has been, in part, attributed to the Myc-
dependent recruitment of lysine-specific demethylase 1 (LSD1) to chromatin (described in 
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Section I.3.3), resulting in demethylation of lysine residues and the induction of localised 
oxidation of DNA (Amente et al. 2010). 
Myc overexpression has also been reported to increase replication stress. This is likely 
to occur as a result of various factors, including alterations in the regulation of DNA replication, 
the encountering of replication forks with ROS-induced base modifications, and aberrations in 
the DNA damage response. Myc overexpression in normal human fibroblasts leads to 
acceleration of the DNA synthesis-phase (S-phase) of the cell cycle (Robinson et al. 2009) 
corresponding with increased activity of origins of replication (Dominguez-Sola et al. 2007). 
The cellular levels of deoxynucleotide triphosphates (dNTPs), the building blocks needed for 
DNA synthesis, have been shown to also increase with overexpression of Myc, presumably to 
support ongoing rapid proliferation (Mannava et al. 2008). Further, Myc has been reported to 
promote aberrant replication at specific loci on DNA, which is likely to contribute to the 
genomic instability observed (Kuschak et al. 2002). Finally, Myc overexpression has been 
shown to deregulate DNA damage-induced cell cycle checkpoint components, thereby 
promoting S-phase progression in the presence of damage (Sheen et al. 2002; Vafa et al. 2002). 
This increased replication activity, premature DNA synthesis initiation, and replication in the 
presence of DNA damage may lead to replication fork stalling /collapse resulting from 
collisions between the replication and transcription machinery (Branzei et al. 2010), altered 
availability of dNTPs (Poli et al. 2012),  and the collision of replication forks with DNA 
damage.  
 
 
 
 
 
 
 
 
 
 
 
 
33 
 
 
 
Figure I.1 Forms of DNA damage. Following induction of DNA damage via various sources, 
as listed in Table I.1, bases may become modified (ie. 8-oxo-dG) (indicated by black square), 
one strand of the DNA duplex may be severed (SSB), both strands of DNA may break (DSB), 
or clusters of various types of lesions can occur at the site of damage (clustered damage). If 
damage such as a SSB persists as a cell undergoes DNA replication, progression of the 
replication fork may stall (indicated by black octagon). Prolonged replication fork stalling or 
excessive DNA damage may then lead to collapse of the replication fork, generating a one-
ended DSB. 
  
Base  modification SSB DSB
DNA replication 
Damaging agent
Fork stalling
one-ended 
DSB
Clustered damage
Undamaged DNA
Replication fork 
encountering SSB
Fork collapse
ie. 8-oxo-dG
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I.3 The response to DSBs during G1 and G2 in the context of chromatin 
As previously introduced, the DSB represents one of the most potentially lethal lesions to cells 
and elaborate molecular pathways have evolved in mammalian cells to respond to this form of 
damage. Cancer-associated alterations in the DDR to DSBs are thought to contribute to genome 
instability and cancer development (Khanna et al. 2001). Further, inherited mutations in these 
crucial mechanisms can lead to various debilitating diseases with symptoms that include cancer 
predisposition, premature aging, growth retardation, and immunodeficiency (O'Driscoll et al. 
2006). 
Over the past decade, results from our lab and others have demonstrated that the 
structural context of DNA at the site of a DSB is crucial in determining which molecular 
pathway is utilised in repair (Goodarzi et al. 2010). Further, the stage of cell cycle and 
availability of a homologous DNA template greatly impacts upon pathway selection. The 
following subsections will introduce mechanisms of DSB repair (Section I.3.1), protein 
signalling at DSBs (Section I.3.2), the structural organization of DNA (Section I.3.3), and 
finally, the repair of DSBs in the context of higher order DNA structure and cell cycle phase 
(Section I.3.4).  
 
I.3.1 DSB repair mechanisms 
As depicted in Figure I.2, the mammalian response to DSBs is comprised of two main pathways 
of repair: non-homologous end joining (NHEJ) and homologous recombination (HR). While 
NHEJ is an efficient yet potentially error-prone mechanism of repair that does not require a 
homologous template, HR is a slower repair process which is relatively error-free and utilises a 
homologous template (typically from the sister chromatid). Alternative end joining pathways 
have been identified, but their role in the context of a functioning classical NHEJ pathway is not 
clear. 
I.3.1.a Non-homologous end joining (NHEJ) 
NHEJ begins when a heterodimeric ring structure composed of the Ku70 and Ku80 subunits 
bind with high affinity to each end of the DNA at the break site rapidly after damage (Downs et 
al. 2004) (Figure I.2A). The Ku70/80 heterodimer then recruits the DNA-dependent protein 
kinase catalytic subunit (DNA-PKcs) to the DNA ends, creating the so-called “DNA-PK 
holoenzyme”.  This results in the functional activation of the DNA-PK protein kinase and may 
protect and bridge DNA ends (Mahaney et al. 2009). Autophosphorylation of DNA-PKcs at two 
clustered sites called ABCDE and PQR then follows, ultimately leading to the exposure of DNA 
termini to other repair factors (Douglas et al. 2002). If the DNA ends are directly compatible, 
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DNA-PK may dissociate from the break site, allowing for access of a complex containing DNA 
Ligase 4 (Lig4), X-ray repair cross-complementing protein 4 (XRCC4), and XRCC-like factor 
(XLF) to Ku-bound ends to perform direct ligation (Goodarzi et al. 2006).  
If DNA termini cannot be directly ligated, they must first be processed by various 
factors. The Artemis endonuclease, which is crucial for removing hairpins generated during 
V(D)J recombination (Ma et al. 2002) and can process various DNA structures in vitro (Ma et 
al. 2005c), also functions at a subset of DSBs repaired by NHEJ (Riballo et al. 2004; Beucher et 
al. 2009) (Section III.1.1). Additional processing factors including the Werner syndrome 
(WRN) helicase, DNA polymerase μ and λ, and polynucleotide phosphatase/kinase (PNK) have 
also been demonstrated to function in a subset of DSBs (Mahaney et al. 2009). Once ends are 
processed, ligation can proceed as described above.  
I.3.1.b Homologous recombination (HR) 
When an undamaged homologous template (a sister chromatid) is available, cells can repair 
DSBs using HR. The initial phase of HR involves both the recruitment of the 
Mre11/Rad50/Nbs1 (MRN) complex to both ends of the DSB, which initially tethers the DNA 
termini for repair, and the resection of DNA ends (Stracker et al. 2011). DNA end resection is 
promoted and carried out by various factors such as the MRN complex, BRCA1, carboxy-
terminal (C-terminal) binding protein interacting protein (CtIP), and BRCA1-associated ring 
domain protein 1 (BARD1), generating single stranded 3’ DNA overhangs (Hartlerode et al. 
2009; You et al. 2009). The Artemis endonuclease is required for a subset of DSBs repaired by 
HR (Beucher et al. 2009)  (Section III.1.1), and recent findings from our lab have supported a 
model in which Artemis functions during end resection in the context of HR.  3’ DNA 
overhangs resulting from resection are immediately coated with replication protein A (RPA) 
molecules, stabilising the ssDNA structure and allowing HR to proceed (Eggler et al. 2002). 
RPA is then displaced from DNA overhangs when the Rad51 recombinase is loaded in a 
BRCA2-mediated process (Venkitaraman 2009), and Rad51 multimers form nucleoprotein 
filaments which seek homologous segments of intact double-stranded DNA (dsDNA), usually 
from the sister chromatid (Ogawa et al. 1993). Once this region of homology is identified, the 
resected strand can invade the dsDNA, forming a DNA joint or a displacement loop (D-loop) 
structure, and  a DNA polymerase can extend the strand, converting the D-loop structure to a 
Holliday Junction (HJ) (Hartlerode et al. 2009). Capture of the second 3’DNA overhang and 
subsequent extension forms a double HJ and branch migration can occur which can be resolved 
by various human proteins such as Bloom syndrome, recQ helicase-like (BLM) helicase or flap 
endonuclease gen homolog 1 (GEN1) (a homolog of yeast YEN1) (Hartlerode et al. 2009). 
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Figure I.2 Overview of the major IR-induced DSB repair pathways. HJ: Holiday junction, 
P: phosphorylated, see text for protein abbreviations. Following the induction of a DSB by IR, 
cells respond to damage primarily using either NHEJ or HR. A. NHEJ begins with the binding 
of the Ku70/80 heterodimer to damaged termini. DNA-PKcs is then recruited and 
autophosphorylated, inducing a conformational change that frees up DNA termini. If ends are 
not directly compatible for ligation, the Artemis endonuclease can be recruited to process DNA 
ends. Ligation of ends is completed by the Lig4/XLF/XRCC4 complex. B. HR may be initiated 
upon binding of the MRN complex (Mre11, Nbs1, Rad50) at the site of damage. Various 
proteins including Mre11, CtIP, BRCA1, BARD1, and Artemis are involved in promoting and 
carrying out resection of DNA ends, leaving 3’ single stranded DNA overhangs which are 
rapidly coated by RPA molecules. RPA is displaced by Rad51 in a process involving BRCA2. 
These Rad51 molecules form nucleoprotein filaments that drive invasion of the nascent strand 
into the homologous duplex DNA. This generates a “D-loop” structure and HJs. The second 3’ 
end is captured and HJs are resolved. 
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I.3.1.c Alternative non-homologous end joining (alt-NHEJ)  
In the absence of canonical NHEJ (c-NHEJ) factors such as the Ku70/80 subunits and the Lig4 
or XRCC4 ligases, alt-NHEJ can function to repair DSBs.  However, this process may result in 
large deletions of genetic material (Roth et al. 1986) and chromosomal translocations (Bennardo 
et al. 2008). The genetic changes introduced by alt-NHEJ may lead to the expression of 
oncogenes and inhibition of tumour suppressors, therefore implicating the pathway in cancer 
(Bentley et al. 2004). Alt-NHEJ requires PARP1 for sensing DSBs and relies on short regions of 
homology that are usually only 5-25 bp long (Wang et al. 2006a; McVey et al. 2008). 5’-3’ 
DNA end resection reveals regions of microhomology upstream and downstream of both ends 
of the DSB, resulting in the loss of DNA sequence (McVey et al. 2008). Increasing evidence 
suggests that the CtIP nuclease is involved in the resection step of alt-NHEJ.  Depletion of CtIP 
in mouse cells reduces the frequency of chromosomal translocations and the usage of 
microhomology at translocation breakpoint junctions, both which are characteristics of alt-
NHEJ (Zhang et al. 2011). Following end resection, DNA strands are then aligned and annealed 
at the regions of microhomology and overhangs are cleaved in a process termed flap trimming 
(McVey et al. 2008). Ligation can then proceed in a manner most likely dependent on ligase 3 
(Lig3) (Wang et al. 2006a).  
I.3.2 ATM-mediated DSB signalling 
The response to DSBs is mediated by protein signalling at the site of damage. This signalling 
cascade coordinates the repair of the breaks with arrest of cell cycle progression and, in some 
cases, cell death. Initiation of this signalling is generally coordinated by the ataxia-telangiectasia 
mutated (ATM) protein, a 350 kDa (kilodalton) phosphoinositol 3-kinase like kinase (PIKK). 
ATM regulates various cellular activities via its ability to modify proteins by phosphorylating 
(transferring PO43- groups to) serine or threonine residues on protein substrates (Shiloh 2003).  
As depicted in Figure I.3.A, ATM normally exists as a homodimer but monomerises in 
response to induction of a DSB (ie. following IR) and becomes autophosphorylated on serine 
1981 (Bakkenist et al. 2003). Binding of the MRN complex to DNA ends promotes recruitment 
of activated ATM to the site of damage via the C-terminus of Nbs1 (Falck et al. 2005; You et al. 
2005) (Figure I.3.B). Activated ATM can then phosphorylate the histone variant H2AX (Section 
I.3.3), at serine 139, generating the form of H2AX referred to as γH2AX. H2AX can also be 
phosphorylated at serine 139 by DNA-PKcs in the response to IR, and by the ataxia-
telangiectasia and Rad3-related (ATR) kinase in the response to replication stress (Ward et al. 
2001; Stiff et al. 2004). The rapid assembly and subsequent spreading of γH2AX molecules at 
the site of a single IR-induced DSB generates a focus which can be visualised using 
immunofluourescence protein labelling and microscopic detection (Lobrich et al. 2010). The 
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enumeration of these γH2AX foci and analysis of their disappearance over time provides a 
valuable method to monitor the repair of DSBs which has been exploited in several sections of 
this thesis. 
 While the initial assembly of γH2AX molecules is not exclusively required for the 
recognition of DSBs, it is required to further promote the formation of ionizing radiation-
induced foci (IRIF) and the subsequent recruitment of other DSB signalling proteins (Celeste et 
al. 2003). Following γH2AX foci formation at break sites, the adaptor protein mediator of DNA 
damage protein 1 (MDC1) is recruited to DNA. MDC1 contains an amino-terminal (N-terminal) 
forkhead-associated (FHA) domain, a central proline- serine- and threonine-rich repeat (PST 
repeat), and tandem BRCA1 C-terminus (BRCT) domains (Stewart et al. 2003; Coster et al. 
2010).  Via its BRCT domains, MDC1 directly interacts with γH2AX, thereby facilitating its 
recruitment (Stucki et al. 2005). Additionally, the FHA and BRCT domains also found in Nbs1 
interact with MDC1, further promoting recruitment and retention (Figure I.3.C). The 
recruitment of MDC1 promotes further accumulation and amplifies the ATM-mediated 
tethering at DSBs (Figure I.3.D). 
Next, an additional wave of ATM tethering is induced by the recruitment and 
accumulation of other proteins including p53 binding protein 1 (53BP1) and the E3 ubiquitin 
(ub)-protein ligases, ring finger protein 8 (RNF8) and ring finger protein 168 (RNF168). RNF8 
is recruited to DSBs via an association with the N-terminal FHA domain of MDC1 and 
subsequently generates K63-linked ub chains on nearby H2A and H2AX histones (Huen et al. 
2007; Mailand et al. 2007). RNF168 then binds these ub chains and propagates further K63-
linked ubiquitination (Stewart et al. 2009), altogether facilitating chromatin relaxation. While 
53BP1 does not appear to directly bind ub chains, its tandem tudor domains have been reported 
to bind methylated residues on histone proteins (Huyen et al. 2004; Botuyan et al. 2006). Ub-
mediated chromatin relaxation may expose these residues, thereby promoting 53BP1 
recruitment (FitzGerald et al. 2009).  
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Figure I.3 Initial ATM-mediated signalling at DSBs. P: phosphorylated. A. ATM normally 
exists as a homodimer but becomes monomerised and autophosphorylated at serine 1981 
following induction of a DSB (ie. from ionizing radiation). B. Rad50, Mre11, and Nbs1 rapidly 
bind and tether DSB ends and ATM gets recruited to the site via an interaction with the c-
terminus of Nbs1. C. Next, activated ATM phosphorylates H2AX on serine 139 (γH2AX), 
which can interact with the BRCT domains of MDC1. MDC1 also interacts with the FHA and 
BRCT domains of Nbs1. D. Finally, accumulation of γH2AX and MDC1 further amplifies DSB 
signalling.  
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I.3.3 Chromatin organization and structure 
The human genome encompasses a vast amount of DNA, comprising up to a total of 6 billion 
bp in diploid cells, which would encompass a distance of 2 meters if stretched linearly. This 
large amount of genetic material must be compacted to fit within the nucleus, which typically 
has a diameter of less than 10 micrometers. In order to achieve this, DNA must be packaged and 
organised into several layers of higher-order structure, as depicted in Figure I.4. 
The first level of DNA packaging begins with the nucleosome, a structure containing 
146 bp of the DNA helix wrapped around an octamer of histone proteins H2A, H2B, H3, and 
H4 (Luger et al. 1997) (Figure I.4.A). These four core histone proteins are highly conserved 
throughout evolution and also share a high degree of sequence and structural similarity 
(Baxevanis et al. 1996).  Histones H2B, H3, and H4 form positively charged alpha helices, 
allowing for a strong interaction with negatively charged sugar- phosphate backbone of DNA. 
Each of the histone proteins has a highly flexible and accessible tail extending from the N-
terminus which can contribute to the dynamic structural properties of chromatin.  Histone tails 
may be altered by post-translational modifications (PTMs) including phosphorylation (addition 
of PO43-), acetylation (addition of COCH3), methylation (addition of CH3), ubiquitination 
(addition of the ubiquitous immunopoietic polypeptide), SUMOylation (covalent attachment of 
small ubiquitin-like modifier (SUMO)), and ADP-ribosylation (transfer of ADP-ribose chains) 
(Sims et al. 2003) (Table I.2). PTMs of histone tails can impact upon various cellular processes 
involving DNA including transcription, chromosome segregation, and recombination. 
Additionally, modifications on histone tails function in DNA damage signalling, remodelling, 
and repair, as will be discussed in more depth below. These modifications may be transient 
events or heritable epigenetic changes which are passed to daughter cells (Delcuve et al. 2009). 
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Figure I.4 The basic structure of chromatin. A. On the first level of chromatin structure, the 
DNA double helix is found wrapped around an octamer of the core histone proteins (H2A, H2B, 
H3, and H4), together making up the nucleosome. The core histones each contain highly 
accessible tails which can be altered by PTMs such as acetylation and methylation. The histone 
H1 protein binds nucleosomes and exiting DNA, locking the structure together. B. Repeating 
units of nucleosomes, separated by “linker DNA” form a structure likened to “beads on a 
string.” Nucleosomes are locked into place by the histone H1 protein. C-D. Chromatin can be 
found to be packaged either in the form of euchromatin (C), a loosely condensed and generally 
transcriptionally active state in which histone tails are often acetylated by a histone 
acetyltransferase (HAT), or in the form of heterochromatin (D), a more compact and generally 
transcriptionally silent state in which histone tails may be methylated by a histone 
methyltransferase (HMT).     
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Histone Residue PTM 
 
Histone Residue PTM 
H2A 
S1 p  
H3 
R2 me 
K5 ac  T3 p 
K9 ac  K4 ac/me 
R11 me  T6 p 
K13 adp  R8 me 
R29 me  K9 ac/me 
K119 ub  S10 p 
K120 p  T11 p 
H2AX 
K5 ac  K14 ac 
K119 ub  R17 me 
S139 p  K18 ac 
Y142 p  K23 ac 
H2B 
K5 ac  R26 me 
K12 ac  K27 ac/me/adp 
S14 p  S28 p 
K15 ac  K36 ac/me 
K20 ac  K37 adp 
K30 adp  Y41 p 
K120 ub  T45 p 
H4 
S1 p  K56 ac 
R3 me  K79 me 
K5 ac     
K8 ac     
K12 ac     
K16 ac/adp     
K20 me     
K91 ac/ub     
 
 
Table I.2 Common histone modifications. S: serine, K: lysine, R: arginine, Y: tyrosine, T: 
threonine, p: phosphorylation, ac: acetylation, me: methylation, adp: adenosine diphosphate 
ribosylation, ub: ubiquitination, su: SUMOylation, (reviewed in (Sims et al. 2003; Bhaumik et 
al. 2007)). 
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Histone H2A, which forms a dimer with H2B, may consist of several variants including 
H2A.1, H2A.2, H2AX, or H2A.Z, which differ by only a small number of amino acids (aa). 
Following DSB induction, H2AX is phosphorylated at serine 139, a modification known as γ-
H2AX which functions in the DDR (Section I.3.2) (Rogakou et al. 1998). When H2A is 
replaced the H2A.Z variant, as observed in nucleosomes adjacent to transcriptional start sites, 
stability of the dimer formed with H2B is lowered, therefore impacting upon higher order 
chromatin structure. (Suto et al. 2000; Placek et al. 2005; Gamble et al. 2010). Another variant 
of H2A, macroH2A, has been identified in nucleosomes on the inactivated X-chromosome in 
female mammals and in various regions on other chromosomes. Replacement of H2A with 
macroH2A can have either a positive or negative impact on transcription (Gamble et al. 2010). 
Nucleosomes are linked together by Histone H1 to form a structure likened to “beads on 
a string,” with up to 80 bp of linker DNA connecting the nucleosomes and contributing to 
stability of the structure (Figure I.4.B). The linked nucleosomes and histone H1 are then further 
organised into 30 nm fibres or filaments (Finch et al. 1976) which are thought to be a dynamic 
structure that may stretch to a loosely packed structure known as euchromatin during active 
transcription (Figure I.4.C).  In euchromatin, histone tails can be found to be acetylated at lysine 
residues including lysines 9, 14, 18, 23 of histone H3, lysines 5, 8, 12, 16 of H4, lysines 5 and 9 
of H2A, and on lysines 5, 12, 15 and 20 of H2B (Sims et al. 2003). The addition of acetyl 
groups by proteins known as histone acetyltransferases (HATs) lowers the positive charge 
involved in the tight interaction with DNA, therefore partially disrupting the N-terminal 
interaction with DNA and relaxing chromatin structure.  
Alternatively, chromatin can be found in a form known as heterochromatin which plays 
a structural role and functions in the silencing of gene expression (Figure I.4.D). Histones in 
heterochromatin regions may be found to be mono-, di-, or tri-methylated on arginine or lysine 
residues including lysines (K) 4, 9, 27, 36, or 79 on H3 and K20 on histone H4 (Table I.2) 
(Sims et al. 2003). Histone methylation, a form of alkylation, involving the transfer of methyl 
(CH3) groups from S-adenosyl methionine to histones, occurs via the histone methyltransferases 
(HMTs). Unlike the case with acetylation, methylation of histone tails does not function to 
modify the charge of the histones at the DNA binding site, but rather serves to “mark” regions 
of chromatin, allowing for protein binding and facilitating downstream heterochromatin 
building events.  
In mammals, DNA may also be methylated, primarily at cytosine-phosphate-guanine 
(CpG) dinucleotides by DNA methyltransferases (DNMTs).  DNMTs transfer methyl groups 
directly to the 5 position of the aromatic ring of cytosine, generating 5-methylcytosine. Between 
70 and 80% of the CpG dinucleotides in the human genome are found to be methylated, and this 
essential modification has been shown to contribute to heterochromatin reorganisation, 
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imprinting, development, and inactivation of the X-chromosome (Jabbari et al. 2004; Ma et al. 
2005a). 
Heterochromatin may be found either in its constitutive form, a stable structure which 
remains compacted throughout various stages of cell development, or in its facultative form, 
which may be reversed under certain conditions, allowing for decondensation and 
transcriptional activity.  
Regions of the genome such as centromeres and telomeres containing repetitive 
segments known as satellite DNA are found as constitutive heterochromatin. Organisation of 
heterochromatin in centromeric regions, in which nucleosomes are found to contain the histone 
H3 variant centromere protein A (CENPA), is crucial for proper chromosome segregation and 
chromosome assembly (Palmer et al. 1987; Dimitri et al. 2009). Constitutive heterochromatin 
can also be found at telomeres, where the compaction of chromatin plays a role in protection of 
chromosome ends along with other telomeric functions (Schoeftner et al. 2009).  
Facultative heterochromatin has been observed to be important in regulating the 
expression of ribosomal DNA (rDNA), which codes for the RNA component of the ribosome. 
As described in more depth in Section III.1.3, rDNA, which is organised into clusters of tandem 
repeats in nucleoli, is under tight transcriptional regulation corresponding to the cellular 
requirement for ribosome generation. While actively transcribed regions of rDNA contain 
euchromatic histone modifications including acetylation of H3 and H4, silenced rDNA regions 
contain methylated H3 tails (Grummt et al. 2008). Acetylation specifically on lysine 9 of H3 
(H3-K9) has been observed to be replaced by methylation under conditions of nutrient 
deficiency (in which ribosome synthesis shuts down). This exchange of an acetyl group for 
methyl groups on H3-K9 occurs via a process involving the energy-dependent nucleolar 
silencing complex (eNoSC), the sirtuin 1 (SIRT1) deacetylase, and the histone 
methyltransferase, suppressor of variegation 3-9 homolog 1 (SUV39H1) (Grummt et al. 2008).  
Another example of facultative heterochromatin is the inactivation of the X 
chromosome (or lyonisation) which generates the Barr body in female mammals and allows for 
equalisation of the amount of gene expression between the sexes. The inactivated X 
chromosome contains uniformly distributed markers of heterochromatin such as methylated H3-
K9 and lacks the acetylated forms of histones found in euchromatin (Wutz 2011). 
The assembly of heterochromatin occurs over various stages, as illustrated in Figure I.5. 
Transcriptional silencing begins with the transcriptional repressors which bind DNA, often via a 
zinc finger motif (Craig 2005). Passive repressors work indirectly, either by blocking activity of 
transcriptional activators or by inhibiting access of activators to DNA. Active repressors can 
function over long distances of DNA and work to actively target regions of the genome for 
heterochromatin formation. The active repressor methyl CpG binding protein 2 (MECP2), for 
example, can be recruited to sites of methylated CpG dinucleotides in promoter regions, leading 
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to recruitment of the histone deacetylase (HDAC) proteins to remove acetyl groups from histone 
tails (Thiel et al. 2004).  
Many repressors do not function independently in silencing, instead working by 
recruiting co-repressors such as kruppel associated box domain (KRAB) associated protein 1 
(KAP-1). KAP-1 binds DNA via its zinc-finger containing KRAB (Figure I.5.A) and becomes 
SUMOylated in a process facilitated by its C-terminal plant homeo domain (PHD) and its 
bromodomain, which recognises acetylated lysines (Zeng et al. 2008) (Figure I.5.B). This 
SUMOylation allows for KAP-1 to act as a molecular scaffold in heterochromatin building. The 
SUMOylated form of KAP-1 recruits the Mi-2/ nucleosome remodelling and deacetylase (Mi-
2/NuRD) complex which includes the chromodomain helicase DNA binding proteins 3 and 4 
(CHD3 and CHD4), also known as Mi-2α and Mi-2β, respectively, as well as the histone 
deacetylase protein 1 (HDAC1) and  histone deacetylase protein 2 (HDAC2) (Xue et al. 1998; 
Denslow et al. 2007). This unique and abundant complex coordinates the disruption of 
nucleosomes with the removal of acetyl groups from lysines on histone tails, therefore 
remodelling DNA (Xue et al. 1998; Denslow et al. 2007).  
As previously introduced, lysines on histone tails are usually found to be methylated in 
heterochromatin. SUMOylated KAP-1 binds the methyltransferase, SET domain bifurcated 1 
(SETDB1), which deposits methyl groups onto lysine 9 of histone H3 (Schultz et al. 2002). In 
addition to SETDB1, SUV39H1 and SUV39H2 are among other lysine methyltransferases that 
work to enhance chromatin compaction (O'Carroll et al. 2000).  
Chromatin compaction is stabilised by chromodomain adaptor proteins such as the 
heterochromatin protein 1 (HP1) family. This family of adaptors, also known as chromobox 
homolog, or CBX, includes three paralogs in humans, known as HP1α, HP1β, and HP1γ. Unlike 
HP1α and HP1β, HP1γ can also be found in regions of euchromatin in mammalian cells (Minc 
et al. 2000). HP1α/β/γ  each contain an N-terminal chromodomain, a highly conserved motif 
found in chromatin remodelling proteins, a chromoshadow domain near the C-terminus, and a 
highly flexible hinge region linking the domains together (Paro et al. 1991; Aasland et al. 1995). 
The chromoshadow domain of HP1 directly interacts with KAP-1, via a PxVxL motif on KAP-
1, facilitating the binding of HP1 to methylated histone tails (Sripathy et al. 2006) (Figure 
I.5.C). HP1 forms homodimers which bridge adjacent nucleosomes together, locking them into 
place. In addition to binding to methylated lysines, dimerized HP1 also further promotes HDAC 
and SUV39H recruitment, which  further contributes to heterochromatin spreading (Craig 
2005). Additional interactions and functions of HP1 will be described in more detail in Chapter 
V.  
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Figure I.5 Heterochromatin building. A: acetyl group, S: SUMO, M: methyl group A. 
Transcriptional silencing can commence with repressors which bind to DNA regions and recruit 
corepressors like KAP-1. KAP-1 can bind acetylated euchromatin via zinc finger (Zn) in its 
KRAB domain. B. SUMOylation of KAP-1 on its PHD-Bromo domain recruits the Mi-2/NurD 
complex, which includes deacetylation activity via HDAC1/2 and nucleosome disruption via 
CHD3. In addition, the methyltransferase SETDB1 can bind SUMOylated KAP-1 and transfer 
methyl groups to histone tails. C. The adaptor protein HP1 is recruited via interactions with 
KAP-1 and methylated lysine tails of histones. HP-1 promotes further methylation by the 
SUV39H methyltransferase and stabilises compaction. 
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I.3.3.a Heterochromatin and cancer 
Heterochromatin plays an important role in the maintenance of genome stability, and changes in 
heterochromatin formation have been identified in various types of human cancer.  
Distinct regions of facultative heterochromatin termed senescence associated 
heterochromatin foci (SAHF) have been identified in various types of human cells upon 
undergoing irreversible arrest of cell cycle (senescence) (Narita et al. 2003). SAHF formation, 
which ultimately contributes to gene silencing, has been demonstrated around genes which 
promote cellular proliferation, reflecting a role of SAHF in senescence, tumour suppression, and 
aging (Zhang et al. 2007). 
Changes in transcriptional silencing have been reported in BRCA1-deficient breast 
cancer and one model proposes that BRCA1-dependent tumour suppression occurs via 
heterochromatin-mediated transcriptional silencing. In a recent study conducted by Zhu and 
colleagues, the targeted deletion of BRCA1 in mice was reported to result in a reduced number 
and more diffused appearance of chromocentres in neurons, suggesting that BRCA1 loss alters 
heterochromatin organisation (Zhu et al. 2011). Further, these authors reported that the 
expression of satellite repeat DNA regions, which is normally repressed by heterochromatin-
mediated transcriptional silencing, was enhanced in cells from mouse or human breast tumours 
deficient in BRCA1 (Zhu et al. 2011). As the ectopic expression of satellite DNA was observed 
to induce genomic instability in human mammary cells, the authors of this study proposed that 
BRCA1-dependent heterochromatin-mediated transcriptional repression prevents genome 
instability and tumourigenesis. Further, the ubiquitin ligase activity of BRCA1 was suggested to 
be involved in this role in heterochromatin. In support of this notion, BRCA1 was found to be 
required for the enrichment of ubiquitinated histone H2A at satellite regions and the ectopic 
expression of H2A-ub in BRCA1-deficient human breast cancer cells restored the 
transcriptional silencing of satellite DNA and other cellular features associated with BRCA1 
deficiency. In summary, BRCA1-mediated ubiquitination of histone H2A and subsequent 
heterochromatin-mediated transcriptional silencing at satellite regions has been proposed to 
promote genome stability and tumour suppression.  
Changes in the expression and function of the heterochromatin protein HP1 have also 
been associated with metastasis in breast cancer (Kirschmann et al. 2000). Studies from 
Drosophila melanogaster demonstrated that while a complete loss of HP1 leads to lethality, 
heterozygous mutants survive and display an increase in euchromatin-like structures. 
Overexpression of HP1 leads to increased transcriptional silencing, consistent with 
heterochromatin formation (Eissenberg et al. 1990; Kirschmann et al. 2000). The role of HP1-
dependent heterochromatin building in tumour suppression is complex and thought to involve 
centromere segregation, telomere end protection, and transcriptional regulation (Dialynas et al. 
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2008). In addition, HP1 appears to play a role in the response to localised DNA damage. HP1α 
has been reported to localise to the sites of DSBs induced by laser irradiation. Depletion of 
HP1α in human osteosarcoma cells leads to impaired recruitment of KAP-1 and 53BP1 to sites 
of laser-induced damage and decreased cell survival in response to γ-irradiation, presumably as 
a result of accumulating DSBs (Baldeyron et al. 2011). In cellular contexts of reduced HP1 
levels, defective repair of DSBs may contribute to instability, ultimately resulting in 
tumourigenesis.  
 
I.3.4 DSB repair in G1 and G2 
 
Over the past decade, results from our lab and others have demonstrated that the structural 
context of DNA at the site of a DSB is crucial in determining DNA repair pathway selection 
(Goodarzi et al. 2010). Given the compact nature of heterochromatin, it is perhaps unsurprising 
that this chromatin superstructure impacts upon DNA repair. Interestingly, the repair of IR-
induced DSBs during the Gap1 (G1) and Gap2 (G2) stages of the cell cycle occurs with two 
distinct phases of kinetics which have been shown to correspond with the two main forms of 
chromatin structure. The proper execution of slow and fast repair has been shown to involve 
distinct sets of proteins. 
As previously mentioned, IR-induced DSBs can be monitored by immunofluorescence 
labelling and enumeration of γH2AX foci. Following irradiation of cells, γH2AX foci rapidly 
accumulate in cell nuclei. While some repair is likely to occur within the first 15-30 minutes 
after damage, assessment of the induction of breaks is commonly examined 30 minutes post IR 
(Lobrich et al. 2010) (Figure I.6A). Monitoring of the reduction in the number of foci over time 
enables assessment of DSB repair. In both G1 and G2, between 75 and 90% of the DSBs 
induced are repaired with rapid kinetics over the course of the first several hours (Figure I.6B). 
Examination of the overlap of γH2AX foci with chromocentres (which can be visualised by 
immunofluorescence as regions with intense 4',6-diamidino-2-phenylindole (DAPI) staining)  
have shown that these rapidly-repaired breaks are generally localised to euchromatic regions of 
DNA in which genetic material is more accessible to repair proteins (Goodarzi et al. 2010). The 
remaining fraction of DSBs induced (10-25%) is repaired with a significantly slower rate of 
repair (generally after 8 hours post IR) and these DSBs localise to regions of chromatin 
compaction (heterochromatin). Depletion of c-NHEJ factors such as Ku70/80, DNA-PKcs, and 
the Lig4/XLF/XRCC4 complex leads to defects in both fast and slow repair (Figure I.6B). 
However, defects exclusively in the slow repair of breaks have been observed in cells depleted 
for ATM-mediated signalling factors or the Artemis endonuclease. In cells lacking ATM itself, 
the MRN complex, H2AX, the mediator proteins (53BP1, RNF8, MDC1, RNF168), or Artemis, 
15-20% of induced lesions persist for days, and in some cases over a week  (Riballo et al. 2004; 
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Goodarzi et al. 2008; Goodarzi et al. 2010; Noon et al. 2010) (Figure I.6B). The defective repair 
observed in cells with deficient ATM-mediated signalling can in fact be alleviated if 
heterochromatin is disrupted, for example, via depletion of or a deficiency in KAP-1, 
HDAC1/2, HP-1, MeCP2, SETDB1, Suv39H1/2, and DNMT3B  (Goodarzi et al. 2008; Brunton 
et al. 2011).  This reflects the fact that ATM-mediated signalling is required to reduce chromatin 
compaction, therefore enabling access of repair proteins to DNA. 
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Figure I.6 DSB detection and kinetics of repair in G1 and G2.  EC: euchromatin, HC: 
heterochromatin A. DSB induction may be monitored in nuclei 30 minutes following ionizing 
radiation (IR) using immunofluorescence labelling of γH2AX foci. B. The rate of DSB repair 
can be assessed by following the loss of γH2AX foci over time. DSB repair in G1 and G2 
consists of a phase of fast repair at EC and of a slow repair phase at HC. Defects in NHEJ 
machinery lead to ineffective fast and slow repair whereas defects in ATM signalling proteins 
and in the Artemis endonuclease prevent the slow phase of repair. Defects in slow repair can be 
restored if heterochromatin is disrupted (Goodarzi et al. 2010; Lobrich et al. 2010). 
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Localised decondensation of heterochromatin at the site of a DSB is facilitated by 
ATM-dependent phosphorylation of the co-repressor KAP-1 on serine 824 (Ziv et al. 2006; 
Goodarzi et al. 2008). The role of the mediator proteins such as 53BP1, RNF8, MDC1, and 
RNF168 in heterochromatic DSB repair is thought to be related to concentrating and retaining 
ATM activity at the site of the break, thereby promoting modifications in chromatin and 
allowing for repair (Noon et al. 2010). ATM-dependent phosphorylation of KAP-1 has been 
proposed to create a structure which interferes with the interaction between the SUMO 
modification of KAP-1 and the CHD3 subunit of the Mi2-NuRD complex. This disruption of 
the interaction is thought to lead to the localised dispersal of CHD3 from chromatin, therefore 
disturbing heterochromatin structure and enabling repair (Goodarzi et al. 2011).  
While epistatic studies have shown that the Artemis endonuclease and ATM function in 
the same pathway of slow DSB repair, the role of Artemis seems to be distinct from the role of 
ATM (Beucher et al. 2009). Given the protein’s endonucleolytic processing capacity, one model 
presented has proposed that Artemis is required to cleave secondary structures that can arise 
when a DSB occurs in a highly repetitive region of DNA. Recent emerging data has indicated 
that Artemis plays an important role in DNA end resection, the initial process in HR and 
alternative end-joining. The structure and functions of Artemis will be introduced in Chapter III. 
Further investigation of the fast and slow repair processes has revealed distinctions in 
repair pathway choice that depend on the stage of cell cycle. Given the absence of a 
homologous template from a sister chromatid during G1 (and Gap 0 phase, also known as G0), 
nearly all DSBs occurring in cells in these stages of the cell cycle are repaired using NHEJ. 
During G1, most DSBs are repaired with NHEJ using rapid kinetics. However, DSBs occurring 
within heterochromatin regions in G1 are repaired with a slower component of end joining 
which requires processing by the Artemis endonuclease (Beucher et al. 2009). 
Despite the presence of homologous sister chromatids in G2, most DSBs in this phase 
are also repaired rapidly by NHEJ.  However, unlike the case during G1, the slow component of 
repair during G2 utilises HR. Cells deficient in components exclusively required for HR such as 
BRCA2 or Rad51 therefore display a defect specifically in the slow component of repair during 
G2 (Beucher et al. 2009). The requirement for ATM-mediated signalling is observed in both G1 
and G2, indicating the fact that heterochromatin decondensation resulting from ATM-dependent 
phosphorylation of KAP-1 occurs upstream of DSB repair.  
 
I.4 The response to DNA damage occurring during replication 
 
The avoidance of genomic instability in normal dividing cells requires both accurate duplication 
of genetic material as well as proper segregation of duplicated chromosomal DNA to the two 
progeny cells. Additionally, cells must be able to correctly repair any damage to DNA that can 
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occur from endogenous or exogenous sources to ensure that the fidelity of the genome is 
maintained. Erroneous DNA replication, chromosome mis-segregation, or defective repair of 
damaged DNA can lead to malignancies detrimental to survival, and therefore organisms have 
evolved vital systems to execute such tasks accurately. Elaborate molecular machines exist 
which precisely regulate the initiation of replication at DNA origins, progression through 
replication, DNA proofreading, cell cycle timing, sister chromatid separation, and, as introduced 
in earlier sections, the repair of breaks or deleterious modifications to DNA.  
 This section will introduce the regulation of DNA replication (Section I.4.1), DDR 
protein signalling in response to replication stress (Section I.4.2), and the activation of excess 
(also referred to as dormant) DNA replication origins in response to replication stress (Section 
I.4.3).  
 
I.4.1 Regulation of DNA replication 
Regulation of the initiation, progression, and completion of DNA replication is carried out by a 
host of proteins, many of which are essential to survival.   
I.4.1.a The nature of replication origins  
Duplication of the genome begins at DNA sequences known as replication origins. The nature 
of these origin sequences is varied across species. In bacteria containing a single circular DNA 
molecule, only one origin is needed to successfully replicate the genome. However, in 
eukaryotic cells, which contain linear chromosomes and larger genomes, multiple origins must 
fire to duplicate DNA in a timely fashion. In Saccharomyces cerevisiae (S. cerevisiae) budding 
yeast, origins are located in autonomously replicating sequence (ARS) elements, specific 
sequences rich in adenine and thymidine which are capable of replicating plasmid DNA when 
inserted into a vector (Stinchcomb et al. 1979; Rehman et al. 2009).  
In higher eukaryotes, the locations of replication origins have proven more difficult to 
define. No known origin consensus sequence exists in mammalian cells, and studies have 
demonstrated that human licensing factors are able to functionally bind to DNA sequences 
indiscriminately (Schaarschmidt et al. 2004). Over the course of an unchallenged S-phase, 
activation of  30,000 -50,000 origins spaced ~100 kilobases (kb) apart  (Huberman et al. 1966; 
Huberman et al. 1968) enables replication of the entire mammalian genome (Mechali 2010). 
Analysis of origin activation has demonstrated that replication in mammalian cells may be 
initiated from clusters of origins in ~1-50 kb zones termed replication or initiation zones (Little 
et al. 1993; Dijkwel et al. 1995; Kamath et al. 2001).  
While mammalian origins are not characterised by any single consensus sequence, 
correlations have been observed between origin location and chromatin architecture (Alabert et 
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al. 2012). Active replication involves the disruption of nucleosomes ahead of replication forks, 
and consequently, active origins of replication have been observed in regions of low 
nucleosome occupancy (Gruss et al. 1993; Cayrou et al. 2011; Lubelsky et al. 2011).  
Studies in Xenopus (Danis et al. 2004), Drosophila (Aggarwal et al. 2004), and human 
cells (Lucas et al. 2007) have demonstrated that histone modifications impacting upon the 
higher-order structure of chromatin play a significant role in origin determination  (Zhou et al. 
2005; Alabert et al. 2012). Interestingly, genomic mapping of mammalian replication origins 
has revealed that origin density correlates with guanine and cytosine - rich promoter regions 
such as CpG islands (Necsulea et al. 2009; Sequeira-Mendes et al. 2009). Activation of the 
30,000-50,000 origins does not occur synchronously during S-phase, as some origins fire 
specifically during the early stages of S-phase and others fire only at later stages. As is the case 
with transcriptional activation, the regulation of the timing of origin firing has been proposed to 
involve heterochromatin formation. Studies examining the activity of CpG island-associated 
origins on the active and silent X-chromosome have demonstrated that the replication of regions 
surrounding methylated (and transcriptionally silenced) regions occurs later in S-phase. 
Conversely, unmethylated CpG islands fire early in S-phase (Gomez et al. 2004).  
Importantly, multiple protein interactions between replication and heterochromatin 
factors have been identified. These interactions and potential implications will be discussed in 
more detail in Section I.5 and Chapter V.   
 
I.4.1.b Origin licensing 
Prior to firing during S-phase, origins of replication must first be licensed in a process that 
begins in the late stages of mitosis-phase (M-phase) and early G1-phase and involves the pre-
replication complex (pre-RC) of proteins. Licensing begins in late M-phase with the binding of 
a complex of proteins known as the origin recognition complex (ORC) (Figure I.7.A).  The 
interaction of ORC with chromatin was recently shown to be mediated, in part, by direct 
binding of ORC1 with Histone H4 dimethylated on K20 (H4K20me2) (Kuo et al. 2012) and 
may also be facilitated by interactions between ORC components and chaperone proteins. 
Following ORC recruitment, the cell division 6 (CDC6) and Cdc10 dependent transcript 
1(CDT1) proteins localise to ORC-bound DNA (Figure I.7.B).  This facilitates chromatin 
loading of the minichromosome maintenance (MCM) helicase complex to CDC6-, CDT1-, and 
ORC-bound DNA, altogether forming the pre-RC (Figure I.7.C). CDC6 and CDT1 are released 
from the pre-RC, which helps to prevent re-licensing of the same origin. Cyclin dependent 
kinase 2 (Cdk2) and cell division 7(Cdc7) promote the recruitment of cell division control 45 
(Cdc45) and the Go, Ichi, Nii, San (GINS) complex (Figure I.7.D) and the subsequent initiation 
of origin firing. Following activation of a licensed origin in S-phase, two replication forks are 
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formed and move in opposite directions (Figure I.7.E). Nucleosomes are disrupted ahead of 
replication forks to facilitate fork progression (Gruss et al. 1993), and ORC likely dissociates 
from DNA upon firing of an origin (Karnani et al. 2011).  
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Figure I.7 Replication origin licensing and firing in mammalian cells.  Pre-RC: pre-
replication complex, M: methylated A. The licensing of origins begins with the binding of the 
heterohexameric ORC complex (ORC1-6) to DNA. ORC recognises and binds DNA in part, by 
recognition of H4K20me2 (Kuo et al. 2012). B. Next, CDC6 and CDT1 are recruited to ORC-
bound DNA. C. This facilitates loading of the MCM helicase onto ORC, CDC6, and CDT1-
bound DNA, altogether forming the pre-RC complex. At this stage, origin licensing is complete. 
D.  Next, CDC6 and CDT1 dissociate from the complex to prevent re-licensing of the same 
origin and Cdc7 and Cdk proteins promote initiation of replication and recruit Cdc45 and GINS 
to licensed origins. E. Origin firing and replication initiate, generating two replication forks 
moving in opposite directions (as indicated by orange arrows). Nucleosomes ahead of the 
replication forks are disrupted in order to allow replication to proceed. 
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I.4.1.b.1 The origin recognition complex components 
Originally identified in S. cerevisiae, ORC is composed of six protein members, named ORC1-6 
in decreasing order of their molecular mass in yeast (Bell et al. 1992) . While the ORC1-5 
proteins are highly conserved members of the ATPases associated with diverse cellular 
activities (AAA+) family of proteins, ORC6 is structurally distinct and less conserved across 
species (Duncker et al. 2009).  
The human ORC1 protein consists of several domains that are highly conserved across 
species (Figure I.8). Human ORC1 contains an AAA+ ATP-binding domain which includes 
Walker A and B motifs (WA and WB, respectively) and sensor 1 and 2 motifs (S1 and S2, 
respectively).  In addition, ORC1 contains an N-terminal bromo-adjacent homology (BAH) 
domain (aa 1-185) and a winged-helix (WH) domain at the C-terminus (aa783-861). In addition, 
a nuclear localisation signal (NLS) has been identified which spans aa240-288 in human ORC1 
(Ghosh et al. 2011). More recently two additional domains have been identified in ORC1. A 
CDK inhibitory domain (CID), which functions in inhibiting Cyclin E-Cdk2 and Cyclin A-Cdk2 
activity, has been mapped to the N-terminus (aa1-250) and a pericentrin-AKAP450 centrosomal 
targeting (PACT) domain  has been mapped to the C-terminus  (aa768-851) (Hossain et al. 
2012). A role for ORC1 in regulating the duplication of centrosomes will be discussed further in 
Section I.5. 
ATP binding of the AAA+ domain has been shown to function in the recruitment and 
assembly of the various subunits of the human ORC (Siddiqui et al. 2007). Studies in S. 
cerevisiae have demonstrated that the initial binding of ORC with DNA occurs in an ATP-
dependent manner, but does not require hydrolysis of ATP. However, the capacity to hydrolyze 
ATP becomes important at later steps of pre-RC component assembly, as it is required for 
subsequent loading of the MCM complex (Bowers et al. 2004; Randell et al. 2006) .   
While ORC2-5 also possess the ATPase and WH domains, ORC1 is the only licensing 
component which contains the BAH domain (Duncker et al. 2009). The ORC1 BAH domain 
has been demonstrated to participate directly in chromatin binding via an interaction with 
histone H4K20me2 (Kuo et al. 2012) and to facilitate protein-protein interactions important in 
replication initiation (Alabert et al. 2012). Expression of an ORC1 BAH mutant construct in 
human epithelial cells affects binding of ORC1 with the origin of replication in the Epstein Barr 
Virus (OriP), origin activity, and association of ORC2 with chromosomal DNA (Noguchi et al. 
2006). While the WH domain has also been proposed to mediate ORC1 binding to DNA in 
archae (Gaudier et al. 2007), it is not clear how much of a role it plays in human cells.  
The recruitment and activity of ORC1 may also be facilitated by interactions with 
protein cofactors.  ORC1 (and ORC6) have been shown to interact with high mobility group 
A1a (HMGA1a), and this interaction is capable of generating an origin of replication in specific 
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sites (Thomae et al. 2008). Other ORC1 interactions, which have been proposed to be important 
for replication initiation and may also impact higher-order chromatin structure, will be 
described in more depth in Section I.5 and Chapter V. 
The recent discovery of an NLS in ORC1 has revealed the fact that nuclear 
translocation of ORC1 can occur independently of the other ORC subunits. In studies performed 
with HeLa cells, deletion of the C-terminal WH domain inhibits the association of ORC1 with 
ORC2 and ORC3 but does not impact upon nuclear translocation (Ghosh et al. 2011). 
Therefore, nuclear localisation of ORC1 and the interaction between ORC1 and the other ORC 
subunits are proposed to be distinct events.  
As depicted in Figure I.8, ORC2-5 also contain the AAA+ domain and a WH domain 
found in ORC1. Unlike ORC1 and ORC6, which may only loosely associate with other ORC 
subunits, ORC2-5 have been shown to more stably interact, thereby forming a core complex 
(Dhar et al. 2000; Dhar et al. 2001b; Vashee et al. 2001). In addition to the AAA+ and WH 
domains, ORC2 has been shown to contain two functional NLS sequences, termed NLS-A (aa 
227-233) and NLS-B (aa 319-336) as well as a domain required for the assembly of ORC 
(aa289-451). In studies with HeLa cells, the two NLS regions have been demonstrated to be 
required not only for nuclear localisation of ORC2 itself, but also for nuclear accumulation of 
the entire ORC2-5 complex (Radichev et al. 2006). A functional NLS region has also been 
identified in the N-terminus of ORC3 (aa1-28). Transfection of human embryonic kidney cells 
with ORC3 deleted for the NLS had no impact on the interaction between ORC2 and ORC3, 
which has been shown to require a 200aa region of the N-terminus of ORC3 (Dhar et al. 2001a; 
Brand et al. 2007).  This suggests that ORC2-3 interact in the cytoplasm and supports the model 
proposed by Ghosh and colleagues that the ORC core complex first forms in the cytoplasm, 
rapidly relocalises to the nucleus via a mechanism requiring the NLS regions of ORC2 and/or 
ORC3, and interacts with ORC1 and/or ORC6  independently translocated to the nucleus 
(Ghosh et al. 2011). ORC3 also contains a coiled-coil motif (aa.45-65) and a MOD1-interacting 
region (MIR) (213-218aa) which are both involved in the interaction of ORC3 with HP1 
(Prasanth et al. 2010). This interaction will be discussed in more depth in Chapter V.  
ORC6, the smallest and most structurally distinct of the ORC subunits, contains a 
unique domain known as the ORC6 fold superfamily domain (Duncker et al. 2009). In addition, 
human ORC6 is predicted to contain a coiled-coil motif towards the C-terminus  (Duncker et al. 
2009). In Drosophila, this region of ORC6 interacts with Pnut, an essential member of the 
septin family of structural proteins that functions in cytokinesis (Huijbregts et al. 2009). 
Interestingly, human ORC6 localises to kinetochores and the mitotic cleavage furrow and small 
interfering ribonucleic acid (siRNA)-mediated depletion of ORC6 leads to mitotic defects 
associated with failed cytokinesis (Prasanth et al. 2002).  Recently, ORC6 was found to contain 
an approximately 20 aa NLS (aa 180-202) which enables nuclear localisation to occur 
58 
 
independently from the other ORC components and which is essential for its function. The 
nuclear localisation of ORC6 is reportedly facilitated by Cdk-dependent phosphorylation of a 
residue in the NLS and by the association of the NLS region with the nuclear transport proteins 
karyopherin alpha 6/1 (Kpna6/1) (Ghosh et al. 2011).While ORC6 lacks the AAA+ domain 
found in the other ORC subunits, it plays a crucial role in origin licensing, in part via 
interactions with ORC1-5, CDC6, and the ORC chaperone protein HMGA1a (Thomae et al. 
2011).  
Regulation of human ORC activity has been demonstrated to be multifaceted, subunit-
specific, and in some cases, cell cycle dependent. The expression of human ORC1 is reported to 
be regulated by the E2F transcription factor and elevated levels have been observed in rapidly 
proliferating tissues and following growth stimulation in normal fibroblasts (Ohtani et al. 1996) 
(Thome et al. 2000). In addition, the chromatin-bound fraction of ORC1 has been reported to be 
elevated in transformed cell lines, including the tumour-derived HeLa line (Di Paola et al. 
2011). ORC1 levels are generally thought to oscillate during cell cycle, with peak levels 
observed in G1 or at the G2/S boundary and reduced levels observed thereafter (Mendez et al. 
2002; Ohta et al. 2003; Tatsumi et al. 2003). As cells transition from G1 to S-phase, ORC1 may 
become poly-ubiquitinated by SKP1-cullin-F-box (SCF)/S-phase kinase-associated protein 2 
(Skp2) ubiquitin ligase complex (Mendez et al. 2002), and subsequently undergo proteolytic 
degradation by the 26S proteasome pathway (Mendez et al. 2002; Tatsumi et al. 2003). 
Phosphorylation of ORC1 by Cdk has also been proposed to regulate licensing by reducing the 
affinity of ORC binding to chromatin. As cells transition from G1 to S-phase, ORC1 can be 
phosphorylated by Cdk1/Cyclin B (Nguyen et al. 2001). Cdk-dependent phosphorylation levels 
are observed to increase during mitosis, and this hyperphosphorylated form of ORC1 inhibits 
ORC-chromatin binding (Li et al. 2004). In contrast to the proliferation and cell cycle dependent 
regulation of ORC1 levels, human ORC2-5 are reported to be expressed in tissues 
independently of proliferative activity (Thome et al. 2000) and generally remain bound to 
chromatin throughout the cell cycle (DePamphilis 2005; Takeda et al. 2005). However, Cdk-
dependent phosphorylation may play a role in regulating the activities of ORC2 and ORC6. In 
S. cerevisiae, Cdk1, which is encoded by Cdc28 (cell division control 28), phosphorylates 
ORC2 at multiple N-terminal sites conserved across various species (Vas et al. 2001).  
Phosphomimetic mutants of threonine 116 and 226 on ORC2  are defective in binding of ORC2 
with chromatin (Lee et al. 2012). Cdk-mediated phosphorylation of threonine 195 of ORC6 has 
been shown to facilitate (though is not required for) the nuclear localisation of ORC6 (Ghosh et 
al. 2011). 
 
59 
 
I.4.1.b.2 CDC6 
 
Another member of the AAA+ family of ATPases originally identified in S. cerevisiae, the 
CDC6 protein, gets recruited to origins following binding of ORC. CDC6 is highly related to 
ORC1, both structurally and phylogenetically, and like ORC1, CDC6 has the capacity to 
hydrolyze ATP (Duncker et al. 2009). Cdc6-mediated ATP hydrolysis stabilises its interaction 
with ORC and promotes loading of the MCM helicase (Randell et al. 2006; Speck et al. 2007; 
Duncker et al. 2009). In addition to its AAA+ domain, human CDC6 also contains a cyclin 
binding (cy) motif near the N-terminus. In the U2OS osteosarcoma-derived cell line, 
exogenously expressed CDC6 was shown to interact with Cdk2/Cyclin A at this motif, leading 
to Cdk-dependent phosphorylation of various residues on CDC6 (Petersen et al. 1999). 
Mutation of these residues in HeLaS3 cells has been reported to impede replication and slow 
progression of S-phase (Herbig et al. 2000).  CDC6 also contains a highly conserved leucine 
zipper, a motif found in DNA binding proteins (Landschulz et al. 1988) and known to mediate 
protein-protein interactions (Petersen et al. 1999).  Like the five largest subunits of the ORC, 
CDC6 also contains a WH domain at its C-terminus (Liu et al. 2000) (Figure 1.8).  
Like ORC1, CDC6 has been found to be hyperphosphorylated during mitosis by the 
CDK1/Cell division control 2 (CDC2) kinase (Fujita et al. 1999), is overexpressed in rapidly 
proliferating cells and tissues (Yan et al. 1998) and is regulated transcriptionally by E2F (Ohtani 
et al. 1998). Overexpression of CDC6 has been reported in various types of tumours (Lau et al. 
2007b) and CDC6 has been considered as a biomarker in cancer (Bowers et al. 2004).  
Following recruitment of the MCM helicase, CDC6 has been reported to dissociate 
from the chromatin-bound pre-RC, providing a mechanism for the prevention of re-licensing of 
replicated DNA (Blow et al. 2005; Arias et al. 2007).  In S. cerevisiae, phosphorylation of sites 
on CDC6 facilitates its SCFCdc4-dependent proteolytic destruction as well as its stable 
association with Cdk. The association of Cdk with CDC6 can result in the inhibition of the 
licensing activity and/or transcription of CDC6 (Arias et al. 2007). In human cells, several 
studies have reported that proteolysis of CDC6 can occur by a mechanism dependent on the 
Cdh1 activated form of the anaphase-promoting complex (APCCdh1). Ubiquitination by this cell 
cycle dependent ubiquitin ligase and subsequent degradation of CDC6 has been demonstrated in 
G1 and in quiescent cells (Petersen et al. 2000).  
Interestingly, in human cells, induction of DNA damage leads to the degradation of 
CDC6 by various mechanisms. Following IR, inhibition of Cdk-dependent phosphorylation of 
serine 54 results in subsequent APCCdh1 -proteolysis (Duursma et al. 2005).  p53 has been 
implicated in facilitating this mechanism of Cdc6 destruction after IR, and RNA interference-
mediated depletion leads to increased replication and stabilization of CDC6 (Duursma et al. 
2005). However, in response to treatment with MMS, which methylates DNA and induces RS 
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and DSBs, destruction of CDC6 has been reported to occur independently of p53 in normal 
human fibroblasts immortalised with telomerase. Further, MMS-induced degradation of CDC6 
can occur independently of APCCdh1 in HeLa cells.  Instead, CDC6 proteolysis following MMS 
treatment requires the Huwe1 ubiquitin ligase (Hall et al. 2007).  
 
I.4.1.b.3 CDT1 
 
In addition to recruiting CDC6, ORC assembly initiates the recruitment of the CDT1 protein. 
First discovered in fission yeast, Schizosaccharonyces pombe (S. pombe) (Roukos et al. 2011), 
CDT1 is essential for the loading of the MCM helicase complex to origins (Nishitani et al. 
2000; Randell et al. 2006). The N-terminus of CDT1 contains a proliferating cell nuclear 
antigen (PCNA) interaction protein box (PIP box) (aa3-9) (Arias et al. 2006) which contains a 
crucial lysine (K+4) which mediates degradation (Havens et al. 2009), a Cy motif (aa68-70) 
(Liu et al. 2004), an NLS (aa48-71) (Nishitani et al. 2004). In addition, CDT1 contains an 
approximately 40 aa domain important for binding with Geminin (Wohlschlegel et al. 2000), a 
protein which inhibits CDT1 activity by preventing binding with CDC6 and the MCM helicase 
(Cook et al. 2004). CDT1 interacts with the MCM complex (predominately MCM6) via its C-
terminus, (aa392-471) (Zhang et al. 2010).  
The regulation of CDT1 accumulation occurs by cell cycle-dependent expression, 
Geminin-mediated inhibition, proteolytic degradation, and Cdk-dependent phosphorylation. 
Studies originally performed in tumour-derived cell lines have demonstrated that human CDT1 
is expressed predominately during G1-phase (Nishitani et al. 2001)  in an E2F-dependent 
manner (Yoshida et al. 2004) and becomes destabilised as cells enter S-phase (Nishitani et al. 
2001). The first 189 aa are sufficient for accumulation of CDT1 during G1 (Nishitani et al. 
2004). Both Geminin binding and APC-dependent proteolytic degradation of CDT1 are thought 
to be important for the prevention of the re-licensing of origins, an event detrimental to precise 
replication of the genome. Studies using Xenopus egg extracts have demonstrated that inhibition 
of either of these regulatory mechanisms leads to re-licensing and re-replication of DNA added 
to extracts   (Li et al. 2005). Phosphorylation of CDT1 by cyclin A-dependent Cdks is also 
thought to promote degradation. Cyclin A/Cdk1 and Cdk2 directly interact with the Cy motif of 
CDT1. While the resulting phosphorylation does not impact upon binding with Geminin, it does 
promote the binding of Cdt1 with the Skp2 component of the SCF ubiquitin ligase complex, 
therefore enabling proteolytic degradation of CDT1 (Liu et al. 2004; Sugimoto et al. 2004). In 
addition to the SCF-mediated degradation, CDT1 degradation can also occur via a mechanism 
dependent on PCNA and the Cul4/DDB1 (Cullin 4/DNA damage binding protein 1) ubiquitin 
ligase, predominately in the response to DNA damage (Senga et al. 2006).  
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Figure I.8 Schematic representation of domains found in human ORC, CDC6, and CDT1. 
See text for abbreviations. 
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I.4.1.b.4 The MCM helicase 
Following the assembly of ORC, CDC6, and CDT1 at potential sites of replication origins, the 
MCM helicase, a highly conserved heterohexomeric complex made up of the subunits MCM2-
7, is loaded onto DNA in a ring shaped structure (Mendez et al. 2003). At each potential origin, 
two catalytically inactive hexomeric complexes of MCM are loaded, and the complexes are able 
to slide on DNA in either direction from the fork (Evrin et al. 2009). Both CDC6 and CDT1 are 
required for the recruitment of MCM to DNA. CDT1 directly binds MCM via the C-terminus of 
CDT1, and this interaction is required for MCM recruitment and impacted by CDC6 activity 
(Cook et al. 2004). Following recruitment of MCM to DNA, CDC6 and CDT1 are no longer 
required to maintain the association of MCM with DNA (Donovan et al. 1997; Cook et al. 
2004) (Figure I.7.D).  
The precise mechanism of MCM helicase loading remains unclear. The structural 
properties and ATPase activity of ORC and CDC6 could potentially facilitate the loading of the 
helicase by opening and closing the MCM ring structure (Evrin et al. 2009). Interestingly, 
CDT1 has also been implicated in chromatin decondensation, which has been proposed to 
enable loading of MCM as a result of increased chromatin accessibility (Wong et al. 2010). 
Like several other components of the pre-RC, the MCM subunits are transcriptionally 
regulated by E2F and their expression peaks during late mitosis and G1-phase (Leone et al. 
1998). As a complex, MCM has robust ATP hydrolysis activity (Schwacha et al. 2001) and has 
been shown to be involved in unwinding DNA during both initiation of replication and 
elongation (Labib et al. 2000; Pacek et al. 2004). Importantly, the helicase activity of MCM2-7 
is induced exclusively upon association with co-factors as outlined below.  Once activated, the 
two MCM heterohexomers allow for bidirectional replication forks moving away from each 
other, therefore forming a structure known as a “replication bubble” (Figure I.7.D).  
 
I.4.1.c Replication initiation and elongation 
 
The initiation of DNA replication by origin firing must be tightly regulated in order to avoid 
genomic instability. The firing of too few or too many origins, the interference with the 
scheduled timing of origin firing, and the re-firing of a single origin all present replication 
problems which can result in chromosomal instability (Blow et al. 2005; Blow et al. 2011).  
Some evidence exists for a p53-dependent “licensing checkpoint” in normal human 
fibroblasts which prevents the premature entry of cells into S-phase if an insufficient number of 
origins are licensed (Nevis et al. 2009). Given the fact that a reduction in the number of 
available origins would result in longer distances between replication forks and therefore 
increased chances of replication fork stalling, this checkpoint may work to prevent replication 
63 
 
stress and subsequent genome instability. As a result of the strict licensing of origins exclusively 
during mitosis and G1, additional origins cannot be assembled once cells enter S-phase. 
Depletion of licensing factors such as CDC6 and CDT1 in normal human fibroblasts has been 
shown to result in reduced entry into S-phase and reduced Cyclin E, which is required for S-
phase entry. Co-depletion of p53 in these cells restored the progression into S-phase, despite a 
substantial reduction in origin availability. Interestingly the prevention of S-phase entry under 
contexts of reduced origin licensing was not observed in tumour-derived cell lines, potentially 
contributing to the inherent genome instability observed in these cells  (Nevis et al. 2009). 
Overexpression of Cyclin E, an event often found in cancer, has been shown to accelerate entry 
into S-phase despite insufficient licensing, and result in altered loading of the MCM helicase 
and defective replication initiation  (Ekholm-Reed et al. 2004). 
When a sufficient number of origins have been licensed and cells are ready to proceed 
to S-phase, replication initiates at early firing origins with the activation of the MCM helicase, 
enabling unwinding of origin DNA (Pacek et al. 2004). The helicase activity of the MCM 
complex becomes activated upon association with Cdc45 and GINS during S-phase. Structural 
studies performed on Drosophila melanogaster MCM bound to Cdc45 and GINS have 
demonstrated that association of the three components results in conformational changes of 
MCM to a more planar configuration, therefore inducing its helicase activity (Costa et al. 2011). 
Cdc45 and GINS are recruited by Cdk proteins as well as the Cdc7 kinase. Cdc7 also 
phosphorylates various MCM subunits, potentially resulting in structural changes which 
promote its helicase activity or increased binding with Cdc45 and GINS (Weinreich et al. 1999) 
(Labib 2010).  
Upon unwinding of DNA and the formation of bi-directional replication forks, the semi-
conservative duplication of eukaryotic DNA is carried out at a rate of ~2-3kb per minute by 
various proteins altogether known as the replisome (Mechali 2010). The unwinding of DNA by 
helicases generates ssDNA, an inherently labile structure which is stabilised in eukaryotes by 
binding of the heterotrimeric protein RPA (Wold et al. 1988; Wold 1997). Synthesis of DNA 
requires the activity of a replicative polymerase which catalyzes the polymerization of dNTPs 
onto a 3’ hydroxyl group of the growing daughter strand. RNA primers generated by a primase 
provide the 3’ hydroxyl group required for replication initiation. The 5’-3’ elongation of newly 
synthesized DNA occurs continuously on the leading strand and semi-discontinuously on the 
lagging strand through the use of 100-1000 nucleotide long Okazaki fragments. Processivity of 
the DNA polymerase is enhanced by loading of the sliding clamp protein PCNA onto DNA by 
replication factor C (RFC), (Maga et al. 2003). In addition to its role in improving processivity 
of the polymerase, PCNA recruits DNA ligase I to sites of replication (Montecucco et al. 1998). 
DNA ligase I functions to catalyze the formation of the phosphodiester bonds necessary to join 
Okazaki fragments. As the replicative helicase unwinds DNA to accommodate progression of 
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the replication fork, supercoiling occurs ahead of the fork, creating a topological problem. The 
DNA topoisomerases relieve this challenge by creating a nick in DNA, allowing for untangling 
of the double helix, and these nicks can then be sealed. In addition, DNA gyrases are thought to 
contribute by introducing negative supercoils.  
In mammalian cells, replication occurs in discrete sites known as replication factories 
(Hozak et al. 1994) which can be visualised using microscopy-based methodology as foci 
containing replisome proteins such as PCNA (Leonhardt et al. 2000).  
 
I.4.2 ATR-mediated signalling at the replication fork 
 
As introduced in Section I.2.3, when a replication fork encounters a lesion in DNA, fork stalling 
may occur, creating an unstable structure containing ssDNA. ssDNA is also generated during 
the initial step of HR as ends are resected by various nucleases (Section I.3.1b). In response to 
the generation of ssDNA, the ATR kinase is activated and works in conjunction with its binding 
partner ATR-interacting protein (ATRIP) to coordinate the resulting DNA damage response 
(Flynn et al. 2011).  Like ATM, ATR is a member of the PIKK family of protein kinases, and it 
phosphorylates various substrates in response to a wide range of DNA damage. The primary 
function of the ATR-dependent signalling pathway is to stabilise stalled replication forks and to 
activate cell cycle checkpoints in response to DNA damage. Therefore, this pathway plays a 
pivotal role in the maintenance of genome stability.  
As depicted in Figure I.9A-B, upon exposure of regions of single stranded DNA 
resulting from replication fork stalling, DNA becomes rapidly coated with RPA. ATRIP 
recognises and directly binds to RPA coated ssDNA (Zou et al. 2003a). This facilitates the 
localisation of ATRIP-bound ATR molecules to stalled replication forks (or to resected regions 
of DNA). The clamp loading protein Rad17 is then recruited in to RPA-coated DNA. Once 
bound to DNA, Rad17 functions in loading the ring shaped Rad9-Rad1-Hus1 (9-1-1) complex 
in a manner comparable to the RFC-dependent loading of PCNA during unchallenged 
replication  (Zou et al. 2003b) (Figure I.9.C). Full activation of ATR requires the ATRIP-
dependent recruitment of the topoisomerase II binding protein 1 (TopBP1) (Kumagai et al. 
2006; Choi et al. 2010). TopBP1 interacts with the 9-1-1 complex via the C-terminal region of 
Rad-9, which enables the interaction between ATR and TopBP1 and subsequent full activation 
of ATR (Lee et al. 2007) (Figure I.9.D). 
Ultimately, the induction of the intra-S-phase checkpoint is dependent on 
phosphorylation of the Chk1 kinase by ATR. ATR-dependent phosphorylation of Chk1 is 
facilitated by the adaptor protein, Claspin (Kumagai et al. 2004). In response to replication 
stress, Rad17 is phosphorylated by ATR, and this phosphorylated form has been shown to 
function in Claspin recruitment and activation (Wang et al. 2006b) (Figure I.9.E). Claspin itself 
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also becomes phosphorylated in response to DNA damage, and this phosphorylation facilitates 
binding with Chk1 (Kumagai et al. 2003). ATR-dependent phosphorylation of Chk1 at serines 
317 and 345 during S-phase leads to its activation and subsequent inhibitory phosphorylation of 
Cdc25A (Stracker et al. 2009).  
The Cdc25 proteins are crucial in cell cycle progression, as they dephosphorylate the 
inhibitory phosphorylation at threonine 14 and tyrosine 15 on Cdk2 (Sebastian et al. 1993). The 
dephosphorylation of Cdk2 is required for its function in the initiation of replication at licensed 
origins (Section I.4.1.c). Chk1-dependent phosphorylation of Cdc25A leads to its proteolytic 
degradation (Mailand et al. 2000; Jin et al. 2003), thereby preventing Cdk2 dephosphorylation 
and inhibiting the initiation of replication.  
 Importantly, Chk1 has been demonstrated to exclusively inhibit the activation of 
origins in new replication factories (ie. late-firing clusters of origins) (Ge et al. 2010). Chk1 
plays a distinct role in the initiation of origins within active replication factories experiencing 
replication stress which will be further discussed in Section I.4.3. 
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Figure I.9 Schematic representation of ATR signalling at a stalled replication fork.  P: 
phosphorylation. A. Interruption of replication results in replication fork stalling, generating 
exposed regions of ssDNA. B. ssDNA is rapidly coated with RPA molecules, and ATR is 
recruited via the direct interaction of its binding partner, ATRIP, with RPA-ssDNA. C. The 
Rad17 clamp loader binds DNA and loads the 9-1-1 ring complex. D. TopBP1is recruited to the 
stalled fork in an ATRIP-dependent manner that also involves binding with the 9-1-1 complex. 
Once recruited, TopBP1 interacts with ATR, leading to full ATR activation. E. Rad17 and the 
mediator protein Claspin are both phosphorylated. This promotes the ability of Claspin to 
facilitate phosphorylation of Chk1 at serines 317 and 345 by ATR. 
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I.4.3 Dormant origin usage in the response to replication damage 
While the origin licensing components are essential for cellular proliferation, cells are able to 
undergo replication and to proliferate when levels of the pre-RC subunits are substantially 
reduced. This observation reflects the fact that cells license up to 10 times more origins than are 
typically required during S-phase (Lei et al. 1996; Donovan et al. 1997; Wong et al. 2011). 
Based on computer modelling of a typical metazoan origin cluster in which origins are activated 
in a stochastic manner during S-phase,  these excess or “dormant” origins unlikely to fire in the 
absence of replication stress are thought to be passively replicated by approaching forks 
initiated from adjacent origins (Blow et al. 2009) (Figure I.10.A-B). As described below, a 
growing body of evidence has supported the model that these dormant origins can be activated 
in response to replication stress, promoting replication recovery and cellular survival (Blow et 
al. 2011) (Figure 1.10.C). 
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Figure I.10 A model for the usage of dormant origins in promoting cellular proliferation 
under conditions of replication stress. (Proposed by Blow, Ge et al, 2011). Double MCM 
heterohexomers are depicted at replication origins on DNA. A. More origins are licensed 
(orange) than are fired (green, green arrows indicate direction of movement of each replication 
fork), leaving excess or “dormant” origins (grey) inactive. B. Over the course of unchallenged 
replication, dormant origins remain inactive and are proposed to be passively replicated by 
nearby activated replication forks (Blow et al. 2009). C. Under conditions of replication stress, 
replication fork stalling occurs (red) and DNA between two stalled replication forks may remain 
unreplicated. A dormant origin within this region may become activated, enabling replication of 
intervening DNA, completion of replication, and cellular proliferation. 
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The initial observations that impaired replication fork progression increases adjacent 
origin firing were made nearly forty years ago (Ockey et al. 1976; Taylor 1977). Since then, 
these observations have been confirmed and explored by methods including the analysis of 
replication initiation at sites known or predicted to contain active and dormant origins in 
eukaryotic cells such as S. cerevisiae (Santocanale et al. 1999), Chinese hamster ovary (CHO) 
cells (Anglana et al. 2003), and, more recently, in human cells (Karnani et al. 2011). Advances 
in methodology for analysing single tracts of DNA replication have enabled further 
investigation of dormant origin firing in human cells. Nucleoside analogues can be incorporated 
into DNA during active replication, labelled with fluorescently-conjugated antibodies, and 
visualised using microscopic analysis of individual DNA fibres. These DNA fibre assays may 
be modified for various purposes, such as comparing inter-origin distances within replication 
clusters in the presence or absence of replication stress activity (Ge et al. 2007). As described 
below, exploitation of this or similar methods have demonstrated that replication stress-inducing 
agents stall the progression of forks previously activated (Merrick et al. 2004) but induce new 
origin firing of adjacent (most likely dormant) origins (Ge et al. 2007; Ibarra et al. 2008a; 
Petermann et al. 2010a; Karnani et al. 2011).  
In order to study replication stress-induced dormant origin activation and subsequent 
cellular consequences, several studies have exploited partial siRNA-mediated depletion of pre-
RC components to reduce dormant origin availability in the presence of replication inhibitors. 
Treatment with hydroxyurea (HU), an agent which inhibits ribonucleotide reductase (RNR) and 
results in decreased dNTP pools and replication fork stalling/collapse, has been shown to 
increase intra-cluster origin activation in U2OS osteosarcoma cells (Ge et al. 2007). This study 
demonstrated that the reduction but not complete ablation of origin licensing capacity via 
siRNA-mediated depletion of MCM5 enhances sensitivity of U2OS cells to the replication 
stress-inducing agents HU, aphidicolin (a DNA polymerase inhibitor) and camptothecin (a 
TopoI inhibitor), presumably as a result of insufficient dormant origin availability. Importantly, 
in the absence of treatment with replication stress-inducing agents, partial depletion of MCM5 
did not significantly impact replication and cellular proliferation, implying that MCM5 
depletion impacted mainly upon dormant origin availability. An independent study performed in 
HeLa cervical carcinoma cells demonstrated that siRNA-mediated depletion of MCM3 also 
enhances sensitivity of cells to aphidicolin. Increases in RPA foci, γH2AX levels, and 
chromosomal instability were observed in MCM3 depleted HeLa cells treated with aphidicolin 
for several days, reflecting enhanced DNA damage (Ibarra et al. 2008a).  
Importantly, the increased origin firing observed in response to replication inhibitors 
has been observed primarily within previously activated replication factories. Conversely, the 
activation of new replication factories (ie. late-firing clusters of origins) is inhibited by 
replication blocks (Ge et al. 2010) in a process involving ATR and Chk1 signalling at stalled 
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forks (Section I.4.2) (Branzei et al. 2005; Karnani et al. 2011). Abrogation of Chk1 function via 
chemical inhibition or siRNA-mediated depletion results in increased origin firing (Feijoo et al. 
2001; Ge et al. 2007; Maya-Mendoza et al. 2007; Karnani et al. 2011), accompanied by a 
decrease in the rate of fork elongation, therefore compromising efficacy of replication  (Maya-
Mendoza et al. 2007). Overall, these results suggest that, while ATR and Chk1inhibit the 
activation of late firing replication clusters in response to replication stress, the firing of 
dormant origins within previously activated clusters may be an important component of the 
DDR in these cell lines. 
Dormant origin activation has also been implicated in replication within regions 
containing fragile sites, specific genomic regions marked by instability. Investigation of origin 
firing within a common fragile site (CFS) in the human genome known as FRA16C, has 
suggested that an increase in origin firing may promote replication completion in this region, 
even in normal growth conditions.  Examination of FRA16C in a human lymphoblastoid cell 
line reported to have a normal karyotype revealed AT-rich sequences which would be predicted 
to form secondary structures and potentially interrupt the progression of replication forks. In 
fact, a correlation was observed between these AT-rich regions with replication fork slowing or 
stalling. A slight decrease was reported in the average inter-fork distance in the FRA16C locus 
when compared with the average inter-fork distance observed across the entire genome (109+/-
7Kb vs. 81+/-16Kb). This suggests that slightly more origins (ie. dormant origins) may be 
activated in the fragile site region of these immortalised lymphoblastoid cells to promote 
completion of replication (Ozeri-Galai et al. 2011).  However, in another study examining the 
FRA3B CFS, tissue-specific differences in origin density and region fragility were reported 
(Letessier et al. 2011). Fragility of FRA3B was much greater in lymphoblastoid cells than in 
various fibroblast lines, and this fragility was strongly associated with a paucity of activated 
origins rather than increased dormant origin firing. The reduction in origin availability in cells 
forces the few forks activated in the region to travel longer distances and therefore increases the 
chances of fork stalling and site fragility. Importantly, this scarcity of origin usage and site 
fragility was not observed in fibroblast cells. Therefore, many questions remain about the usage 
of dormant origins in normal replication of various CFSs in cells from different tissues.  
In addressing the cellular function of dormant origin firing and how this process may be 
regulated, Blow and colleagues have presented a model based on both computer-generated 
modelling of origin firing within a typical 250 kb metazoan origin cluster and findings from in 
vivo studies (Blow et al. 2009; Blow et al. 2011). This model proposes that origin activation 
occurs in a stochastic manner, with some origins less efficient than others and therefore likely to 
be dormant during the course of an unchallenged S-phase. Blow and colleagues reason that in 
the absence of replication stress, dormant origins may be replicated passively by oncoming 
replication forks but that the slowing or stalling of active forks provides a longer timeframe in 
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which the less efficient dormant origins may become activated. Under conditions of replication 
stress, the probability of double fork stalling increases, potentially leaving the DNA between the 
forks unreplicated (Figure I.10.C). Firing of dormant origins within this intervening DNA would 
enable completion of replication, therefore preventing under-replication and subsequent genome 
instability and/or cell death. Therefore, the higher the density of origins licensed, the greater 
protection against replication interruption and subsequent cellular consequences. Given that 
origin licensing occurs strictly before S-phase entry and the benefits of new origin activation in 
the recovery from replication stress, the availability of excess pre-licensed dormant origins has 
been proposed to play a role in the prevention of genome instability (Blow et al. 2011).  
While the replication stress-induced activation of dormant origins has been 
demonstrated in a variety of cells from various eukaryotic species, the dependence of human 
cells on this mechanism for survival has been investigated primarily using tumour-derived cell 
lines. However, the dependence of cells from normal human tissue on this mechanism has yet to 
be fully explored. As increased expression of various components of the pre-RC has been 
reported in cancer (Lau et al. 2007b), perhaps reflecting increased dormant origin capacity, 
distinctions may exist between tumour and non-tumour cells in the reliance on dormant origin 
firing. Several studies have indeed examined the impact of depleting other pre-RC components 
on tumour and normal tissue-derived human cell lines (Prasanth et al. 2002; Machida et al. 
2005; Lau et al. 2006; Feng et al. 2008; Lau et al. 2009; Nevis et al. 2009). However, these 
studies were generally not designed to investigate the impact of specifically depleting dormant 
origin capacity on the recovery from replication stress. Therefore, while the results reflect 
important differences between tumour-derived and normal cells in the requirement of the pre-
RC components to sustain survival in the absence of damage, many questions remain 
unanswered. Interestingly, partial depletion of ORC6 has been reported to enhance sensitivity of 
a colon cancer derived cell line to the pyrimidine analogue 5-Fluorouracil, which directly 
inhibits replication fork progression, and the cross linking agent cisplatin, which also induces 
replication stress (Gavin et al. 2008). This study did not compare the impact of ORC6 depletion 
in tumour-derived cells with normal cells and did not examine the effect of partial ORC6 
depletion on origin firing and replication. However, the enhanced sensitivity to replication 
stress-inducing agents caused by partial depletion of ORC6 may reflect an important role of 
dormant origin availability in survival of these colon cancer-derived cells under conditions of 
replication fork stalling and collapse.  
While few patients have been identified which harbour mutations in pre-RC 
components, several human cell lines and mouse models with deficiencies in origin licensing 
have been examined.  In recent years, mutations in several human pre-RC genes have been 
identified in patients with Meier-Gorlin Syndrome (MGS), a disorder characterised by various 
phenotypic traits including but not limited to pre-and post-natal growth retardation and small 
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head circumference (microcephaly). The clinical and cellular phenotypes of pre-RC-deficient 
MGS patients will be discussed in Section I.6. While mutations in the MCM helicase subunits 
have not been identified in humans to date, two mouse models harbouring hypomorphic 
mutations in MCM2 and MCM4 have been developed and used to study the impact of depleting 
origin licensing capacity on the entire organism. Insertion of an internal ribosome entry site 
(IRES) fused to the CreERT2 gene into the MCM2 transcript and subsequent targeted 
recombination into the wildtype MCM2 locus has provided a tamoxifen-inducible model of 
hypomorphic MCM2 deficiency (MCM2IRES-CreERT2) (Pruitt et al. 2007). Mice homozygous for 
the MCM2 mutation were viable and displayed normal development up through early 
adulthood. However, an increase in cancer incidence was reported in these mice along with 
premature cancer-related death. In addition, the proliferative compartments of various tissues 
were found to be reduced (Pruitt et al. 2007). Mouse embryonic fibroblasts (MEFs) from 
homozygous MCM2IRES-CreERT2/ IRES-CreERT2 mice displayed decreased origin usage following 
exposure to HU as well as a modest increase in DNA damage, as measured by γH2AX and 
53BP1 foci (Kunnev et al. 2010). A mutation identified in mice which results in a single amino 
acid change and chromosomal instability, known as Chaos3 (chromosome aberrations occurring 
spontaneously 3), was identified to destabilise MCM4 (Shima et al. 2007). MCM4Chaos3 was 
observed to be hypomorphic and result in increased aphidicolin-induced chromosome instability 
and cancer incidence (Shima et al. 2007; Kawabata et al. 2011b). MEFs from MCM4Chaos3/Chaos3 
mice displayed reduced levels of chromatin-bound MCM2-7, decreased origin firing, and 
increased γH2AX and RPA foci, (Kawabata et al. 2011b). Unlike the MCM2IRES-CreERT2 mice, 
MCM4Chaos3/Chaos3 mice displayed some embryonic lethality and a small (~15%) decrease in 
embryonic body weight. Further, proliferation of MCM4Chaos3/Chaos3 MEFs has been reported to 
be impaired, which correlates with the upregulation of p21 (Kawabata et al. 2011c). Whether 
deficiencies in the other pre-RC components would also result in increased cancer incidence in 
humans remains unknown. While there are no reports of increased cancer incidence in MGS 
patients with mutations in ORC1, ORC4, ORC6, CDC6, and CDT1, the number of patients is 
too limited to accurately assess this. 
 
I.5 Additional cellular roles of origin licensing machinery 
 
In addition to their crucial role in licensing of replication origins, various components of the 
pre-RC have been found to function in other cellular processes.  As a result, depletion or 
deficiency of these components may result in pleiotropic cellular effects. 
Recent unpublished findings from our lab have identified a role for origin licensing 
factors in the ATR-dependent G2/M checkpoint. Cells from MGS patients with hypomorphic 
mutations in ORC1 (Bicknell et al. 2011b) fail to activate the G2/M checkpoint in response to 
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UV (S. Walker, unpublished results) (Figure I.11A). The activation of this checkpoint, which is 
regulated by ATR signalling (Stiff et al. 2008), involves the inhibition of Plk1 (van Vugt et al. 
2001) and Aurora A kinase activity (Marumoto et al. 2002). Interestingly, this UV-induced 
G2/M checkpoint defect in ORC1-deficient cells can be overcome by treatment with Plk1 or 
Aurora A inhibitors (S. Walker, unpublished results). Similar results have been observed in cells 
from a CDC6-deficient MGS patient (Bicknell et al. 2011a) (S. Walker, unpublished results, 
data not shown). While a role for CDC6 in ATR activation has already been proposed during S-
phase and thought to be mediated by the direct interaction of CDC6 with ATR (Yoshida et al. 
2010), these findings have implicated the origin licensing components in regulating the UV-
induced ATR-dependent G2/M checkpoint upstream of Plk1 and Aurora A inhibition.  
In addition to this role in regulating the transition from G2 to M-phase, components of 
the pre-RC have been shown to function in the regulation of centrosome duplication. Enhanced 
green fluorescent protein (EGFP) –tagged pre-RC components overexpressed in mouse cells are 
reported to colocalise with centrosomes (Stuermer et al. 2007), the microtubule organising 
centres in metazoan cells. Centrosomes are composed of two centrioles as well as surrounding 
pericentriolar material which must be duplicated only once during cell cycle to ensure proper 
organisation of microtubules (Figure I.11B) (Nigg et al. 2011). Given the importance of the 
bipolar microtubule spindle in the segregation of chromosomes to the two progeny cells during 
mitosis, abnormalities in the formation, function, or duplication of centrosomes can result in 
abnormal cytokinesis, genetic aberrations, and genome instability. siRNA-mediated depletion of 
ORC1 has been reported to result in Cdk2 and Cyclin E-dependent re-duplication of 
centromeres and centrioles, while overexpression blocks re-duplication (Hemerly et al. 2009). 
Cyclin A-dependent localisation of ORC1 to centrosomes via the PACT domain of ORC1 has 
been proposed to regulate the prevention of re-duplication (Hossain et al. 2012). Depletion of 
ORC2 in HeLa cells has been reported to result in multipolar spindles and multinucleation 
(Prasanth et al. 2002). ORC6 has implicated in the regulation of centrosome copy number, as 
depletion of ORC6 in DT40 chicken cells results in supernumary centrosomes and subsequent 
mis-segregation of chromosomes (Bernal et al. 2011).  Recent unpublished findings from our 
lab have further supported the model that origin licensing components are required for proper 
centrosome and centriole duplication.  Cells from an ORC1-deficient MGS patient (ORC1-P1) 
(Bicknell et al. 2011b) display supernumary centrosomes and abnormal centrioles (S. Walker, 
unpublished findings) (Figure I.11C). In addition, siRNA-mediated depletion of ORC4, ORC6, 
CDC6, and CDT1 lead to an increase in the fraction of cells containing supernumary 
centrosomes (T. Stiff, unpublished findings).   
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Figure I.11 Additional roles of ORC1. A. ORC1-deficient cells are defective in the UV-
induced G2/M checkpoint. Cells from a normal individual (WT), an ATR-deficient Seckel 
Syndrome patient (ATR-S), or an ORC1-deficient MGS patient (ORC1-P1) individuals were 
untreated or treated with 5J/m2 UV. One hour later, the fraction of mitotic cells was assessed 
(Section II.6.3). A decrease in the mitotic fraction indicates activation of the G2/M checkpoint 
(S. Walker, unpublished results). B. Schematic depicting the location of chromosomes, 
centrosomes, centrioles, and microtubules in a mitotic (metaphase) cell. C. ORC1-deficient cells 
contain supernumary centrosomes. Cells described in (A) were treated with nocodazole for 24 
hours to increase mitotic fraction, centrosomes were examined by immunofluorescence (Section 
II.6) using an antibody to γ-tubulin, and the fraction of mitotic containing >2 centrosomes was 
scored (S. Walker, unpublished results). 
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Several pre-RC components have also been implicated in the building and/or 
maintenance of higher-order chromatin structure (Chakraborty et al. 2011). Various components 
of the pre-RC have been reported to localise to heterochromatin and interact with chromatin 
factors (Table I.3) (Alabert et al. 2012). ORC1, CDT1, and MCM2 interact with the Histone H3 
and H4 acetyltransferase, histone acetyltransferase binding to ORC (HBO1) (Iizuka et al. 1999; 
Burke et al. 2001). As introduced in Section I.4, ORC1 and ORC6 have been reported to interact 
with an AT-rich domain in HMGA1a, a high mobility group protein which binds to the minor 
groove of A-T dinucleotide regions and induces structural changes (Thomae et al. 2008).  The 
interaction localises to heterochromatin regions and has been shown to affect the recruitment of 
ORC to DNA. However, whether the ORC-HMGA1a interaction directly impacts upon 
chromatin structure is unknown. More recently, ORC2 and CDT1 have been shown to interact 
with ORC-associated (ORCA) (Shen et al. 2012). This interaction is thought to participate in the 
recruitment ORC to DNA (Shen et al. 2010). ORC1 has been reported to interact with telomere 
repeat factor 2 (TRF2) and telomere-repeat-encoding RNA (TERRA) and these interaction 
promote localisation of ORC to telomeres to facilitate heterochromatin formation and/or 
replication initiation (Atanasiu et al. 2006; Deng et al. 2009).  Finally, ORC1 and ORC3 directly 
interact with HP1α. As discussed in more depth in Chapter V, the interaction between ORC and 
HP1α has been demonstrated to impact upon heterochromatin structure (Prasanth et al. 2010). 
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Chromatin factors Proposed function Interaction 
HBO1 (Zn domain) RI 
ORC1 (aa210-861) 
CDT1 
H4 (K20me2) RI ORC1 (BAH domain) 
ORCA (WD-repeat domain) RI 
ORC2 
CDT1 
HMGA1a (AT-rich domain) 
RI ORC1 
RI ORC6 
TRF2 (N-term) 
RI, ORC localisation at 
telomeres 
ORC1 
HP1α (chromoshadow 
domain) 
RI, ORC recruitment, HC 
organisation 
ORC1 (N-term) 
ORC3 (MIR domain) 
Table I.3. Interactions reported in humans between chromatin factors and ORC, CDC6 or 
CDT1. RI: replication initiation, HC: heterochromatin 
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I.6 Microcephalic primordial dwarfism  
Microcephalic primordial dwarfism (MPD) encompasses a group of syndromes including 
Seckel Syndrome (Majewski et al. 1982), Microcephalic/Majewski osteodysplastic primordial 
dwarfism types I and II (MOPD I/II), (Majewski et al. 1982; Hall et al. 2004), and MGS (Gorlin 
1992). MPD syndromes are characterised by microcephaly accompanied by severe pre- and 
post-natal growth retardation. Seckel Syndrome patients harbouring mutations in ATR 
(O'Driscoll et al. 2003), centromere protein J (CENPJ) (Al-Dosari et al. 2010), centrosomal 
protein 152 kDa (CEP152) (Kalay et al. 2011), CtIP (Qvist et al. 2011), and ATRIP (Ogi et al. 
2012) have been identified. Mutations in the centrosomal protein pericentrin (PCNT) have been 
reported in MOPD II patients and patients originally classified as having Seckel Syndrome 
(Griffith et al. 2008; Rauch et al. 2008; Willems et al. 2010). Mutations in a component of the 
spliceosome, U4atac snRNA, have also been reported in patients with MOPD I (He et al. 2011; 
Abdel-Salam et al. 2012; Nagy et al. 2012).  
Recently, hypomorphic mutations in the origin licensing components ORC1, ORC4, 
ORC6, CDC6 and CDT1 have been identified in MGS patients (Bicknell et al. 2011a; Bicknell 
et al. 2011b; Guernsey et al. 2011; de Munnik et al. 2012) (Table I.4). These mutations are 
observed to result in either a reduction in protein level or in chromatin binding capacity. 
Because cells license up to 10 fold more origins than are required for a typical round of 
replication, (Section I.4.3), cells from these MGS patients are able to proliferate despite a 
substantial reduction in origin licensing capacity.  
In addition to the short stature and microcephaly characteristic of MPD disorders, most 
of the origin licensing-deficient MGS patients also displayed microtia (abnormal ear 
development), delayed bone age, abnormal or absent patellae (kneecaps) and full lips (de 
Munnik et al. 2012). 
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Selected clinical 
features 
ORC1 
(n=10) 
ORC4 
(n=7) 
ORC6 
(=7) 
CDC6 
(n=1) 
CDT1 
(n=10) 
Microcephaly 8/8 2/5 1/6 0/1 2/9 
Head circumference 
(cm)* 
-9.8 to -4 
-3.2 to -
0.7 
-3.3 to -
1.6 
-1.8 -5 to -1.7 
Height (cm) * 
-5.2 to -
9.6 
-6.4 to -
1.8 
-3.3 to -
0.8 
-3.5 -6 to -0.4 
Short stature 10/10 6/7 6/7 1/1 8/10 
Microtia 9/10 7/7 7/7 1/1 10/10 
Delayed bone age 3/4 4/7 4/5 1/1 2/5 
Abnormal/absent 
patellae 
6/7 7/7 6/7 1/1 10/10 
Full lips 7/10 2/5 5/7 1/1 6/9 
Table I.4. Selected clinical features of MGS patients with biallelic mutations in origin 
licensing factors. Data and images compiled from (Bicknell et al. 2011a; Bicknell et al. 2011b; 
Guernsey et al. 2011; de Munnik et al. 2012). *standard deviations from the age-related normal 
population mean 
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While the limited number of individuals with origin licensing-deficient MGS makes it 
difficult to accurately identify distinctions between these patients, microcephaly seems to be 
more severe in ORC1-deficient patients compared with patients with defects in other licensing 
components (Table I.4). To date, all ORC1-deficient MGS patients have been identified to have 
at least one mutation located within the BAH domain (de Munnik et al. 2012), the region 
involved in interactions with chromatin at H4K20me2 and with HP1α (Figure I.12). In addition 
to having a deficiency in activating replication origins, cells from patients with ORC1-deficient 
MGS display slowed S-phase entry and progression (Bicknell et al. 2011b), abnormal activation 
of the UV-induced G2/M checkpoint, and supernumary centrosomes and centrioles (Figure 
I.11).  
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Figure I.12 ORC1-deficient MGS. A. Schematic depicting the locations of amino acid 
alterations resulting from ORC1 mutations in MGS patients. Blue arrows and numbers depict 
the amino acid alteration in patient 1 (ORC1-P1), red numbers and arrows depict two amino 
acid alterations identified in patient 4 (ORC1-P4), and grey arrows and numbers depict amino 
acid changes identified in other patients. B. Photographs of ORC1-P1, ORC1-P4, and CDT1-
deficient MGS (individual 11). Microtia can clearly be observed in individual 11 (Bicknell et al. 
2011b; de Munnik et al. 2012). 
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I.7 Thesis aims 
In recent years, there has been much progress in our understanding of the crucial biological 
mechanisms which preserve genomic stability. However, many questions remain unresolved.  
 Important advances in technology and methodology have enabled the study of DNA 
repair processes at the level of a single DNA break. DNA damage signalling and repair is now 
being investigated in the context of higher-order chromatin structure, which has revealed 
interesting distinctions in pathway selection in the response to DSBs occurring within 
euchromatin or heterochromatin. However many questions about the precise role of various 
proteins in damage signalling and/or repair in chromatin regions remain unanswered. For 
example, while the role of ATM in heterochromatic DSB repair has been established, the 
precise function of the Artemis endonuclease in repair has yet to be fully elucidated. In Chapter 
III, I will describe a method of site-specific DSB induction using direct delivery of an 
endonuclease capable of introducing breaks within the highly repetitive regions of rDNA. 
Optimisation of this system has allowed for the assessment of DSB repair at regions likely to be 
enriched for heterochromatin. Findings obtained through the use of this methodology have 
consolidated the notion that Artemis functions in heterochromatic DSB repair in a manner that 
is independent of heterochromatin opening. 
Chapters IV and V will then shift to focus on applied research, reflecting my interest in 
therapeutic and disease-related research. 
The identification of MGS patients harbouring mutations in origin licensing machinery 
has opened up many questions about the importance of these factors in cellular processes. 
Availability of cell lines from these patients has enabled the study of the cellular impact of 
diminished origin licensing capacity. As described in Chapter IV, the role of origin licensing in 
the recovery from replication stress was examined in cell lines derived from healthy individuals 
or ORC-deficient MGS patients as well as in tumour-derived cell lines. My findings have 
suggested that while tumour-derived cell lines rely on dormant origin firing to recover from 
replication stress, non-tumour fibroblast cells can recover from replication stress despite a 
substantial reduction in origin licensing.  
Factors involved in replication origin licensing have also been implicated in higher-
order chromatin structure, though questions remain about their precise role. In Chapter V, I will 
present findings which substantiate published results showing that siRNA-mediated depletion of 
ORC results in changes in higher-order chromatin structure. Further, I will demonstrate that 
cells from ORC-deficient MGS patients also display characteristics consistent with disordered 
chromatin and that these chromatin alterations impact the DDR. These findings contribute to our 
understanding of the cellular phenotype of patients with ORC-deficient MGS.  
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Overall, this thesis aims to examine the cellular impact of diminished origin licensing 
capacity with a focus on the response to replication stress and higher-order chromatin structure. 
The implications of the findings presented in this thesis, including the potential therapeutic 
exploitation of origin licensing capacity, will be discussed in Chapter VI.  
 
 
  
83 
 
II Materials and methods  
Unless otherwise stated, lab reagents were obtained from Sigma-Aldrich (Gillingham, UK). 
II.1 Mammalian cell culture 
Reagents for tissue culture were obtained from Gibco®, Invitrogen ™ (Paisley, UK). Cell 
culture dishes and flasks were obtained from Corning®Costar®, Sigma-Aldrich (Gillingham, 
UK). All growth medium described below was additionally supplemented with 2 mM L-
Glutamine and 1% antibiotics (100 U/ml penicillin G and 100 mg/ml streptomycin). 
The wildtype primary fibroblast line 48BR (Keyse et al. 1985) and human telomerase 
(hTERT)-immortalised fibroblast cell lines 1BR3hTERT  (wildtype), BJhTERT  (Jiang et al. 
1999) (wildtype),  F02/385hTERT (Riballo et al. 2004) (Artemis null), and ORC1-P4hTERT 
(Bicknell et al. 2011b)  (ORC1 deficient) were cultured in Dulbecco's Modified Eagle’s 
Medium (DMEM) supplemented with 15% fetal calf serum (FCS). Growth medium for BJ-
MYC-ER, a derivative of BJhTERT which stably expresses a tamoxifen-inducible c-Myc gene 
(Littlewood et al. 1995; Murga et al. 2011) (kindly provided by Dr. Óscar Fernández-Captello), 
was additionally supplemented with 2 µM puromycin.  
MRC-5 (wildtype lung fibroblast), U2OS (osteosarcoma), A549 (adenocarcinomic 
alveolar basal epithelial), HeLa (cervical adenocarcinoma) cell lines (obtained from ATCC) and 
NIH3T3 mouse embryonic fibroblasts (MEFs) were cultured in Minimum Essential Medium 
(MEM) supplemented with 10% FCS. MDA-MB-231 breast adenocarcinoma cells (ATCC) 
were cultured in DMEM supplemented with 10% FCS. 
Lymphoblastoid cell lines (LBLs) derived from healthy individuals (GM02188 and 
AG09387, wild-type) or MGS patients deficient in ORC1 (Bicknell et al. 2011b), ORC6, 
CDC6, or CDT1 (Bicknell et al. 2011a) were cultured in Roswell Park Memorial Institute 
(RPMI)-1640 supplemented with 15% FCS.   
All cell lines were maintained at 37°C in 5% carbon dioxide (CO2) and passaged every 
2-3 days. Adherent cells were passaged by trypsinization with 0.25% trypsin in 1 mM 
Ethylenediaminetetraacetic acid (EDTA)/ phosphate buffered saline (PBS). Stocks of cell lines 
were stored in liquid nitrogen in 70% growth medium, an additional 20% FCS, and 10% 
dimethyl sulfoxide (DMSO).  
II.2 siRNA depletion 
HiPerFect (Qiagen, Hilden, Germany) or Metafectene-Pro (Biotex, Planegg, Germany) 
transfection reagents were used to transfect logarithmically growing cells with siRNA 
oligonucleotides (Table II.1) according to manufacturer’s instructions. Briefly, for transfection 
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with HiPerFect, siRNA oligonucleotides were mixed with HiPerFect transfection reagent and 
Opti-MEM® (Invitrogen, Paisley, UK) and incubated for 10 minutes prior to mixing with cells 
in suspension. For transfection with Metafectene-Pro, siRNA oligonucleotides and the 
transfection reagent were each mixed with Opti-MEM® (Invitrogen, Paisley, UK) in separate 
eppendorf tubes. These mixtures were combined and incubated for 15 minutes prior to mixing 
with cells in suspension.  Unless otherwise stated in text, 0.5-1x105 cells per ml were transfected 
with 20 nM siRNA duplexes and grown for 48-72 hours prior to further analysis.  
For experiments involving titrations of siRNA oligonucleotides, 2 fold serial dilutions 
were initially performed in 1x siRNA buffer (Dharmacon, Thermo Scientific, Loughborough, 
UK) prior to mixing with the transfection reagent and delivery to cells. Each siRNA titration 
was performed in triplicate.  
ON-TARGETplus SMART pool siRNA oligonucleotides are reported to being highly 
specific, as verified by microarray analysis, as a result of unique dual-strand modification 
patterns used to synthesise the reagents 
(http://www.thermoscientificbio.com/uploadedFiles/Resources/sirna-libraries-brochure.pdf). 
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siRNA Species Description Supplier 
siControl N/a Randomly scrambled control sequence Dharmacon 
siORC1single human 5’CGUAUGUUGCUAAAUUGCUUGAGUU3 Invitrogen 
siORC1pool human ON-TARGETplus SMART pool Dharmacon 
siORC1 mouse ON-TARGETplus SMART pool Dharmacon 
siORC6 human ON-TARGETplus SMART pool Dharmacon 
siCDT1 human ON-TARGETplus SMART pool Dharmacon 
siCDC6 human ON-TARGETplus SMART pool Dharmacon 
sip53 human ON-TARGETplus SMART pool Dharmacon 
siKAP-1 human 5’CAGUGCUGCACUAGCUGUGAGGAUA3’ Invitrogen 
siKAP-1 mouse 5’AAGAUGCAGUGAGGAACCAACGUAA3 Invitrogen 
siArtemis human ON-TARGETplus SMART pool Dharmacon 
si53BP1 human 5’AGAACGAGGAGACGGUAAUAGUGGG3 Qiagen 
siRNF8 human ‘A’ 5’GGACAAUUAUGGACAACAA3’ 
‘B’ 5’UGCGGAGUAUGAAUAUGAA3’ 
Invitrogen 
siHP1α human 5’GGUUAAGGGACAAGUGGAAUAUCUA3 Invitrogen 
 
Table II.1. siRNA oligonucleotides. 
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II.3 I-PpoI system of site-specific DSB induction 
II.3.1 Plasmids used for I-PpoI expression and in vitro analysis of activity 
Expression of the intron-encoded Physarum polycephalum endonuclease (I-PpoI) was carried 
out using a pET-45b(+) expression vector (I-PpoI-his / pET-45b(+)) (Wen, Cerosaletti et al. 
2012) constructed and kindly provided by Dr. Jie Wen and Dr. Patrick Concannon. Briefly, the 
open reading frame of I-PpoI was synthesised and cloned into the pUC57 vector, excised by 
restriction digestion, and ligated into the pET-45b(+) expression vector (containing a T7 
promoter, ampicillin resistance (AmpR) gene, and polyhistidine (his)-epitope tag) (Figure 
III.3B). 
For analysis of I-PpoI functional activity in vitro, the 15 bp I-PpoI recognition sequence 
was cloned into the pcDNA3.1 vector (containing a T7 promoter and AmpR gene) (I-PpoI site/ 
pcDNA3.1A(+), Figure III.4A) (also constructed and kindly provided by Dr. Jie Wen and Dr. 
Patrick Concannon). 
These and all other plasmids exploited in this thesis were amplified using DH5α 
competent cells, and isolated by the MaxiPrep purification according to manufacturer’s 
instructions (Qiagen, Hilden, Germany). 
 
II.3.2 I-PpoI protein expression in Escherichia coli 
An inducible system of protein expression exploiting the lac operon regulatory process in 
Escherichia coli (E. coli) was used to generate sufficient volumes of his-tagged I-PpoI. BL21 
(DE3) competent E. coli (New England Biolabs, Hitchin, UK) were transformed with 500 ng of 
the (I-PpoI-his / pET-45b(+))  (Section II.3.1, Figure III.3B) and cultured overnight on lysogeny 
broth (LB)-agar plates supplemented with 100 µg/l ampicillin. The following day, ampicillin-
resistant clones were selected and cultured in a shaking incubator at 225 revolutions per minute 
(rpm) at 37˚C.  Cultures were scaled up and grown in LB supplemented with 100 µg/L 
ampicillin as well as 1 mM zinc acetate to allow for proper protein folding and stability. The 
optical density at a wavelength of 600 nm (OD600) was monitored periodically over time using 
the Ultraspec 2100 pro UV spectrophotometer (Amersham, GE Healthcare Life Sciences, 
Buckinghamshire, UK). Once an OD600 reading of approximately 0.4 was obtained, protein 
expression was induced by adding 1 mM Isopropyl-β-D-thio-galactoside (IPTG) and an 
additional 1mM zinc acetate to the culture. BL21 (DE3) cells were then harvested 3.5-4 hours 
later. Following a wash in PBS, and centrifugation at 8,000 rpm for 10 minutes at 4°C, pellets 
were resuspended in cold lysis buffer (25 mM MOPS-NaOH, 1.25 mM EDTA, 
deoxyribonuclease, and PMSF in PBS) supplemented with 1mM MgCl2 (AnalaR 
NORMAPUR®, VWR, East Grinstead, UK) and a protease inhibitor cocktail (Complete Mini 
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tablet) (Roche Applied Sciences, Burgess Hill, UK). Bacterial plasma membrane was disrupted 
using a French pressure cell press and cellular debris and membranes were separated from 
lysates by centrifugation at 4°C.  
II.3.3 I-PpoI protein purification 
Purification of his-tagged I-PpoI protein was performed using a nickel-nitrilotriacetic acid 
(NTA) purification system. Bacterial lysates were mixed with Nickel-NTA agarose beads 
(Qiagen, Hilden, Germany) to allow for binding of the his tag with nickel ions. Protein-bound 
beads were washed three times in wash buffer (50  mM NaH2PO4.H2O, 300 mM NaCl, 20 mM 
imidazole, pH 8) and the his-tagged I-PpoI protein was eluted from beads using elution buffer 
(50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole at pH 8.0) supplemented with the 
protease inhibitors (Roche Applied Sciences, Burgess Hill, UK). 15 µl of each wash and elution 
fraction were mixed with 3 µl sodium dodecyl sulfate (SDS) loading buffer (10% w/v SDS, 
50% glycerol, 5% β-mercaptoethanol, 0.4 M Tris pH6.8, and 0.6 % w/v bromophenol blue) and 
stored at -20°C. 
Protein samples were separated by SDS polyacrylamide gel electrophoresis (SDS-
PAGE) and gels were stained using Coomassie Blue to examine protein yield at each stage of 
wash and elution (Section II.4). Vivaspin™ centrifugal concentrators (Sartorius, Epsom, UK) 
were used to concentrate protein into storage buffer (0.5 M Tris pH 8.0, 2 mM EDTA, 50% 
glycerol, 75 mM KCl) supplemented with protease inhibitors (Roche Applied Sciences, Burgess 
Hill, UK). Protein concentration was assessed using the colorimetric DC assay (Bio-Rad, Hemel 
Hempstead, UK) according to supplier’s instructions. Purity of concentrated protein was 
assessed by SDS-PAGE electrophoresis and Coomassie Blue staining (Section II.4).  
II.3.4 In vitro I-PpoI plasmid assay 
In vitro activity of purified and concentrated his-tagged I-PpoI was verified using the I-PpoI 
site/ pcDNA3.1A(+) vector (Section II.3.1, Figure III.4A). Indicated concentrations of purified 
I-PpoI protein were incubated with 4 µg of plasmid DNA in I-PpoI buffer (Promega, 
Southampton, UK) diluted in 50 mM Tris-Hydrochloric acid (HCl) pH7.4, 1mM EDTA, 1 mM 
DTT, 10% glycerol and 100 ng/µl bovine serum albumin (BSA) (Promega, Southampton, UK). 
Protein digestion of plasmid DNA was performed at 37ºC for 45 minutes and was then inhibited 
by incubating samples at 60ºC for 20 minutes. Samples were diluted in 6x DNA loading buffer 
(Invitrogen ™, Paisley, UK) and loaded alongside a DNA ladder (Invitrogen ™, Paisley, UK) 
on gel made up of  1% agarose and 0.5µg/ml ethidium bromide intercalating agent in 
Tris/Borate/Ethylenediaminetetraacetic acid (TBE) buffer (89 mM Tris base, 89 mM Boric acid, 
2 mM EDTA). DNA was separated with 100 V for approximately 1 hour in TBE buffer and UV 
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illumination of the gel was used to visualise ethidium bromide labeled DNA bands. Images 
were captured with a gel imaging system (InGenius, Syngene, Cambridge, UK). Efficiency of 
the DNA digestion was assessed by comparing the size of the DNA product after each digestion 
with that of an undigested plasmid control.  
II.3.5 Delivery of I-PpoI to cells 
Purified his-tagged I-PpoI protein and/or Alexa-Fluor 488 (AF-488) (Invitrogen™, Paisley, 
UK) were delivered to cells using the synthetic peptide carrier Pep-1 Cysteamine (Anaspec, 
Cambridge, UK). First, cells were seeded onto glass coverslips and grown in normal growth 
medium for 24-48 hours. Next, peptide carrier and protein complexes were allowed to form for 
30 minutes at 37°C in 500 µl serum-free MEM per sample. A peptide: protein molar ratio of 
1:20-1:40 was used for efficient macromolecule formation (Morris et al. 2001). 1 ml of normal 
growth medium was then added to the volume and media on cells was replaced with the peptide: 
protein complex mixture. At indicated time points following I-PpoI protein delivery, cells were 
fixed for immunofluorescence analysis. DSB induction and repair was assessed by 
immunofluorescence labelling of ?H2AX and/or 53BP1 (Section II.6). 
II.4 SDS-PAGE protein analysis 
II.4.1 Preparation of cell extracts  
Cells were seeded in tissue culture flasks (1x106 cells per flask) and grown for 48 hours. Cells 
were washed in 1 mM EDTA and trypsinized with 0.25% trypsin/EDTA. Trypsin was quenched 
by adding an equal volume of growth medium, and cells were collected and pelleted by 
centrifugation at 1500 rpm for 5 minutes. Cell pellets were washed twice in ice cold PBS, and 
pellets were lysed on ice, in ~20 µL of lysis buffer per 1 million cells.  
For whole cell extracts, cells were lysed in Lysis Buffer A  (50 mM Tris-HCl, 2 mM 
EDTA, 2 mM EGTA, 25 mM NaF, 25 mM B-glycerophosphate, 0.1 mM NaOrthovanadate, 
0.2% Triton X-100, and 0.3% NP-40)  containing 500 mM NaCl and supplemented with 
protease inhibitor (Sigma Aldrich, Gillingham, UK or Roche Applied Sciences, Burgess Hill, 
UK) and phosphotase inhibitor cocktails (Thermo Fisher, Loughborough, UK or Roche Applied 
Sciences, Burgess Hill, UK) for one hour, vortexing every 15 minutes. Pulsed sonication was 
applied to lysates in a 4°C water bath for 15 minutes and lysates were centrifuged at 14,000 rpm 
at 4°C for 20 minutes to separate any remaining cellular residue.  
For fractionation of soluble and insoluble proteins, cells were scored and an equal 
number of cells for each sample were first lysed in Lysis Buffer A containing 150 mM NaCl 
and supplemented with protease and phosphatase inhibitors as described above. One hour later, 
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extracts were centrifuged at 14,000 rpm at 4°C for 10 minutes and the supernatant, containing 
soluble proteins, was transferred to fresh pre-chilled tubes. Pellets were resuspended in Lysis 
Buffer A containing 300 mM NaCl and supplemented as described above and pulsed sonication 
was applied to lysates in a 4°C water bath for 15 minutes.  
All cellular lysates were stored at -80°C, avoiding multiple freeze-thaw cycles to 
minimize protein degradation. Protein concentrations of whole cell extracts and extracts 
containing unbound proteins were estimated using the Bradford Protein Assay (Bio-Rad, Hemel 
Hempstead, UK), according to manufacturer’s instructions, at a UV absorbance of 595 nM. 
Prior to SDS-PAGE, the volume of lysate needed to achieve the desired amount of protein was 
transferred to a new tube and diluted in 2x high SDS loading buffer (5% SDS, 10% glycerol, 
10% β-mercaptoethanol, 0.125 M Tris pH6.8, and 0.2% w/v bromophenol blue).  Insoluble 
fractions were directly diluted in 2X SDS loading buffer. Samples diluted in SDS loading buffer 
were boiled in a 99°C water bath for 5-10 minutes to denature protein, centrifuged briefly and 
loaded onto pre-cast polyacrylamide gels as described below. 
 
II.4.2 Gel electrophoresis 
Proteins were separated using the Laemilli SDS-PAGE system.  Resolving gels made up of 
0.375 M Tris pH8.8, 0.1% SDS, 0.1% ammonium persulfate (APS), 0.1% 
Tetramethylethylenediamine (TEMED) (Fluka, Sigma-Aldrich, Gillingham, UK), and either 
8%, 10%, or 17.5%  polyacrylamide (Protogel, National Diagnostics, Fisher Scientific, 
Loughborough, UK) and stacking gels comprised of 0.125 M Tris pH6.8, 0.1% SDS, 0.1% 
APS, 0.1% TEMED, and 4%, 5%, or 6% polyacrylamide (Table II.2) were prepared prior to 
electrophoresis. Samples were loaded onto pre-cast polyacrylamide gels in 1 mm gel cassettes 
(Invitrogen ™, Paisley, UK). In order to monitor migration of proteins of various sizes, the 
250kDa Precision Plus Protein™ standard (Bio-Rad, Hemel Hempstead, UK) was also loaded 
onto each gel. Polyacrylamide gels were resolved with 100-150 volts (V) in SDS running buffer 
(25 mM Tris-base, 192 mM Glycine, and 0.1% w/v SDS, pH8.3) for 1-2.5 hours using the X-
cell SureLockTM Mini-Cell electrophoresis system (Invitrogen ™, Paisley, UK). Gels were 
removed and subjected either to Coomassie blue staining or immunoblotting.  
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A. Resolving gels. 
Reagent 8% resolving 10% resolving 17.5% resolving 
ddH2O 2.7 ml 2.2 ml 0.2 ml 
30% polyacrylamide 2.13 ml 2.67 ml 4.67 ml 
1 M Tris pH 8.8 3 ml 3 ml 3 ml 
10% SDS 80 µl 80 µl 80 µl 
10% APS 80 µl 80 µl 80 µl 
TEMED 8 µl 8 µl 8 µl 
Total Volume 8 ml 8 ml 8 ml 
B. Stacking gels. 
Reagent 4% stacking 5% stacking 6% stacking 
ddH2O 3.00 ml 2.812 ml 2.6 ml 
30% polyacrylamide 0.67 ml 0.833 ml 1 ml 
0.5 M Tris pH 6.8 1.25 ml 1.25 ml 1.25 ml 
10% SDS 50 µl 50 µl 50 µl 
10% APS 50 µl 50 µl 50 µl 
TEMED 5 µl 5 µl 5 µl 
Total Volume 5 ml 5 ml 5 ml 
Table II.2. 1mm mini SDS-PAGE gels. 
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II.4.3 Coomassie blue staining 
For analysis of total protein levels following electrophoresis of purified I-PpoI protein samples 
(Section II.3), gels were rinsed in water and incubated in Coomassie brilliant blue staining 
solution (0.05% Brilliant Blue R-250, 50% methanol, and ddH2O) for 15 minutes on a shaker. 
Gels were rinsed in ddH2O and washed three times in de-stain buffer (10% v/v acetic acid, 40% 
v/v methanol in ddH2O) for 15 minutes each wash. Gels were dried using a gel dryer and 
vacuum system and were imaged with an Epsom (Hemel Hempstead, UK) scanner.   
II.4.4 Immunoblotting 
Proteins were transferred from gels onto pre-wet 0.4 µm Hybond™-P  polyvinylidene difluoride 
(PVDF) (GE Healthcare Life Sciences, Buckinghamshire, UK) or 0.2 µm nitrocellulose (Bio-
Rad, Hemel Hempstead, UK) membranes in cold transfer buffer (25 mM Tris, 192 mM Glycine, 
20% methanol, pH8.3) with 100 V for 1 hour using the Mini Trans-Blot® system (Bio-Rad, 
Hemel Hempstead, UK) according to manufacturer’s instructions. Membranes were then 
washed with Tris-buffered saline (TBS) (150mM NaCl, 10mM Tris, pH7.5) with 0.1 % Tween-
20 (TSB-T) for 5 minutes on a shaker.  
Membranes were blocked with gentle shaking for 20-60 minutes at room temperature in 
blocking buffer, consisting of 5% w/v non-fat dried milk (NFDM) (Marvel, Premier Foods, St. 
Albans, UK) or 5% BSA in TBS-T. Following a brief wash in TBS-T, membranes were then 
incubated with primary antibodies (Table II.3) diluted in blocking buffer with gentle shaking for 
1 hour at room temperature or overnight at 4°C. Membranes were then subjected to three 10 
minute washes in TBS-T with vigorous shaking. Anti-goat, rabbit, or mouse-horseradish 
peroxidase (HRP)-conjugated secondary antibodies (Dako, Cambridgeshire, UK) were diluted 
at 1:2000 in blocking buffer and applied to membranes for 45-60 minutes at room temperature 
with gentle shaking. Membranes were again subjected to three 10 minute washes in TBS-T, 
excess moisture was removed, and enhanced chemilluminescence (ECL) detection reagents 
(Pierce Biotechnology, Thermo Scientific, Loughborough, UK) were applied according to 
manufacturers’ instructions. Membranes were exposed onto high performance 
chemilluminescence film (Amersham, GE Healthcare Life Sciences, Buckinghamshire, UK) to 
visualise protein bands. Films were developed using an x-ray film processor (Xograph, 
Gloucester, UK) and imaged with an Epsom scanner (Hemel Hempstead, UK).  
Semi-quantitative analysis was performed on tagged image file format (tiff) files from 
scanned images of films using Image J software (National Institutes of Health, 
http://rsbweb.nih.gov/ij/).  
  
92 
 
Protein Clone/# Raised against Species Supp kDa Dilution 
ORC1 N-17 N-terminus Goat polyclonal SCB 120 1:200 
ORC2 H-300 C-terminus 
(aa275-577) 
Rabbit polyclonal SCB 70 1:200 
ORC4 L-15 Internal region Goat polyclonal SCB 45 1:200 
ORC6 FL-252 Full length (aa1-
252) 
Rabbit polyclonal SCB 30 1:200 
CDT1 H-300 C-terminus 
(aa247-546) 
Rabbit polyclonal SCB 65 1:200 
CDC6 180.2 Full length Mouse 
monoclonal 
SCB 62 1:200 
KAP-1 3831 C-terminus 
(aa741-753) 
Goat polyclonal AB 110 1:1000 
p53 DO-1 N-terminus   
(aa11-25) 
Mouse 
monoclonal 
SCB 53 1:200 
β-actin 8226 N-terminus     
(aa1-100) 
Mouse 
monoclonal 
AB 42 1:10,000
Table II.3. Primary antibodies for immunoblotting. AB: Abcam® (Cambridge, UK); SCB: 
Santa Cruz Biotechnology, Inc. (Heidelberg, Germany); Supp: supplier 
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II.5 DNA damage-inducing reagents and IR 
Cells were grown for 48 hours prior to treatment with DNA damage-inducing reagents unless 
otherwise stated.  
For experiments involving IR treatment, cells were grown on glass coverslips in tissue 
culture dishes and were irradiated using a 137Cs source (9 Gy per minute) or with 250 kV X-
rays, delivered at 12 mA (0.5 Gy/minute). The ATM inhibitor (ATMi), KU-55933 (Calbiochem, 
VWR, East Grinstead, UK), was administered to cells at 10 µM 30 minutes prior to IR or I-PpoI 
transduction. KU-55933 is reported to inhibit ATM kinase activity at low concentrations, with 
the half maximum inhibitory concentration (IC50) of ~13 nM, and at a concentration of 10 µM, 
this compound was not found to inhibit other kinases in a commercially-available panel 
(Hickson et al. 2004). The DNA-PK inhibitor (DNA-PKi), NU-7441/KU-57788 (a gift from 
KuDOS Pharmaceuticals) is a highly selective inhibitor of DNA-PK with the IC50 of ~14 nM 
and at a concentration of 10 µM, this compound was also not found to inhibit other kinases in a 
commercially-available panel (Leahy et al. 2004). DNA-PKi was administered to cells at 10 µM 
30 minutes prior to IR or I-PpoI transduction. 4µM of the DNA polymerase inhibitor, 
aphidicolin, was added at the time of IR to prevent cells irradiated in S-phase from progressing 
into G2-phase and to distinguish S-phase cells during analyses.  
For experiments examining the response to replication stress, serial dilutions of reagents 
were initially performed in an appropriate solvent (PBS or DMSO) prior to addition to cells in 
growth medium. HU or H2O2 (Acros Organics, Thermo Scientific, Loughborough, UK) were 
used at concentrations indicated for 24 hours (unless otherwise stated). Cells were then washed 
three times in PBS and incubated in fresh growth media for the indicated times. UCN-01, a 
Chk1/2 kinase inhibitor (Busby et al. 2000; Graves et al. 2000), was either administered as 
single agents to cells at various doses, as indicated, or were added in combination with HU. For 
combination treatments, 50 nM UCN-01 were added 1 hour prior to treatment with HU and 
were re-administered at the same dose following release from HU. Overexpression of the c-Myc 
oncogene was induced in BJ-MYC-ER cells via the addition of tamoxifen to cells at the 
indicated doses.  
 
II.6 Immunofluorescence 
 
For immunofluorescence analysis of adherent siRNA-treated cell lines, cells were transfected 
with siRNA oligonucleotides as indicated (Section II.2), seeded onto glass coverslips in 30 mm 
tissue culture dishes, and grown for 48 hours. Cells were then treated with IR/damage-inducing 
agents (Section II.5) or were incubated with purified I-PpoI protein mixed with Pep-1 
Cysteamine (Section II.3). At the indicated time, cells were then washed in PBS, fixed in 3% 
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w/v paraformaldehyde (PFA)/2% w/v sucrose/PBS for 10 minutes, and washed again in PBS. 
Coverslips were stored in PBS at 4°C.  
Permeabilization was performed at room temperature for 3 minutes in 0.2% w/v Triton 
X-100/PBS. Following three washes in PBS, cells were incubated with the indicated primary 
antibodies (Table II.4) diluted in 2% w/v BSA/PBS for one hour at room temperature. Then, 
cells were washed three times and incubated with anti-mouse- Fluorescein isothiocyanate 
(FITC)-conjugated or anti-rabbit-Cyanine 3(Cy3)-conjugated secondary antibodies diluted at 
1:200 in 2% w/v BSA/PBS for 30 minutes at room temperature away from light. Cells were 
washed again and DNA was fluorescently labeled by incubating cells in 1µg/ml DAPI/PBS for 
10 minutes away from light. Following a final three washes in PBS, cover slips were mounted 
onto glass slides using Vectashield mounting media (Vector Laboratories, Peterborough, UK) 
and edges were sealed using nail varnish. Slides were stored at 4°C prior to analysis.  
Fixation and immunofluorescence labelling in LBLs was performed as described in 
Section II.6.3. 
 
Protein Clone/ # Raised against Species Supp Dilution 
H3K9me3 8898 aa1-100 Rabbit AB 1:800 
H4K20me3 9053 aa1-100 Rabbit AB 1:200 
HP1(αβγ) FL-191 Full length (aa1-191) Rabbit SCB 1:100 
CENP-F ab5 C-terminus Rabbit AB 1:1000 
p-H3(Ser10) 06-570 phosphorylated Ser10 Rabbit UCM 1:400 
53BP1 21083 C-terminus Rabbit AB 1:1000 
γH2AX 18311 phosphorylated Ser139  Mouse AB  1:800 
Table II.4. Primary antibodies for immunofluorescence assays. AB: Abcam® (Cambridge, 
UK); SCB: Santa Cruz Biotechnology, Inc. (Heidelberg, Germany); Supp: supplier; UCM: Upstate & 
Chemicon, Merck Millipore, Watford, UK). 
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II.6.1 DSB repair analysis in G0/G1 cells 
DSBs can be measured by the appearance of distinct γH2AX foci and repair of these breaks can 
be determined by the rate of disappearance of the foci (Lobrich et al. 2010; Brunton et al. 2011). 
Given the fact that DSB repair pathway choice varies with cell cycle phase (Beucher et al. 
2009), methodology was used to distinguish G0/G1-, S-, G2-, and M-phase cells during 
analysis. To achieve this, 4µM aphidicolin was added at the time of damage (Section II.5), 
which prevents cells damaged in S-phase from progressing through the cell cycle and enables 
discrimination of these cells, given the striking pan-nuclear γH2AX signal observed rapidly 
after aphidicolin-induced S-phase damage. Previous studies have demonstrated that the repair of 
DSBs in G0/G1 and G2 is not affected by aphidicolin (Deckbar et al. 2007; Shibata et al. 2010). 
In addition, co-staining slides with an antibody to the cell cycle marker, centromere protein F 
(CENPF) (Table II.4), enables the discrimination of G2- or M-phase cells from other phases of 
cell cycle. Mitotic cells may be distinguished from G2-phase cells by morphological changes in 
chromatin condensation, which may also be observed in the DAPI channel (Beucher et al. 2009; 
Lobrich et al. 2010; Shibata et al. 2010).  
The number of γH2AX foci per G0/G1 nucleus were manually scored in >90 cells per 
condition (unless otherwise stated) using a 100x lens on a Zeiss Axioplan (Carl Zeiss Ltd., 
Cambridge, UK) microscope. Images were acquired with identical exposure settings using 
SimplePCI software and a digital camera (Hamamatsu, Welwyn Garden City, UK). Data is 
presented in box plots including all data from three independent experiments or in bar graphs 
depicting the mean values +/- SD from at least three independent experiments. Statistical 
significance was determined using t-test or Mann-Whitney analyses in SigmaPlot (Systat 
Software, Inc., Hounslow, UK). 
 
II.6.2 Analysis of replication stress-induced damage  
The accumulation of S-phase damage was assessed in cells treated with damage-inducing agents 
(Section II.5) using immunofluorescence labelling of γH2AX, the cell cycle marker CENPF 
(Table II.4), and DNA (DAPI). As described above, S-phase damaged cells display a striking 
pan-nuclear γH2AX signal with minimal CENPF signal (termed γH2AX+). The fraction of 
γH2AX+cells was determined by manually scoring >500 cells per condition. Plots represent the 
mean values +/- SD from at least three independent experiments. Images were acquired as 
described above using a 40x lens.  
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II.6.3 G2/M checkpoint assay 
To assess efficiency of the IR-induced G2/M checkpoint induction, cells were treated with the 
indicated doses of IR, treated with aphidicolin (Section II.5) to prevent S-phase damaged cells 
from progressing through cell cycle, and harvested after 1 or 2 hours for analysis of LBLs or 
fibroblasts, respectively. For examination of the maintenance of this checkpoint, cells were 
treated with 2Gy IR and aphidicolin and were grown for the indicated times prior to harvesting.   
For analysis of the G2/M checkpoint using LBLs, cells were centrifuged at 18,000 RPM 
for 3 minutes, pellets were resuspended in hypotonic buffer (75 mM KCl), and cells were 
incubated for 10 minutes at 37°C to allow for cell swelling. Cells were then centrifuged at 700 
RPM for 5 minutes and resuspended in 1µg/ml DAPI/PBS. LBLs were then mounted onto glass 
slides by cytospinning (700 RPM for 4 minutes), fixed with 3% w/v PFA/2% w/v sucrose/PBS 
for 10 minutes, and washed again in PBS. Mitotic cells were identified by characteristic changes 
in chromatin condensation, as observed by DAPI analysis. 
For analysis of the G2/M checkpoint in fibroblasts, cells were labelled with 1µg/ml 
DAPI/PBS and an antibody to the M-phase marker, Histone H3 phosphorylated at Ser10 (p-
H3(Ser10))  (Table II.4). As described previously (Brunton et al. 2011), mitotic cells were 
identified by positive labelling with p-H3(Ser10) and changes in chromatin condensation, as 
observed by DAPI analysis. 
For all G2/M checkpoint analysis, >400 cells were manually scored per condition. Plots 
depict mean values +/- SD from at least three independent experiments unless otherwise stated.  
 
II.6.4 γH2AX foci expansion into chromocentres 
 
Exponentially growing but nearly confluent NIH3T3 MEFs were transfected with siRNA 
oligonucleotides (Section II.2), seeded onto glass coverslips in tissue culture dishes, and grown 
to confluency. Cells were then treated with 3Gy IR and aphidicolin (Section II.5), grown for 20-
30 minutes, and fixed. Labelling with DAPI, anti-γH2AX, and anti-p-H3(Ser10) was performed 
to enable analysis of DSBs in G0/G1 and to identify DAPI-dense heterochromatin 
(chromocentres) as previously described (Brunton et al. 2011).  
Z-stacked images of G0/G1 cells were taken using a 100x lens, an DeltaVision RT 
Olympus IX70 deconvolution microscope and digital camera, and softWoRx® Suite software  
(Applied Precision, Inc., Image Solutions, Preston, UK). For each cell, 25 sections (~5 µm 
thick) were imaged. Images were deconvolved and regions of γH2AX foci colocalising with 
DAPI-dense regions of HC (chromocentres) were identified in the red channel using 
SoftWoRx®. To assess the size of overlap between γH2AX foci and chromocentres, the total 
area of overlapping regions (depicted in the red channel) was quantified per cell using ImageJ 
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software (National Institutes of Health, Bethesda, Maryland, USA) and normalised to 
chromocentre number. For each experimental condition, all normalised cellular values were 
then averaged. Averaged values were further normalised to the average area of overlap per 
chromocentre in siControl-treated cells, generating values referred to as arbitrary units (A.U.).  
To assess the size of γH2AX foci regions which do no overlap with chromocentres, the area of 
each γH2AX foci (the square pixel number of regions microscopically detected in the green 
channel) was determined using ImageJ. Regions which overlap with chromocentres (detected in 
the red channel as described above) were eliminated from the analysis. The square pixel number 
of non-overlapping γH2AX foci regions was averaged for each experimental condition. All 
plots depict mean values +/- SD >2 independent experiments (n>200 chromocentres). 
 
II.6.5 Analysis of nuclear signal intensity 
siRNA-transfected cells were grown on glass coverslips for 48 hours, left untreated or treated 
with 3Gy IR and aphidicolin (Section II.5), grown for 20-30 minutes, and fixed. Coverslips 
were then stained with DAPI and anti-γH2AX as well as anti-H3K9me3, H4K20me3, or HP 
(αβγ) (Table II.4). Visualisation, imaging, and analysis were performed using a 40x objective on 
a Zeiss Axioplan (Carl Zeiss Ltd., Cambridge, UK) microscope. Images were acquired with 
identical exposure settings using SimplePCI software and a digital camera (Hamamatsu, 
Welwyn Garden City, UK). Nuclear intensity was quantified using SimplePCI in 40-100 cells 
per condition. Box plots depict representative results from a single experiment. Statistical 
significance was determined using t-test or Mann-Whitney analyses in SigmaPlot (Systat 
Software, Inc., Hounslow, UK).At least three independent experiments were performed to 
assess reproducibility.  
II.7 Cell viability, clonogenic survival, and growth rate assays 
II.7.1  Viability assay 
Cells transfected with siRNA (Section II.2) were seeded in 96 well tissue culture dishes (700 
cells per well), grown, and left untreated or treated with damage-inducing reagents (Section 
II.5). Test conditions were carried out in triplicate wells within each dish. Unless otherwise 
stated, viability was assessed seven days after seeding, using the CellTiter-Blue® viability assay 
(Promega, Southampton, UK), which measures the ability of cells to actively metabolize 
resazurin, a redox dye, into resorufin, a fluorescent product. 20 µl CellTiter-Blue® reagent was 
added to 100 µl cell growth medium on cells and to negative control wells (containing growth 
medium but no cells). Dishes were then incubated for 3-4 hours at 37°C in 5% CO2 atmosphere, 
and readings of resorufin fluorescence were taken using the GloMax® multiwall plate reader 
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(Promega, Southampton, UK). Background correction was performed by subtracting the mean 
fluorescence reading from negative control wells from all other readings.  
For assessment of the impact of siRNA treatment on viability in the absence of 
exogenous DNA damage, the mean background-corrected value of the test siRNA-transfected 
but untreated controls was normalized to that of the siControl. Plots depict mean viability (% 
siControl) +/- SD from at least three independent experiments. 
To examine the impact of siRNA treatment on proliferation in the presence of damage-
inducing agents, viability values were obtained by normalizing background-corrected readings 
to the mean value of siRNA-transfected but untreated controls for each siRNA condition. 
Representative plots depict mean viability (% untreated control) +/- standard deviation (SD) 
from triplicate samples (y-axis) versus concentration of the damage inducing agent (x-axis). 
Sensitivity to DNA damage-inducing agents was estimated by calculating the IC50 from 
triplicate dose response curves in each dish with SigmaPlot (Systat Software, Inc., Hounslow, 
UK) using the five-parameter logistic nonlinear regression model. The impact of siRNA 
depletion on sensitivity was compared between cell lines by normalizing the IC50 value of the 
test siRNA to that of the siControl condition. Plots depict mean IC50 values (% siControl) +/- 
SD from at least three independent experiments.  
 
II.7.2 Clonogenic survival 
II.7.2.a Clonogenic survival in U2OS cells 
U2OS cells were transfected with siRNA oligonucleotides (Section II.2), seeded at ~100 cells 
per well in tissue culture dishes, grown for 48 hours, and treated with HU for 24 hours (Section 
II.5).  Dishes were then incubated for 10 days, stained with 1% w/v methylene blue (Fisher 
Scientific Loughborough, UK), washed twice with ddH2O, and left to dry overnight at 37°C. 
Colonies of at least 50 cells were scored manually using the 1x objective on a light microscope. 
The surviving fraction was normalized to that of the untreated control. Plots depict mean values 
+/- SD from at least three independent experiments.  
II.7.2.b Clonogenic survival in 1BR3hTERT cells 
1BR3hTERT cells were transfected with siRNA oligonucleotides (Section II.2), grown for 48 
hours, and treated with HU for 48 hours (Section II.5).  24 hours prior to release from HU, 
feeder cells were irradiated with 35 Gy γ-rays (Section II.5) and plated in MEM supplemented 
with 15% newborn calf serum and additional supplements (Section II.1) at 4x104 cells/dish in 
10 cm dishes. 24 hours after plating feeder cells, 1BR3hTERT cells were washed in 1XPBS, 
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trypsinized, and seeded at 100 cells per dish onto feeder plates.  Dishes were then incubated for 
21 days and colonies were labeled and assessed as described in Section II.7.2.a.  
II.7.3 Growth rate studies 
Exponentially growing cells were seeded at densities comparable to those used for the viability 
assay. Following incubation in normal growth medium at 37°C in 5% CO2 atmosphere for 
indicated times, cells were harvested by trypsinization. Non-viable cells were labeled with 
trypan blue (Gibco®, Invitrogen ™, Paisley, UK) and healthy viable cells were manually 
scored. Cell number was normalized to the initial seeding density.  Results represent mean 
values +/- SD from three experiments. Approximate doubling times were calculated from 
growth curves.  
II.8 Flow cytometry 
Cells were transfected with siRNA oligonucleotides (Section II.2), grown in tissue culture flasks 
for 48 hours, and treated with HU for 24 hours (Section II.5). 30 minutes prior to harvesting 
cells at the indicated times, newly synthesized DNA was labeled with 50 µM of the nucleoside 
analogue bromodeoxyuridine (BrdU) (BD, Oxford, UK) for 30 minutes at 37°C in 5% CO2 
atmosphere. Cells were then collected by trypsinization, washed twice at room temperature in 
1% w/v BSA/PBS with 15 minute 500 g spins, resuspended into 200 µl cold PBS, and fixed by 
slowly pipetting cell suspension into 5 ml 70% aqueous ethanol in polypropylene tubes 
(Falcon™, BD, Oxford, UK).  Fixed cells were then incubated at -20°C for at least 24 hours.  
BrdU staining was carried out with a FITC-conjugated antibody (BD, Oxford, UK) as 
described by the manufacturer. Briefly, fixed cells were centrifuged at 500 g for 10 minutes at 
10°C. Denaturation of DNA was achieved by slowly adding 1 ml 2 M HCl/ddH20 while 
loosening the pellet, and cells were incubated at room temperature for 30 minutes. Cells were 
centrifuged again as described above and 0.1 M sodium tetraborate/water was added to cells for 
2 minutes to neutralize the acid.  Cells were pelleted and washed once in 1% BSA/PBS or 
directly incubated with the FITC-conjugated BrdU antibody diluted 20-25 fold in 1% 
BSA/PBS/0.25% Tween-20 for 30-60 minutes at 37°C or room temperature away from light. 
After a final centrifugation, DNA was stained with 10 µg/ml propidium iodide (PI) and 
0.5 mg/ml ribonuclease (RNAse) in PBS for 10-20 minutes.  
Cellular BrdU and PI levels were detected by flow cytometry using FACSCanto™  
instrumentation (BD, Oxford, UK) and analysed using FACSDiva™ (BD, Oxford, UK) and 
WinMDI2.9 (The Scripps Research Institute, La Jolla, California, USA, 
http://facs.scripps.edu/software.html) software.  Gating for specific cell cycle and BrdU-labelled 
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(BrdU+) populations was determined using experiment controls and applied to all samples 
within each experiment.  
PI histograms are representative of reproducible results. Dot plots depict representative 
images of BrdU versus PI staining; boxed regions containing data points indicate BrdU+ cells 
and adjacent numbers representing the BrdU+ fraction. Bar plots depict mean values +/- SD 
from at least three independent experiments.  
 
II.9 Complementation analysis 
II.9.1 ORC1-GFP plasmid 
A vector for expression of green fluorescent protein (GFP)-tagged ORC1 (ORC1-GFP) 
(Bicknell et al. 2011b) and empty vector were provided by Dr. Andrew Jackson. The coding 
sequence of ORC1 from the open reading frame shuttle clone IOH9757 (ImaGene) was cloned 
into a GFP epitope–tagged mammalian expression vector using Gateway cloning (Invitrogen ™, 
Paisley, UK). 
II.9.2 ORC1 complementation in LBLs 
GM02188 (WT) or ORC1-P1 LBLs in log phase growth were transfected with 2 µg empty 
vector or ORC1-GFP using GeneJuice® transfection reagent (Novagen/Merck Chemicals, 
Nottingham, UK) according to manufacturer’s instructions every 24 hours for 72 hours. 
Efficiency of the G2/M checkpoint was performed as described in II.6.3 in cells positive for 
GFP signal.  
II.9.3 ORC1 complementation in hTERT fibroblasts 
1BR3hTERT (WT) or ORC1-P4hTERT cells were grown for 48 hours prior to transfection to 
achieve log phase growth. Cells were then transfected with indicated concentrations of empty 
vector or ORC1-GFP using Metafectene® Pro transfection reagent (Biotex, Planegg, Germany) 
according to manufacturer’s instructions. Viability was assessed as in Section II.7.1 and 
replication associated DNA damage was assessed as in Section II.6.2 in cells positive for GFP 
signal.  
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III Examination of the role of Artemis in DSB repair during G0/G1 
using a novel system of site-specific break induction 
III.1 Introduction 
III.1.1 The Artemis endonuclease and DSB repair 
Artemis, a member of the metallo-β-lactamase family of nucleases, functions in both V(D)J 
recombination and the slow component of DSB repair at a subset of breaks (Ma et al. 2002; 
Riballo et al. 2004). Artemis is classified as an endonuclease and has the capacity to cleave a 
variety of DNA structures including 5’ or 3’ overhangs, flaps, gapped substrates, hairpins, 
pseudo Y structures, stem-loops, symmetrical bubbles, heterologous loops, and gapped DNA 
(Ma et al. 2005c).  Artemis consists of an N-terminal β-lactamase domain (aa1-135) and a β-
CASP domain (aa155-385) (Ma et al. 2005b) (Figure III.1.A). The C-terminal region of Artemis 
contains multiple PIKK target phosphorylation sites and appears to represent a regulatory region 
(Ma et al. 2005b; Goodarzi et al. 2006). While Artemis is phosphorylated by ATM in response 
to IR (Riballo et al. 2004), mutation of the phosphorylation sites does not impact upon DSB 
repair (Goodarzi et al. 2006). The function of these phosphorylation events still remains 
unknown. 
Artemis was originally identified as the causal genetic defect in a group of Athabascan-
speaking Native Americans with severe combined immunodeficiency (SCID) (SCID-A) (Li et 
al. 1998; Moshous et al. 2001). Mutations in Artemis were also identified in a subset of SCID 
patients with increased cellular radiation sensitivity (RS-SCID) (Moshous et al. 2001). The 
absence of T and B cells and severe immunodeficiency observed in Artemis-defective SCID 
reflects the critical role of Artemis in V(D)J recombination (Jackson et al. 1995). V(D)J 
recombination, which generates sequence diversity of T- and B-cell receptors, involves the 
induction of DSBs by the lymphocyte-specific recombination-activating genes 1 and 2 (RAG1 
and RAG2) proteins in recombination signal sequences near the V(D)J segments. A DNA 
hairpin is generated at each coding end which must subsequently be opened to enable joining of 
segments by the NHEJ machinery. In complex with DNA-PK, Artemis is capable of performing 
the endonucleolytic cleavage 3’ to RAG-generated hairpins (Ma et al. 2001) and alterations in 
this endonuclease lead to defects in the hairpin opening stage of V(D)J recombination 
(Mansilla-Soto et al. 2003). Therefore the critical function of Artemis in V(D)J recombination is 
thought to occur at the hairpin opening stage. 
As introduced in Section I.3, in addition to this role in V(D)J recombination, Artemis is 
known to function in the repair of a subset of DSBs. Cells lacking Artemis display a defect 
exclusively in the slow repair of IR-induced DSBs during G0/G1 or G2-phase, a defect similar 
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to that observed in ATM-defective cells (Riballo et al. 2004) or in cells depleted for the 
mediator proteins (Noon et al. 2010). As introduced in Section I.3.4, the role of ATM in DSB 
repair during both G0/G1 and G2 involves the phosphorylation of KAP-1 on serine 824, which 
is proposed to promote localised decondensation of heterochromatin and DSB repair (Ziv et al. 
2006; Goodarzi et al. 2008). The role of the mediator proteins such as 53BP1 and RNF8 is 
thought to involve the concentration of ATM activity at the site of the break (Noon et al. 2010). 
Under conditions of abnormal global chromatin compaction, the requirement for ATM and the 
mediator proteins in DSB repair can be bypassed since localised heterochromatin 
decondensation is no longer needed. Disruption of heterochromatin, for example, via depletion 
of KAP-1, the histone deacetylases (HDAC1/2), HP-1α/β/γ, MECP2, Suv39H1/2, DNMT3B  
(Goodarzi et al. 2008; Brunton et al. 2011) and SETDB1 (Y. Katsuki, unpublished findings) 
results in an alleviation of the DSB repair defect during G0/G1 as observed in cells depleted for 
ATM or the mediator proteins.   
Similar to observations made in ATM-deficient cells, DSBs persisting in cells lacking 
Artemis have been demonstrated to localise to heterochromatic regions. Recent results from our 
lab have demonstrated that DSBs arising endogenously or from treatment with the oxidative 
damaging agent tert-butyl hydroperoxide (TBH) localise to regions of heterochromatin marked 
by KAP-1 serine 824 phosphorylation in Artemis-deficient cells (Woodbine et al. 2011). Further 
support for a role of Artemis in heterochromatic DSB repair has come from studies exploiting 
IR. 24 hours following IR, persisting DSBs localise to heterochromatin-rich chromocentres in 
Artemis-depleted MEFs (H. Brunton, unpublished findings) (Figure III.1.B) or to 
phosphorylated KAP-1 foci in Artemis defective human fibroblasts (Woodbine et al. 2011) to a 
similar extent as in Ataxia-telangiectasia patient cells which lack ATM. Also similar to ATM-
deficient cells, cells lacking Artemis display a defect in a subset of DSBs repaired by NHEJ 
during G0/G1 (Riballo et al. 2004; Darroudi et al. 2007) and by HR during G2 (Beucher et al. 
2009). However, unlike observations made in cells defective in ATM signalling, the 
requirement of Artemis for repair of IR or TBH-induced DSBs is not relieved in Artemis-
deficient cells by depletion of KAP-1 (Woodbine et al. 2011). These results suggest that 
Artemis does not participate in heterochromatin relaxation, and instead has a role in promoting 
NHEJ or HR-mediated heterochromatic DSB repair distinct to that of ATM and downstream of 
KAP-1 phosphorylation. Overall, while findings from recent studies suggest that Artemis 
functions in the slow repair of heterochromatic DSBs, the precise nature of this role is still being 
investigated. 
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Figure III.1 The Artemis endonuclease and localisation of DSBs persisting in Artemis-
depleted cells A. Schematic depicting domains in the Artemis protein. B. Images of 
immunofluorescence labelling of γH2AX (red) and DAPI (green) in Control or Artemis siRNA-
transfected NIH3T3 MEFs 24 hours after 3 Gy IR (H. Brunton, unpublished findings). 
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The relatively low percentage of IR-induced DSBs that localise to heterochromatic 
regions of the genome poses limitations for monitoring IR-induced heterochromatic DSB repair. 
As introduced in Section I.2.2, IR induces a variety of DNA lesions, including SSBs that 
outnumber DSBs 20:1 (Bradley et al. 1979). Given that the lesions induced by IR occur 
indiscriminately across the genome and that most DNA is organised into euchromatin at any 
given time, the majority of these lesions do not tend to be localised to heterochromatin (Cowell 
et al. 2007; Goodarzi et al. 2008). Aside from generating DNA damage by IR, several systems 
of site-specific DSB induction exist, but these breaks rarely localise to heterochromatin. Further, 
these methods often require stable integration of a target sequence for a cleaving enzyme into 
the genome of a cell line, therefore restricting experiments to particular cell lines. These systems 
of site-specific DSB induction are not ideal for monitoring the kinetics of repair by enumeration 
of γH2AX foci since they are plagued by restrictions such as low cutting frequency and the 
capacity of active enzymes to re-cut at the same site.  
To further examine the requirement for Artemis in DSB repair during G0/G1 and avoid 
the limitations introduced by DSB induction using IR or other existing systems of DSB 
induction, I have utilised a novel system introduced by Dr. Jie Wen and Dr. Patrick Concannon 
exploiting the rDNA-cleaving endonuclease, I-PpoI (Wen et al. 2012).  
 
III.1.2 I-PpoI endonuclease 
 
Several group I introns have the ability to act as mobile genetic elements by encoding rare-
cutting endonucleases which can recognise and cleave DNA at a specific site 12-40 bp within an 
intron-free gene (Dujon 1989). Following induction of a DSB, a group I intron can act as a 
DNA template for repair of the break, thereby incorporating intronic DNA into the previously 
intron-free gene unit via recombination. This mechanism of endonuclease-driven gene 
conversion is known as homing (Dujon 1989; Belfort et al. 1997). Multiple homing 
endonucleases have been identified which recognise and cleave rDNA sequences in various 
species, including I-SceI, which was discovered in the mitochondrial rDNA of S. cerevisiae 
(Colleaux et al. 1990), I-CreI in the chloroplast 23S rDNA of Chlamydomonas reinhardtii 
(single celled green algae) (Sklar et al. 1986), and I-PpoI in the nuclear rDNA of Physarum 
polycephalum (slime mold) (Muscarella et al. 1990).  I-SceI, I-CreI, and I-PpoI cleave rDNA at 
18, 24, and 15 bp recognition sequences, respectively, generating four base 3’ -OH overhangs 
(Sklar et al. 1986; Monteilhet et al. 1990; Muscarella et al. 1990). While the human genome 
does not contain endogenous I-SceI recognition sites, the homing sites for I-CreI and I-PpoI are 
highly conserved, and these endonucleases can cleave sequences in human 28s rDNA when 
exogenously expressed in cells (Monnat et al. 1999).  
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Interestingly, in a study using a system of tamoxifen-inducible I-PpoI expression in 
MCF7 human cells and chromatin immunoprecipitation (ChIP) at I-PpoI sites on chromosomes 
1 and 8, ATM was reported to be required for I-PpoI-induced localised chromatin changes and 
DSB repair (Berkovich et al. 2007). While inherent limitations in this particular system make it 
difficult to accurately assess this role in repair (Section III.I.1), the reported requirement for 
ATM appeared to be greater than that observed following IR. A possible explanation for this 
finding is that I-PpoI-induced DSBs occur in regions enriched for heterochromatin such as 
rDNA. 
 
III.1.3 The nature of rDNA  
rDNA encodes the RNA that is central to protein biosynthesis in the ribosome.  Eukaryotic 
ribosomes are composed of a small (40s) and large (60s) subunit, and contain ribosomal 
proteins and ribosomal RNA (rRNA) (Taylor et al. 2009). The 40s subunit is made up of 18s 
rRNA and ~33 proteins and the 60s subunit is composed of 5s, 5.8s, and 28s rRNA along with 
approximately 46 proteins (Ben-Shem et al. 2011; Rabl et al. 2011). Eukaryotic rDNA is 
organised into the separately-transcribed 5s gene and a 45s gene cluster. The sequences 
encoding 18s, 5.8s, and 28s rRNA are found within the 45S gene cluster and are divided by 
internal transcribed spacer (ITS) units (Gonzalez et al. 1995). 45S gene clusters flanked by an 
external transcribed spacer (ETS) and non-transcribed spacers (NTS) are found in 30-40 tandem 
repeats and localise to the nucleolus, the location of ribosome synthesis (Stults et al. 2008) 
(Figure III.2B, E). In situ hybridization studies using 3H labeled rRNA demonstrated that the 
30-40 tandem repeat rDNA units are located between satellite regions and the short arm of the 
five acrocentric chromosomes (13, 14, 15, 21, and 22) (Henderson et al. 1972) (Figure III.2D). 
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Figure III.2 The nature of rDNA and the I-PpoI recognition site A. I-PpoI binds, recognises 
and cleaves a 15 bp recognition sequence found in the 28s unit of rDNA. I-PpoI cleavage 
generates a DSB with 4 bp 3’ overhangs. B. The 18S, 5.8S, and 28S rDNA sequences are 
clustered in transcriptional units containing internal transcribed spacers (ITS), and are flanked 
by an external transcribed spacer (ETS) and non-transcribed spacers (NTS). C. rDNA clusters 
are found in 30-40 tandem repeats D. In humans, rDNA tandem repeats are found on the short 
arm of the 5 acrocentric chromosomes (13, 14, 15, 21, 22). E. rDNA is organised within 
nucleoli. 50% of rDNA is found to exist within heterochromatin regions, with transcriptionally 
silenced rDNA localising to the periphery of chromocentres. A microscopic image of the 
nucleus of a mouse neuron depicting the close proximity of nucleoli (red) to heterochromatic 
chromocentres (blue) (Singleton et al. 2011).  
107 
 
While transcription of the rRNA genes is necessary to accommodate the cellular 
requirement for ribosomal biogenesis, a substantial fraction of rDNA remains transcriptionally 
silent (Santoro 2005). Unlike other regions of the genome, approximately half of rDNA is found 
in a transcriptionally silent structure throughout the cell cycle (Conconi et al. 1989). Non-
transcribed rDNA repeat units localise to the periphery of chromocentres (Akhmanova et al. 
2000), suggesting that transcriptionally silenced rDNA genes are associated with 
heterochromatin. rDNA repeat regions on the acrocentric chromosomes, termed nucleolar 
organiser regions (NORs), are key to the formation and structural integrity of the nucleolus 
(Bartova et al. 2010). In support of the notion that rDNA genes are frequently found to be 
associated with heterochromatin, analysis of 28S rDNA in mouse-human hybrid cells has 
demonstrated that transcriptionally-silenced NOR regions of the acrocentric chromosomes 
associate with nucleoli (Sullivan et al. 2001) and nucleoli are reported to colocalise with 
chromocentres in MEFs (Singleton et al. 2011). Consequently, the 28S rDNA region, which 
contains the I-PpoI recognition site, is likely to be more highly enriched for heterochromatin 
than non-rDNA regions of the genome.  
 
III.1.4 Systems of site-specific DSB induction which exploit I-PpoI  
 
In recent years, several studies have exploited the I-PpoI endonuclease for the study of protein 
dynamics at site-specific DSBs (Berkovich et al. 2007; Berkovich et al. 2008; McCord et al. 
2009; Wen et al. 2012).  Studies performed by Berkovich, Kastan and colleagues and by 
Michishita, Chua, et al., employed a tamoxifen-inducible system of I-PpoI expression. Using 
this method, I-PpoI-induced DDR protein recruitment was primarily assessed at a cut site 
identified on chromosome 1 within an intron of disabled homolog 1 (DAB1), a gene involved in 
brain development (Lambert de Rouvroit et al. 1998; Berkovich et al. 2007).  Quantitative 
polymerase chain reaction (PCR) analysis of cutting at the chromosome 1 site and southern 
blotting with a 28S rDNA probe demonstrated that I-PpoI-mediated cleavage occurs within the 
first several hours after induction of expression in this system (Berkovich et al. 2007). While 
this methodology has proven successful for assessment of protein recruitment to the sites of 
breaks by ChIP, inherent limitations preclude its exploitation for accurate assessment of DSB 
repair. One major disadvantage of the inducible system originally developed by Berkovich et al. 
is that a second wave of I-PpoI-induced cleavage and DSB signalling is observed after 8 hours 
post induction of protein expression (Berkovich et al. 2007). As cells are exposed to tamoxifen 
continuously upon its addition, the expression of active protein is likely an ongoing process over 
the course of several hours. The ongoing presence of I-PpoI in cells likely results in multiple 
rounds of enzymatic cleavage at I-PpoI recognition sites. In contexts in which DSB induction is 
continual, the precise monitoring of repair is impossible. Further confounding DSB repair 
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analysis following continual expression of I-PpoI over time, cellular overexpression of I-PpoI is 
detrimental to cell viability (Monnat et al. 1999). In addition to these limitations, this system 
requires the establishment of stably transduced cell lines containing the inducible protein 
construct, which ultimately limits the use of this system to specific cell lines. None the less, 
examination of 28S rDNA cleavage following tamoxifen induction of I-PpoI expression 
revealed a substantial (~2-2.5 fold) increase in maximum cutting efficiency which persisted 
over time in the presence of ATM inhibition (Berkovich et al. 2007). This result not only 
suggests that ATM is required for the repair of I-PpoI-induced DSBs within 28S rDNA (since 
these DSBs persist unrepaired), but also, as discussed in later sections, supports the notion that 
multiple cycles of enzymatic cleavage may occur in this system. As ATM has been 
demonstrated to function in the slow component of DSB repair at heterochromatin regions 
(Goodarzi et al. 2008), this finding may imply that the rDNA site recognised by I-PpoI is more 
likely to be found within heterochromatin than other sites in the genome. Therefore, a system of 
site-specific DSB induction which exploits I-PpoI may provide a model for the study of DSB 
repair in regions enriched for heterochromatin.  
 In order to address some of the restrictions associated with previous I-PpoI-based 
methodologies, Dr. Jie Wen, Dr. Patrick Concannon, and colleagues have developed a novel 
system of I-PpoI DSB induction using direct protein transduction of his-tagged I-PpoI (I-PpoI-
his) with cell-penetrating peptides (CPPs) (Wen et al. 2012). Synthetically generated CPPs have 
the capacity to translocate across cellular membranes and deliver cargoes such as purified 
proteins to both cytoplasmic and nuclear compartments (Milletti 2012). Importantly, this 
method of protein delivery is highly efficient, results in little to no cytotoxicity, and is not 
limited to specific cell lines (Henriques et al. 2005a; Milletti 2012). Using this system, rapid 
accumulation (within one hour) of functional I-PpoI was observed both by immunoblot and 
quantitative PCR analysis of cleavage at the cut site on chromosome 1 (Wen et al. 2012). 
Additionally, ChIP-based analysis of both NBS and phosphorylated ATM recruitment and 
immunofluorescence-based analysis of nuclear γH2AX levels demonstrated that DDR signalling 
at the site of I-PpoI-induced DSBs can be detected within one hour after transduction. However, 
examination of DSB repair in specific phases of cell cycle by γH2AX foci analysis was not 
specifically examined. Importantly, I-PpoI levels were observed to decline 5 hours following I-
PpoI delivery, a finding likely to reflect rapid turnover of purified I-PpoI in cells. Further, while 
a defect in I-PpoI-induced DSB repair was observed in NHEJ-defective cells, enzymatic cutting 
efficiency (assessed by quantitative PCR) was not enhanced in these cells (Wen et al. 2012). 
Importantly, this result suggests that the system introduced by Wen et al. is not limited by the 
repeated cycles of cleavage and repair observed in the tamoxifen-inducible system of I-PpoI 
expression.  
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Aside from system-specific limitations, other factors must be considered in the use of I-
PpoI to study heterochromatic DSB repair. In addition to the well-characterised I-PpoI 
recognition sites in 28s rDNA and the DAB1 gene, at least ten additional I-PpoI recognition 
sites have been identified in other locations in the human genome on chromosomes 1, 2, 3, 7, 
and 11 (Berkovich et al. 2007; Wen et al. 2012) and the efficiency of I-PpoI cutting at these 
regions must also be considered. As demonstrated by quantitative PCR using primers spanning 
the site within DAB1 and these newly identified recognition sites, cutting efficiency of CPP-
delivered I-PpoI is similar across these sites and never exceeds 30% (Wen et al. 2012). While 
the cutting efficiency of CPP-delivered I-PpoI at the 28S rDNA repeat sites has not fully been 
explored, the potential availability of up to 300 rDNA-associated recognition sites in the 
genome (Berkovich et al. 2008) may result in the majority of I-PpoI-induced DSBs occurring 
within rDNA.  
 
III.1.5 Aims of this chapter 
 
Results from a previous study (Berkovich et al. 2008) have suggested that there is a substantial 
requirement for ATM in the repair of I-PpoI-induced DSBs. ATM has previously been 
demonstrated to be required for the repair of DSBs occurring within regions of heterochromatin 
(Goodarzi et al. 2008). Therefore, one possible explanation for the observations made by 
Berkovich and colleagues may be that the genomic loci targeted by I-PpoI are enriched for 
heterochromatin. Consequently, the repair of I-PpoI-induced DSBs may require ATM to a 
greater extent than the repair of IR-induced DSBs, which are induced at random throughout the 
genome. However, limitations in the system used for monitoring I-PpoI-induced DSB repair 
have made it difficult to interpret this data. Further, the requirement for Artemis and the ATM 
signalling mediator proteins in the repair of I-PpoI-induced DSBs has not previously been 
explored. ATM, the mediator proteins, and Artemis are required for the repair of a subset of 
DSBs (Riballo et al. 2004; Goodarzi et al. 2008; Noon et al. 2010). The function of ATM and 
the mediator proteins in DSB repair has been demonstrated to involve phosphorylation of the 
heterochromatin factor KAP-1, a process thought to regulate chromosome remodeling 
(Goodarzi et al. 2008; Noon et al. 2010; Goodarzi et al. 2011). In contrast, the precise role of 
Artemis in DSB repair is still being examined.    
Here, I have investigated the requirement for Artemis in DSB repair using a novel 
system of I-PpoI-mediated DSB induction developed by Wen, Concannon, and colleagues (Wen 
et al. 2012). This system addresses multiple limitations associated with previous methodology, 
thereby enabling its utilisation for DSB repair analysis. I aimed to consolidate previous findings 
which suggest that I-PpoI-induced DSBs occur within regions enriched for heterochromatin and 
to examine the requirement for Artemis in the repair of these DSBs using γH2AX foci analysis. 
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As DSB repair pathway choice is impacted by cell cycle phase (Beucher et al. 2009), I have 
restricted my analyses to G0/G1 cells. In Sections III.2.1-2, I will present results from 
optimisation experiments for the expression, purification, and CPP-mediated cellular delivery of 
functional I-PpoI protein. Section III.2.3 will introduce my methodology for analysis of DSB 
repair in G0/G1 cells and in Section III.2.4, I will present findings demonstrating that Artemis 
and the ATM signalling mediator proteins are required for a substantial fraction of I-PpoI-
induced DSBs and that depletion of the heterochromatin factor KAP-1 alleviates the 
requirement for the mediator proteins but not for Artemis. Finally, in Section III.2.5, I will 
discuss my conclusions and the implications of these findings.  
III.2 Results 
III.2.1 Expression of the I-PpoI protein in E.coli 
As introduced in Section III.1, I set out to exploit a system of site-specific DSB induction within 
regions enriched for heterochromatin for the study of DSB repair factors. To do so, I aimed to 
introduce purified I-PpoI protein directly into cells using CPP-mediated delivery as recently 
described (Wen et al. 2012). To obtain sufficient amounts of purified I-PpoI for the subsequent 
delivery of the protein to cells, a system of protein expression in E.coli and Nickel-NTA 
purification was first optimised (Figure III.3.A).  
Protein expression was achieved by transforming BL21 (DE3) competent E. coli (a T7 
expression strain) with a pET-45b(+) expression vector containing the genetic sequences 
encoding his-tagged I-PpoI (I-PpoI-his / pET-45b(+)). As depicted in Figure III.3.B, the pET-
45b(+) vector also contains sequences encoding an AmpR gene to enable selection of efficiently 
transformed bacteria, the bacterial origin of replication (ori), the lactose (lac) operator which 
blocks transcription of the lacI gene encoding the lac repressor, and the T7 RNA polymerase 
promoter. In the absence of a lac analogue such as IPTG, the lac repressor binds the lac 
operator, therefore blocking transcription of the adjacent sequence encoding I-PpoI-his. 
However, upon addition of IPTG, this block is removed, with transcription initiating from the 
T7 promoter and hence expression of protein. 
Ampicillin-resistant I-PpoI-his-transformed bacterial clones were selected and grown in 
the presence of zinc acetate, as proper protein folding and stability of I-PpoI has been reported 
to require divalent metal ions (Flick et al. 1997). Growth of bacteria was monitored carefully by 
taking OD600 readings periodically, and upon entry into log phase of growth, protein expression 
was induced by adding IPTG, again in the presence of zinc acetate. While bacterial growth rate 
varied slightly between preparations, cells usually reached early log phase within ~4 hours, and 
therefore IPTG was typically added around 5 hours after initial growth (Figure III.3.C). Given 
the slightly toxic nature of IPTG and zinc acetate treatment, bacteria entered a quasi-stationary 
111 
 
phase state upon addition of these reagents. Several trial experiments demonstrated that 
following IPTG induction, 3-4 hours of protein expression is sufficient to generate working 
material of I-PpoI protein. Therefore, cells were typically harvested and lysed 8-9 hours after 
initial growth.  
A system of purification exploiting the affinity of the his-epitope tag for Nickel-NTA 
was used to isolate I-PpoI-his from all other proteins. Efficiency of the purification was 
assessed by subjecting eluted protein to SDS-PAGE and labelling proteins with Coomassie blue. 
A substantial amount of a ~22 kDa protein was detected in the purified elutions, corresponding 
to the size of the ~18-20 kDa I-PpoI protein (Monnat et al. 1999), his-epitope tag, and 
intervening linker (Wen et al. 2012) (Figure III.3.D). While bands corresponding with 30kDa 
and 60kDa proteins were also detected, levels of these proteins were significantly lower than 
that of the ~22 kDa I-PpoI-his fusion protein. Eluted protein samples were next subjected to 
concentration by ultrafiltration and protein levels were subsequently assessed by SDS-PAGE 
and Coomassie blue staining. Again, the ~22 kDa I-PpoI-his fusion protein was observed to be 
the main product within the purified protein sample (Figure III.3.E). 
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Figure III.3 Expression of I-PpoI in E.coli A. Schematic representation of I-PpoI protein 
expression and purification. B. Map of I-PpoI-his / pET-45b(+) expression vector C. 
Representative growth curve of subclones of BL21(DE3) E.coli transfected with the I-PpoI 
expression vector. Black arrow indicates the time of IPTG addition in the +IPTG sample. Blue 
arrow indicates the time bacteria were harvested. Growth was determined by taking OD600 
readings at indicated times after initial seeding in flasks. D. Samples of bacteria were harvested 
pre- or post-IPTG addition (PreI and PostI respectively) and lysed.  PostI lysates were cleared, 
providing input (In.) samples for purification. Pre-cleared (PreC) samples were saved. Protein 
purification was performed with Nickel-NTA beads, and samples from all wash and elution 
steps were saved. Indicated lysates were then subjected to SDS-PAGE and gels were stained 
with Coomassie Blue. Black arrow indicates a band corresponding to the ~22 kDa I-PpoI-his. E. 
Concentration of elutions from (D) was performed using ultrafiltration columns. I-PpoI protein 
levels were assessed in the input, flow through, wash, and the final product samples as in (D).   
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Next I verified that the purified I-PpoI-his protein was functionally active using an in 
vitro assay. To test for enzymatic activity, a pcDNA3.1A(+) plasmid containing the 15 bp I-PpoI 
recognition sequence was used as a DNA substrate for the I-PpoI enzyme (Figure III.4.A). 
Purified I-PpoI-his protein was incubated with I-PpoI site/ pcDNA3.1A(+) plasmid DNA to 
allow enzymatic cleavage of the recognition site. A digestion reaction containing commercially 
purchased I-PpoI was used as a positive control for active protein, and a reaction containing 
DNA but no protein was included as a negative control (undigested plasmid). Following 
digestion, DNA was separated on an agarose gel and visualised using ethidium bromide 
labelling and UV illumination. The primary DNA product following digestion with 
commercially purchased I-PpoI or I-PpoI-his was approximately 5.5-6 kb, corresponding to the 
predicted size of the linearized I-PpoI site/ pcDNA3.1A(+) plasmid  (Figure III.4.B).  DNA 
digested with 1.5 µg commercially purchased I-PpoI or 0.5 µg  I-PpoI-his also contained a 
much less abundant product which migrated at the same size as the undigested control, most 
likely representing a small amount of uncut DNA. However, incubation of DNA with 0.75 µg I-
PpoI-his resulted in complete digestion, indicating high enzymatic activity (Figure III.4.B). 
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Figure III.4 Purified I-PpoI protein is functionally active.  A. Map of I-PpoI site / 
pcDNA3.1A(+) vector  B. Indicated µg of purified I-PpoI was incubated with the PpoI site 
/pcDNA3.1A(+) vector for 45 minutes, the digestion was stopped, and DNA samples were 
separated alongside a DNA size standard on a 1% agarose-TBE gel containing ethidium 
bromide to enable DNA detection by UV illumination. Black arrows indicate sizes 
corresponding to cut or uncut plasmid. 
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III.2.2 Optimisation of peptide-mediated protein delivery to cells  
Next, the functional I-PpoI-his protein obtained by E.coli expression and Nickel-NTA 
purification was delivered to human cells using the pep-1-cysteamine delivery reagent, a 
technique also exploited by Dr. Jie Wen, Dr. Patrick Concannon, et al. (Wen et al. 2012). Pep-1 
is a short amphipathic CPP that can be used to deliver biologically active protein across the cell 
and nuclear membranes in a transmembrane-potential-mediated process (Morris et al. 2001; 
Henriques et al. 2005b). The ampiphatic nature of pep-1 allows interaction with lipid 
membranes and addition of a cysteamine group enhances the shuttling of the protein (Figure 
III.5.A).  Pep-1 contains a flexible spacer region flanked by an N-terminal hydrophobic domain 
which enables cell membrane penetration and a hydrophilic C-terminus which acts as an NLS 
(Morris et al. 2001). Incubation of protein molecules with this CPP generates complexes which 
can then be shuttled across the cell membrane and distributed within the cytoplasm, nucleus, or 
both compartments (Figure III.5.B). Importantly, the ratio of pep-1 to protein molecules has 
been reported to impact upon the efficacy of delivery (Morris et al. 2001). 
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Figure III.5 The CPP pep-1-cysteamine as a tool for protein delivery. A. Schematic 
depiction of the regions of the pep-1-cysteamine CPP. Functions of domains are indicated in 
grey text. B. Schematic depiction of the delivery of protein molecules to cells using pep-1-
cysteamine (see text for details).  
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I first tested the efficiency of this system of pep-1-cysteamine-mediated protein 
transduction in the tumour-derived HeLa cell line. To this end, cells were transduced with pep-
1-cysteamine and an IgG antibody conjugated to the AF-488 fluorescein fluorophore, and 
efficiency was monitored by immunofluorescence-based detection of fluorescein. While 
covalent fluorescence labelling alters the physiochemical properties of CPPs and therefore 
cannot be used for accurate monitoring of peptide delivery efficiency (Szeto et al. 2005), 
introduction of a fluorescent protein or fluorescently labelled antibody such as AF-488 provides 
a tool for monitoring the protein distribution in cells.  
The efficacy of pep-1-cysteamine-mediated protein delivery was first assessed in HeLa 
cells using a range of α-AF-488 concentrations (0.05-1µg). A peptide:protein molar ratio of 
1:20-1:40 was used as ratios within this range are reported to facilitate maximum efficiency of 
macromolecule formation (Morris et al. 2001). As negative controls, I included samples of cells 
treated with pep-1 mixed with BSA or with AF-488 alone. Cells were fixed 1, 2, 3, or 6 hours 
following exposure of cells to peptide:protein mixtures and the cellular distribution of AF-488 
was analysed using immunofluorescence microscopy.  As early as 1-2 hours after protein 
transduction, AF-488 signal was observed in cells exposed to both pep-1-cysteamine and AF-
488 (Figure III.6.A). AF-488 signal was observed both as diffused signal and in aggregates 
consistent with published observations following pep-1-mediated protein delivery (Morris et al. 
2001); detection of large protein aggregates increased with increasing antibody (Figure III.6.A) 
or  pep-1-cysteamine concentrations.  
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Figure III.6 Direct protein delivery by pep-1-cysteamine results in high transduction 
efficiency. A. HeLa cells grown on coverslips were treated with indicated pep-1:protein 
mixtures and fixed 2 hours later. Nuclei were labelled with DAPI and cells were visualised and 
imaged using immunofluorescence microscopy.  B. Cell cycle phase can be distinguished by 
immunofluorescence labelling of CENPF. Representative images of CENPF levels in G0/G1-, 
S-, G2-, and M-phase cells are shown. C-E. HeLa cells were exposed to pep-1-cysteamine and 
0.1 µg α-IgG-AF-488 and fixed 2 hours later. Immunofluorescence labelling with DAPI and α-
CENPF was performed and AF-488 localisation was assessed by immunofluorescence 
microscopy in >200 G0/G1 or G2 cells. Representative images are displayed in (C) and 
quantification of the fraction of AF-488- and AF-488+ cells or cells displaying exclusively 
cytoplasmic AF-488, or nuclear AF-488 cells are presented in (D-E).  
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Efficiency of protein delivery was next assessed specifically in G0/G1 and G2 cells 2 
hours after delivery of 0.1 µg AF-488. To distinguish cell cycle phase, immunofluorescence 
staining for CENPF was performed. CENPF staining is bright in G2/M-phase, mild in S-phase, 
and minimal to absent during G0/G1 and mitotic cells can be distinguished by morphological 
changes such as chromatin condensation (Lobrich et al. 2010; Brunton et al. 2011) (Figure 
III.6.B). The distribution of AF-488 was assessed in CENPF- G0/G1 and CENPF+ G2 cells, and 
cytoplasmic and/or nuclear localisation was noted. High exposure images were captured 
allowing distinction of the cytoplasmic compartment from extracellular background (Figure 
III.6.C). Quantification of the fraction of AF-488- or AF-488+ cells provided an initial 
assessment of transduction efficiency. Complete absence of AF-488 (AF-488-) was observed in 
very few G0/G1 or G2 cells (10% or 5%, respectively) 2 hours following transduction, 
reflecting the high (>90 %) efficiency of pep-1-mediated protein delivery also reported by Wen, 
Concannon and colleagues (Wen et al. 2012)  (Figure III.6.D-E). Consistent with published 
findings (Morris et al. 2001), no cellular toxicity was observed following addition of pep-1 at 
concentrations used in these and subsequent experiments (3-5 µM). Cytoplasmic distribution of 
AF-488 was observed in most cells, but ~40-50% of cells displayed exclusive cytoplasmic 
localisation, with the remaining fraction containing both nuclear and cytoplasmic distribution 
(Figure III.6.D-E). Very few cells displayed an exclusively nuclear distribution (data not 
shown). It is important to note, however, that some levels of transduced AF-488 may be below 
the limit of visual detection using the assay.  
III.2.3 Analysis of DSB induction and repair of I-PpoI induced breaks 
Next, pep-1-mediated delivery of I-PpoI was assessed. Cells were exposed to varying 
concentrations of I-PpoI protein with pep-1-cysteamine and aphidicolin was added at the time 
of protein delivery to facilitate identification of S-phase cells and prevent cells from progressing 
to later stages of cell cycle (Section II.6.1).  As negative controls, samples of cells treated with 
pep-1 mixed with BSA or with I-PpoI-his alone were included in each experiment. Cells were 
fixed at one hour intervals following exposure to peptide:protein mixtures. Immunofluorescence 
labelling of DNA (DAPI), DSBs (γH2AX or 53BP1), and cell cycle (CENPF) allowed the 
analysis of site-specific DSB induction in G0/G1 cells as described above.  
Within one to three hours following pep-1-cysteamine-mediated delivery of 0.5-1 µg I-
PpoI-his, an increase was observed in γH2AX (or 53BP1) foci per G0/G1 cell, indicating 
efficient induction of I-PpoI-generated DSBs (Figure III.7.A). 1 µg protein was used for CPP-
mediated I-PpoI delivery in all subsequent experiments. Using similar transduction conditions, 
Wen, Concannon and colleagues, routinely detect I-PpoI-his in the nuclear fraction of cells and 
efficient cutting of various recognition sites as early as 1 hour following CPP-mediated protein 
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delivery (Wen et al. 2012). In contrast to 3Gy IR-induced DSBs, I-PpoI-induced DSBs were 
less numerous, less uniform in size (with some larger foci most likely containing clustered 
DSBs), and often (though not exclusively) observed near the periphery of nucleoli, which 
appear as dark regions in the DAPI channel (Figure III.7.A). A maximum number of ~30 
γH2AX foci were typically observed in G0/G1 cells exposed to I-PpoI, consistent with previous 
reports that I-PpoI expression results in cleavage of 10 % of the ~300 rDNA target sites in the 
human genome (Monnat et al. 1999; Berkovich et al. 2007).  
Enumeration of γH2AX foci revealed that I-PpoI-induced DSB number peaked within 3 
hours after protein transduction and that repair of most DSBs occurred after a further 2-3 hours 
later (Figure III.7.B). Similarly, quantitative PCR analysis (indiscriminate of cell cycle) has 
demonstrated that, for most of the ten additional I-PpoI recognition sites recently identified, 
enzymatic cleavage peaks 1-3 hours after protein transduction and resolution of cleavage has 
been completed within a further 3 hours later (Wen et al. 2012). Importantly, no accumulation 
of DSBs was observed after the first several hours post I-PpoI transduction (between 3-24 hours 
post I-PpoI transduction) (Figure III.7.B), similar to observations made by Wen and colleagues 
using quantitative PCR analysis. In addition, no cellular toxicity was observed over time 
following pep1-mediated I-PpoI delivery. As previously introduced, using their tamoxifen-
inducible system of I-PpoI expression in MCF7 cells, Berkovich and colleagues observed a 
potential second wave of enzymatic cleavage and DSB signalling after 8 hours post-tamoxifen 
administration, suggesting that continuous expression of I-PpoI in their system may result in 
multiple rounds of enzymatic cleavage (Berkovich et al. 2007). As discussed in Section III.3, I 
considered my findings likely to reflect the fact that CPP-mediated delivery of I-PpoI does not 
result in the ongoing/continuous cycles of enzymatic cleavage likely to be associated with 
tamoxifen-induced I-PpoI expression.  
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Figure III.7 Direct delivery of the I-PpoI endonuclease delivery by pep-1-cysteamine 
results in DSB induction in HeLa cells. A. HeLa cells were exposed to 1 µg I-PpoI and fixed 
3 hours later or irradiated with 3Gy and fixed 30 minutes later. 4 µM aphidicolin was added at 
the time of treatment to facilitate identification of S-phase cells and prevent cells from 
progressing to later stages of cell cycle. Immunofluorescence labelling with DAPI, α-γH2AX, 
and α-CENPF was carried out and images of CENPF- G0/G1 cells were captured. Regions 
within white boxes are enlarged in far right panels. B. Cells were exposed to I-PpoI as in (A) 
and harvested at indicated times. γH2AX foci per G0/G1 cell were scored. Plots depict mean +/- 
SD from 3 independent experiments. C. 1 µg I-PpoI was delivered with 0.1 µg α-AF-488, cells 
were fixed 3 hours later, and immunofluorescence labelling was carried out with DAPI and α-
53BP1. Representative images are displayed in left panels, results from quantification of cell 
fractions containing AF-488 (as in Fig. III.6D) and 53BP1 foci are displayed in right panel. D. 
BSA (control) or 1 µg I-PpoI was delivered to cells, and 3 hours later, cells were fixed and 
immunofluorescence labelling with DAPI and α-His was carried out. E. As in (D) except cells 
were transfected with an empty vector or a control vector with a His-tag and fixed 24 hours 
later. Indicated dilutions of α-His were tested. 
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As measured by 53BP1 foci formation, pep-1-cysteamine-mediated delivery of I-PpoI 
to HeLa cells results in DSB induction in ~50% of cells (Figure III.7.C). This fraction of cells, 
likely to represent those with nuclear levels of I-PpoI, was comparable to the fraction of cells 
which display detectable nuclear fluorescein after CPP transduction of AF-488 (Figure III.6.D). 
Similarly, co-delivery of both 1 µg I-PpoI and 0.1 µg α-AF-488 revealed a comparable 
transduction efficiency (>90%) and cellular distribution of protein cargo (nuclear AF-488 
detected in ~50% of cells)  (Figure III.7.C). While attempts were made to monitor I-PpoI-his 
protein delivery by immunofluorescence staining with α-his, no change in his levels were 
observed after pep-1-mediated I-PpoI delivery (Figure III.7.D). However, this most likely 
reflected inefficiency of the antibody for use in immunofluorescence, as changes in his levels 
were also not observed upon efficient transfection of cells with a control vector containing a his-
tag (Figure III.7.E).  
The variation in γH2AX foci characteristics observed after I-PpoI protein delivery has 
posed a challenge in monitoring repair of I-PpoI-induced DSBs over time by γH2AX foci 
enumeration. As described above, a range in DSB size, intensity, and distribution was observed 
within cells following I-PpoI protein delivery when compared with DSBs arising from IR. 
Further, intercellular variations in nuclear uptake were observed. Given these intracellular and 
intercellular variations, γH2AX foci were scored in a higher number of G0/G1 cells (60) per 
experiment than typically scored for assessment of IR-induced DSB repair (20-30 cells 
(Goodarzi et al. 2008). In addition, experiments were repeated at least three times and all data 
was combined and presented in box plots to enable visualisation of data distribution. The 
significant variation in intercellular DSB number is highlighted by comparison of box plots 
depicting the number of γH2AX foci per cell in endonuclease versus IR-treated cells (Figure 
III.8.A-B). However, as presented previously by bar graph (Figure III.7.B), the peak induction 
of I-PpoI-generated DSBs 3 hours after protein delivery and repair of most DSBs after a further 
3 hours remains evident when plotting these results by box plot (Figure III.8.A). Overall, while 
intercellular variation in IR-induced DSB number is generally low, enabling analysis of mean 
values presented in column/bar graphs, I-PpoI-generated DSBs display substantial intercellular 
variation and were plotted by box plot for subsequent analysis.  
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Figure III.8 DNA-PK and ATM are required for the repair of a substantial fraction of I-
PpoI-induced DSBs in HeLa G0/G1-phase cells. For descriptions of the DNA-PKi and ATMi, 
see Section II.5. A. As in Figure III.7.B except all data from 3 independent experiments (60 
G0/G1 cells scored per experiment) are displayed in box plots. Asterix indicate a statistically 
significant difference compared with 0hr or – DNA-PKi samples, depending on plots (*** 
p<0.001). B. HeLa cells were treated with 3Gy IR, fixed at indicated times, and enumeration of 
γH2AX foci in at least 30 cells per experiment was performed. Results are depicted as in (A). C. 
Cells were treated with 10 µM DNA-PKi for 30 minutes prior to I-PpoI protein delivery as 
described. D. As in (C) except cells were treated with 10 µM KU-55933 (+ATMi) or a DMSO 
control (-ATMi). Repair of DSBs was monitored by immunofluorescence labelling and 
enumeration of 53BP1 foci. 
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Using this method of data analysis and presentation, I went on to examine the impact of 
small molecule inhibition or siRNA-mediated depletion of DSB factors on the repair of I-PpoI-
induced DSBs during G0/G1.  
As previously introduced, the repair of DSBs in G0/G1 cells occurs mainly by c-NHEJ, 
a process mediated by the DNA-PK holoenzyme (Section I. 3). Treatment of cells with NU-
7441/KU-57788, a highly selective inhibitor of DNA-PK (DNA-PKi) (Section II.5) is reported 
to inhibit DNA-PK kinase activity at low doses, with an IC50 of ~14 nM (Leahy et al. 2004). 
Treatment of primary human fibroblasts with a related DNA-PKi, NU7026, results in a 
substantial defect in the repair of IR-induced DSBs in G1- and G2-phase cells, consistent with 
the notion that c-NHEJ plays a significant role in DSB repair during these phases of cell cycle 
(Beucher et al. 2009).  
To assess the impact of inhibiting c-NHEJ on the number of I-PpoI-induced DSBs over 
time in G0/G1 cells, NU-7441/KU-57788, an inhibitor of DNA-PK (DNA-PKi) was added to 
cells 30 minutes prior to the time of protein delivery (Section II.5). Consistent with the notion 
that I-PpoI-generated DSB repair occurs primarily by c-NHEJ in G0/G1 cells, DSBs induced in 
the presence of the DNA-PKi remained unrepaired 6 hours and up to 24 hours after addition of 
I-PpoI (Figure III.8.C-D). Importantly, I observed no increase in the maximum number of DSBs 
induced by pep-1-delivered I-PpoI in DNA-PKi-treated cells compared with control cells 
(Figure III.8.A,C). Similarly, Wen and colleagues have observed no increase in the maximum 
cutting efficiency of CPP-delivered I-PpoI in cells lacking functional Lig4, another component 
of c-NHEJ (Wen et al. 2012). These findings again support the notion that CPP-mediated I-PpoI 
delivery may not result in ongoing cycles of enzymatic cutting since, if this did result, one might 
predict to see an increase in the maximum number of I-PpoI-induced DSBs in DSB repair-
deficient cells compared with repair-proficient cells (the number of initially induced DSBs 
which remain unrepaired would be added to the number of newly induced DSBs).  
Next, to substantiate previous reports that the repair of a substantial fraction of I-PpoI-
induced DSBs require ATM (Berkovich et al. 2007) using direct delivery of I-PpoI, cells were 
treated with KU-55933, an inhibitor of ATM (ATMi) (Section II.5), 30 minutes prior to protein 
delivery and DSB number assessed  0, 3, or 6 hours after transduction (Figure III.8.E-F). As 
ATM inhibition results in reduced γH2AX foci size in specific cell lines such as NIH3T3 
(Brunton et al. 2011) and HeLa (unpublished observations), and  a fraction of I-PpoI-induced 
DSBs are small and difficult to score, DSBs were monitored by 53BP1 foci, another marker of 
DSBs. Using this measure, ATM inhibition was observed to result in a significant defect in I-
PpoI-induced DSB repair (Figure III.8.E-F). Comparison of the median values of I-PpoI-
induced 53BP1 foci per cell revealed that ~ 60% of DSBs detected at 3 hours (median =15) 
persisted 6 hours after transduction (median=9) in ATMi-treated cells, while only ~15% of 
DSBs persist at this timepoint in control cells. As ATM is required for the repair of 10-20% of 
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DSBs induced by IR (Riballo et al. 2004) (Figure III.12.A), this result may indicate a greater 
requirement for ATM in the repair of I-PpoI-induced DSBs. However, as previously stressed 
and discussed in Section III.3, variations in DSB induction associated with I-PpoI delivery may 
impact upon interpretation of these results and must be carefully considered. Importantly, while 
the maximum cutting efficiency of I-PpoI was enhanced in ATM defective cells using the 
system described by Berkovich et al. (Berkovich et al. 2008), I did not observe a significant 
difference in the maximum number of DSBs using CPP-mediated I-PpoI delivery in ATMi-
treated cells (Figure III.8.E-F). As discussed above and in Section III.3, this finding again 
supports the notion that repeated cycles of enzymatic cutting, which would be predicted to result 
in an increase in maximum DSB number in repair-deficient cells, is not a major factor in the 
system of CPP-mediated I-PpoI delivery. 
To confirm that observations of I-PpoI-induced DSB repair kinetics and foci variation 
were not restricted to the tumour-derived HeLa cell line, I-PpoI induction of DSBs was also 
assessed in an hTERT-immortalised fibroblast line (1BR3hTERT) derived from a normal 
individual. 1BR3hTERT cells have a stable karyotype, show genomic stability, and have an 
intact G1/S checkpoint (unpublished observations). Delivery of 1 µg I-PpoI to an hTERT-
immortalised control fibroblast line (1BR3hTERT) resulted in maximal DSB induction by 3 
hours. Similar to that observed in HeLa cells, most I-PpoI-induced were repaired within several 
hours in 1BR3hTERT cells (Figure III.9.A). As observed in HeLa cells, I-PpoI-induced DSBs 
(measured by γH2AX or 53BP1 foci) in 1BR3hTERT cells displayed variation in size and 
intensity compared to IR-induced DSBs (Figure III.9.B). 
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Figure III.9 Direct delivery of the I-PpoI endonuclease delivery by pep-1-cysteamine 
results in DSB induction in control human fibroblasts. A. I-PpoI-induced DSBs were 
assessed in 1BR3hTERT control fibroblasts as in Figures III.7.A-B and 8.A. B. Representative 
images of DAPI, γH2AX, and 53BP1 immunofluorescence labelling in 1BR3hTERT cells 30 
minutes after 1Gy IR or 3 hours after I-PpoI delivery. 
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III.2.4 Artemis, 53BP1, and RNF8 are required for the repair of I-PpoI-induced 
DSBs 
The availability of an hTERT-immortalised fibroblast cell line from an Artemis-defective RS-
SCID patient (F02/385hTERT) has enabled analysis of I-PpoI-induced DSB repair in the 
absence of the Artemis endonuclease. F02/385hTERT cells have a normal cell cycle but are 
radiosensitive as a result of a defect in the repair of ~10-20% IR-induced DSBs (Riballo et al. 
2004)  (Figure III.10.A) and display endogenous DSB accumulation over extended times of 
culture (Woodbine et al. 2011). Delivery of 1 µg I-PpoI to F02/385hTERT resulted in maximal 
DSB induction within 3 hours, similar to 1BR3hTERT control fibroblasts (Figure III.10.B-C). 
However, most I-PpoI-induced DSBs remained unrepaired 6-24 hours following protein 
delivery in F02/385hTERT (Figure III.10.C-D). As the fraction of DSBs requiring Artemis for 
repair have been observed to localise to heterochromatin regions in MEFs (Figure III.1) and 
human cells (Woodbine et al. 2011), this observation suggests that a substantial fraction of I-
PpoI-induced DSBs may occur within heterochromatin regions.  
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Figure III.10 Artemis-null human fibroblasts display a substantial defect in the repair of 
I-PpoI-induced DSBs during G0/G1. A. IR-induced DSB repair efficiency was assessed in 
1BR3hTERT (control) (A) or F02/385hTERT (Artemis null) (B) G0/G1-phase fibroblasts as in 
Figure III.8.B. C-D. I-PpoI-induced DSB repair efficiency was assessed in 1BR3hTERT 
(control) (C) or F02/385hTERT (D) G0/G1-phase fibroblasts as in Figures III.7.A-B and 8.A. E. 
Comparison of the number of DSBs per G0/G1 cell 6 hours after protein transduction in 
1BR3hTERT versus F02/385hTERT (as in D-E). 
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To extend these findings, the requirement for Artemis in the repair of I-PpoI-induced 
DSBs was also confirmed by siRNA depletion in HeLa cells using siRNA conditions routinely 
used in our lab and shown to effectively deplete the endonuclease. HeLa cells were transfected 
with ON-TARGETplus SMART pool siRNA oligonucleotides targeting Artemis which are 
reported by the manufacturer to being highly specific (Section II.2), though this was not verified 
here. Cells were transfected with 20 nM siControl or siArtemis, grown for 24 hours, transfected 
a second time with siRNA oligonucleotides, and grown for a further 48 hours. While I found the 
currently available α-Artemis antibodies to be inefficient for analysis by immunofluorescence or 
immunoblotting, my colleagues have previously been able to demonstrate effective depletion of 
Artemis in HeLa cells by immunoblot 48 hours after a single transfection with the same 
oligonucleotide pool used for the purpose of this thesis (Beucher et al. 2009). Here, I assessed 
the efficiency of Artemis depletion in HeLa cells indirectly by assessing IR-induced DSB repair 
efficiency in siControl vs. siArtemis cells. As previously published and confirmed above, 
Artemis-defective fibroblasts are deficient in the repair in ~10-20% IR-induced DSBs (Figure 
III.10.A, Riballo et al. 2004). A similar DSB repair defect has also been demonstrated in 
Artemis-depleted HeLa cells using the siRNA knockdown conditions described above (Beucher 
et al. 2009). Here, I assessed the IR-induced DSB repair efficiency of siControl vs. siArtemis-
treated HeLa cells and again observed defective repair of ~10-20% IR-induced DSBs in 
siArtemis-treated cells (Figure III.11.A). Therefore, I considered my siRNA knockdown 
conditions likely to be efficient in the depletion of the Artemis endonuclease. Using these 
knockdown conditions, the impact of siRNA depletion of Artemis on I-PpoI-induced DSBs was 
assessed. Similar to observations in Artemis-defective fibroblasts, depletion of Artemis resulted 
in defective repair of the majority of I-PpoI-induced DSBs (Figure III.11.B-C).  Unrepaired 
DSBs in siArtemis-treated cells persisted 6-24 hours following I-PpoI delivery (Figure III.11.D-
E) and were observed to vary in size and distribution (Figure III.11. E).   
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Figure III.11 Artemis depletion in HeLa results in a defect in the repair of substantial 
fraction of I-PpoI-induced DSBs during G0/G1. HeLa cells were transfected with control or 
Artemis siRNA, grown for 24 hours, transfected again, and grown for a further 48 hours. A. IR-
induced DSB repair efficiency was assessed as in Figure III.8.B. B-C. I-PpoI-induced DSB 
repair efficiency was assessed as in Figures III.7.A and 8.A.  D. Comparison of the number of 
DSBs per G0/G1 cell 6 hours after protein transduction in siControl versus siArtemis treated 
HeLa cells (as in B-C). E. Representative images of siControl or siArtemis treated HeLa cells 
24 hours after I-PpoI protein delivery. 
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Next, I examined the requirement for the ATM signalling mediator proteins RNF8 and 
53BP1 in the repair of I-PpoI-induced DSBs in G0/G1. Mediator proteins such as RNF8 and 
53BP1 are thought to concentrate ATM signalling at DSBs and are required for robust ATM-
dependent phosphorylation of KAP-1 (Noon et al. 2010). Consistent with this, siRNA-mediated 
depletion of these factors results in a defect in the repair of ~10-20% IR-induced DSBs which is 
comparable to that observed in ATM- or Artemis-defective cells (Noon et al. 2010). RNF8 or 
53BP1 were depleted in HeLa cells by transfection with siRNA oligonucleotides characterised 
in Noon et al. 2010 and as described in Table II.1. For the purpose of this thesis, I used identical 
53BP1 and RNF8 siRNA depletion conditions previously demonstrated to be efficient based on 
an observed reduction in nuclear protein levels (in the case of 53BP1, by immunofluorescence), 
inability of cells to form 53BP1 foci, and reduction in localised KAP-1 phosphorylation (Noon 
et al. 2010). These siRNA conditions are routinely observed in our lab to result in the DSB 
repair defect described above and specificity of the 53BP1 siRNA oligonucleotide has 
previously been confirmed by complementation of the DSB repair defect after expression of 
siRNA-resistant 53BP1 (Noon et al. 2010). Here, I assessed the efficiency of si53BP1 or 
siRNF8 knockdown indirectly by assessing IR-induced DSB repair efficiency in these cells. 
Similar to the reported findings described, I observed a defect in the repair of 10-20% IR-
induced DSBs (Figure III.12A) and therefore considered these knockdown conditions likely to 
efficiently deplete the proteins. Using these conditions, I-PpoI-induced DSB repair was 
monitored as described above. Similar to observations made after depletion of Artemis or 
inhibition of ATM, depletion of RNF8 or 53BP1 resulted in a substantial defect in the repair of 
I-PpoI-induced DSBs (Figure III.12B-G). 
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Figure III.12 The mediator proteins RNF8 and 53BP1 are required for the repair of the 
majority of I-PpoI-induced DSBs in HeLa G0/G1-phase cells. A. HeLa cells were transfected 
twice over 72 hours with indicated siRNA oligonucleotides. ATM was added 30 minutes prior 
to IR. Cells were treated with 3Gy IR, aphidicolin was added at the time of IR, and cells were 
harvested at indicated times later. For each experiment, γH2AX foci enumeration was 
performed in 30 cells per sample. Plot depicts mean values +/- SD from three independent 
experiments. B-G. HeLa cells were transfected with siControl (B-C), siRNF8 (D-E), or si53BP1 
(F-G) as described in Figure III.10.C and repair of DSBs was monitored after delivery of 1 µg I-
PpoI. Plots depict γH2AX foci number per G0/G1 cell. Representative images of DAPI and/or 
γH2AX staining in cells fixed at indicated times after I-PpoI delivery. 
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Findings from our lab have demonstrated that global heterochromatin relaxation by 
KAP-1 depletion relieves the requirement for ATM and the mediator proteins in IR-induced 
DSB repair (Goodarzi et al. 2008; Noon et al. 2010; Brunton et al. 2011). Here, I examined the 
impact of heterochromatin relaxation on the requirement for Artemis, RNF8, or 53BP1 in the 
repair of I-PpoI-induced DSBs.  
To this end, siRNA-mediated depletion of KAP-1 was performed using an siRNA 
oligonucleotide (Table II.1) and knockdown conditions previously demonstrated to efficiently 
deplete KAP-1 in HeLa cells by immunofluorescence analysis and to relieve the requirement for 
ATM and the mediator proteins in IR-induced DSB repair (Goodarzi et al. 2008; Goodarzi et al. 
2011) . The specificity of this siKAP-1 oligonucleotide was previously illustrated by the finding 
that expression of siRNA-resistant KAP-1 in cells treated with siKAP-1 and ATMi restores 
ATM-dependent repair (Goodarzi et al. 2008). While in Chapter V, I demonstrate the efficiency 
of KAP-1 depletion in human fibroblasts by immunoblot, here I verified KAP-1 knockdown in 
HeLa cells indirectly by assessing the impact of siKAP-1 treatment on the requirement for 
ATM, 53BP1, and RNF8 in IR-induced DSB repair (Figure III.13.A). Similar to published 
results by Goodarzi and colleagues, I observed that depletion of KAP-1 combined with siRNF8, 
si53BP1, or ATMi successfully alleviated the DSB repair defect associated with treatment with 
siRNF8, si53BP1, or ATMi alone; therefore I considered KAP-1 knockdown and siKAP-1-
mediated heterochromatin relaxation to be efficient (Figure III.13.A). Importantly, I observed an 
IR-induced DSB repair defect in cells co-depleted for KAP-1 and Artemis. This result 
substantiated similar findings from our lab that were recently published (Woodbine et al. 2011) 
and will be discussed in later sections. 
Next, cells were co-depleted for KAP-1 and RNF8, 53BP1, or Artemis and the number 
of DSBs per G0/G1 cell was assessed at indicated times after I-PpoI delivery. 6 hours after 
direct delivery of I-PpoI, a similar number of DSBs were observed in cells treated with siKAP-1 
and 53BP1 (Figure III.13.D-E) or siKAP-1 and RNF8 (Figure III.13.F- G) as observed in cells 
treated with siControl and siKAP-1 (Figure III.13.B-C) or siControl alone (Figure III.12.B). 
This finding suggests that RNF8 and 53BP1 function in I-PpoI-induced DSB repair to facilitate 
heterochromatin decompaction, similar to observations made after IR (Noon et al. 2010). 
Further, as cells co-depleted for KAP-1 and the mediator proteins fully repair most I-PpoI-
induced DSBs within six hours after transduction, the repair defect observed at this time in cells 
transfected exclusively with siRNF8 or si53BP1 is most likely related to defective 
heterochromatin decompaction. In contrast to these observations, cells co-depleted for KAP-1 
and Artemis displayed a defective in I-PpoI-induced DSB repair similar to that observed in cells 
depleted for Artemis alone (Figure III.13.H-I). This observation strongly suggests that Artemis 
functions downstream of localised heterochromatin relaxation in I-PpoI-induced DSB repair.  
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Figure III.13 Depletion of KAP-1 alleviates the requirement for RNF8 and 53BP1 but not 
for Artemis in the repair of I-PpoI-induced DSBs in G0/G1. HeLa cells were transfected 
with siKAP-1 in combination with siControl (A-B), siRNF8 (C-D), si53BP1 (E-F), or siArtemis 
(G-H) as described in Figure III.10.C and repair of DSBs was monitored after delivery of 1 µg 
I-PpoI. Plots depict γH2AX foci number per G0/G1 cell. Representative images of DAPI and/or 
γH2AX staining in cells fixed 6 hours after I-PpoI delivery.  
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III.3 Discussion 
While recent studies have shed light on the function of ATM signalling in heterochromatic DSB 
repair, the precise role of Artemis in this process is still being explored. Here I have optimised a 
system for site-specific DSB induction in regions likely to be enriched for heterochromatin 
using direct delivery of the I-PpoI endonuclease. This system has been exploited to investigate 
the cellular requirement for Artemis in DSB repair. These findings have demonstrated that 
Artemis as well as ATM, DNA-PK, and the mediator proteins are required for the repair of a 
very substantial fraction of I-PpoI-generated DSBs during G0/G1. Further, these results have 
indicated that unlike the requirement for ATM signalling factors, the requirement for Artemis in 
I-PpoI-induced DSB repair cannot be overcome by heterochromatin relaxation. 
Various techniques for inducing DNA damage and monitoring DSB repair may be 
exploited for the study of DDR factors and are accompanied by distinct advantages and 
disadvantages. As discussed below, several of the advantages and disadvantages associated with 
these techniques must be considered in their use for heterochromatic DSB repair analysis in the 
context of G0/G1. 
Some commonly used methods for monitoring DSB repair include γH2AX foci 
enumeration, pulse-field gel electrophoresis (allowing for physical assessment of DNA size), 
and analysis of breakage on the level of chromosomes (Lobrich et al. 2010). γH2AX foci 
enumeration is currently a favoured assay in our lab for assessment of DSB repair in G0/G1. 
Advantages of this technique include the ability to discriminate cells based on cell cycle phase 
or protein expression, the sensitivity of the assay (single DSBs can be visualised as a γH2AX 
focus, enabling assessment after very low and physiologically relevant levels of damage), and 
the application of this methodology for live cell analysis. However, disadvantages include the 
fact that γH2AX foci represent an indirect measure of DSBs, that γH2AX may also mark lesions 
other than DSBs, and that multiple clustered DSBs may be contained within a single γH2AX 
focus, therefore leading to underestimation of DSB number. While pulse-field gel 
electrophoresis has also proven to be useful in DSB repair analysis, much higher cell numbers 
and IR doses (10-80 Gy) are required for this technique than for γH2AX foci enumeration. 
Analysis of chromosome breaks in G0/G1 cells may be performed by fusion of G0/G1 and M-
phase cells. However, only ~1 in 3-6 DSBs may be visualised as a chromosome break in these 
fused cells, limiting sensitivity of the assay. In this section, I aimed to assess the repair of I-
PpoI-induced DSBs (which occur at a relatively low frequency) specifically in G0/G1 cells; 
therefore γH2AX foci enumeration was selected for analysis. 
DSB induction is typically performed by treatment with chemical agents, irradiation, or 
inducible expression of an endonuclease. However, treatment with IR and most chemical 
reagents generates multiple types of DNA lesions (ie. IR induces ~20 SSBs for every 1 DSB 
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generated (Lobrich et al. 2010)) across the genome. As previously introduced, throughout the 
genome, the majority of chromatin is found as euchromatin, with only ~10-20% DNA found as 
heterochromatin. As IR-induced damage may occur at random in the genome, this poses 
limitations for its use in site-specific DSB analysis at heterochromatin. Systems of site-specific 
DSB induction exploiting endonucleases such as I-SceI (Pierce et al. 1999; Pierce et al. 2005; 
Mao et al. 2008) have proven valuable in the study of NHEJ- and HR-mediated repair pathways. 
However, these systems typically involve establishing cell lines with stably integrated 
enzymatic recognition sites and transfection with a protein expression vector. Further, these 
systems generally do not induce DSBs in regions specifically enriched for heterochromatin. 
Recently developed systems exploiting the I-PpoI endonuclease and ChIP methodology have 
proven valuable in the analysis of DDR protein recruitment at site-specific DSBs. As I-PpoI 
cleaves 28S rDNA (Monnat et al. 1999), heterochromatin content is generally higher in rDNA 
regions than other regions of the genome (Conconi et al. 1989), and a previous study reported 
that ATM-defective cells have a very substantial defect in I-PpoI-induced DSBs (Berkovich et 
al. 2007), I considered that I-PpoI may introduce DSBs in regions enriched for heterochromatin 
and provide a useful tool for examining the DDR at heterochromatic DSBs. However, earlier I-
PpoI-based techniques have relied on inducible protein expression in a stable cell line 
(Berkovich et al. 2007) or transfection with an I-PpoI expression vector (Monnat et al. 1999) 
and result in cytotoxicity and repeated cycles of enzymatic cleavage. Here, I have exploited a 
novel system developed by Dr. Jie Wen, Dr. Patrick Concannon, et al. based on CPP-mediated 
delivery of purified I-PpoI (Wen et al. 2012). This system has addressed several disadvantages 
associated with previous techniques and, as presented here, enabled analysis of I-PpoI-mediated 
DSB repair by γH2AX foci enumeration in multiple cell lines.  
As outlined in the results section, prior to using this system to examine the role of 
Artemis in DSB repair, optimisation of I-PpoI expression (using a vector kindly provided by Dr. 
Wen and Dr. Concannon) and purification, CPP-mediated protein delivery, and I-PpoI-
generated DSB induction was performed. Conditions were identified which enabled the 
generation of sufficient amounts of purified I-PpoI-his and purified protein was demonstrated to 
be functional in an in vitro plasmid-based assay. CPP-mediated protein delivery, using pep-1-
cysteamine, was observed to be non-toxic and efficient, as measured by observation of cellular 
morphology and detection of fluorescein following AF-488 transduction. Using conditions for 
Pep-1-mediated delivery of I-PpoI reported to result in detectable nuclear protein and enzymatic 
cutting of recognition sites (Wen et al. 2012), DSB induction (detected by immunofluorescence 
labelling of γH2AX foci) was observed within 1-3 hours following transduction. However, 
inter- and intra-cellular variations in DSB number, size, and distribution were evident.  
Several experimental and physiological factors are likely to contribute to the variation 
in DSBs observed after CPP-mediated I-PpoI delivery, and their impact upon the accurate 
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analysis of DSB repair must be carefully considered. First, intercellular variation in the uptake 
of pep-1:protein complexes and sub-cellular distribution of delivered protein may be a 
contributing factor to γH2AX foci variation. Unlike IR, which generally induces DNA damage 
in a synchronous fashion across all cells in a treated population, it is possible that CPP-mediated 
delivery of the endonuclease occurs over time, therefore posing a challenge in determining the 
total number of DSBs induced. If I-PpoI-induced DSBs are indeed generated asynchronously 
and if a fraction of these DSBs are repaired rapidly, the precise monitoring of DSB repair over 
time would prove difficult using most assays. Further, while protein transduction is observed to 
be highly efficient (>90%), the intracellular distribution of delivered I-PpoI may not be uniform, 
potentially impacting upon the probability of enzymatic cutting at recognition sequences. In 
addition, the efficiency of enzymatic cutting may be recognition site-dependent. Cutting 
efficiency of CPP-delivered I-PpoI is reported to be similar (10-30%) at the 11 non-rDNA 
recognition sites in the human genome (Wen et al. 2012) but this analysis was not performed in 
a cell- (or cell cycle-) specific manner. Further, cutting efficiency of 28S rDNA has not been 
investigated with this novel system. Previous systems which exploit the expression of  I-PpoI 
protein in human cells have reported that I-PpoI cleaves ~10% of the ~300 rDNA target sites in 
the genome (Monnat et al. 1999; Berkovich et al. 2007), a finding consistent with my 
observation that CPP-delivered I-PpoI induces up to 30 γH2AX foci. As rDNA contain ~300 I-
PpoI recognition sites while only 11 additional recognition sites have been identified in the 
genome, it is likely that the majority of I-PpoI-generated DSBs occur within the rDNA. 
However, this has not directly been shown. Another potentially confounding variable is the 
induction of clustered DSBs. As the 28S rDNA I-PpoI recognition sequence is found in a 
repeating gene cluster, I-PpoI-induced DSBs may occur within close proximity to one another. 
This clustered damage may make it difficult to distinguish between foci representing single 
DSBs or multiple DSBs. In support of this hypothesis, a fraction of I-PpoI-induced γH2AX foci 
were observed to be brightly staining and large, potentially due to clustered damage within 
rDNA. Given the observed variation in I-PpoI-induced γH2AX foci, potentially arising from 
these or other factors, γH2AX foci were scored in a greater number of cells than typically 
scored and all results from at least three independent experiments were presented in box plots to 
display variation.   
While the potentially confounding factors described above are also likely to be 
associated with other I-PpoI-based systems, CPP-mediated I-PpoI delivery has addressed 
several factors associated with previous systems which originally prevented accurate assessment 
of DSB repair across cell lines. For example, I have suggested that multiple rounds of enzymatic 
cutting over extended times are less likely to confound DSB repair analysis after CPP delivery 
of I-PpoI than after induction of tamoxifen-dependent protein expression. In a system in which 
the continuous presence and activity of the enzyme results in ongoing rounds of cleavage, an 
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increase in DSB number may be predicted to occur at times following the initial wave of DSB 
induction. Further, an increase in the overall maximal cutting frequency would be predicted to 
occur in cells depleted for key DSB repair factors as the number of newly generated DSBs over 
time would be added to the number of unrepaired DSBs in these cells. Consistent with this 
prediction, analysis of cutting efficiency in cells expressing tamoxifen-induced I-PpoI indicate a 
possible second wave of cutting after 8 hours post-induction and an increase in the maximum 
cutting efficiency in cells lacking functional ATM or treated with an ATMi (Berkovich et al. 
2007). In contrast, here I have reported that the maximum number of DSBs detected by 
immunofluorescence analysis of γH2AX foci does not increase after 3 hours post CPP delivery 
of I-PpoI to cells, suggesting that the majority of enzymatic cleavage occurs within the first 3 
hours and does not recur over time. Further, I have reported that inhibition or depletion of the 
DSB repair factors ATM and DNA-PK (or of Artemis, RNF8, or 53BP1) impacts upon the 
repair of I-PpoI-induced DSBs but does not result in an increase in the maximum number of 
DSBs scored at any time. As described above, this suggests that while the DSBs induced within 
the first 3 hours after protein delivery remain unrepaired in these DSB repair-deficient cells, no 
new DSBs are induced after this time. Further supporting my findings are the observations made 
by Wen and colleagues using quantitative PCR analysis of the recognition site on chromosome 
1 that cutting efficiency of I-PpoI does not increase after the first 3 hours following CPP-
mediated delivery and that there is no increase in maximum cutting efficiency in cells defective 
in c-NHEJ  (lack Lig4) (Wen et al. 2012). Together, these findings suggest that multiple rounds 
of enzymatic cutting and re-cutting are likely to occur after inducible protein expression but to 
be minimal after direct protein delivery. Wen, Conannon, et al have proposed that I-PpoI, once 
delivered to the cell using CPPs, is turned over rapidly, and in support of this, levels of I-PpoI-
his are detected early (1-2 hours) after transduction but rapidly diminish over time (Wen et al. 
2012). In addition, potentially as a result of rapid protein turnover and/or the low toxicity 
associated with CPP-mediated protein delivery, the method of protein introduction exploited 
here was not observed to affect cell viability. Finally, as CPP-mediated I-PpoI delivery is not 
restricted to specific cell lines, DSB repair can be assessed and compared in cell lines from 
various genetic backgrounds (ie. from patients with mutations in DDR genes).  
Using this system of CPP-mediated protein delivery and DSB repair analysis by γH2AX 
foci enumeration, I have demonstrated that a very substantial fraction of I-PpoI-induced DSBs 
require Artemis, ATM, RNF8, 53BP1 and DNA-PK for repair during G0/G1. While, for the 
reasons described above, the precise assessment of the % I-PpoI-induced DSBs which require 
these factors for repair is not feasible, comparison of median or the value range in the upper and 
lower quartiles (25-75%) over time allows for very rough approximations of the fraction of 
persisting DSBs. Using this method of comparison, in control cells, only a small fraction of 
DSBs scored at 3 hours (25-75 % range ~1-21, median~13) persist at later times (6-24 hours) in 
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control cells, with DSB number returning to base line values (range 1-3, median~2). In contrast, 
while the number of DSBs scored 3 hours after transduction was similar in Artemis, ATM, 
RNF8, 53BP1 or DNA-PK inhibited/depleted cells, anywhere from 50-90 % of DSBs persisted 
6-24 hours later in these cells (median values between 8-12). Importantly, KAP-1 depletion was 
observed to alleviate this repair defect in cells treated with ATMi, siRNF8, or si53BP1, with the 
median number of DSBs falling to baseline levels. As KAP-1 depletion results in global 
heterochromatin relaxation, this suggests that the very substantial repair defect observed in 
ATMi, siRNF8, or si53BP1-treated cells is associated with an inability to promote the localised 
heterochromatin decompaction which normally facilitates DSB repair (Goodarzi et al. 2008). 
Further, this finding suggests that I-PpoI delivery may induce a high fraction of DSBs within 
heterochromatin (presumably at rDNA regions), therefore resulting in an enhanced reliance on 
these specific DDR factors.  
A substantial defect in I-PpoI-generated DSB repair was observed in Artemis-depleted 
cells even after co-depletion of KAP-1. Similarly, depletion of KAP-1 did not alleviate the 
requirement for Artemis in repair of IR-induced DSBs. These observations substantiated 
findings from IR- and TBH-based experiments recently published (Woodbine et al. 2011) and 
suggest that Artemis functions in DSB repair in a process distinct to ATM signalling-dependent 
heterochromatin opening. While the function of ATM and Artemis may be distinct, epistasis 
analysis has demonstrated that ATM and Artemis operate in the same pathway, both promoting 
NHEJ during G0/G1 and HR during G2 (Riballo et al. 2004; Beucher et al. 2009).  
In considering the role of the Artemis endonuclease in heterochromatic DSB repair, 
several possible models exist. One model postulates that the endonucleolytic activity of Artemis 
helps to remove lesions or secondary structures inhibitory to the completion of NHEJ or HR. 
During G0/G1, Artemis activity is reported to require DNA-PK (Goodarzi et al. 2006) and is 
thought to promote NHEJ (Beucher et al. 2009). Goodarzi et al. originally proposed that 
Artemis functions in NHEJ to process DSBs with long overhangs (ie .two SSBs in close 
proximity) that cannot readily be ligated (Goodarzi et al. 2006). This model proposes that DNA 
ends are first bound by Ku and DNA-PKCs and subsequent autophosphorylation of DNA-PKcs 
induces structural changes which activate Artemis-dependent processing of ends, thereby 
facilitating end ligation (Goodarzi et al. 2006). During G2, Artemis activity does not require 
DNA-PK and is instead thought to promote HR (Beucher et al. 2009). As DNA end resection is 
required for HR, Beucher, Lobrich et al. have proposed that Artemis promotes repair during G2 
by cleaving secondary structures which block the progression of DNA end resection. Given the 
structural complexity of heterochromatin and tendency to contain repeat sequences such as 
satellite regions, one might expect that secondary structures (such as hairpins) may arise more 
frequently in heterochromatic DSBs and therefore require Artemis-dependent processing. 
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 Another more recent model postulates that some level of resection may occur at 
heterochromatic DSBs during both G0/G1 and G2 and that the function of Artemis involves 
promoting DNA end resection. While resection can be readily detected in G2 by techniques 
such as immunofluorescence labelling of RPA or BrdU foci, these foci are generally more 
difficult to detect in IR-treated G0/G1 cells. However, some resection may still occur in G0/G1, 
though less extensive than the resection visualised in G2 cells. As DSBs arising within 
heterochromatin regions rapidly relocalise to the periphery of heterochromatic regions (Jakob et 
al. 2011), one potential function of resection may be to promote this relocalisation, ultimately 
facilitating repair. As described below, further analysis of resection at I-PpoI-induced DSBs 
within rDNA could potentially further these studies. 
While the findings presented here provide insight into the nature of I-PpoI-generated 
DSBs and factors required for their repair, further studies are needed to extend these findings 
and fully exploit the potential utility of this novel system of I-PpoI delivery. Quantitative PCR 
analysis has previously been used to monitor induction and repair of I-PpoI-induced cleavage at 
non-rDNA recognition sites (Berkovich et al. 2007; Wen et al. 2012). This methodology has 
been useful in examining certain DDR aspects such as the role of ATM-dependent 
phosphorylation of NBS. However, the likelihood of these genomic regions falling within 
heterochromatin regions is low and, therefore, other strategies may be needed to examine I-
PpoI-generated DSBs which occur within heterochromatin-rich regions. In order to substantiate 
my findings, quantitative PCR using primers spanning the 28S rDNA site or southern blotting 
using a 28S rDNA probe could feasibly be used to assess I-PpoI associated DNA cleavage and 
repair. For example, control or Artemis-null fibroblasts grown to confluency (to enrich for 
G0/G1) could be exposed to I-PpoI and harvested at various times after protein transduction for 
DNA extraction. Analysis of rDNA site cleavage over time by quantitative PCR or southern blot 
may then provide a measure for repair which could be compared in control and Artemis-
defective fibroblasts. Further, the requirement for Artemis and extent of DNA end resection at 
DSBs in rDNA could be examined in G0/G1 cells using this system of I-PpoI delivery. 
Quantitative PCR primer sets which vary in distance from the rDNA recognition site could be 
used to assess the extent of I-PpoI-induced DSB end processing. This method may be applied to 
examine the molecular requirements for resection. ChIP-based assays could also be applied to 
samples from control and Artemis-null cells treated with I-PpoI, to assess chromatin binding of 
resection factors, again using primers which recognise sequences at various distances from the 
28S rDNA site. However, the repetitive nature of rDNA may present difficulties for primer 
efficiency.  
In summary, here I have exploited a novel system of site-specific DSB induction by 
CPP-mediated delivery of I-PpoI to examine the requirement for Artemis in DSB repair. 
Artemis, ATM, RNF8, 53BP1, and DNA-PK were found to be required for the repair of a 
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substantial fraction of I-PpoI-induced DSBs during G0/G1 and heterochromatin relaxation via 
KAP-1depletion relieved the requirement for ATM, RNF8, and 53BP1 but not for Artemis. As 
ATM, RNF8, and 53BP1 are required specifically for the repair of heterochromatic DSBs, these 
results have suggested that I-PpoI-induced DSBs may occur in regions enriched for 
heterochromatin (ie. within rDNA). In addition, these findings have implicated Artemis as 
functioning downstream of heterochromatin decompaction to promote DSB repair, a result also 
recently observed and reported in IR-based studies (Woodbine et al. 2011). Further exploitation 
of this system of site-specific DSB induction may extend our understanding of the precise role 
of Artemis in DSB repair.  
Later chapters will now transition to the primary focus of this thesis: examination of the 
cellular impact of diminished capacity for DNA replication origin licensing. The effects of 
diminished origin licensing capacity were investigated in the context of potential therapeutic 
exploitation in oncology and in the context of ORC-deficient MGS. This transition has reflected 
my interest in disease-relevant research. 
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IV The impact of diminished origin licensing capacity on sensitivity to 
replication stress in tumour versus non-tumour cells 
IV.1 Introduction 
IV.1.1 Cellular alterations associated with cancer 
As introduced in Chapter I, some of the earliest changes which occur during tumour 
development include the increased expression of oncogenes and decreased expression of tumour 
suppressor genes (Pedraza-Farina 2006). These changes are associated with a host of other 
alterations including, but not limited to, hyper-replication, altered regulation of DNA replication 
factors, genome instability, changes in survival and/or apoptotic pathways, and alterations in the 
mechanisms required to respond to the cellular threat of DNA damage such as cell cycle 
checkpoints and repair pathways (Hanahan et al. 2000; Halazonetis et al. 2008) . These changes 
each promote the proliferation of cancer cells and can propagate further alterations conducive to 
tumour development and survival.  
One source of DNA damage found to be enhanced in tumours is replication stress 
(Bartek et al. 2012) (Section I.2.3). Replication stress may result from cellular changes 
associated with cancer such as the aberrant expression of the c-Myc oncogene (Murga et al. 
2011), hyper-replication, structures or lesions which block the progression of replication forks 
or replication inhibiting reagents (Burhans et al. 2007). Alterations in genes involved in 
regulating the transition from G1 to S-phase are frequently associated with cancer and these 
alterations are thought to contribute to replication stress. Up to 50% of tumours harbour 
mutations in TP53 (Vogelstein et al. 2000), which implies that p53 plays a crucial role in 
prevention of tumourigenesis. Alterations in other factors with regulate the G1-S transition, such 
as p16 or the retinoblastoma (RB) protein, are associated with a wide variety of tumour types 
(Bartkova et al. 1997; Bartek et al. 2001). In the context of such alterations, inappropriate S-
phase entry of cells harbouring DNA damage may occur (Bartkova et al. 1997; Bartek et al. 
2001), resulting in an increase in replication, replication-associated damage and genome 
instability. Under conditions of insufficient replication origin licensing capacity, regulation of 
the G1-S-phase transition is also thought to be crucial to prevent unscheduled S-phase entry and 
subsequent genome instability (Nevis et al. 2009). 
Replication inhibitors are frequently used in the treatment of cancer but they can also 
impact upon any rapidly dividing normal tissue, which underlies the clinical side effects 
associated with chemotherapy (Helleday et al. 2008). Alternative therapeutic strategies which 
selectively target cancer cells may reduce these potential side effects. In this chapter, I aim to 
examine a potential therapeutic strategy of this nature.   
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IV.1.2 Mechanisms of replication stress recovery 
As previously introduced (Section I.4.3), one of the ways in which cells may withstand 
replication stress is via the activation of dormant origins, allowing replication through DNA 
between two stalled forks, completion of genome replication and survival (Blow et al. 2011). 
However, most studies examining replication stress-induced dormant origin firing have been 
performed in tumour-derived cell lines using agents such as HU and aphidicolin (Ge et al. 2007; 
Ibarra et al. 2008a; Ge et al. 2010; Karnani et al. 2011). Overexpression of various pre-RC 
components has been observed in tumour cells (Lau et al. 2007b), and could function both to 
accommodate hyper-replication and to provide increased dormant origin availability to facilitate 
proliferation in the face of enhanced replication stress. Dormant origin firing has also been 
proposed to promote genome stability and tumour suppression in MEFs even in the absence of 
replication stress-inducing reagents (Kawabata et al. 2011b). However, these studies were 
performed using mice expressing hypomorphic mutations in the MCM helicase and it is unclear 
whether a similar effect would be observed in human cells deficient in ORC, CDC6, or CDT1. 
While no increase in cancer predisposition has been reported in human patients with 
deficiencies in the pre-RC components, MGS is a rare disorder, and it is therefore difficult to 
accurately assess changes in cancer incidence. 
In addition to dormant origin firing, several other mechanisms exist which may promote 
recovery from replication fork stalling and/or collapse (Petermann et al. 2010a). As briefly 
introduced in Section I.2.3 and reviewed by Petermann and Helleday, replication fork stalling 
refers to a potentially transient delay in the progression of active replication forks which can be 
caused by a variety of obstacles. Replication fork stalling generates a DNA structure which 
requires stabilisation and, under contexts in which replication fork stability is compromised, 
forks may ultimately collapse. While the progression of stalled replication forks may be 
resumed following removal of the obstacle, collapsed replication forks are proposed to represent 
inactivated replication structures from which the replication machinery has dissociated 
(Petermann et al. 2010a). The term “replication fork collapse” is only loosely defined and refers 
to the generation of a variety of replication structures vulnerable to additional processing. For 
example, under certain contexts, replication forks may collapse into structures known as “one-
ended DSBs” which require processing by DSB repair proteins, as described below.  
As depicted in Figure IV.1, recovery from replication stress inducing agents such as HU 
involves fork remodelling and/or HR-mediated repair. HU-induced fork stalling is reported to 
result in the binding and activation of PARP1, subsequent recruitment of Mre11, activation of 
Mre11-dependent resection (Bryant et al. 2009), and X-ray repair cross-complementing protein 
3 (XRCC3)-dependent replication fork restart and/or repair (Petermann et al. 2010b). Recovery 
from replication inhibition is also promoted by the DNA helicases, WRN (Sidorova et al. 2008), 
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BLM (Davies et al. 2007), and SWI/SNF-related matrix-associated, actin-dependent regulator of 
chromatin, subfamily A-like 1 (SMARCAL1) (Ciccia et al. 2009). While Rad51 activity 
promotes replication recovery after both short (ie. 2 hours) or long (ie. 24 hours) treatments with 
HU (Arnaudeau et al. 2001; Saintigny et al. 2001; Petermann et al. 2010c), Rad51 foci 
formation has been reported mainly after longer replication blocks (Petermann et al. 2010b). 
Therefore, Rad51 loading may be more extensive after longer exposures to HU, perhaps in order 
to support HR-mediated recovery. In response to 24 hour treatment with HU, PARP-1 is 
thought to promote HR-mediated repair of damaged forks and, as a consequence, PARP1 
inhibition results in reduced Rad51 foci formation, recombination frequency, and survival 
(Bryant et al. 2009). These findings support a model proposed by Dr. Eva Petermann and Dr. 
Thomas Helleday that replication stress recovery may be dependent on the length of time in 
which replication is inhibited. Shorter arrest times (ie. 2 hours) may be associated mainly with 
fork stalling which activates HR-independent but Rad51-dependent replication fork 
remodelling. In contrast, longer periods of arrest (ie. 24 hours) may result in increased 
replication fork collapse, generating one-ended DSBs which require HR for repair (Petermann 
et al. 2010b). Overall, these mechanisms of replication fork restart and/or repair may act 
alongside dormant origin firing to promote efficient cellular recovery from replication arrest. 
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Figure IV.1 Pathways of Rad51-dependent recovery from replication stress. Adapted from 
(Petermann et al. 2010a). Treatment with HU blocks the progression of replication forks. 
Release from short or long periods of HU treatment (2 or 24 hours, respectively) results in the 
recruitment of PARP1 and subsequent Mre11-dependent end resection at stalled replication 
forks. XRCC3 is recruited to forks, leading to Rad51 loading. A 2 hour treatment with HU 
results in more minimal Rad51 loading while 24 hour HU treatment results in more extensive 
Rad51 loading and filament formation. DNA helicases may promote fork remodelling after 
short HU treatments, or HR-mediated repair after longer HU treatments, leading to replication 
recovery.  
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IV.1.3 Aims of this chapter 
While dormant origin firing has been demonstrated to promote recovery from reagents such as 
HU or aphidicolin in tumour-derived cell lines (Ge et al. 2007; Ibarra et al. 2008a; Ge et al. 
2010; Karnani et al. 2011), questions remain about whether normal human fibroblasts depend 
on dormant origin firing for recovery from replication stress. This is an important question 
because if cells in normal tissue have a diminished dependency upon dormant origin usage 
(perhaps by exploiting other pathways of recovery), therapeutic treatment with inhibitors of 
origin licensing components may be predicted to specifically sensitise tumour cells to 
replication stress without greatly affecting non-tumour tissue. Therefore, inhibitors of origin 
licensing components could be potentially useful therapeutic agents in combination with 
replication stress-inducing treatments.  
Here, I aimed to compare the ability of non-tumour and tumour cells to recover from 
replication stress under conditions of diminished origin licensing capacity. To test this, I have 
employed siRNA-mediated depletion of licensing components such as ORC1, using conditions 
likely to deplete dormant origin availability without impacting upon cell growth, combined with 
HU treatment. In Sections IV.2.1-2, work will be presented from the comparison of ORC1 
expression and reliance on ORC1 to maintain proliferation in the presence or absence of HU in 
1BR3hTERT non-tumour fibroblasts and U2OS osteosarcoma cells. In addition, this section 
will describe findings from the comparison of ORC1-deficient MGS patient cell lines with 
control cells. Section IV.2.3 will present results from the examination of HU-induced new 
origin firing in U2OS cells depleted for ORC1 and Sections IV.2.4-5 will present results from 
the comparison of replication recovery and S-phase associated DNA damage in 1BR3hTERT 
and U2OS cells after treatment with HU. In Section IV.2.6, I will present findings from the 
combined partial depletion of additional licensing components and HU treatment in 
1BR3hTERT and U2OS cells and Section IV.2.7 will compare HU sensitivity of additional non-
tumour and tumour-derived cell lines following ORC1 depletion. Section IV.2.8 will examine 
the impact of ORC1 depletion on sensitivity to H2O2, an agent which induces oxidative stress 
and indirectly generates replication stress. Section IV.2.9 will describe findings demonstrating 
that the combined depletion of p53 and ORC1 results in enhanced loss of viability in the 
presence or absence of HU in 1BR3hTERT non-tumour cells. Section IV.2.10 will examine the 
impact of diminished origin licensing capacity on proliferation following aberrant expression of 
the c-Myc oncogene, and Section IV.2.11 will present finding from the combined treatment of 
U2OS osteosarcoma cells with ORC1 siRNA, UCN-01 (a Chk1 inhibitor at low doses), and HU. 
Finally, all findings presented in this chapter will be discussed in Section IV.3.  
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IV.2 Results 
IV.2.1 Substantial depletion of origin licensing capacity does not impact upon 
viability in  non-tumour and tumour-derived cells 
To examine the cellular impact of reduced origin licensing capacity, I began by exploiting 
siRNA-mediated depletion of ORC1 in the non-tumour fibroblast line 1BR3hTERT and the 
tumour-derived line U2OS. 1BR3hTERT, an hTERT-immortalised fibroblast line derived from 
a normal individual,  has a stable karyotype, shows genomic stability, and has an intact G1/S 
checkpoint (unpublished observations). The U2OS cell line is derived from an osteosarcoma, 
expresses normal p53 and RB but lacks p16 (Grossel et al. 1999). These cells are reported to 
lack the so-called “licensing checkpoint” (Hall et al. 2007). Further, the use of dormant origin 
firing has been reported to promote recovery from HU in this cell line (Ge et al. 2007).  
While ORC1 is essential for cellular replication and viability, cells can survive with a 
significant reduction in ORC1, as shown by the viability of ORC1-deficient MGS patient cells 
(Bicknell et al. 2011b). This likely reflects the fact that a reduction in ORC1 levels may 
diminish dormant origin availability, while a sufficient number of origins remain to promote 
replication. Here, I aimed to identify conditions of ORC1 siRNA (siORC1) treatment in 
1BR3hTERT and U2OS cells which reduced the level of protein and thus the availability of 
dormant origins while not impairing viability in the absence of exogenous damage. To this end, 
a single siRNA oligonucleotide targeting ORC1 which was previously described (Bicknell et al. 
2011b) (Table II. 1) was used. While specificity of this siRNA oligonucleotide has not been 
verified by complementation studies, treatment of 1BR3hTERT cells with siORC1 results in a 
similar delay in the progression of cells from G1 to S-phase as observed in  hTERT-
immortalised fibroblast cells from an ORC1-deficient MGS patient (Bicknell et al. 2011b). 
Here, cells were transfected with a range of siRNA oligonucleotide concentrations, incubated 
for 7 days, and assessed for viability using the fluorescence-based CellTiter-Blue® assay which 
measures the metabolic activity characteristic of viable cells. As positive controls for viability, 
non-transfected cells (0 nM siRNA) or cells transfected with various concentrations of randomly 
scrambled oligonucleotides (siControl) were examined. As negative controls for background 
fluorescence, samples including growth medium and the CellTiter-Blue® reagent but no cells 
were included in each experiment, and all samples were performed in triplicate within each 
experiment. 
Using this assay, I observed diminished proliferation with increasing siORC1 
concentrations, consistent with the notion that oligonucleotide concentration correlates with 
knockdown efficiency (Figure IV.2.A-B). No significant change was observed in viability 
between non-transfected or siControl-transfected cells. Interestingly, a greater loss of viability 
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was observed after lower siORC1 concentrations in U2OS cells compared with 1BR3hTERT 
cells. This result may reflect differences in siRNA-mediated knockdown efficiency between 
tumour and non-tumour cell lines. In addition, it may reflect a greater reliance of the tumour-
derived cell line on ORC1-dependent origin licensing to maintain viability under conditions of 
hyper-replication and/or replication stress. The maximum ORC1 siRNA concentrations which 
did not inhibit viability (5 nM or 0.6 nM in 1BR3hTERT or U2OS cells, respectively) were 
selected from the siRNA dose response experiments and results were confirmed in three 
independent experiments (Figure IV.2.C).  
Next, the efficiency of ORC1 protein depletion was assessed 48 hours after cells were 
transfected with siControl or siORC1 at the concentrations indicated above (Figure IV.2.D). 
Immunoblotting revealed that U20S cells express higher levels of ORC1 compared with 
1BR3hTERT cells, consistent with previous findings that tumour-derived cells overexpress 
ORC proteins (Karakaidos et al. 2004; McNairn et al. 2005; Lau et al. 2007a; Di Paola et al. 
2012). Although -ORC1 antibodies are inefficient for immunoblotting, a marked reduction in 
ORC1 protein could be observed in both lines following siORC1 (Figure IV.2.D).  Low levels 
of residual ORC1 were routinely detected in siORC1-treated U20S but not 1BR3hTERT cells. 
However, since ORC1 is essential, it is likely that 1BR3hTERT cells retain residual, although 
undetectable, ORC1. Nonetheless, these results suggest that U20S cells require a higher level of 
ORC1, and therefore origin licensing capacity, to maintain viability compared to normal 
fibroblasts. 
I considered these siORC1 conditions likely to diminish dormant origin licensing 
capacity and went on to use them in subsequent experiments. 
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Figure IV.2 Substantial depletion of ORC1 does not impact upon viability in non-tumour 
1BR3hTERT fibroblasts and osteosarcoma-derivedU2OS cells. A-B. 1BR3hTERT (A) or 
U2OS (B) cells were transfected with siControl or siORC1 oligonucleotides (0.1-20 nM), and 
viability assessed 7 days later. Results represent mean +/- SD from triplicate samples within one 
representative experiment. Black arrows indicate the oligonucleotide concentration 
subsequently utilised. C. As in (A-B), except 1BR3hTERT and U2OS cells were transfected 
with 5 or 0.6 nM siORC1, respectively and results depict mean % viability +/- SD from three 
independent experiments. D. 1BR3hTERT and U2OS cells were transfected with 5 or 0.6 nM 
siORC1, respectively. ORC1 protein levels were assessed by immunoblotting 48 hours later. β-
actin was a loading control. 
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IV.2.2 ORC1 depletion differentially impacts upon the recovery of non-tumour 
and tumour-derived cells from HU-induced replication stress  
Next, the impact of ORC1 depletion on recovery from replication stress was assessed in 
1BR3hTERT and U2OS cells. To this end, HU, a clinically relevant chemotherapeutic agent 
which induces replication fork stalling and/or collapses, was exploited. As previously 
introduced, HU inhibits RNR, the enzyme required to supply cells with the nucleotide pools 
required for DNA synthesis, and has been demonstrated to induce dormant origin firing in 
U2OS cells (Ge et al. 2007). siRNA transfection was as performed as described above and cells 
were exposed to differing concentrations of HU for 24 hours. HU was removed and viability 
monitored 4 days later. Despite efficient protein depletion, as verified by immunoblot (Figure 
IV.2.D), treatment of 1BR3hTERT with siORC1 did not impact upon HU-induced loss of 
viability (Figure IV.3.A).  However, ORC1 depletion resulted in a marked increase in HU-
induced loss of viability in U2OS cells (Figure IV.3.B).  
To verify that the viability assay reflects cellular survival and clonogenicity, clonogenic 
survival was examined in U2OS cells 10 days after HU removal (Figure IV.3.C). Although 
these two assays monitor different endpoints, a similarly enhanced sensitivity to HU was 
observed in siORC1-treated U2OS cells. I therefore considered the viability assay to be a valid 
measure of HU sensitivity and used it for subsequent experiments. 
I next went on to verify that the effect of ORC1 depletion on HU sensitivity was not 
limited to the single ORC1-targeting oligonucleotide (siORC1 single) by testing the effect of 
transfection with a distinct ON-TARGETplus SMART pool targeting ORC1 (siORC1 pool). 
Again, while specificity of siORC1 pool was not verified here, ON-TARGETplus SMART pool 
oligonucleotides are reported by the manufacturer to being highly specific (Section II.2). 
1BR3hTERT and U2OS cells were transfected with 5 nM or 0.6 nM, respectively, of siORC1 
pool and 48 hours later ORC1 depletion was verified by western blot. Similar to observations 
made after transfection with siORC1 single, depletion of ORC1 was efficient in both cell lines 
using these conditions (Figure IV.3.D). Cells were then transfected with siControl, siORC1 
single, or siORC1 pool as described, treated with HU for 24 hours, and assessed for viability 4 
days after HU removal.  Similar results were observed after treatment with either siORC1 single 
or siORC1 pool, confirming that the effects observed were reproducible with separate siRNA 
oligonucleotides.  
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Figure IV.3 ORC1 depletion enhances sensitivity of tumour-derived U2OS cells but not 
non-tumour 1BR3hTERT cells to 24 hour treatment with HU. A-B. 1BR3hTERT (A) or 
U2OS (B) cells were transfected with siControl or siORC1 oligonucleotides (0.1-20 nM), and 
viability assessed 7 days later. Results represent mean +/- SD from triplicate samples within one 
representative experiment. Reproducibility was verified in at least six independent experiments. 
C. U2OS cells transfected with siRNA as described were treated with HU (0.05-2 mM) for 24 
hours. Clonogenic survival was estimated 10 days following HU removal. Results represent 
mean +/- SD from three independent experiments. D. As in Figure IV.2.D except cells were 
transfected with siControl or a distinct pool of ORC1 siRNA oligonucleotides (siORC1 pool). 
E-F. As in (A-B), except cells were transfected with siControl, siORC1 single, or siORC1 pool. 
Reproducibility was verified in three independent experiments. 
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In considering possible explanations for the observation that ORC1 depletion 
specifically sensitises tumour-derived U2OS cells to HU, I reasoned that differences in the rate 
of cell cycle progression and/or DNA replication between tumour and non-tumour cells may 
impact upon the effects of HU, which specifically impacts cells during S-phase. Therefore, I 
monitored the population doubling time (Figure IV.4.A-B) and rate of HU-induced replication 
stress accumulation in a given cellular population (Figure IV.4C-D). The growth of 
1BR3hTERT and U2OS cells was monitored for up to 96 hours (Figure IV.4.A) and the 
doubling time was estimated from the results (Figure IV.4.B). As expected, the tumour-derived 
U2OS cell line doubled more quickly than 1BR3hTERT cells, with U2OS cells doubling within 
~30 hours. In contrast, 1BR3hTERT cells doubled every ~48 hours; hence there could be a 
fraction of cells that have not entered S-phase within the 24 hour HU exposure time tested 
above. As the effects of HU are specific to S-phase, a 24 hour exposure time is therefore 
unlikely to affect the entire population of 1BR3hTERT fibroblasts. To determine the fraction of 
cells which display the effects of HU after various exposure times, HU-induced replication 
stress was monitored by immunofluorescence labelling with H2AX and the G2/M-phase 
marker, CENPF (Figure IV.4.C-D). Cells harbouring S-phase specific damage can be visualised 
as having bright, pan-nuclear H2AX levels and minimal CENPF staining (here referred to as 
H2AX+). Examination of the % H2AX+ population at various times after HU addition 
revealed that >95% cells had undergone replication fork arrest by ~48 hours after HU in 
1BR3hTERT cells (Figure IV.4.C) or ~30 hours after HU in U2OS cells treated with siControl 
or siORC1 (Figure IV.4.D). 
1BR3hTERT cells were next transfected with siRNA oligonucleotides as previously 
described and treated with HU for 48 hours, a treatment time observed to induce replication 
stress in most cells in the population. HU was then removed and both cellular viability (Figure 
IV.4.E) and clonogenic survival (Figure IV.4.F) were assessed after a further 4 or 21 days, 
respectively. Despite this longer HU exposure and efficient ORC1 depletion, as routinely 
observed by western blot (Figure IV.2.D), treatment with siORC1 was not observed to impact 
the HU sensitivity of 1BR3hTERT cells measured in either of these assays (Figure IV.4.E-F).  
To compare relative sensitivity of 1BR3hTERT and U2OS cells to 24 or 48 hour HU 
exposure times, the concentration at which viability was reduced by 50% (IC50) was calculated 
from viability curves. The relative IC50 value was then estimated by comparison of the IC50 of 
siORC1-transfected cells to that of siControl-transfected cells (Figure IV.4.H). Whilst siORC1 
did not affect sensitivity in 1BR3hTERT to both 24 and 48 hour treatments with HU, it 
enhanced sensitivity in U20S cells. Therefore, the resistance of 1BR3hTERT cells to siORC1-
induced hypersensitivity is not explained by their slower cell cycle progression.  
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Figure IV.4 ORC1 depletion does not impact upon sensitivity of 1BR3hTERT fibroblasts 
to 48 hours of HU exposure. A. Exponentially growing 1BR3hTERT and U2OS cells were 
seeded at sub-confluent numbers similar to those used for the viability assay. Cells were grown 
in normal growth medium and harvested at the indicated time points. Cell number was assessed 
by manual scoring of live cells. Dead cells were detected by trypan blue staining and excluded. 
Cell number was normalized to the number seeded (t=0hr). Results represent the mean and SD 
from three experiments B. Cell doubling time was estimated from data in (A). Results represent 
mean and SD from three experiments. C-D. 1BR3hTERT (C) and U2OS (D) cells transfected 
with siRNA as described were treated with 2 mM HU for indicated times and HU-induced S-
phase damage was assessed by immunofluorescence labelling of γH2AX. Nuclei containing 
bright γH2AX pan-nuclear staining were scored as γH2AX+. Black arrows indicate the time of 
HU treatment required to obtain >95% γH2AX+ cells. E. As in Fig.IV.3.A except cells were 
exposed to HU for 48 hours. F. Clonogenic survival was assessed as in Figure IV.3.C except 
siRNA-treated 1BR3hTERT cells were seeded on a feeder layer and survival was estimated 21 
days following removal from 48 hour HU removal. G. As in Fig.IV.3.B except cells were 
exposed to HU for 48 hours. H. Relative HU IC50 values were estimated from the viability 
curves obtained in cells treated with HU for 24 (Fig.IV.3A-B)  or 48 hours (E, G) Results depict 
mean values +/- SD from three independent experiments. 
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To substantiate these findings without relying on siRNA-mediated depletion, I next 
examined non-tumour cell lines derived from two MGS patients which carry mutations in 
ORC1. As previously introduced, MGS is characterised by microcephaly, both pre- and post-
natal growth retardation, and skeletal abnormalities. Mutations in the origin licensing 
components ORC1, ORC4, ORC6, CDC6, and CDT1 have been identified in patients with MGS 
(de Munnik et al. 2012). ORC1-deficient MGS cells display diminished replication efficiency in 
a plasmid-based assay and slowed S-phase entry and progression (Bicknell et al. 2011b).   
ORC1-P1 LBLs have homozygous mutations in the BAH domain of ORC1 
(p.Glu127Gly) (Bicknell et al. 2011b).  Similar to published findings (Bicknell et al. 2011b), 
ORC1-P1 displayed reduced cellular levels of ORC1 (Figure IV.5.A). Examination of viability 
5 days after treatment with HU (Figure IV.5.B) or aphidicolin (Figure IV.5.C) revealed that 
ORC1-P1 LBLs were slightly more resistant than control LBLs to HU or aphidicolin at 
concentrations greater than 1 mM and 5 µM, respectively, with no enhanced sensitivity 
observed at any concentrations tested.  
Next, I examined an hTERT-immortalised fibroblast line derived from a distinct ORC1-
deficient MGS patient (ORC1-P4hTERT). ORC1-P4hTERT cells have hypomorphic mutations 
in the BAH domain (p.Arg105Gln) and C-terminus (p.Arg720Gln) (Bicknell et al. 2011b). 
Examination of ORC1 levels in insoluble (proteins bound to chromatin or other structures) or 
soluble (unbound) protein extracts  from 1BR3hTERT and ORC1-P4hTERT suggested that 
ORC1 chromatin binding is partially impaired in the MGS patient cells (Figure IV.5.D), as 
previously reported (Bicknell et al. 2011b). Interestingly, I observed resistance at higher HU 
concentrations rather than marked sensitivity of ORC1-P4hTERT to 24 hour treatment with HU 
(Figure IV.5.E). To confirm that this observed resistance to HU was not related to a slower cell 
cycle progression, HU treatment time was adjusted to achieve complete S-phase arrest in 
1BR3hTERT and ORC-P4hTERT (representing 48 or 72 hour exposures, respectively) (Figure 
IV.5.F). Under these conditions, resistance but not sensitivity to 0.5 mM HU was also observed 
(Figure IV.5.G). 
Overall, as depletion of ORC1 was observed to enhance sensitivity of tumour-derived 
U2OS cells but not non-tumour 1BR3hTERT cells to HU in both viability and clonogenic 
survival assays, I considered that of tumour-derived cells may have an increased reliance on 
dormant origin firing to recover from replication stress. 
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Figure IV.5 ORC1-deficient MGS patient cells do not display enhanced HU sensitivity. A. 
ORC1 protein levels were assessed by immunoblot in control (GM02188, WT) LBLs or in 
LBLs derived from an ORC1-deficient MGS patient (ORC1-P1). B-C. Viability was assessed 4 
days after release from 24 hour HU (B) or aphidicolin (C) treatment in Control or ORC1-
deficient fibroblasts. D. ORC1 protein levels were assessed in soluble and insoluble fractions in 
1BR3hTERT and ORC1-P4hTERT by immunoblotting. E. 1BR3hTERT or ORC1-P4hTERT 
were treated with HU (0.03-40 mM) for 24 hours. Viability was assessed 4 days post HU 
removal. F.  HU-induced S-phase damage was assessed in1BR3hTERT or ORC1-P4hTERT 
cells as in Figure IV.4.C-D. Arrows indicate the time of HU treatment required to obtain 100% 
γH2AX+ cells in 1BR3hTERT (black fill) and ORC1-P4hTERT (white fill). G. 1BR3hTERT or 
ORC1-P4hTERT cells were treated with 0.5 mM HU for 48 or 72 hours, respectively. Viability 
was assessed as above. 
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IV.2.3 ORC1 depletion reduces HU-induced new origin firing in tumour-derived 
U2OS cells 
To verify that ORC1 depletion results in diminished new origin firing after HU, as assumed in 
my hypothesis, HU-induced new origin firing was assessed using the DNA fibre assay in 
collaboration with Dr. Eva Petermann and Dr. Rebecca Jones (University of Birmingham). The 
DNA fibre assay can be exploited to measure origin activity by transiently labelling replicating 
DNA with two distinct nucleoside analogues prior to HU treatment or following release from 
the agent (Petermann et al. 2010b). As depicted in Figure IV.6.A, U2OS cells were treated with 
0.6 nM siORC1, grown for 48 hours, pulsed with CldU for 20 minutes, exposed to 2 mM HU 
for 24 hours, and pulsed with IdU for 1 hour. Cells were harvested and acid treated DNA fibre 
spreads were prepared, stained, and imaged using immunofluorescence methodology. 
CldU+/IdU+ replication tracks are considered to represent either ongoing tracts or tracts which 
restarted after HU removal, CldU+/IdU- replication tracks are considered to represent stalled 
forks that have not reinitiated replication and CldU-/IdU+ tracks represent tracts with newly fired 
origins (such as dormant origins)  (Figure IV.6.B).   
To assess levels of fork stalling and new origin firing in siControl or siORC1-
transfected cells, the number of these structures was quantified and normalised to the total 
number of replication tracks labelled with CldU (referred to as “% all CldU labelled”).While the 
fraction of forks stalled was similar after both siRNA treatments, siORC1-transfected U2OS 
cells displayed reduced new origin firing. As a control, fork stalling and new origin firing was 
assessed in cells not treated with HU and were found to be similar after siControl or siORC1 
(Figure IV.6.C).  
These findings strongly suggest that depletion of ORC1 diminishes dormant origin 
firing after HU whilst not affecting origin firing in unperturbed U2OS cells. Further 
examination into the impact of ORC1 depletion on HU-induced new origin firing in 
1BR3hTERT cells may shed light on whether non-tumour cells are able to restart stalled forks 
despite diminished dormant origin availability.  
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Figure IV.6 ORC1 depletion reduces HU-induced new origin firing in U2OS cells 
(Experiments performed by E. Petermann and R. Jones). A. Schematic of experimental setup for 
the DNA fibre assay. B. Representative images of labelled DNA fibres. CldU+ (red) and IdU+ 
(green)-labelled tracks represent ongoing/progressing forks, CldU+ IdU- represent fork stalling, 
and CldU- IdU+ represent new origin firing. C-D. The fraction of replication tracts containing 
stalled forks or newly fired origins was determined by scoring at least 130 structures per 
experiment. Values were then normalised to the number of all CldU labelled tracts. Results 
represent the mean values +/- SD from multiple independent experiments. 
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IV.2.4 ORC1 depletion reduces replication restart in tumour-derived U2OS cells 
but not in non-tumour 1BR3hTERT cells following release from HU 
Next, the impact of ORC1 depletion on overall replication restart was assessed in 1BR3hTERT 
and U2OS cells released from HU using a BrdU-based assay. While this assay does not 
distinguish between fork restart and dormant origin firing, it can provide a measure of 
replication re-entry at early times after release from HU.  
As depicted in Figure IV.7.A, siRNA-transfected cells were grown for 48 hours and 
exposed to 2 mM HU for 24 hours. Either immediately (0 hours) or at various times after release 
from HU (2, 4, or 24 hours), cells were pulse labeled with the nucleoside analogue, BrdU, 
which is incorporated into actively replicating DNA. Cells were then harvested, BrdU was 
labeled with an FITC-conjugated antibody to BrdU, DNA was stained by PI, and cells were 
analysed by flow cytometry. Both positive controls for active replication (cells untreated with 
HU but pulse-labeled with BrdU) and negative controls (cells untreated with either HU or 
BrdU) were included in each experiment. BrdU intensity was plotted vs. PI intensity, and the 
fraction of BrdU+ actively replicating cells was determined from control samples (Figure 
IV.7.B-D).  
Consistent with the analysis of replication inhibition, 24 hour HU treatment abolished 
BrdU incorporation in both cell lines (Figure IV.7.B-D). In 1BR3hTERT, BrdU incorporation 
was substantially recovered at 2 hours post HU removal and was similar in siControl or 
siORC1-treated cells. In marked contrast, although siControl-treated U20S cells also recovered 
DNA synthesis at 2 hours following HU removal, DNA synthesis was dramatically reduced at 
this time in siORC1-treated U20S cells. Since this difference is observed at early times (2 hours) 
post HU removal, this suggests that siORC1 does not impair early replication restart in HU-
treated 1BR3hTERT but does so in U20S.  
The DNA fragmentation associated with apoptosis can be identified as a sub-G1 
population by PI staining and flow cytometry (Darzynkiewicz et al. 1997). In siControl or 
siORC1-treated U2OS cells, the fraction of cells displaying sub-G1 DNA content was 
determined at early times after release from HU (Figure IV.7.D). As early as 0.5 hours 
following release from HU, an increase in sub-G1 cells was observed in ORC1-depleted 
samples, suggesting that at least some loss of viability may be attributed to the induction of 
replication stress-associated apoptosis (Figure IV.7.E).  
Together with the results obtained in the fibre assay, these findings strongly suggest that 
depletion of ORC1in U2OS cells impairs replication restart after release from HU via 
diminished dormant origin firing. In contrast, despite substantially reduced ORC1 levels, 
1BR3hTERT cells are able to recover replication after release from HU, potentially via 
alternative replication recovery mechanisms (Figure IV.1).  
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Figure IV.7 ORC1 depletion reduces replication restart following release from HU in 
U2OS but not 1BR3hTERT cells. A. Schematic of experimental setup for the BrdU assay. B-
D. The BrdU+ fraction of cells, representing active replication, was determined in siRNA-treated 
1BR3hTERT or U2OS cells 0, 2, 4, or 24 hours after release from 24 hour treatment with 2mM 
HU. (B) depicts mean values +/- SD from three independent experiments and representative 
plots of BrdU vs. PI are depicted in (C-D), with the boxed regions containing blue data points 
indicating BrdU+ cells and numbers in blue text representing the BrdU+ cell fraction. E. The 
fraction of sub-G1 cells was quantified in U2OS cells as in (C) except cells were harvested 0.5, 
1, or 2 hours following release from HU. 
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IV.2.5 ORC1 depletion results in the persistence of S-phase DNA damage in 
U2OS cells but not in 1BR3hTERT cells following release from HU 
Next, I examined whether the reduced replication restart observed in ORC1-depleted U2OS 
cells results in an accumulation of S-phase DNA damage, a threat to cell viability if left 
unrepaired. As depicted in Figure IV.8.A, siRNA-transfected cells were treated with HU as 
described, HU was washed out, and cells were fixed either immediately (0 hours) or 24 hours 
after release from HU. Immunofluorescence labelling of nuclei with DAPI, DNA damage with 
α-γH2AX, and G2/M-phase cells with α-CENPF was performed and staining was analysed 
using microscopic techniques. Replication stress from sources such as oncogene overexpression 
(Murga et al. 2011) or treatment with HU or aphidicolin (Lobrich et al. 2010), results in bright, 
pan nuclear γH2AX staining in CENPF- S-phase cells. The fraction of γH2AX+CENPF- cells 
was scored and compared across samples (Figure IV.8.B-C). Immediately following HU 
treatment, most cells were CENPF- (consistent with S-phase arrest) and showed pan-nuclear 
γH2AX staining, demonstrating the presence of collapsed/stalled replication forks; untreated 
cells had a lower fraction of γH2AX+cells. 24 hours post HU removal, few siControl or 
siORC1-transfected 1BR3hTERT cells were γH2AX+, consistent with the observed recovery of 
replication. Similarly, the number of γH2AX+siControl-treated U20S cells was dramatically 
reduced 24 hours post HU removal. In stark contrast, approximately 50 % of siORC1-treated 
U20S cells retained γH2AX staining 24 hours post HU removal while not staining for CENPF, 
consistent with the notion that they represent damaged S-phase cells. This analysis shows that 
1BR3hTERT undergo replication fork arrest and activate the DNA damage response after HU 
treatment but efficiently recover despite substantial depletion of ORC1. 
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Figure IV.8 ORC1 depletion results in the persistence of HU-induced S-phase DNA 
damage in U2OS but not 1BR3hTERT cells. A. Schematic of experimental setup for the S-
phase DNA damage assay. B-C. The γH2AX+ CENPF- fraction of cells, representing cells 
harbouring S-phase DNA damage, was determined in siRNA-treated 1BR3hTERT or U2OS 
cells 0 or 24 hours after release from 24 hour treatment with 2mM HU.  (B) depicts mean values 
+/- SD from three independent experiments. (C) depicts representative immunofluorescence 
images showing DAPI (blue, DNA), CENPF (red, cell cycle phase) or γH2AX (green, DNA 
damage). 
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IV.2.6 Depletion of additional licensing components sensitises tumour-derived but 
not non-tumour cells to HU-induced replication stress 
In order to verify that the effects observed were not specific to ORC1 depletion, I next 
examined the impact of depleting additional licensing components on HU sensitivity. First the 
expression levels of ORC6 and CDC6 in exponentially growing 1BR3hTERT and U2OS cells 
were assessed by western blot. Similar to the observed increased in ORC1 expression in U2OS 
cells, the expression of both ORC6 and CDC6 was found to be enhanced in U2OS cells 
compared to 1BR3hTERT (Figure IV.9.A).  
Next, the impact of depletion of ORC6 and CDC6 on HU sensitivity was assessed. 
1BR3hTERT or U2OS cells were transfected with 5 nM or 0.6 nM, respectively, of ON-
TARGETplus SMART pool siRNA oligonucleotides targeting ORC6 or CDC6 (Section II.2) 
and protein depletion was confirmed by western blotting 48 hours later. Transfection of 
1BR3hTERT and U2OS cells with 5 nM or 0.6 nM, respectively, of siRNA oligonucleotides 
substantially depleted ORC6 or CDC6 (Figure IV.9.B-C) but did not impede cellular 
proliferation. Specificity of these siRNA oligonucleotide pools was not verified here.  
Viability assessment in 1BR3hTERT cells revealed that neither siORC6 nor siCDC6 
affected HU sensitivity (Figure IV.9.D), similar to findings obtained with siORC1 transfection. 
In marked contrast, HU sensitivity was enhanced in U2OS cells following treatment with 
siORC6 or CDC6 similar to that observed after treatment with siORC1 (Figure IV.9.E). 
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Figure IV.9 Depletion of ORC6 or CDC6 enhances HU sensitivity of U2OS but not 
1BR3hTERT cells. A. Whole cell extracts were separated by SDS-PAGE and indicated protein 
levels were assessed by western blot. β-actin served as a loading control. B. As in (A) except 
1BR3hTERT cells were transfected with 5 nM of ORC1, ORC6 or CDC6, and grown for 48 
hours prior to lysis. C. As in (B) except U2OS cells transfected with 0.6 nM siORC1, siORC6, 
or siCDC6. D-E. 1BR3hTERT or U2OS cells were treated with siRNA as described in (A-B), 
treated with HU for 24 hours, and assessed for viability 4 days after release from HU. Viability 
plots from triplicate samples within representative experiments are depicted F. Relative HU IC50 
values from U2OS viability plots from three independent experiments are depicted. 
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IV.2.7 ORC1 deficiency or depletion results in enhanced HU sensitivity in 
additional tumour-derived cell lines without affecting HU sensitivity of 
additional non-tumour cell lines  
Next, in order to verify that the observations made were not specific to 1BR3hTERT and U2OS 
cells, the impact of reduced ORC1 levels on HU sensitivity was investigated in additional non-
tumour fibroblasts (BJhTERT, 48BR, and MRC-5) and tumour-derived lines (HeLa and MDA-
MB-231). BJhTERT is derived from foreskin tissue and immortalised with hTERT. 48BR 
(derived from skin tissue) and MRC5 (derived from fetal lung tissue) represent primary 
fibroblast lines to complement the analysis of hTERT-immortalised lines. HeLa cells, derived 
from cervical carcinoma, are reported to have a defective origin licensing checkpoint (Nevis et 
al. 2009) and require dormant origin firing to efficiently recovery from treatment with 
replication stress-inducing agents (Ibarra et al. 2008a). MDA-MB-231 cells are derived from 
breast adenocarcinoma and carry mutations in genes encoding proteins such as p16 (deleted) 
(Herman et al. 1995), p53 (Olivier et al. 2002), and the BRAF and KRAS oncogenes (activating 
mutations) (Wan et al. 2004).  
For all lines, the optimum siORC1 oligonucleotide concentration that failed to impact 
upon viability was examined (Figure IV.10). BJhTERT cells showed slightly diminished 
viability above 5 nM siORC1 similar to 1BR3hTERT cells; 5 nM was chosen for analysis 
(Figure IV.10.A). HeLa cells were resistant to high oligonucleotide concentrations; 0.6 nM was 
chosen to allow comparison to U20S (Figure IV.10.B). 48BR, MDA-MB-231, and MRC-5 
displayed diminished viability above 1 nM siORC1; 1 nM was chosen for analysis (Figure 
IV.10.C-E). The failure of these ORC1 knockdown conditions to impact upon viability was 
verified in three additional independent experiments (Figure IV.10.C-G). ORC1 depletion was 
also verified by immunoblot in all additional cell lines using siRNA oligonucleotide 
concentrations selected. Similar to observations made when comparing ORC1 levels in 
1BR3hTERT and U2OS cells, ORC1 expression was enhanced in HeLa and MDA-MB-231 
tumour-derived cell lines compared to BJhTERT, 48BR, and MRC-5 non-tumour cells (Figure 
IV.10.F). Importantly, the treatment of each additional cell line with siORC1 using the 
conditions selected was observed to result in a reduction in ORC1 protein levels.  
The time of HU treatment required to achieve complete HU-induced S-phase damage 
was also assessed in each cell line (Figure IV.11.A-E) and used for subsequent viability 
experiments. Similar to the observations previously made using 1BR3hTERT and U20S cells, 
siORC1 enhanced HU sensitivity of HeLa and MDA-MB-231 without substantially impacting 
upon sensitivity of BJhTERT, 48BR or MRC-5 cells (Figure IV.11.F-J). For MRC-5, slightly 
enhanced sensitivity was observed at high HU doses but there was no impact on the IC50 value. 
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Figure IV.10 Identification of siORC1 conditions likely to deplete dormant origin licensing 
capacity in additional non-tumour (BJhTERT, 48BR, and MRC-5) and tumour-derived 
cell lines (HeLa and MDA-MB-231). A-E. The impact of increasing siORC1 concentrations 
on viability was assessed as in Figure IV.2.A-B in BJhTERT (A), 48BR (B), MRC-5(C), HeLa 
(D), or MDA-MB-231 (E). F. ORC1 depletion using conditions identified in A-E was verified 
by immunoblot. G. The impact of siRNA oligonucleotides (using conditions identified in A-E) 
was assessed as in Figure IV.2.C. 
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Figure IV.11 ORC1 depletion enhances HU sensitivity of additional tumour-derived cell 
lines (HeLa and MDA-MB-23) but not of additional non-tumour cell lines (BJhTERT, 
48BR, and MRC-5). A-E. HU-induced S-phase damage was assessed in BJhTERT (A), 48BR 
(B), MRC-5(C), HeLa (D), or MDA-MB-231 (E) cells as in Figure IV.4.C-D. The impact of 
increasing siORC1 concentrations on viability was assessed as in Figure IV.2.A-B in BJhTERT 
(A), 48BR (B), MRC-5(C), HeLa (D), or MDA-MB-231 (E). F. ORC1 depletion using 
conditions identified in A-E was verified by immunoblot. G. The impact of siRNA 
oligonucleotides (using conditions identified in A-E) was assessed as in Figure IV.2.C. 
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IV.2.8 ORC1 depletion enhances sensitivity of tumour-derived HeLa and U2OS 
cells but not of non-tumour 1BR3hTERT and BJhTERT to H2O2-induced 
oxidative damage 
Having shown that ORC1 depletion hypersensitises U20S and HeLa but not 1BR3hTERT or 
BJhTERT cells to HU-induced replication fork stalling/collapse, I next used a similar approach 
to examine recovery from oxidative stress, which is also found to be enhanced in tumour cells 
(Szatrowski et al. 1991). The primary lesions generated by H2O2 involve ROS-mediated DNA 
base damage (Section I.2.1) and are distinct to those induced by HU. While the primary lesions 
induced by H2O2 are not replication-specific, a fraction of H2O2-induced lesions may be 
encountered by the replication fork during S-phase, causing replication stalling. Consistent with 
this notion, H2O2-induced DNA damage signalling (detected by γH2AX labelling) is found to 
colocalise with replication factories (Zhao et al. 2011). Therefore, H2O2 is likely to indirectly 
induce replication fork stalling/collapse.  
To assess the impact of diminished origin licensing on the recovery of non-tumour or 
tumour cells from oxidative stress, cells were treated with siRNA oligonucleotides as previously 
described, and H2O2 was added in differing concentrations. 24 hours later, H2O2 was washed out 
and after a further four days, viability was assessed. Strikingly, whilst siORC1 did not affect 
sensitivity of 1BR3hTERT or BJhTERT to H202, U20S and HeLa cells showed marked 
hypersensitivity (Figure IV.12.A-E). 
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Figure IV.12 ORC1 depletion sensitises tumour-derived but not non-tumour cell lines to 
H2O2-induced oxidative damage. 1BR3hTERT (A), U20S (B), BJhTERT (C), or Hela (D) 
cells were transfected with siRNA as described in Figures IV.3 and IV.11.  48 hours later, cells 
were treated with H2O2, with concentrations adjusted to account for substantial differences in 
sensitivity between cell lines. 24 hours later, H2O2was removed and viability assessed 4 days 
later. A-D. Representative viability plots. E.  Estimated IC50 values. 
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IV.2.9 Co-depletion of ORC1 and the p53 tumour suppressor in 1BR3hTERT 
cells enhances loss of viability in the presence and absence of HU.  
p53 loss abrogates the damage-induced G1/S checkpoint, enhancing S-phase progression and 
replication stalling (Wahl et al. 1997). Additionally, p53 is required for a licensing checkpoint 
which prevents S-phase entry until sufficient origins have been licensed (Shreeram et al. 2002; 
Ge et al. 2009). Here, I examined whether p53 depletion in 1BR3hTERT, using an ON-
TARGETplus SMART pool targeting p53 (Dharmacon, Thermo Scientific, Loughborough, UK) 
affects viability and HU sensitivity when combined with diminished origin licensing. As 
previously described (Section II.2), ON-TARGETplus SMART pool siRNA oligonucleotides 
are reported by the manufacturer to being highly specific as a result of unique dual-strand 
modification patterns used to synthesise the reagents. While, specificity of this oligonucleotide 
pool was not verified here, efficiency of p53 depletion was tested by immunoblot. 
1BR3hTERT cells were transfected with siControl, sip53, siORC1 or combined 
siORC1+sip53 using 5 nM siRNA oligonucleotides. Depletion of p53 was verified by western 
blot 48 hours after siRNA transfection and found to be efficient in both sip53 and 
siORC1+sip53-transfected cells (Figure IV.13A). Next, viability was assessed in the absence of 
HU 7 days after siRNA transfection. While no significant impact on viability was observed after 
transfection with siORC1 or sip53 alone, treatment with both sip53+siORC1 diminished 
viability by ~1.7x (Figure IV.13B). Assuming that the siRNA oligonucleotide pool employed in 
these studies specifically targets p53, and therefore these results reflect the impact of p53 
depletion, these findings suggest that in undamaged cells, siORC1 more markedly affects 
viability in the absence of p53. Assessment of sensitivity to 24 hour treatment with HU revealed 
that combined depletion of ORC1 and p53 also resulted in enhanced sensitivity to replication 
stress (Figure IV.13C). 
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Figure IV.13 Co-depletion of ORC1 and p53 in 1BR3hTERT cells enhances loss of 
viability in the presence and absence of HU. A. 1BR3hTERT cells were transfected with 5 
nM of indicated siRNA oligonucleotides and 48 hours later, efficiency of protein depletion was 
verified by immunoblotting. B. Cells transfected with siRNA as in (A) were assessed for 
viability 7 days after transfection as in Figure IV.2.C. C-D. HU sensitivity was assessed as in 
Figure IV.3.A-B. Viability plots are depicted in (C) and HU IC50 plots in (D). 
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IV.2.10  Depletion of ORC1 combined with aberrant oncogene expression results in 
enhanced DNA damage and loss of viability  
Overexpression of the c-Myc oncogene, which is frequently observed during carcinogenesis, 
enhances DNA damage, hyper-replication, replication stress, and proliferation (Dominguez-Sola 
et al. 2007; Herold et al. 2009b; Robinson et al. 2009). Further, c-Myc overexpression is 
reported to increase ROS levels and to disrupt p53 function, therefore allowing cells containing 
damage to progress into S-phase (Vafa et al. 2002). This consequence of c-Myc expression may 
contribute to the enhanced replication stress observed.  
The proliferative requirement for dormant origin licensing capacity was examined in a 
BJhTERT derivative cell line expressing c-Myc fused to a tamoxifen-inducible estrogen 
receptor (BJ-MYC-ER) (Dominguez-Sola et al. 2007; Herold et al. 2009b; Robinson et al. 2009) 
(kindly provided by Dr. Óscar Fernández-Capetillo) (Figure IV.14.A). First, efficiency of ORC1 
depletion was verified after treatment of BJ-MYC-ER cells with 5 nM siORC1 (Figure 
IV.14.B). Efficient tamoxifen-dependent induction of c-Myc expression has been demonstrated 
in a similar system to result in enhanced replication stress, as monitored by pan-nuclear γH2AX 
staining (Murga et al. 2011). This assay was therefore used to monitor efficiency of c-Myc 
induction and to examine the impact of diminished origin licensing capacity on c-Myc-induced 
replication stress. 24 hours post tamoxifen addition, ~30 % of siControl-transfected BJ-MYC-
ER cells were H2AX+, suggesting that c-Myc overexpression induces replication stress (Figure 
IV.14.C). Following siORC1, ~60 % of BJ-MYC-ER cells were H2AX+, raising the possibility 
that siORC1 causes enhanced or persistent c-Myc-induced replication arrest. 
Next, the viability of siControl or siORC1-treated BJ-MYC-ER cells was assessed 
following addition of tamoxifen/induction of c-Myc overexpression. First, viability was 
assessed 5 days following addition of 2 µM tamoxifen, a dose found to induce replication stress, 
as described above. BJhTERT cells not containing the c-Myc-expressing system were included 
to verify that addition of 2 µM tamoxifen did not impact upon viability in the absence of 
oncogene-induced replication stress. An approximately 70% loss in viability was observed in 
ORC1-depleted BJ-MYC-ER cells following tamoxifen-mediated induction of c-Myc 
expression while no loss of viability was observed in tamoxifen-treated BJhTERT cells (Figure 
IV.14.C). These results suggest that viability is specifically impacted by increased expression of 
the c-Myc oncogene in ORC1-depleted non-tumour fibroblasts. To extend these findings, 
viability was assessed in siControl or siORC1-treated BJ-MYC-ER 5 days after the addition of a 
range of tamoxifen concentrations.  ORC1-depletion was again observed to result in viability 
loss at multiple concentrations of tamoxifen (Figure IV.14.D-E).  
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Figure IV.14 Depletion of ORC1 combined with overexpression of the c-Myc oncogene in 
BJhTERT cells results in enhanced DNA damage and loss of viability. A. Schematic of the 
inducible c-Myc expression system in BJhTERT cells (BJ-MYC-ER). B. BJ-MYC-ER cells 
were transfected with 5 nM siControl or siORC1, grown for 48 hours, and ORC1 depleted was 
verified by immunoblot. C. BJ-MYC-ER cells were treated with siRNA oligonucleotides as in 
(B) and tamoxifen was added for 24 hours to induce expression of c-Myc. S-phase-induced 
DNA damage was then assessed by immunofluorescence labelling with γH2AX as previously 
described. D. BJhTERT or BJ-MYC-ER cells were transfected with siRNA oligonucleotides as 
described and treated with tamoxifen. 5 days later, viability was assessed. E. As in (D) except 
BJ-MYC-ER cells were treated with a range of tamoxifen concentrations. F. IC50 values were 
estimated from viability plots in (E).  
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IV.2.11 Chk1 inhibition further enhances the sensitivity of ORC1 or ORC6-
depleted tumour-derived U2OS cells to HU  
The DNA damage response kinase Chk1 is reported to be required for inhibition of late firing 
origins, promoting the firing of dormant origins within active replication clusters (Ge et al. 
2010). In response to HU-induced DNA damage, Chk1 is also reported to play a role in 
promoting Rad51 phosphorylation and subsequent HR-mediated repair (Sorensen et al. 2005). 
Chk1 inhibitors show promise as therapeutic agents in the treatment of cancer (Dai et al. 2010) 
in combination with replication stress-inducing agents such as HU or Gemcitabine (Montano et 
al. 2012). Here, I aimed to investigate whether the combined depletion of origin licensing 
inhibition, inhibition of Chk1 and treatment with HU could enhance cell death in tumour-
derived cells and therefore represent a potential therapeutic strategy.  
To examine this question, U2OS cells were transfected with siControl, siORC1, and 
siORC6 as previously described and treated with a range of HU concentrations for 24 hours. 
50nM of UCN-01, a selective inhibitor of Chk1 at submicromolar doses (Graves et al. 2000), 
was added for the last 0.5 hours of HU treatment and following release from HU (Figure 
IV.15.A) to examine the impact of Chk1 inhibition on the recovery from replication arrest.  
Assessment of viability revealed that the depletion of ORC1 or ORC6 enhanced sensitivity to 
UCN-01+HU in U2OS cells (Figure IV.15.B).  
These findings have positive implications for chemotherapeutic treatment with origin 
licensing inhibitors, Chk1 inhibitors, and HU, and tumour cells may be particularly sensitive to 
this combination.  
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Figure IV.15 Combined treatment with siORC1 or siORC6 and UCN-01 enhances HU 
sensitivity in U2OS cells. A. Schematic depicted experimental setup. Cells were transfected 
with 0.6 nM of siControl, siORC1, or siORC6. 48 hours later, HU was added at a range of 
concentrations (0.01-2 mM). 23.5 hours after HU addition, 50 nM UCN-01 was added to HU 
and cells. After a further 30 minutes, cells were washed, UCN-01 was re-administered, and cells 
were incubated for a further 4 days prior to viability assessment. B. Viability plots are depicted.  
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IV.3 Discussion 
Recent studies primarily from work using tumour-derived cell lines have provided evidence that 
dormant origins can be utilised to promote recovery from replication fork stalling or collapse 
(Woodward et al. 2006; Ge et al. 2007; Ibarra et al. 2008b; Blow et al. 2009; Kawabata et al. 
2011a). Since tumour cells display elevated oxidative damage (Maiti 2012) and replicative 
stress (Negrini et al. 2010) as well as increased expression of origin licensing components (Lau 
et al. 2007b), I reasoned that the requirement for dormant origin availability to maintain 
proliferation may be elevated in tumour cells. This raises the possibility that targeting origin 
licensing components could specifically inhibit cancer cell growth, potentially implicating 
origin licensing as a potential therapeutic target. Here, I have evaluated this by examining the 
reliance of various non-tumour and tumour-derived cell lines on origin licensing capacity to 
maintain viability under conditions of increased replication stress. 
 Consistent with previous findings (Karakaidos, Taraviras et al. 2004; McNairn and 
Gilbert 2005; Lau, Tsuji et al. 2007; Di Paola and Zannis-Hadjopoulos 2012), I observed higher 
ORC1 expression in tumour-derived cell lines (U2OS, HeLa, and MDA-MB-231) than non-
tumour cells (1BR3hTERT, BJhTERT, 48BR, and MRC-5). Further, higher levels of ORC1 
were required to maintain viability in U2OS and HeLa cells compared to non-tumour cells. 
While the increased expression of licensing components is likely to support increased DNA 
replication, this change may also provide enhanced dormant origin licensing capacity to 
promote ongoing proliferation in the face of enhanced replication stress. Consistent with 
findings that only 10 % of licensed origins are utilised during unchallenged replication (Anglana 
et al. 2003; DePamphilis et al. 2006; Gilbert 2010), I observed that both viability and replication 
could be maintained in both non-tumour and tumour-derived cells despite substantial depletion 
of origin licensing factors such as ORC1. I was able to identify siORC1 conditions which 
substantially depleted ORC1 levels but allowed for viability in the absence of exogenous 
replication stress in both non-tumour and tumour-derived cells, and considered these conditions 
to mainly deplete dormant origin licensing capacity. In support of this notion, conditions of 
ORC1 depletion which did not impact upon viability or replication fork stalling in the absence 
of HU were observed to reduce new origin firing (assessed by the DNA fibre assay) 1 hour after 
release from HU in U2OS cells.   
The exploitation of these siORC1 treatment conditions revealed a marked sensitisation 
of the tumour-derived lines to HU, compared to non-tumour cells. Further, these observations 
were similar after ORC1 depletion using distinct oligonucleotides and after HU treatment times 
adjusted to result in complete S-phase arrest, indicating that the findings were not specific to the 
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siORC1 oligonucleotide or HU exposure time selected. Using the longer term clonogenic 
survival assay, considered the “gold standard” for measuring cell killing, I continued to observe 
enhanced HU sensitivity in ORC1-depleted U2OS cells but similar sensitivity in ORC1-
depleted 1BR3hTERT cells, therefore validating the viability assay and substantiating my 
findings. The ability to routinely detect residual ORC1 in the siORC1-treated tumour but not in 
siORC1-treated non-tumour cells demonstrates that the observed distinctions between the cell 
lines cannot simply be explained by more efficient ORC1 knockdown in the tumour cells. In 
addition, no enhanced sensitivity was observed in the non-tumour ORC1-deficient MGS patient 
cells, despite the reduced levels of chromatin-bound ORC1 and replication licensing capacity 
reported in these cells (Bicknell et al. 2011b). Similar observations were observed when 
depleting additional licensing components ORC6 and CDC6 in 1BR3hTERT and U2OS cells.  
Overall replication restart, as measured by BrdU incorporation, was found to be 
unaffected in siORC1-treated non-tumour cells, while it was markedly impaired in siORC1-
treated U2OS cells by 2 hours and out to 24 hours following release from HU. Further, DNA 
fragmentation, identified by flow cytometry-based analysis of a sub-G1 population, was 
observed in siORC1-treated U2OS cells within 0.5-2 hours after release from HU. As detection 
of a sub-G1 population is associated with apoptosis (Darzynkiewicz et al. 1997), this result may 
suggest that the depletion of dormant origin capacity in tumour-derived U2OS cells results in 
some induction of cell death rapidly after release from HU. The distinctions in replication restart 
observed in siORC1 treated non-tumour and tumour cells were found to correlate with the 
persistence of S-phase-associated DNA damage 24 hours after release from HU and, ultimately, 
viability. Further investigation of replication recovery, S-phase damage resolution, and 
induction of cell death after extended times following HU release may be informative. As 
tumour-derived cells display increased expression of licensing components and increased 
proliferation compared with non-tumour cells, the number of active replication origins required 
to support replication is likely to be greater in tumour cells even under conditions of diminished 
dormant origin supply. It is feasible, therefore, that the recovery of the rapid replication 
observed in U2OS cells requires a longer timeframe than was measured in these experiments.  
These results described above suggest that 1BR3hTERT cells can efficiently employ 
other mechanisms of recovery from replication inhibition while U2OS cells have a greater 
reliance on dormant origin firing to do so. As previously introduced, HR-independent 
replication fork remodelling and HR-mediated repair of one-ended DSBs may represent 
potential mechanisms of recovery from replication stress (Petermann et al. 2010a). Perhaps 
these alternative mechanisms are exploited more readily in non-tumour cells than tumour cell 
lines and therefore may be used to promote efficient replication recovery in the absence of 
dormant origins. Further DNA fibre experiments which assess the ability of ORC1-depleted 
1BR3hTERT cells to restart stalled forks may shed light on this hypothesis.  
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One possible explanation for differential usage of replication recovery mechanisms in 
non-tumour and tumour cells may be related to differences in the stability of stalled replication 
forks. The prevention of fork collapse (inactivation of a replication fork) is required to avoid 
genome instability, one of the hallmarks of cancer (Segurado et al. 2009). If replication fork 
stability is compromised and sources of replication stress are enhanced in tumour-derived cells, 
this could feasibly result in increased fork collapse, although this has yet to be definitively 
demonstrated. Comparison of fork restart and new origin firing after various HU treatment times 
have suggested that new (dormant) origin firing is enhanced after conditions which induce 
replication fork collapse while fork restart may represent the main recovery mechanism 
activated by conditions which induce transient fork stalling (Petermann et al. 2010b). An 
enhanced reliance on dormant origin firing in contexts of increased fork collapse may be 
attributed to the fact that the replication machinery is thought to dissociate from collapsed forks, 
perhaps precluding efficient fork restart via HR-independent mechanisms (Forment et al. 2012). 
Therefore, both HR-mediated repair of inactivated forks and dormant origin firing may promote 
efficient recovery of replication in response to fork collapse. While this model may be 
appealing, more thorough investigation is needed to examine its validity.    
Extending my findings of a differential impact of diminished licensing capacity on HU 
sensitivity, I obtained similar results when examining sensitivity to H2O2-induced oxidative 
damage. Tumour cells have been reported to produce higher levels of ROS than non-tumour 
cells, in part resulting from the overexpression of oncogenes such as c-Myc (Vafa et al. 2002). 
While ROS may induce DNA lesions irrespective of cell cycle, replication stress may also be 
indirectly induced when forks encounter ROS-induced base damage. In support of this notion, a 
fraction of H2O2–induced damage signalling (as measured by γH2AX labelling) colocalises with 
replication factories (Zhao et al. 2011). Therefore, my observations that ORC1 depletion 
specifically sensitises tumour-derived cell lines to H2O2 demonstrate that my findings are not 
specific to HU treatment and extend to other sources of replication stress.    
My findings have demonstrated that co-depletion of p53 and ORC1 in non-tumour 
1BR3hTERT cells results in an enhanced loss of viability both in the absence and presence of 
HU. These results suggest that p53-depleted 1BR3hTERT cells have a greater reliance on 
dormant origin availability, potentially as a result of enhanced replication stress and/or reduced 
ability to recover using alternative mechanisms. Consistent with this notion, p53-/- MEFs treated 
with 2mM HU for 24 hours display increased Rad51 formation, enhanced DSBs (as measured 
by PFGE), and reduced replication recovery compared to p53+/+ MEFs  (Kumari et al. 2004). In 
addition to the well-characterised role of p53 in cell death and preventing cells which harbour 
DNA damage from proceeding to S-phase (Di Leonardo et al. 1994),  p53 signalling has been 
implicated in preventing premature S-phase entry in normal human fibroblasts depleted for 
origin licensing machinery (Nevis et al. 2009). Therefore, loss of factors such as p53 which 
178 
 
regulate the G1-S-phase transition may enhance endogenous replication stress by allowing cells 
with DNA lesions or, under conditions of diminished dormant origin supply, with too few 
origins to enter into S-phase. This premature S-phase entry may ultimately result in increased 
fork stalling/collapse. In response to HU, p53 has also been reported to associate with stalled 
forks in a BLM-dependent but ATM and Chk1-independent manner (Ho et al. 2006) where it is 
thought to regulate the DDR (Sengupta et al. 2003).  p53 has also been shown to regulate the 
activity of RNR, reflecting a role in replication regulation, particularly in the presence of 
damage (Xue et al. 2003).  dNTP pools are rate limiting for replication elongation, but 
upregulation of RNR and increased dNTP levels promote fork progression in the presence of 
DNA damage (Poli et al. 2012). Therefore, p53 loss is likely to have pleiotropic effects. Overall, 
p53 loss may enhance replication stress or prevent recovery from fork stalling/collapse by 
multiple mechanisms, placing a greater reliance on dormant origin firing to recover replication. 
As loss of viability is observed in HU-treated cells depleted for both ORC1 and p53, some p53-
independent cell death may contribute to HU sensitivity in these experiments.  
As described in Section IV.2.10, overexpression of c-Myc in normal human fibroblasts 
(BJhTERT) was observed to result in an enhanced reliance on origin licensing capacity to 
maintain viability. Overexpression of the c-Myc oncogene has been reported to increase 
replication stress, accelerate S-phase progression, and lead to the accumulation of ROS (Vafa et 
al. 2002; Dominguez-Sola et al. 2007; Robinson et al. 2009; Murga et al. 2011).  Perhaps to 
support increased replication, c-Myc has also been shown to impact upon cellular dNTP levels 
(Mannava et al. 2008). Further, c-Myc expression has be demonstrated to impede the DNA 
damage response (Guerra et al. 2010), interfere with p53 function (Vafa et al. 2002), and 
facilitate proliferation in the presence of damage (Herold et al. 2009a). Therefore, as c-Myc 
overexpression may lead to enhanced S-phase entry, hyper-replication, and replication stress, 
dormant origin firing may be more crucial to maintain proliferation in this context. Further 
examination of the impact of diminished dormant origin supply on the proliferative capacity of 
cells which overexpress additional oncogenes such as Ras may extend these findings.  
Finally, I demonstrated that ORC depletion further sensitises tumour cells to combined 
treatment with HU and a Chk1 inhibitor. As Chk1 inhibitors have shown promise in clinical 
trials studying the outcome of treatment with Chk1 and replication inhibitors, my findings 
implicate that origin licensing inhibition could provide added benefit to current clinical 
strategies.  
As discussed in more depth in Chapter VI, further examination of tumour types 
particularly sensitive to ORC depletion may increase our understanding of the potential clinical 
utility of diminished origin licensing capacity. As both HR-mediated repair and dormant origin 
firing may promote recovery from replication stress, tumours with mutations in HR factors such 
as BRCA1 or BRCA2 may be particularly sensitive to inhibitors of licensing components. 
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Further, combination treatment with reagents which inhibit factors required for HR, replication 
restart, or replication fork stability (ie. inhibitors of Chk1, PARP1, or ATR) may yield 
interesting results.  
Altogether, my findings have demonstrated that the 3 tumour cell lines selected for 
analysis have a greater reliance on dormant origin firing than the 4 non-tumour cell lines 
examined to maintain viability and recovery from replication stress. Importantly, ORC1 
expression was observed to be increased in all of the selected tumour-derived cell lines in 
comparison to that observed in the selected non-tumour cell lines. Upregulation of origin 
licensing factors may not, however, be universal across all tumours. In support of this notion, a 
previous study reported that CDT1 and CDC6 expression is elevated in ~50% of NSCLC 
tumours from a selected panel (Karakaidos et al. 2004). While the frequency of ORC1 
overexpression in tumours has not been thoroughly examined, it may be similar to that reported 
for CDT1 and CDC6. Further examination of a broader panel of cell lines may help to 
substantiate my findings and to determine whether tumour cells which do not overexpress 
licensing components also display enhanced sensitivity to replication stress under conditions of 
reduced origin licensing capacity.  
 As depicted in the model depicted in Figure IV.16, non-tumour cells display normal 
replication, cell cycle checkpoints, and DDR mechanisms. Therefore multiple mechanisms of 
replication stress recovery may be available in these cells. In non-tumour cells, the partial 
depletion of licensing factors, which reduces licensing capacity and availability of dormant 
origins, does not impact upon sensitivity to replication stress, as alternative mechanisms may 
promote replication restart, DNA damage recovery and viability (Figure IV.16.A).  In contrast, 
as a result of alterations such as the increased expression of oncogenes and decreased expression 
of tumour suppressor genes, tumour cells often display hyper-replication, increased expression 
of origin licensing factors, enhanced oxidative damage and/or replication stress, defective cell 
cycle checkpoints, and altered DDR mechanisms. These changes result in a greater reliance on 
dormant origin firing to recover from replication stress. Depletion of dormant origin availability 
in these cells results in impaired replication restart, DNA damage recovery, and viability (Figure 
IV.16.B). 
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Figure IV.16 Model for the differential reliance on dormant origin firing in non-tumour 
and tumour cells.  A. Non-tumour cells have normal levels of replication, normal cell cycle 
checkpoint activity, and a fully functional DDR. Depletion or inhibition of licensing factors 
reduces dormant origin firing (as indicated by the x). Under conditions of elevated replication 
stress and diminished dormant origin firing, alternative replication stress recovery mechanisms 
allow for replication restart, DNA damage recovery, and viability/survival. B. Tumour cells 
frequently display hyper-replication, increased expression of origin licensing factors, enhanced 
ROS and replication stress, defects in cell cycle checkpoints, and alterations in other DDR 
mechanisms. Therefore, these cells rely more heavily on dormant origin firing to recover from 
replication stress. Inhibition or depletion of licensing factors results in diminished origin 
licensing and reduced dormant origin firing in response to replication stress. After excess 
replication stress or treatment with replication inhibiting reagents, diminished dormant origin 
firing results in impaired replicating restart, DNA damage recovery, and viability.  
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The findings presented in this chapter provide evidence that the down-regulation of 
origin licensing components enhances the sensitivity of various tumour but not non-tumour cell 
lines to replicative stress, providing a potential route for specific sensitisation of tumour cells. 
Therefore, origin licensing may represent a suitable target for drug-based cancer therapy which 
may be particularly efficient in tumours which display high levels of replication stress or in 
combination with replication stress-inducing chemotherapeutic agents. Based on my findings, 
inhibition of licensing may be particularly effective in tumours deficient in p53 or which 
overexpress c-Myc. Further, combined treatment with origin licensing and Chk1 inhibitors may 
enhance sensitivity of tumours to replication-inhibiting chemotherapeutics. However, more 
work is needed to assess the feasibility of using small molecules to target licensing components. 
The binding of ORC1 to chromatin, a prerequisite for origin licensing, has recently been 
reported to occur via a highly specific interaction between the BAH domain of ORC1 and H4 
dimethylated at lysine 20. A dynamic aromatic cage within the BAH domain of ORC1 mediates 
high affinity binding with H4K20me2 (Kuo et al. 2012). While further investigation is needed, 
this site could provide a route for drug targeting.  
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V The impact of reduced levels of origin licensing factors on higher-
order chromatin structure and the IR-induced DDR 
V.1 Introduction 
As previously introduced, components of the pre-RC function in processes distinct to origin 
licensing including regulating centrosome duplication and transcriptional silencing. For the 
purpose of this chapter, evidence for a role of licensing factors in heterochromatin will be 
discussed.  
V.1.1 HP1 and heterochromatin 
As introduced in Chapter I, the mammalian HP1 adaptor protein family consists of the α, β and 
γ subunits which each contain a chromodomain and chromoshadow domain (Paro et al. 1991; 
Aasland et al. 1995) (Figure V.1.A). While HP1α and HP1β are predominantly found at 
heterochromatin regions and promote stabilization of chromatin compaction, HP1γ can also be 
found in euchromatin regions (Minc et al. 2000). In HeLa cells, HP1α is found to localise 
primarily to the periphery of nucleoli (the site of centromeric and pericentric heterochromatin) 
during interphase and to centromeric regions of chromosomes during mitosis (Minc et al. 1999).  
The binding of HP1 with chromatin has been attributed mainly to the interaction 
between the chromodomain of HP1 and trimethylated Histone H3K9 (H3K9me3) (Bannister et 
al. 2001; Lachner et al. 2001), a well-established marker of heterochromatin. Dimers of HP1 
linked by the chromoshadow domain (Cowieson et al. 2000) bridge neighbouring nucleosomes 
together and act as molecular scaffolds for binding of other heterochromatin factors such as 
HDAC and the SUV39H1 methyltransferase (Craig 2005; Grewal et al. 2007). Once targeted to 
heterochromatin, HP1 can promote further H3K9 trimethylation (Kourmouli et al. 2005) and 
spreading of chromatin compaction across extended regions of DNA (Verschure et al. 2005). 
The association of HP1 with chromatin is highly dynamic (Cheutin et al. 2003) and is 
thought to be regulated by multiple protein-protein interactions which occur primarily via the 
chromoshadow domain of HP1. The association of the HP1 chromoshadow domain with a 
PxVxL motif of KAP-1 facilitates binding of HP1 to methylated histone residues (Sripathy et al. 
2006). HP1 chromatin association is also promoted and regulated by SUV39H1 (Melcher et al. 
2000), which selectively methylates H3K9 residues (Rea et al. 2000). In addition to providing 
the H3K9me3 residues which facilitate chromatin binding of HP1, a direct interaction between 
the chromoshadow domain of HP1 and SUV39H1 has been identified and is thought to 
contribute to HP1 binding (Yamamoto et al. 2003; Stewart et al. 2005).  
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However, the interactions between HP1 and  H3K9me3 or SUV39H1 are not alone 
sufficient to recruit HP1 (Stewart et al. 2005) and HP1 recruitment may also occur in an 
H3K9me3-independent manner (Luijsterburg et al. 2009) (Quivy et al. 2004). Therefore other 
protein-protein interactions are required to promote the dynamic association of HP1 with 
chromatin. During S-phase in mouse cells, HP1α is reported to interact with chromatin assembly 
factor 1 (CAF-1) in a manner independent of SUV39H1 activity and H3K9me3 near pericentric 
heterochromatin (Quivy et al. 2004). As nucleosomes are disrupted ahead of replication forks 
during S-phase (Groth et al. 2007), CAF-1-dependent recruitment of HP1α may function to 
facilitate H3K9 methylation on newly synthesized DNA, therefore promoting epigenetic 
inheritance of the histone mark. Similarly, in replicating HeLa cells, a complex containing CAF-
1, HP1α, and the SETDB1 methyltransferase has been observed near pericentric 
heterochromatin (Loyola et al. 2009). A model has been proposed in which CAF-1 first directs 
the deposition of H3 onto newly synthesized DNA and subsequently promotes 
monomethylation of H3K9 tails at pericentric heterochromatin via recruitment of 
HP1α/SETDB1. Monomethylated H3K9 tails may then serve as a platform for trimethylation by 
SUV39H1/2, resulting in further spreading of HP1α binding and chromatin compaction (Loyola 
et al. 2009). In addition to these protein interactions and as described in the next section, the 
direct binding of HP1 with various ORC subunits is reported to promote HP1α recruitment. 
HP1 targeting to specific regions of heterochromatin and/or retention on chromatin may 
also be regulated by various PTMs identified on both the chromo- and chromoshadow domains 
of the HP1 subunits (LeRoy et al. 2009) or on various residues of interacting partners. 
SUMOylation of HP1α was recently reported to target the protein to regions of pericentric 
heterochromatin (Maison et al. 2011) and subsequent deSUMOylation has been proposed to 
promote its retention in these regions (Maison et al. 2012). During mitosis, HP1 has been 
observed to dissociate from chromatin in a process mediated by Aurora kinase B-dependent 
phosphorylation of H3 serine 10 (pH3(S10)). This phosphorylation event may disrupt the 
interaction between HP1 and H3K9me3, leading to the ejection of HP1 from chromatin (Fischle 
et al. 2005).  
V.1.2 Pre-RC factors and heterochromatin across eukaryotic species 
As previously introduced, the six subunits of human ORC are required for the efficient licensing 
of DNA replication origins and various subunits have also been demonstrated to participate in 
chromatin compaction. The function of the ORC subunits ORC1-5 in replication initiation is 
known to be highly conserved across species. While current evidence suggests that a role for 
ORC in heterochromatin may also be conserved, distinctions are apparent in the protein 
interactions thought to govern this role. 
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A link between replication licensing factors and transcriptional silencing was first 
identified in S. cerevisiae (Foss et al. 1993) and has since been shown to involve the interaction 
of an N-terminal region of ORC1 with silent information regulator 1 (SIR1), a trans-acting 
factor involved in silencing of the HM mating-type loci (Triolo et al. 1996). In addition, binding 
sites for ORC1 have been identified in the four silencer sequences that flank the repressed HM 
mating-type region (Rusche et al. 2003). Binding of ORC1 with SIR1 at silencer sequences is 
sufficient to silence transcription, using a mechanism comparable to heterochromatin formation 
in higher eukaryotes (Triolo et al. 1996).  Importantly, the functions of ORC components in 
silencing and replication initiation are genetically separable. Introduction of Drosophila 
melanogaster ORC2 complements the silencing defect but not the replication defect of a yeast 
ORC2 mutant (Ehrenhofer-Murray et al. 1995). Further, targeting of SIR1 to the HM mating-
type silencer alleviates the requirement for ORC in transcriptional silencing (Chien et al. 1993; 
Fox et al. 1997). In addition, ORC5 alleles which are functional in replication initiation but non-
functional in heterochromatin building and vice versa have been identified in S. cerevisiae  
(Dillin et al. 1997). 
In other eukaryotic species such as Drosophila melanogaster, Xenopus (Pak et al. 
1997), mouse (Auth et al. 2006), and human (Prasanth et al. 2010),  various pre-RC components 
have been reported to interact with the chromoshadow domain of HP1α (Figure V.1A-B). In 
Drosophila, ORC2 colocalises with heterochromatin regions and HP1 (Pak et al. 1997). In the 
maternally loaded cytoplasm of early Drosophila embryos, both ORC2 and  ORC6 co-
immunoprecipitate with HP1, and HP1 localization is altered in ORC2 mutants (Shareef et al. 
2003).  In Drosophila, the compaction of euchromatin into heterochromatin can be observed as 
position effect variegation, resulting in altered gene expression patterns. This process was found 
to be altered in ORC2 or HP1 mutants (Pak et al. 1997). In mouse, both ORC2 and CDC6 have 
been reported to interact with HP1α (Auth et al. 2006).  As described in more depth below, 
human ORC1 and ORC3 directly interact with the chromoshadow domain of HP1α. These 
interactions requires a domain overlapping with the BAH domain of ORC1 or the MIR and 
coiled-coil motif of ORC3 (Prasanth et al. 2010) (Figure V.1). 
While S. cerevisiae SIR1 bears no sequence similarity to Drosophila melanogaster, 
Xenopus, mouse, or human HP1, both proteins are crucial in transcriptional silencing and are 
thought to be regulated, in part, by interactions with ORC. The functionally conserved role for 
ORC in chromatin compaction may therefore reflect a need for replication licensing proteins to 
regulate heterochromatin (Leatherwood et al. 2003). 
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Figure V.1 Schematic depicting human ORC1, ORC3, and HP1α interaction domains. A. 
HP1α contains a chromodomain and chromoshadow domain connected by a hinge region. 
Domains involved in protein interactions described here are depicted in grey text. B. Schematic 
of ORC1 domains as in Figure I.8 with the region required for its interaction with HP1α 
indicated by grey text. C. Regions of ORC3 are depicted as in (B). 
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V.1.3 The role of human pre-RC factors in regulating chromatin compaction 
To date, much of the evidence for a role of human pre-RC factors in the establishment of 
pericentric and/or centromeric heterochromatin has been reported by Dr. Supriya Prasanth, Dr. 
Bruce Stillman, and associated colleagues. Interestingly, this group has proposed that individual 
ORC subunits may play distinct roles in heterochromatin formation (Chakraborty et al. 2011). 
The authors have suggested that differences in the chromatin binding characteristics of various 
ORC subunits may, in part, underlie these distinctions. 
In 2002, Prasanth and colleagues demonstrated that ORC6 functions in chromosome 
segregation (Prasanth et al. 2002), a process also found to be regulated by HP1-dependent 
centromeric heterochromatin formation (Kellum et al. 1995; Taddei et al. 2001). In 2004, the 
same group demonstrated that human ORC2 colocalises with HP1α and HP1β at 
heterochromatin regions during G1- and S-phase. During G1 and mitosis, ORC2 was found to 
localise specifically to centromeric heterochromatin. This study also demonstrated that 
depletion of ORC2 results in altered HP1α and HP1β localisation, changes in S-phase 
progression, and chromosome abnormalities during mitosis (Prasanth et al. 2004). 
 In a comprehensive study published in 2010, Prasanth and colleagues demonstrated 
that human ORC1 and ORC3 (but not ORC2, ORC4, ORC5, or ORC6) interact directly with 
HP1α (Prasanth et al. 2010). However, it is likely that, when associated in a complex, other 
ORC components may also indirectly interact with HP1α. In this study, distinctions were 
observed when examining the association of individual ORC subunits with HP1α. While the 
chromatin association of HP1α and ORC3 (and ORC2) were found to be highly dynamic, ORC1 
association was found to be significantly more stable. Further, depletion of ORC1 or ORC5 was 
reported to result in the redistribution of HP1α to the periphery of nucleoli whereas depletion of 
ORC2 or ORC3 results in loss of HP1α foci. Interestingly, ORC1-depleted cells were reported 
to display abnormal chromatin organization. Here, ORC1 depletion was observed to result in 
clustering of centromeres which colocalised with HP1α at the periphery of nucleoli. While the 
authors demonstrated that depletion of ORC3 or ORC2 resulted in abnormal compaction of the 
satellite repeats in centromeric heterochromatin, the impact of depletion of ORC1, ORC5, or 
ORC6 on satellite repeat compaction was not presented. Finally, this study demonstrated that 
depletion of ORC1, ORC2, or ORC3 does not impact upon Polycomb-associated repressive 
marks such as H3K27me3 (Prasanth et al. 2010). However, results demonstrating the impact of 
ORC depletion on H3K9me3 or the additional heterochromatin marker H4K20me3 were not 
presented. 
In addition to the role of the human ORC in establishing pericentric and/or centromeric 
heterochromatin, ORC subunits have been demonstrated to function in heterochromatin 
formation at telomeres. In a manner dependent on TERRA and a direct interaction with TRF2, 
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ORC is recruited to telomeres. Interruption of this interaction (via ORC2 depletion) results in a 
reduction in H3K9me3 levels at telomeres (Deng et al. 2009).  
 
V.1.4 Heterochromatin and the ATM-dependent DDR 
 
As previously introduced, the DDR to IR-induced DSBs occurring in G0/G1 and G2 is mediated 
primarily by ATM-dependent protein signalling. Following treatment with IR, ATM becomes 
autophosphorylated and dissociates into active monomers (Bakkenist et al. 2003). In response to 
DSBs, activated ATM rapidly phosphorylates H2AX at Ser139 (generating γH2AX) (Burma et 
al. 2001). γH2AX accumulation facilitates the recruitment of DDR proteins to sites of damaged 
DNA, which can be visualised as IRIF. In addition, ATM signalling coordinates the IR-induced 
arrest of cell cycle progression, a crucial process which provides time for the repair of DSBs 
and prevents genome instability (Lukas et al. 2004; Deckbar et al. 2011). ATM-dependent 
activation of the G2/M checkpoint involves phosphorylation of the Chk2 kinase, resulting in 
Cdc25 phosphorylation and inactivation of Cyclin B1 and Cdk1. The ATM-dependent G2/M 
checkpoint has been proposed to have a defined threshold of sensitivity as both the induction 
and maintenance of the checkpoint are influenced by the number of DSBs present (Buscemi et 
al. 2004; Deckbar et al. 2007). While ATM autophosphorylation and γH2AX foci can be 
detected after IR doses as low as 0.2 Gy (Bakkenist et al. 2003), Chk2 phosphorylation and full 
induction of cell cycle arrest is reported to occur only after doses above 0.5-1Gy, corresponding 
to >20 DSBs (Buscemi et al. 2004; Deckbar et al. 2007). Further, wildtype fibroblast cells 
irradiated with 1 Gy only sustain the G2/M arrest for 4 hours and progress into mitosis despite 
persisting DSBs. Analysis of premature chromosome condensation  (PCC) breaks, which each 
correspond to 3-6 DSBs, has revealed that cells re-enter cell cycle progression when 3-4 PCC 
breaks or ~10-25 DSBs γH2AX foci can still be detected in G2-phase cells (Deckbar et al. 
2007). Importantly, the majority of mitotic chromosome breaks arise in cells that have been 
released from checkpoint arrest rather than in irradiated mitotic cells.  
As introduced in Chapter I.3.4, an accumulating body of evidence has demonstrated that 
heterochromatin acts as a barrier to IR-induced DSB repair which may be overcome by ATM-
dependent signalling events (Ziv et al. 2006; Goodarzi et al. 2008; Goodarzi et al. 2010). 
Importantly, heterochromatin relaxation overcomes the requirement for ATM in DSB repair, as 
demonstrated in cells depleted for KAP-1, HP1αβγ, HDAC1/2, MeCP2, and DNMT3B 
(Goodarzi et al. 2008; Brunton et al. 2011) and in SUV39H1/2 -/- MEFs (Goodarzi et al. 2008). 
As discussed below, the requirement for ATM is also alleviated in cells from patients with 
disordered chromatin syndromes (Brunton et al. 2011).  
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Various human syndromes have been characterised which are associated with 
disordered chromatin including Rett syndrome, immunodeficiency with centromere instability 
and facial anomalies (ICF), and Hutchinson-Gilford progeria syndrome (HGPS) (Ausio et al. 
2003). Rett syndrome, a progressive neurodevelopmental disorder, is associated with mutations 
in MeCP2 which result in an altered capacity to organise heterochromatin (Amir et al. 1999; 
Agarwal et al. 2011). In addition to the role of MeCP2 in transcriptional silencing mediated by 
its binding to methylated CpG islands and subsequent recruitment of corepressors proteins such 
as HDAC1/2 (Section I.3.3), MeCP2 directly interacts with HP1. This interaction has been 
proposed to stabilise the association of both proteins with heterochromatin (Agarwal et al. 
2007). A large fraction of patients with ICF, a rare syndrome associated with immunodeficiency 
and facial anomalies, carry mutations in DNMT3B methyltransferase (Hansen et al. 1999). Cells 
from ICF patients are reported to display hypomethylation of satellite repeats, disruption of 
constitutive heterochromatin, and abnormal subcellular distribution of HP1 subunits (Luciani et 
al. 2005; Brun et al. 2011). Finally, HGPS is a premature aging syndrome associated with 
mutations in lamin A (Shumaker et al. 2006). As nuclear lamins not only provide the structural 
composition of the nucleus but also play a role in transcriptional silencing, lamin A-deficient 
HGPS patients display heterochromatin loss (Dechat et al. 2008).  
Findings from the examination of disordered chromatin syndrome patient cells have 
supported the model that heterochromatin not only poses a barrier to DSB repair but also 
restricts IR-induced DSB signalling (Brunton et al. 2011). Consistent with the notion that 
heterochromatin compaction is altered in these patient cells, precluding the requirement for 
ATM-dependent heterochromatin relaxation in DSB repair, treatment with an ATMi was not 
observed to impact upon DSB repair. Interestingly, IR-induced γH2AX signalling was enhanced 
in primary fibroblasts from a patient with Rett syndrome. Importantly, this enhanced γH2AX 
signalling was associated with regions of heterochromatin, as demonstrated by 
immunoprecipitation with H3K9me3. As heterochromatin regions can readily be visualised in 
MEFs as DAPI-dense chromocentres, siRNA-mediated depletion has been exploited in NIH3T3 
cells to examine the impact of altered chromatin structure on the expansion of γH2AX 
signalling at heterochromatin regions. While depletion of KAP-1, MeCP2, or DNMT3B did not 
impact upon the size or structure of chromocentres, depletion of these factors was found to 
enhance the expansion of γH2AX signalling at regions of heterochromatin. Both IR-induced 
ATM autophosphorylation and Chk2 phosphorylation were also enhanced in primary fibroblasts 
from a patient with Rett syndrome. Further examination demonstrated that this enhanced 
signalling results in increased sensitivity of the ATM-dependent G2/M checkpoint. Full 
activation of the G2/M checkpoint is inefficient in control cells, with little to no induction of the 
checkpoint observed at doses <0.25 Gy and complete induction was only observed at doses >1 
Gy, corresponding to >20 DSBs (Buscemi et al. 2004; Deckbar et al. 2007; Fernet et al. 2010). 
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However, cells from patients with Rett syndrome, ICF, or HGPS exhibited a hyperactive G2/M 
checkpoint, with partial checkpoint induction detected after treatment with just 0.1 Gy. 
Altogether findings suggest that heterochromatin may act as a barrier to ATM-dependent DSB 
signalling and the efficiency of the G2/M checkpoint. Further, these results demonstrate that this 
barrier is partially alleviated in cells from patients with disordered chromatin syndromes, 
resulting in alterations in the IR-induced DDR. 
 
V.1.5 Aims of this chapter 
 
As described above, studies in S. cerevisiae, Drosophila melanogaster, Xenopus and human 
cells have revealed that various members of the pre-RC are involved in heterochromatin 
formation. In human cells, members of ORC directly interact with HP1α and impact upon 
heterochromatin organization (Prasanth et al. 2010). Heterochromatin is thought to act as a 
barrier to DSB signalling and repair, and this barrier is observed to be alleviated in cells from 
patients with disordered chromatin syndromes or in cells depleted for heterochromatin factors 
(Goodarzi et al. 2008; Brunton et al. 2011). Recently, mutations in ORC1, ORC4, ORC6, CDC6 
and CDT1 were identified in patients with MGS (Bicknell et al. 2011a; Bicknell et al. 2011b). 
Here, I have examined whether cells depleted for pre-RC components or MGS patient cells 
deficient in pre-RC components display cellular characteristics consistent with alterations in 
higher-order chromatin structure.  
In Section V.2.1-2, I will present findings which demonstrate that the requirement for 
ATM in DSB repair is partially alleviated in fibroblasts derived from an ORC1-deficient MGS 
patient or in cells depleted for ORC1. In Section V.2.3, I will demonstrate that the sub-cellular 
distribution of heterochromatin markers HP1 and H3K9me3 is altered in these cells. The 
exploitation of high-resolution microscopy and analysis of γH2AX signal expansion at 
chromocentres in MEFs has enabled examination of DSB signalling at regions of 
heterochromatin (Brunton et al. 2011). Here, I have used this methodology to show that ORC1 
depletion enhances IR-induced DSB signalling at heterochromatin (Section V.2.4). Section 
V.2.5 will present results which demonstrate that ORC1-deficient MGS cells or cells depleted 
for ORC1 or HP1α have a hypersensitive IR-induced G2/M checkpoint. In Section V.2.4, I will 
demonstrate that cells depleted for ORC6 or cells from an ORC6-deficient MGS patient also 
display characteristics consistent with alterations in both heterochromatin organization and the 
IR-induced DDR. Results presented in this subsection will also demonstrate that 
heterochromatin organization and the IR-induced DDR are not significantly impacted in cells 
depleted for CDC6 or CDT1 or in cells from patients with CDC6 or CDT1-deficient MGS. 
Finally, in Section V.3 I will discuss the results presented in this chapter.  
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V.2 Results 
V.2.1 Fibroblast cells from an ORC1-deficient MGS patient display partial 
alleviation of the DSB repair defect caused by ATM inhibition 
 
Examination of IR-induced DSB repair in ORC1-MGS patient cells was first performed in our 
lab by Dr. Tom Stiff and colleagues. For these experiments, an hTERT-immortalised fibroblast 
line derived from an MGS patient carrying mutations in the BAH domain and C-terminus in 
ORC1 was utilised (Bicknell et al. 2011b). As previously described, these cells (ORC1-
P4hTERT) display reduced levels of chromatin-bound ORC1 protein (Bicknell et al. 2011b) 
(Figure IV.5.D). Control hTERT-immortalised fibroblasts or ORC1-P4hTERT cells were grown 
to plateau phase to enrich for G0/G1, treated with an ATMi for 30 minutes, and irradiated with 
3 Gy. Cells were fixed at various times after IR and DSB repair was assessed in G0/G1 cells by 
γH2AX analysis. Using this methodology, Dr. Tom Stiff and colleagues observed that the 
requirement for ATM was partially alleviated in ORC1-deficient MGS cells during G0/G1.  
I next went on to substantiate this finding in sub-confluent cells. 1BR3hTERT control 
fibroblasts and ORC1-P4hTERT cells were treated with ATMi and IR as described above, and 
aphidicolin was added at the time of irradiation to prevent the progression of S-phase cells into 
G2-phase (Figure V.2). As depicted in Figure V.2.A, in the absence of the ATMi, ORC1-
P4hTERT cells displayed similar repair kinetics to control fibroblasts during G0/G1.  ATM 
inhibition resulted in a defect in the repair of ~20 % of the induced DSBs in control cells, with 
~12 DSBs persisting 24 hours after exposure to 3 Gy. However, consistent with the observations 
made by Dr. Stiff and colleagues, this defect was partially rescued in ORC1-P4hTERT cells, 
and only ~5 DSBs persisted 24 hours after IR (Figure V.2).  
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Figure V.2 The requirement for ATM in DSB repair is partially alleviated in cells from an 
ORC1-deficient MGS patient.  hTERT-immortalised cells from a healthy individual 
(1BR3hTERT) or an MGS patient carrying mutations in ORC1 (ORC1-P4hTERT) were treated 
with DMSO (-ATMi) or 10 µM ATMi (+ATMi) for 30 minutes and irradiated with 3 Gy. 4µM 
aphidicolin was added at the time of irradiation to prevent the progression of cells damaged in 
S-phase and to facilitate cell cycle discrimination. Cells were fixed at indicated times and 
subjected to immunofluorescence labelling with γH2AX and CENPF antibodies. DSB repair 
was assessed by enumeration of γH2AX foci in G0/G1 (CENPF-) A. Mean values +/- SD from 
at least three independent experiments are depicted. B. Representative images of γH2AX and 
DAPI staining in CENPF- G0/G1 cells 24 hours after 3 Gy IR. 
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V.2.2 Control fibroblast cells depleted for ORC1 or HP1α display partial 
alleviation of the DSB repair defect associated with ATM inhibition 
To further substantiate this observation and to compare findings with those obtained after 
depletion of heterochromatin factors, the requirement for ATM in IR-induced DSB repair was 
assessed in 1BR3hTERT control fibroblasts transfected with a single ORC1-targeting 
oligonucleotide (siORC1 single), a distinct siORC1 oligonucleotide pool (siORC1 pool), or 
siKAP-1. As the role of ORC1 in heterochromatin association has been suggested to involve its 
direct interaction with HP1α (Prasanth et al. 2010), cells depleted for HP1α were also assessed. 
The combined depletion of the three HP1 subunits (HP1αβγ) has already been demonstrated to 
result in an alleviation of the requirement for ATM in DSB repair (Goodarzi et al. 2008). Here, I 
have examined cells transfected with an siRNA oligonucleotide which specifically targets the 
HP1α subunit (siHP1α).  First, cells were transfected with a single ORC1-targeting 
oligonucleotide (siORC1 single), with a distinct siORC1 oligonucleotide pool (siORC1 pool), 
siKAP-1, or siHP1α and knockdown was assessed by immunoblotting for ORC1 or KAP-1 
(Figure V.3.A) or by immunofluorescence analysis of HP1 levels (using an antibody raised to 
HP1α but which also recognises HP1β and γ) (Figure V.3.B). Next, DSB repair was assessed by 
γH2AX foci analysis 0.5 or 24 hours after 3 Gy IR in the presence or absence of an ATMi. 
Depletion of ORC1, KAP-1, or HP1α did not impact upon the number of DSBs induced 0.5 
hours after 3Gy (Figure V.3.C) nor on DSB repair measured 24 hours after IR in absence of 
ATMi (Figure V.3.D). However, depletion of these components resulted in an alleviation of the 
requirement for ATM in DSB repair 24 hours after IR (Figure V.3.D-E). KAP-1 depletion 
resulted in a nearly complete restoration of DSB repair capacity while ORC1 or HP1α depletion 
resulted in a partial restoration of repair. 
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Figure V.3 The requirement for ATM in DSB repair is partially alleviated in control 
fibroblasts depleted for ORC1 or HP1α. 1BR3hTERT cells were transfected with 
siORC1single, siORC1pool, siKAP-1, or siHP1α. A-B. 48 hours later, ORC1 or KAP-1 levels 
were assessed by immunoblotting (A) and by immunofluorescence analysis of HP1 using an 
antibody antibody raised to HP1α but which also recognises HP1β and γ (B). C-D. Cells were 
transfected with siRNA oligonucleotides as in (A) and the requirement for ATM in DSB repair 
was assessed as in Figure V.2A. E. Representative images of cells transfected with siControl or 
siORC1pool and assessed 24 hours later after IR as in (D). 
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V.2.3 The sub-cellular distribution of HP1 and H3K9me3 is altered in ORC1-
deficient MGS fibroblasts and in cells depleted for ORC1 
To evaluate whether changes in heterochromatin can be detected in ORC1-depleted control 
fibroblasts or in ORC1-deficient MGS cells, nuclear levels of HP1 were assessed by 
immunofluorescence using an antibody which recognises the three HP1 subunits (α, β, and γ). 
As controls, I also carried out this analysis following transfection with siHP1α or siKAP1. 
Quantification of nuclear intensity enabled an approximation of overall nuclear levels of HP1.  
As described above, depletion of HP1α resulted in markedly reduced nuclear levels of HP1  
(Figure V.3.B, Figure V.4.B). In addition, nuclear HP1 levels were reduced (although less 
dramatically) following KAP-1 depletion (Figure V.4.A-B). Consistent with a previous report 
that depletion of ORC1 impacts upon HP1 distribution (Prasanth et al. 2010), HP1 levels were 
observed to be reduced, though this reduction was not as dramatic as that observed after KAP-1 
or HP1α depletion. Comparison of HP1 levels in 1BR3hTERT and ORC1-P4 hTERT cells 
showed a significant decrease in the ORC1-P4 patient. 
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Figure V.4 ORC1-deficient MGS patient cells or control fibroblasts depleted for ORC1 
display a reduction in nuclear HP1 levels. A-B. 1BR3hTERT cells were transfected with 
siRNA oligonucleotides as described in Figure V.3 and nuclear levels of HP1 were assessed by 
immunofluorescence labelling with an antibody which recognises HP1α, β, and γ. 
Representative images are depicted in (A). Results from quantification of the nuclear intensity 
of HP1αβ+γ signal from a single representative experiment are depicted in (B). Similar results 
were obtained in two further experiments. >40 nuclei were scored per experiment. Statistical 
significance was assessed using the Mann-Whitney test. Asterisks denote statistical significance 
(*: p<0.05, **: p<0.01, ***:  p<0.001). C-D. Nuclear levels of HP1 were assessed in 
1BR3hTERT or ORC1-P4hTERT cells as in (A-B). 
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Next, a similar analysis was carried out using antibodies which recognise two additional 
heterochromatin markers, H3K9me3 and H4K20me3. As expected, transfection of 1BR3hTERT 
cells with siKAP-1 or siHP1α resulted in a significant reduction in H3K9me3 (Figure V.5.A). 
H3K9me3 levels were also observed to be reduced in ORC1-depleted cells (Figure V.5.A) or in 
ORC1-P4hTERT cells (Figure V.5.B-C). In contrast, while depletion of KAP-1 or HP1α 
resulted in a reduction in H4K20me3 (Figure V.6.E), no significant change was observed in 
cells depleted for ORC1 (Figure V.6.D-E) or in ORC1-P4hTERT cells (Figure V.6.F). 
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Figure V.5 ORC1-deficient MGS patient cells or control fibroblasts depleted for ORC1 
display a reduction in nuclear H3K9me3 levels. A. 1BR3hTERT cells were transfected with 
siRNA oligonucleotides as described in Figure V.3 and nuclear levels of H3K9me3were 
assessed by immunofluorescence labelling. Quantification of nuclear H3K9me3 levels was 
performed as in Figure V.4.B. B-C. H3K9me3 levels were assessed in 1BR3hTERT or ORC1-
P4hTERT cells as in (A). Representative images captured by high-resolution microscopy are 
depicted in (B) and quantifications are depicted in (C).  D-F. As in (A) except cells H4K20me3 
analysis was performed. Representative images of H4K20me3 staining in siControl or siORC1-
transfected cells are depicted in (D). 
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V.2.4 ORC1 depletion results in enhanced γH2AX signal expansion at 
heterochromatin regions  
Pericentric and centromeric heterochromatin can be visualised by regions of intense DAPI 
staining, termed chromocentres, in G0/G1-phase NIH3T3 murine cells (Guenatri et al. 2004; 
Goodarzi et al. 2008) (Figure V.6.A). As heterochromatin may act as a barrier to DSB 
signalling, cells depleted for heterochromatin factors such as KAP-1, MeCP2, or DNMT3B 
display enhanced γH2AX signal expansion at chromocentres (Brunton et al. 2011). Here, I 
evaluated whether depletion of ORC1 also impacts upon IR-induced DSB signal expansion at 
heterochromatin regions.  
First, the efficiency of ORC1 depletion in MEFs was assessed. Cells were transfected 
with a pool of siRNA oligonucleotides targeting mouse ORC1. 48 hours later, cells were lysed 
and extracts were subjected to SDS-PAGE. Immunoblotting demonstrated that transfection with 
siORC1 results in reduced levels of ORC1 in NIH3T3 cells (Figure V.6.B).  
As described previously, analysis of γH2AX foci and chromocentres using high-
resolution microscopy may be exploited to assess the overlap of DSB signalling at 
heterochromatin regions (Brunton et al. 2011). I applied this methodology to assess the impact 
of ORC1 depletion on DSB signal expansion in NIH3T3 cells. Analysis of chromocentres was 
restricted to G0/G1-phase cells because these regions become more diffused during G2 
(Goodarzi et al. 2009). To enrich for G0/G1, cells were grown to confluency. To further 
facilitate discrimination of cell cycle phase, aphidicolin was added at the time of IR and cells 
were labelled with α-Histone H3 phosphorylated on serine 10 (pH3(S10)), which can be readily 
detected during both G2 and mitosis in NIH3T3 (Brunton et al. 2011). Cells were treated with 3 
Gy IR, fixed 30 minutes later, and subjected to immunofluorescence labelling with α-γH2AX 
and DAPI.  Imaging of γH2AX foci, DAPI dense chromocentres, and pH3(S10) signal was 
performed using a DeltaVision high-resolution microscope. Z-stacked images of γH2AX foci 
and DAPI dense chromocentres were captured in pH3(S10)- G0/G1 cells, and images were 
deconvolved. Background DAPI staining was eliminated from images to highlight only DAPI-
dense chromocentres and colocalisation of γH2AX foci with chromocentres was measured and 
visualised in the red channel (Figure V.6.C). Next, the mean area of -γH2AX foci regions 
overlapping with chromocentres (depicted in the red channel) was quantified per cell with 
ImageJ. The area of overlap was then normalised to chromocentre number in each cell. Average 
cellular values were determined for each experimental condition and normalised to the average 
area of overlapping regions in siControl-treated cells (arbitrary units (A.U.)). Figure V.6.D 
depicts the mean A.U. +/- SD from two independent experiments. In order to compare the mean 
area of γH2AX foci which do not overlap with chromocentres between siControl and siORC1-
treated cells, the area of each γH2AX foci (the square pixel number of regions detected in the 
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green channel) was determined using ImageJ. Regions which overlap with chromocentres 
(detected in the red channel as described above) were eliminated from the analysis. The average 
square pixel number of non-overlapping foci regions was determined for each experimental 
condition and the mean square pixel number +/- SD from two independent experiments is 
depicted in Figure V.6.E. 
Consistent with the previously reported observation that most (80-85 %) IR-induced 
DSBs occur within regions of euchromatin (Goodarzi et al. 2010), the majority of γH2AX foci 
were observed to occur within regions not overlapping with chromocentres in both siControl 
and siORC1-transfected cells. The remaining fraction (~15-20 %) in siControl-transfected cells 
were observed near the periphery of chromocentres. As depicted, increased expansion of the 15-
20 % remaining γH2AX foci into chromocentre regions was observed in siORC1-transfected 
cells. Quantification of the size of overlapping region revealed a 4 fold increase in siORC1-
treated cells compared with the control (Figure V.6.D). Importantly, ORC1 depletion did not 
impact upon the size of γH2AX foci that did not overlap with chromocentres (Figure V.6.E). 
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Figure V.6 ORC1 depletion in NIH3T3 murine cells results in increased expansion of IR-
induced γH2AX foci at regions of heterochromatin. A. Heterochromatin can be visualised in 
NIH3T3 cells as DAPI-dense regions. A representative image of NIH3T3 cells treated with 3Gy 
IR, fixed 30 minutes later, and stained with DAPI and α-γH2AX is depicted. White * indicate 
DAPI-dense chromocentres. B. ORC1 protein levels were assessed in NIH3T3 cells 48 hours 
after mock transfection (mock), or transfection with siControl or siORC1 by western blotting. β-
actin was included as a loading control.  C-E. siRNA-transfected NIH3T3 cells were exposed to 
3Gy IR, treated with 4µM aphidicolin to facilitate discrimination of cell cycle phase, and fixed 
at indicated times. Immunofluorescence labelling with DAPI and α-γH2AX, and α-pH3(S10) (a 
marker of G2/M-phase in MEFs) was performed. Z-stacked images were acquired using a 
DeltaVision Axiovert high resolution microscope. G1 cells were selected for imaging, images 
were deconvolved, and overlapping DAPI-dense and α-γH2AX labelled regions were visualised 
using the red channel (SoftWorx). Representative images of DAPI (blue), α-γH2AX (green), 
overlap (red), merged channels, and enlarged images of chromocentres are depicted in (C). The 
mean area of -γH2AX foci regions overlapping with chromocentres per cell were quantified 
with ImageJ and normalised to the number of chromocentres per cell. Average cellular values 
were determined for each experimental condition and normalised to the average area of 
overlapping regions in siControl-treated cells (arbitrary units (A.U.)). Results in (D) depict 
mean A.U. values +/-SD from two independent experiments. The mean area of only γH2AX 
foci which do not overlap with chromocentres (in square pixels) was quantified using ImageJ. 
Results depict mean values +/-SD from two independent experiments (E). 
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V.2.5 Cells from ORC1-deficient MGS patients or cells depleted for ORC1 or 
HP1α display hypersensitivity of the IR-induced G2/M checkpoint 
As previously introduced, cells from patients with disordered chromatin syndromes display 
hypersensitivity of the G2/M checkpoint which is likely to be attributed to enhanced ATM-
dependent DSB signalling (Brunton et al. 2011). As I observed that a reduction in ORC1 
partially alleviates the requirement for ATM in DSB repair and enhances IR-induced γH2AX 
signalling, I next examined the sensitivity of the ATM-dependent IR-induced G2/M checkpoint 
in these cells.  
Cells in mitosis can be visualised after immunofluorescence labelling with DAPI and 
with an antibody that recognises pH3(S10) (Figure V.7.A). Enumeration of the fraction of cells 
in mitosis and monitoring the reduction in this fraction after IR provided a measure for efficacy 
of the G2/M checkpoint.  
Using this methodology, I first examined the impact of ORC1, HP1α, or KAP-1 on the 
initial activation of the checkpoint. 1BR3hTERT cells were transfected with siRNA 
oligonucleotides, exposed to a range of IR doses (0.1-3 Gy) and fixed 2 hours later. For all 
G2/M checkpoint analysis, aphidicolin was added at the time of IR to prevent cells damaged in 
S-phase from progressing through the cell cycle. Immunofluorescence labelling of DAPI and 
pH3(S10) was performed and the fraction of cells in mitosis was scored. Consistent with 
previous reports (Deckbar et al. 2007), siControl-treated 1BR3hTERT cells were observed to 
have an inefficient G2/M checkpoint, and showed very minimal checkpoint induction after 0.1 
Gy and complete arrest of cells at doses >1 Gy (Figure V.7.B). Also consistent with a previous 
results (Brunton et al. 2011), KAP-1 depletion was observed to enhance sensitivity of the G2/M 
checkpoint. Depletion of HP1α resulted in enhanced cell cycle arrest at lower doses that was 
comparable to that observed after KAP-1 depletion. Importantly, depletion of ORC1 using 
distinct siRNA oligonucleotides resulted in enhanced activation of the G2/M checkpoint, though 
this increase was not as dramatic as that observed in KAP-1 or HP1α-depleted cells.  
Next, I examined the impact of ORC1 depletion on the maintenance of the G2/M 
checkpoint. Cells were transfected with siORC1 and treated with 2 Gy IR. Again, aphidicolin 
was added at the time of IR as described above.  The G2/M checkpoint was then monitored 1, 2, 
6, 8, or 12 hours after IR to identify the length of time cells remain arrested. Consistent with 
reported results, (Deckbar et al. 2007), a fraction of siControl-treated 1BR3hTERT cells were 
observed to reinitiate cell cycle progression 6 hours after IR (Figure V.7.C). In contrast, ORC1-
depleted cells maintained complete G2/M arrest at this time. Mitotic re-entry was observed in 
ORC1-depleted cells 8 and 12 hours after IR. 
These analyses were next applied to ORC1-P4hTERT cells to assess sensitivity of the 
G2/M checkpoint. As depicted in Figure V.7.D, checkpoint activation in ORC1-P4hTERT was 
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observed after treatment with 0.1 Gy IR.  Further, the fraction of cells exhibiting G2/M arrest 
was greater at doses <1 Gy in ORC1-P4hTERT MGS patient cells than control fibroblasts. As a 
control, G2/M checkpoint activation was also monitored in a second control cell line 
(BJhTERT) and found to be similar to that of 1BR3hTERT (Figure V.7.E). Next, in conjunction 
with my colleague, Liang Xue, I examined the maintenance of G2/M arrest in ORC1-P4hTERT 
cells. Similar to findings after ORC1 depletion, we observed that ORC1-P4hTERT cells exhibit 
prolonged G2/M checkpoint maintenance (Figure V.7.F). 6 hours after IR, a fraction of 
1BR3hTERT cells began entering mitosis while ORC1-P4hTERT cells remained arrested. 
While a fraction of the ORC1-deficient patient cells did eventually progress into mitosis by 8 
hours, this fraction was lower than that observed in control cells. 
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Figure V.7 Cells from an ORC1-deficient MGS patient or cells depleted for ORC1 or 
HP1α display hypersensitivity of the IR-induced G2/M checkpoint. A. Representative 
images of a pH3(S10)- interphase cell or pH3(S10)+ mitotic cells. B. Activation of the G2/M 
checkpoint was assessed in 1BR3hTERT cells transfected with indicated siRNA 
oligonucleotides. Cells were exposed to a range of IR doses (0.1-3 Gy), aphidicolin was added 
at the time of IR, and cells were fixed 2 hours later. Immunofluorescence labelling with α-
pH3(S10) and DAPI was performed and the number of pH3(S10)+ mitotic cells was scored in 
>400 cells per condition in each experiment. Plots depict mean values +/- SD from three 
independent experiments. C. As in (B) except G2/M checkpoint maintenance was assessed at 
various times after treatment with 2 Gy IR. D-E. G2/M checkpoint activation was assessed 
in1BR3hTERT, BJhTERT, and ORC1-P4hTERT cells. F. G2/M checkpoint maintenance was 
assessed as in (C). Results depict mean values +/- SD from six independent experiments 
performed by myself and Liang Xue.  
A B
pH
3S
(1
0)
D
A
PI
Stage of mitosisInterphase
0
20
40
60
80
100
120
0 2 4 6 8 10 12
IR (Gy)
M
ito
tic
 c
el
ls
 (
%
 o
f c
on
tro
l)
G2/M checkpoint induction
G2/M checkpoint maintenance
siControl
siORC1single
Time (hr) after 2Gy IR
M
ito
tic
 c
el
ls
 (
%
 o
f c
on
tro
l)
0
20
40
60
80
100
120
0 0.5 1 1.5 2 2.5 3
siControl
siORC1 #1
siORC1 #2
siKAP-1
siHP1α
C D
0
20
40
60
80
100
120
0 0.5 1 1.5 2 2.5 3
0
20
40
60
80
100
120
0 2 4 6 8 10 12
IR (Gy)
M
ito
tic
 c
el
ls
 (
%
 o
f c
on
tro
l)
G2/M checkpoint induction
G2/M checkpoint maintenance
Time (hr) after 2Gy IR
M
ito
tic
 c
el
ls
 (
%
 o
f c
on
tro
l)
F
1BR3hTERT
ORC1-P4hTERT
1BR3hTERT
ORC1-P4hTERT
si 1single
si ontrol
si 1pool
si P-1
0
20
40
60
80
100
120
0 0.5 1 1.5 2 2.5 3
1BR3hTERT
BJhTERT
IR (Gy)
M
ito
tic
 c
el
ls
 (
%
 o
f c
on
tro
l)
G2/M checkpoint inductionE
204 
 
Next, I aimed to exploit complementation analysis to further substantiate the notion that 
the hypersensitivity of the G2/M checkpoint observed in ORC1-deficient MGS patient cells is a 
consequence of reduced ORC1 levels. ORC1-P4 hTERT fibroblasts were not used for this 
analysis as ORC1 overexpression was found to result in loss of viability in these cells (Section 
IV.2.2). Instead, complementation analysis was carried out in LBLs derived from an ORC1-
deficient MGS patient (ORC1-P1). Consistent with a previous report (Bicknell et al. 2011b), 
ORC1 levels were observed to be reduced in ORC1-P1 cells compared with GM02188 control 
LBLs (WT1) (Figure V.8.A). To achieve ORC1 overexpression, LBLs were transfected with an 
ORC1-GFP expression vector three times over 72 hours. Using these conditions, ORC1-GFP 
overexpression was found to be highly efficient, with >90 % of cells expressing detectable GFP 
signal (Figure V.8.B). Examination of G2/M checkpoint activation revealed that ORC1-P1 cells 
transfected with an empty vector exhibit hypersensitivity of G2/M arrest, similar to observations 
made in ORC1-P4hTERT cells (Figure V.8.C). Importantly, transfection with ORC1 cDNA 
relieved this hypersensitivity and conferred a level of G2/M arrest similar to that observed in 
LBLs derived from a normal individual. 
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Figure V.8 ORC1 complementation restores normal G2/M checkpoint signalling in ORC1-
P1 MGS patient cells. A. ORC1 levels were assessed by immunoblot in WT1 and ORC1-P1 
LBLs. B. WT1 and ORC1-P1 LBLs were transfected with an ORC1-GFP expressing construct 
three times over 72 hours. GFP levels were assessed by immunofluorescence and the fraction of 
cells expressing GFP was estimated. C. G2/M checkpoint activation was assessed as in Figure 
V.7B. 
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V.2.6 ORC6-deficient MGS patient cells or cells depleted for ORC6 display 
characteristics consistent with disordered chromatin 
To extend my observations that cells with reduced ORC1 levels display alterations in both 
heterochromatin organization and the IR-induced DDR, I also examined the cellular impact of a 
reduction in ORC6, CDC6, or CDT1 levels. As previously introduced, hypomorphic mutations 
in ORC6, CDC6, and CDT1 have been reported in patients with MGS (Bicknell et al. 2011a; 
Bicknell et al. 2011b; Guernsey et al. 2011; de Munnik et al. 2012).  While we have obtained 
LBLs derived from individuals with ORC6, CDC6, or CDT1 mutations, fibroblast cell lines 
from these patients are currently unavailable. Unfortunately, γH2AX foci cannot be accurately 
quantified in round LBLs, and instead, siRNA-mediated depletion of these licensing 
components in control fibroblasts was exploited to examine whether a reduction in levels of 
these proteins impacts upon IR-induced DSB repair.  
 Efficiency of protein knockdown was first verified by immunoblotting 48 hours 
following siRNA-mediated depletion (Figure V.9A). Next, the impact of protein depletion on 
heterochromatin distribution was assessed. Since ORC1 depletion results in a significant 
reduction in nuclear H3K9me3, this heterochromatin marker was also assessed in cells depleted 
for ORC6, CDC6, or CDT1. Strikingly, depletion of ORC6 resulted in diminished H3K9me3 
levels (Figure V.9.B). However, despite substantial depletion of protein levels as detected by 
immunoblotting, siCDC6 or siCDT1 did not impact upon H3K9me3.  
Next, the requirement for ATM in DSB repair was assessed in siORC6, siCDC6, or 
siCDT1-transfected cells as previously described. DSB induction was observed to be similar in 
siControl, siORC6, siCDC6, or siCDT1-transfected cells 0.5 hours after IR (Figure V.9.C). 
Examination of cells 24 hours after IR revealed that, similar to that observed after ORC1 
depletion, ORC6 depletion resulted in a partial alleviation of the requirement for ATM in DSB 
repair (Figure V.9.D). In contrast, cells depleted for CDC6 or CDT1 were defective in the repair 
of ~15 % DSBs following treatment with an ATMi. 
 In addition, examination of the efficiency of G2/M checkpoint activation revealed that 
depletion of ORC6, but not CDC6 or CDT1, resulted in hypersensitivity of the G2/M 
checkpoint (Figure V.9.E). Availability of LBLs derived from individuals with mutations in 
ORC6, CDC6, or CDT1 also enabled analysis of the G2/M checkpoint in MGS patient cells. 
Similar to findings observed after siRNA-mediated depletion, ORC6-deficient MGS patient 
cells also displayed enhanced sensitivity of the G2/M checkpoint activation while checkpoint 
arrest was only minimally affected in CDC6 or CDT1-deficient MGS patient cells (Figure 
V.9.F). ORC6-deficient MGS patient cells also exhibited delayed mitotic progression after 
irradiation with 2 Gy (Figure V.9.G). 
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Figure V.9 Depletion of ORC6 but not of CDC6 or CDT1 results in cellular characteristics 
consistent with disordered chromatin. 1BR3hTERT cells transfected with indicated siRNA 
oligonucleotides were grown for 48 hours. A. ORC6, CDC6, and CDT1 levels were assessed by 
immunoblotting. β-actin served as a loading control. B. Nuclear H3K9me3 levels were assessed 
as described in Figure V.5. C-D. DSB repair was assessed in siRNA-transfected cells treated 
with DMSO (-ATMi) or 10 µM ATMi (+ATMi) as described in Figures V.2. E-F. Efficiency of 
the G2/M checkpoint activation was assessed in siRNA-transfected cells (E) or LBLs from 
healthy individuals (GM02188=WT1, AG09387=WT2) and MGS patients with mutations in 
indicated genes (F). G. G2/M checkpoint maintenance was assessed in LBLs from a healthy 
individual (WT1) or from an ORC6-deficient MGS patient. 
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V.3 Discussion 
Human ORC subunits have previously been reported to contribute to heterochromatin 
organisation (Prasanth et al. 2010) but, until recently, cells from human patients which harbour 
mutations in pre-RC components were not available. Several MGS patients with mutations in 
various ORC components, CDC6, and CDT1 have now been identified. MGS is characterised 
by bone abnormalities, microcephaly and both pre- and post-natal dwarfism (Bicknell et al. 
2011a; Bicknell et al. 2011b; Guernsey et al. 2011; de Munnik et al. 2012). While these features 
are detected in most MGS patients with mutations in pre-RC components, distinctions in the 
severity of these symptoms have been observed between patients (de Munnik et al. 2012). 
Understanding the cellular features which distinguish these patients may shed light on 
differences in the severity of phenotypes associated with MGS. The impact of these disease-
associated mutations on heterochromatin organisation and the IR-induced DDR has not fully 
been explored. Here I have examined these features in cells from MGS patients and in control 
fibroblasts depleted for ORC1, ORC6, CDC6, or CDT1.   
Following initial observations made by colleagues in our lab, I have substantiated 
findings that the requirement for ATM in DSB repair is partially bypassed in ORC1-deficient 
patient cells. Cells from patients with disordered chromatin syndromes such as Rett syndrome 
also display a reduced requirement for ATM in DSB repair (Brunton et al. 2011). This finding is 
attributed to the notion that heterochromatin acts as a barrier to DSB repair and that ATM-
dependent signalling is required for localised changes in heterochromatin which promote 
subsequent repair (Goodarzi et al. 2010). ORC1 directly interacts with HP1α via a motif in the 
BAH domain of ORC1, and depletion of ORC1 has been reported to alter the nuclear 
distribution of HP1α (Prasanth et al. 2010). Importantly, Prasanth and colleagues have 
demonstrated that depletion of ORC2 or ORC3 results in the loss of HP1α foci and in abnormal 
compaction of satellite repeats. In contrast, ORC1 was reported to result in an accumulation of 
HP1α at the periphery of nucleoli, and the authors proposed that these regions may consist of 
clustered centromeric heterochromatin (Prasanth et al. 2010). Therefore, a model has been 
proposed in which ORC1 regulates heterochromatin organisation only at specific regions via its 
interaction with HP1α. Consequently, in the absence of ORC1, the interaction between ORC3 
and HP1α may still promote HP1α recruitment to specific regions of heterochromatin 
(Chakraborty et al. 2011). 
Here, we have found that the alleviation of the requirement for ATM in DSB repair is 
less dramatic in ORC1-P4hTERT cells than that observed in cells depleted for KAP-1. Several 
possible explanations may exist. Firstly, as suggested by Prasanth, Stillman, and colleagues, 
ORC1 may only function in the organization of certain regions of heterochromatin. Thus, 
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heterochromatin organisation may be functional within specific regions in ORC1-P4hTERT 
cells and the repair of DSBs occurring in these regions may still require ATM-dependent 
signalling. Alternatively, even if the interaction between ORC1 and HP1α is disrupted, some 
ORC1-independent recruitment of HP1α to heterochromatin may still occur. In this scenario, 
while less HP1α may be associated with chromatin, this may still enable some degree of 
compaction. Secondly, mutations in ORC1 found in MGS patients are hypomorphic, and 
therefore result in reduced levels of protein, or in the case of ORC1-P4hTERT cells, reduced 
chromatin association of ORC1. Only one of the two ORC1 mutations identified in ORC1-
P4hTERT cells is localised within the BAH domain (aa 105) (Bicknell et al. 2011b). Therefore 
our observations that the requirement for ATM in DSB repair is only partially alleviated in 
ORC1-P4hTERT cells may reflect the ability of some residual protein to interact with HP1α and 
function in heterochromatin organisation. Thirdly, our results may reflect the fact that HP1α 
itself is not exclusively required for heterochromatin organisation.  
A partial alleviation of the requirement for ATM in IR-induced DSB repair was also 
observed in control fibroblasts depleted for ORC1 using multiple siRNA oligonucleotides. 
While depletion of protein was observed to be efficient by immunoblotting, ORC1 is essential 
for cellular proliferation; hence, some residual protein is likely to exist in ORC1-depleted 
control fibroblasts. Consequently, it may not be possible to address the question of why only 
partial alleviation of the requirement for ATM in DSB repair is observed using siRNA-mediated 
protein depletion. However, as the requirement for ATM in DSB repair is reduced both in 
fibroblasts from an ORC1-deficient MGS patient and in cells depleted for ORC1, our 
observations are likely to reflect a direct impact of ORC1. Depletion of all three HP1 subunits 
was previously reported to relieve the requirement for ATM for DSB repair (Goodarzi et al. 
2008). Here I have also demonstrated that depletion of the HP1α subunit alone provides similar 
results.  
In support of the notion that heterochromatin organisation is altered in ORC1-deficient 
MGS cells, nuclear levels of the heterochromatin markers HP1αβγ and H3K9me3 were found to 
be reduced in ORC1-P4hTERT. Similar findings were obtained after siRNA-mediated depletion 
of ORC1. As alterations in the recruitment of HP1α are likely to result in reduced recruitment of 
SUV39H1 and in reduced trimethylation of H3K9, these findings may reflect an important role 
of ORC1 in HP1α recruitment. Perhaps surprisingly, nuclear levels of H4K20me3, an 
additional heterochromatin marker, were not altered in ORC1-deficient MGS patient cells or in 
ORC1-depleted fibroblasts. In contrast, a reduction in nuclear H4K20me3 levels were detected 
in cells depleted for KAP-1 or HP1α. This result may reflect a differential impact of ORC1 on 
H3K9me3 versus H4K20me3. However, this finding may simply reflect the sensitivity of this 
analysis. Subtle changes in H4K20me3 may not be detected by analysis of nuclear levels of 
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protein, and therefore, further exploration of the impact of ORC1 on H4K20me3 using high-
resolution microscopy may be informative.  
Examination of IR-induced γH2AX foci which colocalise with chromocentres in MEFs 
revealed that depletion of ORC1also results in the expansion of DDR signalling at 
heterochromatin regions. Similar to observations in NIH3T3 cells depleted for MeCP2 or 
DNMT3B, which are altered in Rett syndrome and ICF, respectively, ORC1 depletion was 
found to result in an increase in the size of γH2AX foci regions which overlap with 
chromocentres (Brunton et al. 2011). In contrast, the size of γH2AX foci which did not overlap 
with chromocentres was unaffected in ORC1-depleted cells. These findings suggest that ORC1 
depletion specifically impacts upon DSB signalling at heterochromatin regions and does not 
affect signalling within euchromatin. As heterochromatin is thought to restrict DSB signalling, 
this observation is consistent with the notion that a reduction in ORC1 results in altered 
heterochromatin organisation and enhanced ATM-dependent DSB signalling.  
Alterations in ATM-dependent signalling and the G2/M checkpoint have also been 
observed in cells from patients with disordered chromatin syndromes such as Rett syndrome, 
ICF, and HGPS (Brunton et al. 2011). Similarly, hypersensitivity of the G2/M checkpoint was 
observed in cells from distinct ORC1-deficient MGS patients and in cells depleted for ORC1. 
Both activation and maintenance of the checkpoint were observed to be altered in ORC1-
P4hTERT cells and ORC1-depleted 1BR3hTERT cells. Further, overexpression of ORC1 was 
found to restore normal sensitivity of the G2/M checkpoint in ORC1-P1 LBLs. These findings 
demonstrate that a reduction in ORC1 results in enhanced sensitivity of the G2/M checkpoint, 
likely as a result of enhanced ATM-mediated DSB signalling.  
Finally, I demonstrated that ORC6 also impacts upon heterochromatin organisation and 
the IR-induced DDR. Similar to observations made after ORC1 depletion, ORC6-depleted 
fibroblasts displayed reduced levels of H3K9me3, a partial alleviation of the requirement for 
ATM in DSB repair, and enhanced sensitivity of the G2/M checkpoint. Further, LBLs from an 
ORC6-deficient MGS patient displayed hypersensitive G2/M checkpoint activation and 
prolonged maintenance of the checkpoint. In contrast, depletion of CDC6 or CDT1 did not 
impact these cellular characteristics. Further supporting these findings, G2/M checkpoint 
efficiency was similar in control LBLs and in LBLs from patients with CDC6 or CDT1-
deficient MGS. Therefore, these results have suggested that ORC-dependent heterochromatin 
organisation is performed either independently of pre-RC formation or prior to CDC6 and 
CDT1 recruitment. Importantly, these results demonstrate that cellular distinctions exist 
between ORC-deficient MGS and CDC6 or CDT1-deficient MGS patients. 
In considering the evolutionary reason for the close link between ORC and 
heterochromatin, there are several possible explanations. As DNA replication involves histone 
deposition, one possible explanation may be that changes in higher-order chromatin structure in 
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ORC-depleted cells arise indirectly from replication defects. However, as the function of ORC 
in heterochromatin is genetically separable in S. cerevisiae (Bell et al. 1995; Dillin et al. 1997), 
this explanation is unlikely. A second model proposes that the association of ORC with 
heterochromatin via interactions with chromatin factors facilitates the replication of these 
transcriptionally silenced regions which are inherently difficult to replicate (Leatherwood et al. 
2003). While this model explains why ORC would be recruited to heterochromatin regions, it 
does not fully address why ORC is also involved in the formation of heterochromatin. 
Alternatively, a third explanation may be that ORC recruitment to heterochromatin and ORC-
dependent spreading of chromatin compaction functions to regulate the scheduled replication of 
specific genomic regions during S-phase. As introduced in Chapter I, the timing of replication 
of DNA regions is regulated, in part, by chromatin compaction, with euchromatin generally 
replicating early in S-phase and heterochromatin replicating later. Various ORC subunits may 
contribute to this regulation by promoting heterochromatin formation, for example, via the 
recruitment of HP1 to chromatin. In support of this notion, mutation of Drosophila ORC2 
results in altered timing of replication, with some euchromatic regions getting duplicated later 
than regions normally known to exist as heterochromatin (Loupart et al. 2000; Chakraborty et 
al. 2011). Further, loss of Drosophila HP1 results in alterations in the timing of replication of 
repeat regions (Schwaiger et al. 2010) and mouse cells lacking SUV39H1/2 duplicate DNA 
within chromocentre regions earlier in S-phase than control cells (Wu et al. 2006). It may be 
feasible that the recruitment of ORC to chromatin, mediated by factors such as HMGA1a and 
ORCA, promotes HP1α recruitment and subsequent chromatin compaction specifically at 
regions which are replicated late in S-phase. Based on my findings that CDC6 and CDT1 do not 
have as significant an impact on heterochromatin organisation as ORC components, this process 
may occur prior to or independently from assembly of the pre-RC. While the model that ORC is 
specifically involved in the regulation of replication timing in human cells is appealing, further 
investigation is needed to either confirm or challenge this possibility.  
Overall, the results presented in this chapter support a model in which ORC subunits 
function in heterochromatin formation in human cells to a greater extent than other pre-RC 
components such as CDC6 and CDT1. The findings presented in this chapter have also 
implicated ORC1 and ORC6-deficient MGS as a disordered chromatin syndrome, potentially 
distinguishing these disease phenotypes from CDC6 or CDT1-deficient MGS. The question of 
whether a defect in heterochromatin organisation contributes to the clinical manifestation of 
MGS will be discussed in Chapter VI. Finally, I have demonstrated that cells from ORC-
deficient MGS patients or in ORC-depleted fibroblasts display a partial alleviation of the 
requirement for ATM in DSB repair, enhanced DSB signalling, and hypersensitivity of the 
G2/M checkpoint.  
212 
 
VI Conclusions and perspectives 
VI.1 Major thesis aims 
The maintenance of genome stability is crucial for the prevention of tumourigenesis. The 
molecular pathways which regulate replication activity, the segregation of chromosomes during 
mitosis, cell cycle progression, transcriptional activity, cellular survival or death, and the 
response to various types of DNA damage are vital in maintaining genome stability. 
Consequently, aberrations in these pathways may contribute to cancer development and 
represent cancer biomarkers or therapeutic targets. In addition, the abnormal regulation of some 
of these molecular pathways may lead to other clinical phenotypes such as premature aging, 
immunodeficiency, microcephaly, and dwarfism (O'Driscoll et al. 2006). The ongoing study of 
molecular pathways involved in the maintenance of genome stability has contributed to our 
understanding of the etiology of various human diseases and potential therapeutic strategies. 
However, many questions remain.  
As presented in this thesis, I have investigated the impact of reduced levels of various 
molecular components on DNA damage repair and signalling, recovery from replication stress, 
and heterochromatin formation. While my work presented in Chapter III was focused on 
examining DSB repair in regions enriched for heterochromatin, my interest in more clinically-
relevant research led my pursuit of the work presented in Chapters IV and V. As described in 
Chapter IV, I embarked on a comprehensive analysis of the impact of diminished dormant 
origin availability on replication stress recovery in non-tumour and tumour-derived cell lines. 
Ultimately, this work aimed to assess the potential therapeutic strategy of targeting origin 
licensing for treatment of cancer and has provided several positive implications. In Chapter V, I 
aimed to examine the impact of deficient origin licensing capacity on higher-order chromatin 
structure and the IR-induced DDR in the context of MGS patient cells. This work has had 
implications in the characterisation of ORC-deficient MGS.  
 
VI.2 Examination of the role of Artemis in DSB repair during G0/G1 using a 
novel system of site-specific break induction  
 
As previously introduced, the subset of IR-induced DSBs which occur within regions of 
heterochromatin are specifically repaired with slow kinetics by a pathway involving ATM, the 
mediator proteins, and the Artemis endonuclease (Riballo et al. 2004; Goodarzi et al. 2008; 
Noon et al. 2010). Heterochromatin has been proposed to act as a barrier to DSB repair which 
may be alleviated by ATM-dependent phosphorylation of KAP-1 (Goodarzi et al. 2008) and 
subsequent changes in chromatin remodelling (Goodarzi et al. 2011). While DSBs persisting in 
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Artemis-defective cells localise to regions of heterochromatin, in contrast to that observed in 
ATM-deficient cells, the requirement of Artemis for repair of IR-induced DSBs is not alleviated 
by heterochromatin relaxation via KAP-1 depletion (Woodbine, Brunton et al. 2011). These 
results suggest that Artemis has a role in heterochromatic DSB repair distinct to that of ATM 
and downstream of heterochromatin relaxation. However, the precise role of Artemis is still 
being examined. The development of new techniques for assessing heterochromatic DSB repair 
may prove beneficial in further examination of the function of Artemis in DSB repair. 
Previous studies of the role of ATM and Artemis in DSB repair have primarily 
exploited IR to induce DNA damage. However, the relatively low percentage of IR-induced 
DSBs that localise to heterochromatic regions has posed limitations for monitoring repair at 
these regions using γH2AX foci enumeration. Routine detection of a defect specifically in IR-
induced heterochromatin DSB repair typically relies on distinctions between few γH2AX foci 
(ie. comparing an average of 2-4 foci per nucleus in repair-efficient cells and an average of 10-
12 foci in repair-defective cells at 24 hours after 3 Gy IR). Further, accurate determination of 
foci number for a sample must be determined in cellular populations which contain cell to cell 
variations in foci number (Lobrich et al. 2010). Alternative systems of DSB induction involving 
endonucleases are often limited by low cutting frequency and the capacity of active enzymes to 
re-cut at the same site. Further, these previously employed systems have generally not been 
specific to the induction of DSBs occurring within regions enriched for heterochromatin. In 
Chapter III, I aimed to optimise a system for monitoring the repair of site-specific DSBs 
occurring within regions enriched for heterochromatin.   
 
VI.2.1 Exploitation of a novel system for monitoring the repair of DSBs likely to 
occur in heterochromatin regions 
 
In Chapter III, I have described a novel system established by Dr. Jie Wen, Dr. Patrick 
Concannon, et al. for the induction of site-specific DSBs by CPP-mediated delivery of I-PpoI, 
an endonuclease which recognises and cleaves a site within 28S rDNA. I was able to 
successfully optimise the expression and purification of functionally active I-PpoI and observed 
DSB induction (by detection of γH2AX or 53BP1 foci) following direct delivery of purified I-
PpoI using the pep-1-cysteamine CPP. Consistent with a recently published report (Wen et al. 
2012), CPP-mediated delivery of I-PpoI was not observed to induce cytotoxity or DSB 
accumulation in DSB repair-defective cells, suggesting that multiple rounds of enzymatic 
cutting are unlikely using this system.  
The human genome contains multiple I-PpoI recognition sites, precluding the need to 
integrate a recognition sequence. ~300 possible rDNA I-PpoI recognition sites exist in the 
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human genome (Monnat et al. 1999) and ~11 additional sites have been recently identified 
(Berkovich et al. 2007; Wen et al. 2012). As a substantial fraction (~50%) of rDNA is found to 
be in a transcriptionally silenced state throughout the cell cycle (Conconi et al. 1989), I-PpoI-
induced DSBs may occur in regions which have a higher heterochromatin content than that of 
the entire genome (~20%) (Miklos et al. 1979). 
Consistent with a previous report which exploited a tamoxifen-inducible system of I-
PpoI expression (Berkovich et al. 2007), cells treated with an ATMi were observed to be 
defective in the repair of a substantial fraction of I-PpoI-induced DSBs. Here, I have 
additionally demonstrated that depletion of the Artemis endonuclease or of RNF8 or 53BP1, 
which mediate ATM-dependent DSB signalling, also results in a substantial defect in I-PpoI-
induced DSB repair during G0/G1. Previous work has demonstrated that DSBs persisting in 
cells with reduced levels of ATM, Artemis, RNF8, or 53BP1 localise to regions of 
heterochromatin (Goodarzi et al. 2008; Noon et al. 2010; Woodbine et al. 2011) and these 
factors are thought to be required specifically for heterochromatin DSB repair. Therefore, my 
observation that inhibition or depletion of ATM, Artemis, or the mediator proteins results in a 
substantial defect in I-PpoI-induced DSB repair may support a model in which I-PpoI-induced 
DSBs occur in regions enriched for heterochromatin. In further support of this model, global 
heterochromatin relaxation, via KAP-1 depletion, was observed to alleviate the requirement for 
ATM, RNF8, and 53BP1 in repair of I-PpoI-induced DSBs. However, further investigation is 
needed to prove or disprove the notion that I-PpoI-induced DSBs occur in regions enriched for 
heterochromatin. Examination of γH2AX foci colocalisation with regions of heterochromatin 
(ie. labelled with H3K9me3 antibodies or by visualisation of DAPI-dense chromocentres in 
MEFs) may help to address this point. I have also presented findings which demonstrate that 
inhibition of the NHEJ factor DNA-PK results in a significant defect in DSB repair during 
G0/G1. Altogether, these results are consistent with the model that heterochromatic DSBs in 
G0/G1 cells require ATM-dependent signalling for heterochromatin relaxation and Artemis 
(potential roles will be discussed below), and are repaired primarily by NHEJ (Beucher et al. 
2009). 
VI.2.2 Artemis functions in the repair of I-PpoI-induced DSBs in a manner 
independent of chromatin relaxation 
Significantly, global chromatin relaxation via KAP-1 depletion did not alleviate the requirement 
for Artemis in the repair of I-PpoI-induced DSBs during G0/G1. This finding is similar to 
observations made after treatment with TBH or IR published last year (Woodbine et al. 2011) 
and suggests that the role of Artemis in heterochromatic DSB repair is distinct to ATM 
signalling-dependent heterochromatin relaxation. 
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Artemis has been demonstrated to promote heterochromatic DSB repair by NHEJ 
during G0/G1 and by HR during G2. Several possible models exist which explain the functional 
role of Artemis at these stages of the cell cycle. One model (Beucher et al. 2009) postulates that 
Artemis functions to remove secondary structures or lesions which block the progression of 
NHEJ during G0/G1 or of HR-associated resection during G2. During G0/G1, DNA-PK 
autophosphorylation may activate the endonucleolytic activity of Artemis, enabling the 
processing of ends which cannot readily be ligated, such as those containing secondary 
structures (Goodarzi et al. 2006). During G2, secondary structures may feasibly arise during the 
process of resection-mediated generation of ssDNA. As secondary structures may be more 
likely to arise in transcriptionally silenced repeat regions such as rDNA, the resolution of DSBs 
arising in heterochromatin may have a greater requirement for this form of Artemis-dependent 
processing. However, another model currently favoured in our lab is that Artemis specifically 
functions to promote DNA end resection. While resection is known to be required for HR 
during G2, this model postulates that some resection (though less extensive) may also be 
required for a component of NHEJ-mediated repair during G1, and is specifically required at 
heterochromatic DSBs. This model poses that heterochromatic DSB repair requires both 
heterochromatin relaxation and resection of DNA, irrespective of whether cells are in G0/G1 or 
G2. Following heterochromatin opening and resection, the molecular pathway used to repair 
heterochromatic DSBs is dependent upon cell cycle phase. The slow kinetics associated 
specifically with heterochromatic DSBs could then be explained by the need for 
heterochromatin relaxation and resection to precede repair at these regions.  
While my results described above are consistent with the suggestion that Artemis is 
required for heterochromatic DSB repair but functions downstream of heterochromatin 
relaxation, further exploitation of this system I-PpoI-mediated DSB induction is needed to 
clarify the function of Artemis in end resection during G0/G1.  
 
VI.2.3 The nature of I-PpoI-induced DSB repair 
 
While potential limitations in this system of I-PpoI delivery (ie. asynchronous induction of 
DSBs, variations in cellular uptake, differences sub-cellular protein distribution, and DSB 
clustering) discussed in Section III.3 preclude the precise monitoring of DSB repair over time, 
assessment of the range of γH2AX foci per cell at various times has provided an approximation 
of repair kinetics. Similar to results from quantitative PCR analysis published by our 
collaborators (Wen et al. 2012), peak DSB induction was observed to occur within 1-3 hours 
and complete or nearly complete repair was observed ~6-7 hours after CPP-mediated I-PpoI 
delivery (3-6 hours after peak induction) in control G0/G1 cells. If I-PpoI-induced DSBs do, in 
fact, occur in rDNA regions enriched for heterochromatin, this result is perhaps surprising, 
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given our current understanding that repair of IR-induced DSBs within heterochromatin occurs 
with slow kinetics (> 8 hours) (Goodarzi et al. 2010).  
In considering explanations for these observations, several possibilities exist. First, the 
structure of I-PpoI-dependent DSBs may require less extensive processing prior to their repair. 
Unlike the range of DSBs which may be induced by IR, DSBs generated by I-PpoI consist of 
short (4 bp) 3’ overhangs (Monnat et al. 1999). If Artemis functions in heterochromatic DSB 
repair during G0/G1 to process DNA ends incompatible with direct ligation (such as long 
overhangs), as suggested in previous models (Goodarzi et al. 2006; Beucher et al. 2009), 
perhaps less processing is required for the repair of I-PpoI-induced DSBs with short overhangs. 
However, I consider this possibility to be unlikely. While the structure of each unique I-PpoI-
induced DSB may be simple relative to most IR-induced DSBs, I-PpoI-induced DSBs may 
occur in close proximity within clustered rDNA repeats and within regions of high chromatin 
complexity. Therefore, in vivo, I-PpoI-induced DNA damage is likely to be complex in nature 
as it may consist of clustered DNA lesions, resulting from multiple forms of damage in close 
vicinity on the DNA. A second explanation may be that differences in the nature of 
heterochromatin at rDNA impacts upon the kinetics of DSB repair. The reversibility of 
heterochromatin structure at rDNA is crucial, as under physiological states which require 
ribosomal synthesis, rDNA genes must be activated for transcription by RNA Polymerase 1 
(Preuss et al. 2007). Hence, it may be possible that heterochromatin is more dynamic at rDNA 
regions than other DNA regions and therefore repair at heterochromatic DSBs in rDNA may 
require less extensive chromatin remodelling and/or DSB resection. A third possibility which 
must be considered is that clustering of I-PpoI-induced DSBs within rDNA significantly limits 
the monitoring of heterochromatic DSB repair by γH2AX foci analysis, therefore impacting 
upon assessment of DSB repair kinetics.  While a limited number of γH2AX foci are visible at 
later times after protein transduction (ie. 6 hours), these foci may consist of multiple DSBs 
which cannot be distinguished by eye. Further analysis of γH2AX foci at later times after 
transduction using high resolution (ie. confocal) microscopy may facilitate the analysis of DSB 
clustering. The kinetics of I-PpoI-induced DSBs assessed by quantitative PCR by Wen, 
Concannon, and colleagues were examined using primers which span the non-rDNA recognition 
sites (Wen et al. 2012). As the higher-order chromatin structure at these sites is less clear, 
assessment of repair kinetics at rDNA regions likely to be enriched for heterochromatin could 
therefore be improved by analysis using quantitative PCR primers which span the rDNA 
recognition site or by southern blot using a 28S rDNA probe. If improvements can be made to 
the I-PpoI system to address the possibilities described above, it would be important to 
substantiate the finding that I-PpoI-induced DSBs are in fact repaired more rapidly. 
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VI.2.4 Summary and implications 
In summary, I have optimised a system for monitoring the repair of DSBs likely to occur in 
regions enriched for heterochromatin. This system exploits a novel method of I-PpoI delivery 
developed by Dr. Jie Wen, Dr. Patrick Concannon, and colleagues, and enables the analysis of 
DSB repair during specific stages of the cell cycle. Using this system, I have demonstrated that 
Artemis is required for the repair of a substantial fraction of I-PpoI-induced DSBs and functions 
in a process distinct to heterochromatin opening, similar to observations made after TBH and IR 
(Woodbine et al. 2011). Therefore, this work may contribute to our understanding of 
heterochromatin DSB repair at rDNA regions and has consolidated findings that Artemis is 
required for repair at heterochromatic regions in a role independent of chromatin relaxation.  
Many interesting questions about heterochromatic DSB repair remain which could 
potentially be investigated using this novel I-PpoI-dependent system of DSB induction now 
optimised for routine use. The analysis of I-PpoI-induced cleavage of 28s rDNA recognition 
sites and repair of these breaks could be assessed in cells deficient in DDR factors by 
quantitative PCR using primers spanning the 28S rDNA site or by southern blot using a 28S 
rDNA probe. The extent of DNA end resection at DSBs in rDNA could be examined in G0/G1 
cells (ie. cells grown to confluency) using quantitative PCR primer sets which vary in distance 
from the rDNA recognition site. This method may be useful in examining DNA end resection in 
cells deficient in enzymes required for resection, such as Artemis and CtIP. This system may be 
applied to assess chromatin binding of DDR factors by ChIP analysis using primers which 
recognise sequences at various distances from the 28S rDNA site. Finally, changes in higher-
order chromatin structure (ie. the loss of chromatin-bound factors such as H3K9me3) which 
occur during I-PpoI-induced DSB repair may be investigated in various cellular backgrounds by 
ChIP-based analysis.  
  
VI.3 The impact of diminished origin licensing capacity on replication stress 
recovery in tumour versus non-tumour cells 
Upon completion of the work described above, my interest in translational medicine inspired a 
transition in my research project. As described in Chapter IV, I next examined the impact of 
depleting DNA replication origin licensing factors on the sensitivity of tumour and non-tumour 
cell lines to replication stress.  
One of the hallmarks of cancer cells is a limitless replicative potential (Hanahan et al. 
2000), and, consequently, cancer cells are frequently characterised by an increase in DNA 
replication. The increased availability of replication materials (ie. dNTPs) and overexpression of 
enzymes required for replication (Scanlon et al. 1989) are thought to contribute to this increase 
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in replication. In addition, alterations in DNA origin licensing components have been reported 
in various tumour types (Lau et al. 2007b), perhaps to accommodate increased DNA replication 
by enhancing replication origin licensing activity (Di Paola et al. 2010; Di Paola et al. 2011).  
Enhanced levels of replication stress have been reported in cancer cells and are thought 
to contribute to the genome instability which drives tumour development (Negrini et al. 2010; 
Bartek et al. 2012). Cancer-associated alterations in DDR mechanisms may promote sustained 
proliferation despite enhanced replication fork stalling/collapse. One mechanism used to recover 
from replication-associated damage is the firing of excess or dormant replication origins (Blow 
et al. 2011). One model proposed by Blow and colleagues assumes that origin activation occurs 
in a stochastic manner and that dormant origin activation protects against the hazardous effects 
of double fork stalling (Blow et al. 2009). Therefore, increased origin density was suggested to 
correlate with increased protection from replication stress (Blow et al. 2011). Consequently, the 
overexpression of licensing factors and enhanced origin licensing capacity observed in cancer 
(Lau et al. 2007b) may not only enable increased replication but also support proliferation under 
conditions of replication stress by increasing dormant origin availability.  
In Chapter IV, I examined whether partial depletion of licensing components enhances 
sensitivity to replication stress specifically in tumour-derived cell lines. Here, I predicted that 
non-tumour cells, which express much lower levels of origin licensing components, replication 
materials, and replication machinery and which display an intact DDR, do not rely as heavily on 
dormant origin firing to recover from replication stress, instead using alternative recovery 
mechanisms. This research has both fundamental and translational aspects as discussed below.  
 
VI.3.1 Diminished origin licensing capacity specifically sensitises tumour-derived 
cell lines to replication stress-inducing agents  
 
To examine my hypothesis described above, several non-tumour (1BR3hTERT, BJhTERT, 
48BR, and MRC-5) and tumour-derived (U2OS, HeLa, and MDA-MB-231) cell lines were 
selected. In support of previous reports that transformed cells display increased expression of 
origin licensing factors, (Lau et al. 2007b), I observed an increase in the expression of ORC1 in 
each of the 3 tumour-derived cell lines. In addition, tumour-derived cells were observed to 
divide more rapidly than non-tumour cell lines, consistent with the notion that increased 
replication is associated with cancer. Further, shorter exposures to HU were required to achieve 
complete S-phase arrest in the tumour-derived cell lines. Consistent with the well-established 
observation that cells license origins in excess, both non-tumour and tumour cells were able to 
sustain proliferation despite a substantial depletion of origin licensing capacity. Interestingly, in 
the absence of HU, higher levels of ORC1 were required to maintain viability in the 3 tumour-
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derived cell lines examined, perhaps reflecting increased endogenous levels of replication stress. 
For each cell line, I identified conditions of siRNA-mediated depletion of ORC1 which did not 
impact upon viability and considered these conditions likely to deplete dormant origin capacity. 
Using these conditions, I demonstrated that diminished dormant origin licensing 
capacity sensitised multiple tumour-derived but not non-tumour cells to replication stress (HU) 
and oxidative stress (H2O2), two types of damage found to be enhanced in cancer. The enhanced 
HU sensitivity of U2OS osteosarcoma cells partially depleted for ORC1 correlated with 
diminished new origin firing, reduced recovery of replication, and an accumulation of S-phase 
associated damage. These findings suggest that the enhanced HU sensitivity of siORC1-treated 
U2OS cells is associated with impaired recovery from replication stress.  
The lack of enhanced sensitivity to replication stress in non-tumour cells depleted for 
ORC1 was confirmed in 4 primary or hTERT-immortalised cell lines as well as ORC1-deficient 
MGS patient fibroblasts and LBLs. Therefore my findings were not restricted to a specific cell 
line or to depletion of ORC1 using siRNA oligonucleotides. Further, diminished licensing 
capacity did not impact upon sensitivity of non-tumour cells to HU treatment times adjusted to 
achieve complete S-phase arrest, suggesting that the lack of enhanced sensitivity of ORC1-
depleted non-tumour cells was not simply a reflection of slower cell cycle progression.  
Observations were similar following depletion of other licensing components (ORC6 and 
CDC6) and therefore not limited to ORC1 depletion. Importantly, despite substantial depletion 
of ORC1, non-tumour 1BR3hTERT cells were capable of recovering replication at early times 
after release form HU. This observation suggests that 1BR3hTERT cells may exploit alternative 
mechanisms of replication recovery under conditions of diminished dormant origin supply. 
Examination of replication fork restart and new origin firing in ORC1-depleted 1BR3hTERT 
cells would confirm and extend this observation. In addition, examination of the impact of the 
increased expression of licensing components or decreased expression of factors required for 
alternative recovery mechanisms in non-tumour cells may further support this model.  
It should be noted, however, that the results presented in Chapter IV are restricted to the 
tumour-derived and non-tumour cell lines that were examined. Further examination is needed to 
assess whether these findings represent frequent differences between tumour and non-tumour 
cell lines and whether they are observed in all cancer types or in specific forms of cancer. 
Increased ORC1 expression was observed in each of the tumour-derived cell lines that were 
investigated. Assessment of a broader panel of tumour-derived cell lines with differing levels of 
ORC1 expression may help to extend these findings and to explore the relationship between 
ORC1 expression and enhanced HU sensitivity under conditions of reduced origin licensing 
capacity.  
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VI.3.2 Depletion of p53 or overexpression of c-Myc results in enhanced loss of 
viability in non-tumour cells partially depleted for ORC1  
 
Alterations which reduce the expression of tumour suppressor genes such as TP53 or which 
increase the expression of oncogenes such as c-Myc are frequently found in cancer (Spencer et 
al. 1991; Vogelstein et al. 2000) and are likely to contribute to enhanced levels of replication 
stress. Among the many effects of these alterations, reduced levels of p53 or increased 
expression of c-Myc may impact upon the regulation of the G1-S-phase transition, increase 
replication activity, and/or alter the DDR. Here, I have examined the impact of both alterations 
on viability in ORC1-depleted non-tumour cells.  
Co-depletion of the p53 tumour suppressor gene and ORC1 in non-tumour 
1BR3hTERT cells was observed to enhance viability loss, both in the absence and presence of 
HU treatment. p53 regulates multiple cellular processes such as the  G1/S transition (ie. the 
“origin licensing checkpoint” (Nevis et al. 2009)), DNA damage-induced cell cycle arrest (Wahl 
et al. 1997), apoptosis, RNR-mediated dNTP production (Xue et al. 2003), and the resolution of 
stalled replication forks (Sengupta et al. 2003; Ho et al. 2006). Therefore, several possibilities 
exist which may explain why HU sensitivity is enhanced in non-tumour cells co-depleted for 
p53 and ORC1.  
One possible explanation for the observed increase in viability loss following co-
depletion of ORC1 and p53 in non-tumour cells is related to the role for p53 in the replication 
stress DDR distinct to its function in cell cycle checkpoint activation. p53 is reported to directly 
associate with stalled forks in a BLM-dependent but ATM-Chk1-independent manner and to 
negatively regulate HR-based replication fork recovery (Ho et al. 2006) (Sengupta et al. 2003). 
Further, p53 has been proposed to protect cells from HU-induced one-ended DSBs (Kumari et 
al. 2004), structures thought to require HR-mediated repair (Petermann et al. 2010a; Petermann 
et al. 2010b). Given these observations and the fact that p53 localises to structures associated 
with fork remodelling, one model has been presented which proposes that p53 promotes HR-
independent fork restart (Subramanian et al. 2005). As discussed above, HR-mediated repair 
and dormant origin firing may work together to promote the efficient recovery from replication 
fork collapse. It may be feasible, therefore, that the loss of p53 may result in greater replication 
fork collapse and an enhanced reliance on HR and dormant origin firing for replication 
recovery.  
A second possibility is that both the loss of the G1/S DDR checkpoint associated with 
p53 depletion and enhanced replication stress arising from diminished dormant origin licensing 
capacity may result in high levels of DNA damage which ultimately impact upon viability. Over 
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time, cells may accumulate DNA damage from endogenous sources such as ROS or from HU-
associated damage which cannot be efficiently resolved in the absence of dormant origin firing. 
Under conditions of p53 depletion, loss of the G1/S checkpoint may then result in increased 
levels of replication stress as cells harbouring DNA damage may progress into S-phase. A 
cellular threshold for replication stress may exist, and when levels rise above this threshold, 
cells may induce cellular death pathways reflected by the loss of viability observed in my 
studies. 
A third more appealing possibility is related to changes in S-phase entry associated with 
p53 loss. Both in the presence and absence of DNA damage, cells depleted for p53 display 
accelerated S-phase entry (Deckbar et al. 2010). As previously introduced, there is some 
evidence for the existence of a licensing checkpoint which prevents cells from entering S-phase 
before a sufficient number of origins have been licensed (Ge et al. 2009). This licensing 
checkpoint has been demonstrated to be regulated by p53 and RB and is deficient in various 
tumour cell lines such as U2OS and HeLa (Nevis et al. 2009). One possibility is that tumour 
cells override the origin licensing checkpoint to enhance proliferation and, therefore, partial 
depletion of ORC1 may result in S-phase entry despite the reduced number of dormant origins; 
co-depletion of p53 and ORC1 in non-tumour cells may mimic this condition. In support of this 
notion, co-depletion of p53 and the other licensing factor, Cdc6, in non-tumour cells has been 
demonstrated to result in premature S-phase entry, reduced rates of DNA replication, and an 
accumulation of S-phase DNA damage (Nevis et al. 2009).  
As presented in Chapter IV, overexpression of the c-Myc oncogene in a non-tumour 
background also results in enhanced replication stress and loss of viability following ORC1 
depletion. As overexpression of c-Myc is reported to enhance DNA damage, hyper-replication, 
replication stress, and oxidative damage and to disrupt p53 function (Vafa et al. 2002; 
Dominguez-Sola et al. 2007; Herold et al. 2009b; Robinson et al. 2009), various possible 
explanations for these results may exist and may be related to those described above. 
Interestingly, c-Myc has been reported to play a non-transcriptional role in DNA replication by 
stimulating replication origin activity and in fact, immunoprecipitates with various pre-RC 
components (Dominguez-Sola et al. 2007). In addition, c-Myc upregulates the transcription of 
Cdt1 (Watson et al. 2002) and E2F1 (Fernandez et al. 2003) which regulates the expression of 
various pre-RC components. Therefore, the overexpression of c-Myc may promote increased 
origin licensing to facilitate hyper-replication. In addition, an increase in dormant origin 
availability in cells which overexpress c-Myc may promote proliferation under conditions of 
enhanced replication stress. The examination of c-Myc-induced changes in ORC1 expression in 
BJ-MYC-ER cells may help to evaluate these possibilities.  
Overall, the depletion of p53 or the overexpression of c-Myc may enhance loss of 
viability in ORC1-depleted non-tumour cells by multiple mechanisms. Further investigation 
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using ORC1-depleted non-tumour cells depleted for additional components involved in the 
G1/S transition (such as RB and p16) or which overexpress other oncogenes (such as Ras) 
would help to extend these findings. 
 
VI.3.3 Diminished origin licensing capacity enhances sensitivity of tumour but not 
non-tumour cells to HU combined with Chk1 inhibition 
 
As presented in Chapter IV, inhibition of Chk1 just prior to and following release from HU 
further enhances HU sensitivity in ORC1-depleted osteosarcoma cells. As Chk1 functions to 
regulate DNA replication origin firing, stabilise forks, and to promote HR, the impact of Chk1 
inhibition on viability in HU and siORC1-treated cells may be multifaceted. 
DNA damage-activated Chk1 signalling is required to inhibit the activation of late-
firing replication clusters but allows dormant origin firing in activated factories which harbour 
stalled/collapsed replication forks (Ge et al. 2010). Under conditions of replication stress, this 
function of Chk1 has been proposed to redirect the limited supply of replication machinery 
towards dormant origin activation in order to promote replication recovery. As previously 
discussed, enhanced replication stress may accumulate in HU-treated tumour cells depleted for 
ORC1. In this context, inhibition of Chk1 may result in the inappropriate activation of late-
firing origins, resulting in an even greater increase in replication stress and loss of viability.  
Chk1 also functions to stabilise stalled replication forks, and consequently, an 
accumulation of aberrant replication fork structures has been observed after Chk1 inhibition in 
the absence (Petermann et al. 2006) and presence of replication inhibitors (Kastan et al. 2004). 
Therefore, Chk1 inhibition combined with HU treatment may result in enhanced replication fork 
collapse requiring dormant origin firing for recovery.  
Finally, Chk1 is also reported to promote the HR-mediated repair of HU-induced 
lesions (Sorensen et al. 2005). Chk1 has been reported to interact with Rad51, resulting in 
Chk1-dependent phosphorylation on threonine 309, and this process is thought to directly 
regulate Rad51 activity. Consequently, inhibition or siRNA-mediated depletion of Chk1 
combined with HU treatment results in the deficient formation of Rad51 foci, a reduction in 
HR-mediated repair, and an accumulation of replication associated-DSBs (Sorensen et al. 2005).  
In summary, multiple explanations may exist for the enhanced HU sensitivity observed 
in ORC1-depleted U2OS inhibited for Chk1. Chk1 inhibitors have shown promise as 
chemotherapeutic agents (Dai et al. 2010) in combination with replication stress-inducing agents 
such as HU and gemcitabine (Montano et al. 2012).  Therefore this finding may have positive 
implications for the utility of dormant origin licensing inhibitors. 
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VI.3.4 Summary and implications 
 
In Chapter IV, I presented results demonstrating that diminished dormant origin capacity 
specifically sensitises multiple tumour-derived cell lines to HU or H2O2-induced replication 
stress. Further, I have presented findings which indicate that depletion of the p53 tumour 
suppressor gene or increased expression of the c-Myc oncogene results in enhanced loss of 
viability in ORC1-depleted non-tumour cells.  
Here, I have presented possible explanations to address these observations. First, I have 
suggested that, in contrast to non-tumour cells which may more readily exploit alternative 
mechanisms of replication restart or repair, tumour derived cell lines (or non-tumour cells 
depleted for p53 or which overexpress c-Myc) have a greater reliance on dormant origin firing 
for replication stress recovery. The expression of origin licensing components may be elevated 
in tumour-derived cell lines (or cells which overexpress the c-Myc oncogene), resulting in an 
increased supply of origins which may support hyper-replication. As an increase in dormant 
origin availability is likely to increase the efficiency of recovery from replication stress, tumour 
cells may frequently utilise this mechanism. Further, cellular changes associated with cancer 
may downregulate the use of alternative mechanisms of replication fork recovery. I have also 
suggested that replication fork collapse may occur more readily in tumour-derived cell lines or 
in non-tumour cells depleted for p53 or which overexpress c-Myc. An increase in fork collapse 
may result from cancer-associated changes which prevent fork stabilization, and may 
preferentially require dormant origin firing and/or HR-mediated repair. Finally, I have 
suggested that the distinctions between the requirement of non-tumour and tumour-derived cell 
lines for dormant origin availability may be related to cancer-associated changes in the G1/S 
checkpoint which result in toxic levels of replication stress. Many tumour cell lines or non-
tumour cells which overexpress c-Myc display alterations in S-phase entry, hyper-replication, 
and enhanced replication stress. Defects in the G1/S DDR checkpoint may result in further 
replication stress, as cells harbouring DNA damage prematurely enter S-phase. In addition, loss 
of the licensing checkpoint in tumour cells may result in premature S-phase entry under 
conditions of diminished origin supply (ie. after ORC1 depletion), again resulting in enhanced 
levels of replication stress.  
The research presented in Chapter IV has both fundamental and translational aspects 
with several important potential implications. From a fundamental research perspective, these 
findings may contribute to our understanding of differences in replication stress recovery in 
tumour vs. non-tumour cells. Further examination of the relative dependence of ORC1-depleted 
tumour and non-tumour cells on HR-independent replication restart, HR-mediated repair, or 
dormant origin firing may help to clarify the mechanistic differences which result in the 
distinctions I have observed.  In addition, this research has had a translational aspect, and has 
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implicated origin licensing as a potentially suitable target for drug-based cancer therapy. My 
findings that tumour-derived cell lines or cells harbouring cancer-associated changes are 
hypersensitive to HU-induced damage suggest that administration of a licensing inhibitor at low 
doses may specifically sensitise tumour cells to replication stress-inducing chemotherapeutic 
agents. Findings from this work have implied that licensing inhibitors may be particularly 
effective tumours which overexpress licensing factors such as ORC1, which display increased 
expression of the c-Myc oncogene, and/or which display defects in the G1/S checkpoint. 
Further, these results have suggested that a strategy combining replication stress-inducing 
agents with Chk1 and licensing inhibitors may be particularly effective. Further investigation 
into tumour backgrounds particularly sensitive to the combined treatment with an inhibitor of 
origin licensing and replication stress inducing agents may help to expand upon these findings. 
In addition, assessment of druggability of licensing components such as ORC1 and ORC6 is 
necessary to validate this approach.  
VI.4 The impact of reduced levels of origin licensing factors on higher-order 
chromatin structure and the IR-induced DDR 
An accumulating body of evidence has demonstrated that the components of the pre-RC 
function in multiple cellular processes other than replication origin licensing such as 
heterochromatin organisation. Various subunits of ORC have been demonstrated to localise to 
heterochromatin in human cells, and this localisation is promoted by interactions with chromatin 
factors such as ORCA, HMGA1a, and HP1α (Alabert et al. 2012). Direct interactions between 
ORC subunits and HP1α have been identified, and these interactions are proposed to facilitate 
heterochromatin organisation in human cells (Prasanth et al. 2010). 
Mutations in pre-RC components have been identified in MGS, a disorder characterised 
by bone abnormalities, microcephaly and growth retardation (Bicknell et al. 2011a). In Chapter 
V, I have examined whether cells from ORC, CDC6, or CDT1-deficient MGS or cells depleted 
for these components display characteristics associated with alterations in heterochromatin. 
Additionally, I have examined the sensitivity of the ATM-dependent DNA damage signalling 
and the G2/M checkpoint in these cells as alterations in these processes have been observed in 
cells from patients with disordered chromatin syndromes (Brunton et al. 2011). As discussed 
below, these findings have implications in our understanding of the cellular phenotype of MGS 
patients which carry mutations in various pre-RC components.   
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VI.4.1 ORC1-deficient MGS patient cells and ORC1-depleted control fibroblasts 
display alterations in nuclear levels of heterochromatin markers 
 
Several mutations located in the BAH domain of ORC1 have been identified in cells from MGS 
patients (Bicknell et al. 2011a; Bicknell et al. 2011b). As ORC1 interacts with HP1α via a 
region within the BAH domain, and this interaction is thought to facilitate the recruitment of 
HP1α to chromatin (Prasanth et al. 2010), the BAH domain mutations identified in ORC1-
deficient MGS patients may be predicted to impact upon the HP1α-dependent heterochromatin 
organisation. Consistent with this notion, nuclear levels of HP1 were found to be altered ORC1-
P4hTERT cells, which harbour one mutation in the BAH domain and a second mutation in the 
C-terminus of ORC1 (Bicknell et al. 2011b). Analysis of cells depleted for ORC1 using siRNA 
oligonucleotides also displayed reduced levels of HP1, substantiating these results. I extended 
these findings to examine the impact of ORC1 on the heterochromatin marker H3K9me3. 
Consistent with observations of altered HP1 localisation, H3K9me3 was found to be reduced in 
ORC1-P4hTERT cells or control fibroblasts depleted for ORC1. As SUV39H1, a 
methyltransferase which promotes H3K9 trimethylation, is recruited to heterochromatin by HP1 
binding and subsequently propagates H3K9 trimethylation across regions of DNA (Craig 2005), 
the disruption of HP1 localisation in cells with reduced ORC1 may explain this finding. 
Perhaps surprisingly, total nuclear levels of H4K20me3 were found to be unaffected by 
ORC1 depletion or deficiency while depletion of KAP-1 or HP1α resulted in decreased 
H4K20me3 levels. H4K20 trimethylation is performed by distinct methyltransferases, 
SUV420H1 and/or SUV420H2, but is thought to be facilitated by SUV39H1-dependent 
trimethylation of H3K9 (Schotta et al. 2004). However, some H4K20 trimethylation occurs 
independently of H3K9me3 levels and while the HP1 subunits display dynamic association with 
chromatin, SUV420H2 remains stably associated with chromatin in a potentially HP1-
independent manner (Souza et al. 2009). Therefore, these results could be explained by several 
models. First, the fact that HP1α localisation, H3K9 trimethylation, and heterochromatin are 
only partially affected in ORC1-deficient or depleted cells may still provide the platform for 
SUV420H1/2-dependent trimethylation of H4K20. Alternatively, in support of the findings of 
Souza and colleagues, some H4K20 trimethylation may occur independently of HP1 and 
H3K9me3, and therefore is not impacted by ORC1-deficiency or depletion. However, 
limitations in my analysis must be considered. Subtle changes in heterochromatin structure may 
not be detected by analysis of overall nuclear levels of H4K20me3. Therefore, further 
examination of the effect of ORC1 reduction on H4K20me3 may help to clarify these results.  
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Overall, these findings have indicated that ORC-deficient MGS patient cells display 
alterations in the distribution of heterochromatin markers and suggest that heterochromatin 
organisation may be altered.  
VI.4.2 The requirement for ATM in DSB repair is partially alleviated in ORC1-
deficient MGS patient cells and ORC1-depleted control fibroblasts  
ORC1-P4hTERT cells or fibroblasts depleted for ORC1 using multiple siRNA oligonucleotides 
were observed to display a partial alleviation of the requirement for ATM in IR-induced DSB 
repair. As previously described, ATM is required specifically for the repair of heterochromatin 
DSBs, and this requirement is alleviated when heterochromatin becomes disordered (Brunton et 
al. 2011). Therefore, these findings suggest that heterochromatin organisation is disrupted when 
ORC1 levels are reduced. As discussed in Chapter V.3, the observation that the DSB repair 
defect associated with ATM inhibition is only partially alleviated in these cells may have 
multiple explanations. For example, residual levels of functional ORC1 in these cells may 
support some HP1α recruitment to all or specific regions of chromatin. This notion is supported 
by the findings by Prasanth and colleagues that HP1α localization is not completely disrupted in 
ORC1-depleted cells, but is rather redirected to the periphery of nucleoli (Prasanth et al. 2010). 
In addition, this observation may reflect the fact that HP1α recruitment to chromatin is only 
partially driven by binding with ORC1, and therefore some HP1α-dependent heterochromatin 
formation may occur in the absence of functional ORC1. Finally, recruitment of the HP1α 
subunit may not be sufficient to support heterochromatin formation at certain regions. Detailed 
examination of the role of the interaction between ORC1 and HP1α may provide further 
understanding of the observations made in ORC1- deficient or depleted cells. However, the 
findings obtained from these studies have demonstrated that the requirements for IR-induced 
DSB repair are altered in ORC1-deficient MGS patient cells.  
VI.4.3 The impact of reduced ORC1 levels on IR-induced DSB signalling and 
sensitivity of the G2/M checkpoint  
Depletion of MeCP2 or DNMT3B, the heterochromatin factors altered in Rett syndrome or ICF, 
respectively, has been demonstrated to enhance IR-induced DSB signalling at heterochromatin 
regions (Brunton et al. 2011). Here, I also observed that depletion of ORC1 in NIH3T3 MEFs 
results in enhanced expansion of γH2AX foci into heterochromatin-rich chromocentres. This 
finding supports the model that cells with reduced ORC1 levels display enhanced IR-induced 
DSB signalling at heterochromatin regions, an alteration that is also proposed to impact upon 
sensitivity of the G2/M checkpoint (Brunton et al. 2011).  Therefore, I examined the impact of a 
reduction in ORC1 levels on G2/M checkpoint activity in ORC1-deficient or depleted cells. 
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Both hypersensitivity of G2/M checkpoint activation and prolonged G2/M checkpoint 
maintenance were observed in ORC1-P4hTERT cells or cells depleted for ORC1. Further, 
overexpression of ORC1 was observed to restore G2/M checkpoint activity in ORC1-P1 LBLs 
to levels similar to that in control LBLs. These results have substantiated the model that ATM-
dependent DSB signalling is enhanced at heterochromatin in ORC1-deficient MGS cells, likely 
as a result of altered heterochromatin organisation.  
VI.4.4 A reduction in ORC6 but not CDC6 or CDT1 results in cellular 
characteristics associated with disordered chromatin 
Finally, I demonstrated that ORC6-depleted 1BR3hTERT cells displayed a similar partial 
alleviation of the requirement for ATM in DSB repair, hypersensitivity of the IR-induced G2/M 
checkpoint, and reduction in H3K9me3 levels. Further, LBLs from an ORC6-deficient MGS 
patient display both hypersensitive activation and prolonged maintenance of the G2/M 
checkpoint. ORC6 is thought to translocate to the nucleus independently of the other ORC 
subunits (Chesnokov 2007; Ghosh et al. 2011), displays a more dynamic association with other 
ORC subunits (Ghosh et al. 2011), and has functions independent of the other ORC subunits 
(Prasanth et al. 2002). Therefore this observation may reflect a function of ORC6 in 
heterochromatin formation that is independent of ORC1. The association of ORC6 with 
HMGA1a at heterochromatin regions (Thomae et al. 2011), for example, may facilitate 
heterochromatin binding of the other ORC components, including HP1α-bound ORC1 (or 
ORC3). Therefore, ORC6 may also indirectly promote the recruitment of HP1α to chromatin, 
facilitating heterochromatin formation. However, as ORC6 is also detected in complex with the 
remaining ORC components (Ghosh et al. 2011), the role of ORC6 in heterochromatin 
organisation may be related to that of ORC1 and ORC3-associated HP1α recruitment. 
In contrast, cells depleted for CDC6 or CDT1 displayed characteristics similar to 
siControl treated cells. In addition, sensitivity of the G2/M checkpoint was observed to be 
similar in control LBLs and LBLs from CDC6- or CDT1-deficient MGS patients. These 
findings suggest that the role of the pre-RC components in heterochromatin formation may 
primarily be directed by ORC. In this scenario, CDC6 and CDT1 may be recruited only after 
ORC binds DNA and promotes heterochromatin spreading, where they function in origin 
licensing. While further examination would clarify these distinctions in the molecular 
requirements of pre-RC components in heterochromatin organisation, my results have 
demonstrated that heterochromatin disruption may be a feature specific to ORC-deficient MGS.  
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VI.4.5 Summary and Implications 
 
My findings presented in Chapter V have implicated, for the first time, ORC1-deficient MGS as 
a disordered chromatin syndrome. Further, results from siRNA-mediated depletion of ORC6 
and the analysis of ORC6-deficient MGS patient cells suggest that ORC6-deficient MGS may 
also be classified as a disordered chromatin syndrome. In contrast, CDC6- or CDT1-deficient 
MGS patient cells do not display alterations in heterochromatin as dramatic as those observed in 
ORC-deficient MGS patient cells. In addition, I have demonstrated that IR-induced DSB 
signalling and the ATM-dependent G2/M checkpoint are hypersensitive in cells containing 
reduced ORC1 or ORC6 levels, consistent with findings in cells from classified disordered 
chromatin syndrome patients (Brunton et al. 2011).  
As speculated in the discussion in Chapter V, ORC and HP1-dependent 
heterochromatin formation may help to function the timing of replication, as euchromatin 
regions are replicated early in S-phase, and heterochromatin regions are replicated later in S-
phase. In support of this notion, HP1 has recently been reported to modulate replication timing 
in Drosophila (Schwaiger et al. 2010), and depletion of HP1 results in early replication of 
heterochromatin regions. If too many origins are activated early in S-phase as a result of altered 
replication timing in cells defective in ORC-dependent recruitment of HP1, dNTP pools may 
not be large enough to accommodate synchronous replication and replication may slow. Results 
from my studies have suggested that CDC6 and CDT1 may not play as much of a role in 
heterochromatin organisation as the ORC subunits. However, further work is needed to 
substantiate this model.  
While my findings have demonstrated that distinctions exist in the cellular phenotypes 
of ORC or CDC6/CDT1-deficient patients, it is not clear whether these cellular phenotypes 
directly impact upon the clinical features of MGS. Interestingly, microcephaly and short stature, 
two of the key clinical features observed in ORC-deficient MGS patients, have also been 
reported in patients with various disordered chromatin remodelling syndromes such as Rett 
syndrome, Rubinstein-Taybi Syndrome, Coffin-Lowry Syndrome, and alpha-thalassemia/mental 
retardation syndrome (Ausio et al. 2003). However, unlike the nature of these phenotypes in 
MGS patients, the microcephaly and short stature described in patients with disordered 
chromatin syndromes are usually observed only after birth and are often progressive. While the 
disordered chromatin resulting from reduced levels of ORC components may contribute to the 
microcephaly or growth defects in MGS, these clinical features are also observed in CDC6 and 
CDT1-deficient MGS patients. Furthermore, no other clinical features have been observed 
which distinguish ORC-deficient MGS patients from CDC6 or CDT1-deficient MGS patients 
(de Munnik et al. 2012). Therefore, the disordered chromatin phenotype that I have observed 
specifically in ORC-deficient cells may contribute but not represent the main cause of the 
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clinical phenotypes that have been reported. However, one potential clinical manifestation of the 
impact of ORC deficiency on heterochromatin may be progeria, a feature observed in patients 
with other disordered chromatin syndromes such as HGPS. Alterations in telomeric 
heterochromatin, resulting in telomere uncapping, may promote enhanced DDR signalling 
and/or senescence (d'Adda di Fagagna et al. 2003; Schoeftner et al. 2009). This, in turn, may 
result in premature ageing. Further examination of MGS patients as they age will be needed to 
assess whether such a phenotype is apparent in ORC-deficient MGS.  
While the limited number of patients identified to date makes it difficult to draw any 
major conclusions, no increase in cancer incidence has been reported in patients with ORC-
deficient MGS or with Rett Syndrome. One potential factor contributing to this observation may 
be the observations of hypersensitive DNA damage signalling in ORC-deficient MGS and Rett 
cells as presented here and by other colleagues in our lab (Brunton et al. 2011). In wild-type 
cells, a threshold of 10-25 DSBs, which corresponds to IR doses >0.5 Gy, is reported to be 
required for ATM-dependent initiation and maintenance of G2/M checkpoint arrest (Deckbar et 
al. 2007). The inherent imperfection of the G2/M checkpoint may contribute to genome 
instability and cancer by allowing the progression of cells harbouring DSBs into mitosis. 
Chromosome breakage may then ensue in these cells, potentially contributing to tumourigenesis 
(Krempler et al. 2007; Lobrich et al. 2007). In contract to wild-type cells, both ORC-deficient 
MGS and Rett Syndrome cells display hypersensitive DSB signalling which prevents cells from 
progressing from G2 to mitosis when <20 DSBs are present (after <0.5 Gy). Therefore, while 
defects in heterochromatin formation may result in several adverse clinical phenotypes, they 
may also help to prevent genome instability and cancer.  
 
VI.5 Final summary 
Gaining more insight into the mechanisms which prevent genome instability will help to further 
our understanding of the molecular basis behind human diseases such as cancer. The molecular 
mechanisms which regulate DNA replication, DNA damage detection and repair, recovery from 
replication stress, and the maintenance of higher-order chromatin structure all play a role in the 
maintenance of genome stability. In this thesis, I have examined the requirement for Artemis in 
the repair of heterochromatic DSBs. I have exploited a novel system of CPP-mediated I-PpoI 
delivery to induce site-specific DSBs in regions likely to be enriched for heterochromatin. Using 
this system, I have demonstrated that there is a substantial requirement for Artemis in the repair 
of I-PpoI-induced DSBs and that this requirement is not alleviated by global heterochromatin 
relaxation. These findings have substantiated recently published work from our lab investigating 
the requirement for Artemis in the repair of IR-induced DSBs in heterochromatin. Further, these 
findings have suggested that CPP-mediated I-PpoI delivery may be exploited to further study 
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the molecular mechanisms which govern heterochromatic DSB repair. However, the primary 
focus of this thesis has been to examine the cellular impact of diminished DNA replication 
origin licensing capacity. Here, I have demonstrated that partial depletion of origin licensing 
components specifically sensitises several tumour-derived cell lines to replication stress, 
without impacting upon the sensitivity of several non-tumour cell lines. I have also shown that 
depletion of the p53 tumour suppressor or overexpression of the c-Myc oncogene in a non-
tumour background results in enhanced loss of viability under conditions of diminished origin 
licensing capacity. These findings have suggested that origin licensing factors may represent 
suitable therapeutic targets for the treatment of cancer. In addition, I have demonstrated that a 
reduction specifically in ORC1 and ORC6, but not in CDC6 or CDT1, results in alterations in 
heterochromatin organisation and in the IR-induced DDR. These findings have contributed to 
our understanding of the cellular consequences of ORC depletion and the cellular features of 
specific forms of MGS.  
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DNA Damage and Repair
DiminishedOrigin-LicensingCapacity Speciﬁcally Sensitizes
Tumor Cells to Replication Stress
Kristin M. Zimmerman1, Rebecca M. Jones2, Eva Petermann2, and Penelope A. Jeggo1
Abstract
Previous studies have shown that dormant licensed replication origins can be exploited to enhance recovery from
replication stress. Since tumor cells express high levels of origin-licensing proteins, we examined whether depletion
of such factors might speciﬁcally sensitize tumor versus nontumor cells. Consistent with previous ﬁndings, we
observed that three tumor-derived cell lines overexpress ORC1, a licensing component, compared with four
nontumor cell lines and that a greater level of ORC1 was required to maintain viability in the tumor cells. We
determined siRNA-mediated knockdown conditions for each line that maximally reduced ORC1 but did not
impact upon viability, which we considered would optimally deplete dormant origins. ORC1 depletion
hypersensitized the tumor-derived cells to hydroxyurea andH202 but did not affect the sensitivity of the nontumor
lines. Similar results were observed following depletion of ORC6 or CDC6. Furthermore, codepletion of p53 and
ORC1 modestly impaired viability of 1BR3hTERT nontumor ﬁbroblasts and more dramatically caused
hypersensitivity to hydroxyurea. Finally, overexpression of the c-Myc oncogene combined with ORC1 depletion
in nontumor BJhTERT cells diminished viability. Collectively, these ﬁndings suggest that tumor cells may have a
reliance on origin-licensing capacity, suggesting that licensing factors could represent a target for drug-based cancer
therapy. Mol Cancer Res; 11(4); 370–80. 2013 AACR.
Introduction
To replicate the human genome in a timely manner,
replication is initiated bidirectionally from multiple origins.
However, this necessitates that replication origins only ﬁre
once during each cell cycle to avoid rereplication. Origin
licensing occurs from late mitosis to G1 phase and involves
assembly of the origin recognition complex (ORC), encom-
passing ORC1 to ORC6, onto origin sequences (1, 2).
Together with CDC6 and CDT1, ORC loads the hetero-
hexameric MCM2-7 complex which provides helicase
activity, generating the prereplication complex (pre-RC;
refs. 3–6). Cells exploit several mechanisms to prevent origin
reﬁring, including the inhibition of MCM2-7 loading
onto origins during S–G2 and the tight regulation of other
pre-RC components via proteasome-mediated degradation
(1, 2).
Only a fraction of licensed origins are used for replication,
with nonﬁred origins being considered dormant (7–9).
Following replication stress, the activation of checkpoint
kinases stabilizes stalled replication forks (10). In addition,
dormant origins can be exploited to promote recovery from
replication stress (11–15). However, replication fork stalling
also activates an intra-S-phase checkpoint response that
inhibits late-ﬁring origins (16–18). Although apparently
conﬂicting with the notion that replication fork stalling
exploits dormant origins, recent studies have shown that
origins are organized in clusters, with activation occurring
stochastically and inactivating further origins within the
cluster (14, 19). Although damage response signaling inhi-
bits the ﬁring of origins in new clusters, a distinct process
promotes dormant origin ﬁring within a cluster in which
double fork stalling has occurred (14). This model is intrin-
sically appealing as it implies that dormant origins are only
activated near a stalled fork where they are needed, whereas
new replication is diminished elsewhere to preclude further
replication in the presence of DNA damage. Support for this
model has come from studies involving siRNA-mediated
depletion of MCM2-7 in human cells, which suppresses
dormant origin usage, inhibits the rate of DNA synthesis,
and reduces cell survival in response to replication-inhibiting
agents (11–13).
Until recently, studies on dormant origin usage were
predominantly undertaken in tumor cells and it was unclear
whether the same process occurs in primary cells. Interest-
ingly, an increase in the number of stalled replication forks
in unchallenged S-phase cells was observed in mouse
embryonic ﬁbroblasts (MEF) expressing a hypomorphic
Mcm4Chaos3 allele, which impairs MCM2-7 complex stabil-
ity and reduces the number of dormant origins (15).
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Signiﬁcantly, Mcm4Chaos3 mice are cancer prone (20).
Importantly, Mcm4Chaos3 cells have a normal rate of repli-
cation and helicase activity. Thus, reducing the number of
dormant origins need not affect replication but can impede
recovery from either endogenous or damage-induced repli-
cation stress. Although other pathways of replication fork
recovery exist, a failure to use dormant origins is proposed to
cause genomic instability.
Two recent studies identiﬁed mutations in origin-licens-
ing components (ORC1, ORC4, ORC6, CDT1, and
CDC6) in Meier–Gorlin syndrome (MGS), a disorder
characterized bymicrocephaly, proportionate dwarﬁsm, and
bone abnormalities including small or absent patellae (21–
23). Cells from patients with MGS, despite having substan-
tially reduced origin licensing capacity, grow well in culture
consistent with the notion that only a fraction of licensed
origins are required to sustain replication (22).
Carcinogenesis necessitates multiple genetic changes to
support often rapid and uncontrolled proliferation. Most
tumor cells suffer high replication stress, due to uncontrolled
proliferation and/or enhanced genomic instability. Interest-
ingly, several studies have reported that origin-licensing
proteins are overexpressed in tumor-derived cell lines
(24–27). Given this, we reasoned that tumor cells might
have a greater demand for origin licensing than nontrans-
formed cells, either to sustain rapid replication and/or to
enhance recovery from the increased level of replication
stalling/collapse. Given the ﬁnding that nontransformed
cells can grow efﬁciently with substantially reduced licensing
capacity, we considered that ORC proteins might represent
targets to speciﬁcally sensitize tumor cells. Here, we examine
this possibility by investigating the impact of diminished
origin licensing capacity in tumor versus nontransformed
cells. Strikingly, our results suggest that tumor cells more
frequently rely on dormant origin usage following exposure
to agents that cause replication stress compared with non-
tumor cells.
Materials and Methods
Cell culture
Cell lines were purchased from the American Type Cul-
ture Collection (ATCC) or established and authenticated in-
house or by scientiﬁc collaborators indicated in references.
All cell lines were tested for mycoplasma contamination
before use and assessed for ORC1 expression by immuno-
blot. Control primary skin ﬁbroblasts (48BR), control
hTERT-immortalized ﬁbroblasts 1BR3hTERT or
BJhTERT (ATCC), and ORC1-P4hTERT, derived from
an ORC1-deﬁcient patient with MGS, were cultured in
Dulbecco's modiﬁed Eagle's medium supplemented with
15% fetal calf serum (FCS, Invitrogen; ref. 22, 28–30).
Medium for BJ-MYC-ER, a derivative of BJhTERT expres-
sing a tamoxifen-inducible c-Myc gene, was supplemented
with 2 mg/mL puromycin (Invitrogen). MRC-5 is a primary
fetal lung ﬁbroblast cell line. MRC5, U2OS, and HeLa cells
(ATCC) were cultured in minimal essential medium con-
taining 10% FCS. Cells were transfected with siRNA oli-
gonucleotide pools (Thermo Scientiﬁc Dharmacon; ORC1,
p53, ORC6, or CDC6) or Stealth siRNA targeting ORC1
(Invitrogen; ref. 22) using HiPerFect (Qiagen) or Dharma-
FECT (Thermo Scientiﬁc Dharmacon). siControl repre-
sents scrambled oligonucleotides (Thermo Scientiﬁc
Dharmacon).
Viability assay
siRNA-transfected cells were seeded in 96-well dishes,
treated as described and viability was assessed using the
CellTiter-Blue assay (Promega). Viability was normalized to
the siRNA-transfected but untreated control. The half
maximal inhibitory concentration (IC50) values from via-
bility curves were calculated with SigmaPlot (Systat
Software, Inc.) using the ﬁve-parameter logistic nonlinear
regression model. IC50 values represent the mean SD of 3
independent experiments.
Immunoblotting
For whole-cell extracts, cells were lysed in buffer A (22)
containing 500 mmol/L NaCl and supplemented with
protease (Sigma-Aldrich) and phosphatase inhibitors
(Thermo Fisher Scientiﬁc) for one hour on ice and sonicated
at 4C. Fractionation of chromatin-bound and unbound
proteins was conducted as previously described (22). Lysates
were resolved by electrophoresis, transferred onto polyviny-
lidene diﬂuoride (GEHealthcare) and immunoblotted using
a-ORC1, ORC6, CDC6, p53 (Santa Cruz Biotechnology,
Inc.), or b-actin (Abcam) antibodies.
Drug treatments
siRNA-transfected cells were seeded into dishes and grown
for 48 hours. Hydroxyurea (Sigma-Aldrich) orH2O2 (Fisher
Scientiﬁc/AcrosOrganics) was added for the indicated times.
Cells were washed 3 times in PBS and incubated in fresh
medium as indicated.
Clonogenic survival
Clonogenic survival was assessed as previously described
(31). Brieﬂy, cells were transfected with siRNA, treated as
described, and incubated for 10 days (U2OS) or for 21 days
using irradiated feeder cells to enhance plating efﬁciency
(1BR3hTERT). Survival was normalized to the siRNA-
transfected but untreated control. Plotted values represent
the mean  SD of 3 independent experiments.
DNA ﬁbre assay
Cells were labeled with 25 mmol/L chlorodeoxyuridine
(CldU) for 20 minutes, washed 3 times with medium,
incubated in 2 mmol/L hydroxyurea for 24 hours, washed
3 times again, and pulse-labeled with 250 mmol/L iodo-
deoxyuridine (IdU) for 1 hour. Labeled cells were harvested
andDNAﬁbre spreads were prepared as previously described
(32). CldU and IdU were detected by incubating acid-
treated ﬁbre spreads with rat a-bromodeoxyuridine
(BrdUrd) (1:1,000, AbD Serotec) and mouse a-BrdUrd
(1:750, Becton Dickinson) monoclonal antibodies for 1
hour. Slides were ﬁxed with 4% paraformaldehyde and
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incubated with AlexaFluor 555-conjugated goat a-rat IgG
(1:500, Molecular Probes) and AlexaFluor 488-conjugated
goat a-mouse IgG (1:500, Molecular Probes) for 1.5 hours.
Images of DNA ﬁbres were acquired on a Nikon E600
microscope using a 60 (1.3NA) lens, a Hamamatsu digital
camera, and the Volocity package (Perkin Elmer). For
quantiﬁcation, at least 130 structures were counted per
experiment using ImageJ software (NI H, http://rsbweb.
nih.gov/ij/).
Replication recovery assay
siRNA-transfected cells were treated with hydroxyurea
and labeled with 50 mmol/L BrdUrd; Becton Dickinson 30
minutes before harvesting. Cells were ﬁxed, BrdUrd-labeled,
propidium iodide-stained and analyzed by ﬂuorescence-
activated cell sorting (FACS) as previously described (31).
g-H2AX immunoﬂuorescence
Cells were processed for g-H2AX analysis as previously
described (33) using a-g-H2AX and a-CENPF (Abcam)
and 40, 6–diamidino–2–phenylindole (DAPI) labeling of
DNA. Cells harboring S-phase–associated DNA damage,
referred to as g-H2AXþ, were detected by bright, pan-
nuclear g-H2AX and minimal CENPF signal (34, 35).
g-H2AXþ cells were manually scored in more than 500
cells per condition. Images of cells were acquired with
identical exposure settings on a Zeiss Axioplan2 microscope
using a  40 (0.75 NA) lens, a Hamamatsu digital camera,
and SimplePCI software (Hamamatsu).
Results
Substantial ORC1 depletion does not impact upon
proliferation
We aimed to compare how diminished origin licensing
capacity affects recovery from replication stress in tumor-
derived versus nontumor cell lines. We used 1BR3hTERT
and U20S osteosarcoma cells as nontumor and tumor cell
lines, respectively. 1BR3hTERT, an hTERT-immortalized
ﬁbroblast line derived from a normal individual, has a stable
karyotype, shows genomic stability, and has an intact G1–S
checkpoint (Unpublished observations). Because ORC1 is
essential, we sought knockdown conditions that reduce
ORC1 protein levels without impeding proliferation. Via-
bility, monitored using the CellTiter-Blue assay, was
assessed following siRNA-mediated knockdown of ORC1
in 1BR3hTERT and U20S using a range of siRNA oligo-
nucleotide (scrambled or ORC1-speciﬁc) concentrations.
We observed diminished proliferation with increasing
siORC1 concentrations, consistent with the notion that
oligonucleotide concentration correlates with knockdown
efﬁciency (Fig. 1A and B). Since tumor and nontumor cell
lines differ in the efﬁciency of siRNA-mediated knockdown
and requirement for ORC1, the impact was distinct for each
line. The highest siORC1 concentration that did not sig-
niﬁcantly impede viability was 5 or 0.6 nmol/L for
1BR3hTERT and U20S, respectively (Supplementary Fig.
S1A). Immunoblotting revealed that U20S has higher
ORC1 protein levels compared with 1BR3hTERT, consis-
tent with previous ﬁndings that tumor-derived cells over-
express ORC proteins (Fig. 1C; ref. 24–27). Although
a-ORC1 antibodies are inefﬁcient for immunoblotting, a
marked reduction in ORC1 protein could be observed in
both lines following siORC1 (Fig. 1C). Routinely, low
residual ORC1 was detectable in siORC1-treated U20S
cells, whereas residual ORC1 was not detectable in
siORC1-transfected 1BR3hTERT. As ORC1 is essential,
it is likely that 1BR3hTERT retain residual, although
undetectable, ORC1. This suggests that U20S cells require
a higher level of ORC1 to maintain viability compared with
1BR3hTERT, consistent with the notion that tumor cells
have a greater need for origin-licensing proteins compared
with nontumor cells. Having identiﬁed knockdown condi-
tions that substantially deplete ORC1 without impeding
viability, which we anticipated would substantially reduce
the level of dormant origins, we proceeded to examine the
impact on recovery from damage-induced replication arrest.
ORC1 depletion impairs recovery from hydroxyurea in
U20S but not 1BR3hTERT
We examined sensitivity to hydroxyurea, which depletes
ribonucleotide reductase and enhances fork stalling/collapse,
in 1BR3hTERT and U20S following siControl or siORC1.
siRNA transfection was conducted as described above and
cells were exposed to differing concentrations of hydroxyurea
for 24 hours. Hydroxyurea was removed and viability
monitored 4 days later (Fig. 1D and E). To compare the
effect of siORC1 between the cell lines, we estimated the
hydroxyurea concentration that reduced viability by 50%
(the IC50 value). The relative IC50 value was calculated by
comparison with the IC50 of siControl-transfected cells (Fig.
1H). Strikingly, while siORC1 did not affect hydroxyurea
sensitivity in 1BR3hTERT, it signiﬁcantly enhanced sensi-
tivity in U20S. Similar effects were observed following
transfection of cells with a distinct pool of ORC1 siRNA
oligonucleotides (Supplementary Fig. S1B–S1D). To verify
that the resistance of 1BR3hTERT cells is not simply a
consequence of their slower cell-cycle progression, resulting
in a lower fraction of cells progressing into S-phase, we
monitored the population doubling time (Supplementary
Fig. S1E-S1F) and rate of hydroxyurea -induced g-H2AX
formation in the 2 cell lines (Fig. 1F and G). We estimated
that by 48 hours, all 1BRhTERT cells had undergone
replication fork arrest after hydroxyurea. However, exami-
nation of viability following 48-hour hydroxyurea treatment
yielded similar results (Fig. 1H). Thus, the resistance of
1BR3hTERT cells to siORC1-induced hypersensitivity is
not explained by their slower cell-cycle progression. To verify
that the viability assay reﬂects clonogenicity, we also exam-
ined clonogenic survival of U20S following 24-hour
hydroxyurea treatment (Fig. 1I) and of 1BR3hTERT fol-
lowing 48-hour hydroxyurea treatment (Fig. 1J). Although
these 2 assays monitor different endpoints, a similar impact
was observed, validating use of the viability assay.
To substantiate these ﬁndings without relying on siRNA-
mediated depletion, we also examined an hTERT-
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Figure 1. siORC1 impairs recovery of U2OS but not 1BR3hTERT cells from hydroxyurea. 1BR3hTERT (A) or U2OS (B) cells were transfected with siControl or
siORC1 oligonucleotides (0.1–20 nmol/L), and viability assessed 7 days later. Results represent mean  SD from triplicate samples. Black arrows
indicate the oligonucleotide concentration subsequently used. C, 1BR3hTERT and U2OS cells were transfected with 5 or 0.6 nmol/L siORC1, respectively.
ORC1 protein levels were assessed by immunoblotting 48 hours later. b-actin was a loading control. D and E, 1BR3hTERT and U2OS cells were transfected
with siRNA for 48 hours and treated with hydroxyurea (HU; 0.03–40 mmol/L) for 24 hours. Viability was assessed for 4 days following hydroxyurea
removal. F and G, 1BR3hTERT and U2OS cells transfected with siRNA as described were treated with 2 mmol/L hydroxyurea for indicated times and
hydroxyurea -induced S-phase damage was assessed by immunoﬂuorescence labelling of g-H2AX. Nuclei containing bright g-H2AX pan-nuclear
staining were scored as g-H2AXþ. Black arrows indicate the time of hydroxyurea treatment required to obtain 100% g-H2AXþ cells. H, viability was assessed
after transfection with siRNA and treatment with hydroxyurea for 24 or 48 hours as in (D and E). Hydroxyurea IC50 values were estimated from the viability
graphs. I, U2OScellswere treatedwith siRNA as described above and thenwith hydroxyurea (0.05–2mmol/L) for 24 hours. clonogenic survival was estimated
at 10 days following hydroxyurea removal. J, as in (I), except 1BR3hTERT cells were treated with hydroxyurea for 48 hours and clonogenic survival was
estimated 21 days following hydroxyurea removal. Additional controls are shown in Supplementary Fig. S1. K, ORC1 protein levels were assessed in
chromatin-bound and unbound fractions in 1BR3hTERT and ORC1-P4hTERT by immunoblotting. L, 1BR3hTERT or ORC1-P4hTERT were treated with
hydroxyurea (0.03–40 mmol/L) for 24 hours. Viability was assessed 4 days after hydroxyurea removal. M, 1BR3hTERT or ORC1-P4hTERT cells were treated
with 0.5 mmol/L hydroxyurea for 48 or 72 hours, respectively. Viability was assessed as above.
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immortalized ﬁbroblast line derived from an ORC1-deﬁ-
cient MGS patient (ORC1-P4hTERT; ref. 22). ORC1 is
expressed at normal levels in ORC1-P4hTERT but chro-
matin binding of ORC1 is impaired (ref. 22; Fig. 1K).We
observed resistance rather than marked sensitivity of ORC1-
P4hTERT cells to hydroxyurea at higher concentrations
potentially due to a lower number of replication origins
(Fig. 1L). We also adjusted hydroxyurea treatment time to
achieve complete hydroxyurea-induced S-phase arrest in
1BR3hTERT and ORC-P4hTERT (representing 48 or
72-hour exposures, respectively). Under these conditions,
resistance, but not sensitivity, to 0.5 mmol/L hydroxyurea
was also observed (Fig. 1M).
U20S cells show diminished recovery of DNA synthesis
and accumulated DNA damage following siORC1
compared with 1BR3hTERT
To examine whether siORC1 affects replication recovery,
1BR3hTERTorU20Swere treated with siRNA as described
above and exposed to 2 mmol/L hydroxyurea for 24 hours.
Following hydroxyurea removal, cells were incubated for 2,
4, or 24 hours, and BrdUrd added for the ﬁnal 30 minutes.
BrdUrd incorporation, representing recovery of DNA syn-
thesis, was assessed by FACS (Fig. 2A and B). Hydroxyurea
treatment abolished BrdUrd incorporation in both cell lines,
consistent with replication inhibition. Strikingly, in
1BR3hTERT, BrdUrd incorporation was substantially
recovered at 2 hours after hydroxyurea removal and was
similar in siControl or siORC1-treated cells. In marked
contrast, although siControl-treated U20S cells also recov-
ered DNA synthesis at 2 hours following hydroxyurea
removal, DNA synthesis was dramatically reduced at this
time in siORC1-treated U20S cells. Because this difference
is observed at early times (2 hours) after hydroxyurea
removal, this suggests that siORC1 does not impair rapid
recovery of replication in hydroxyurea -treated
1BR3hTERT but does so in U20S.
We also examined whether the inability of siORC1-
treated U2OS to recover replication causes accumulated
DNA damage. Either immediately (0) or 24 hours following
treatment with 2 mmol/L hydroxyurea, cells were examined
for g-H2AX, a marker of DNA damage, and CENPF, a G2
–M-phase marker. Immediately following hydroxyurea
treatment, most cells were CENPF (consistent with S-
phase arrest) and showed pan-nuclear g-H2AX staining,
showing the presence of collapsed/stalled replication forks;
untreated cells had a lower fraction of g-H2AXþ cells (Fig.
2C and D). 24 hours after hydroxyurea removal, few
siControl or siORC1-transfected 1BR3hTERT cells were
g-H2AXþ (Fig. 2D), consistent with the observed recovery
of replication. Similarly, the number of g-H2AXþ siCon-
trol-treated U20S cells was dramatically reduced 24 hours
after hydroxyurea removal (Fig. 2C andD). In stark contrast,
approximately 50% of siORC1-treated U20S cells retained
g-H2AX staining 24 hours after hydroxyurea removal.
g-H2AXþ cells were negative for the G2–M marker,
CENPF, consistent with the notion that they represent
damaged S-phase cells. This analysis shows that
1BR3hTERT undergo replication fork arrest and activate
the DNA damage response after hydroxyurea treatment but
efﬁciently recover despite substantial depletion of ORC1.
ORC1 depletion reduces new origin ﬁring after
hydroxyurea in U20S
The DNA ﬁbre assay allows replication at new versus
preexisting origins to be monitored (36).We exploited the
technique to assess new origin ﬁring in U2OS cells after
release from hydroxyurea exposure. siRNA-transfected cells
were exposed to CldU for 20minutes, then either exposed to
IdU for 20 minutes (control) or CldU was washed out, and
cells were exposed to hydroxyurea for 24 hours. Following
hydroxyurea removal, IdU was added for 1 hour. CldUþ
/IdU replication tracks are considered to represent stalled
forks that have not reinitiated replication; CldU/IdUþ
tracks represent ones with newly ﬁred origins (Supplemen-
tary Fig. S2C–S2D). To monitor new origin ﬁring, the
fraction of CldU/IdUþ tracks was assessed. In untreated
U20S cells, ORC1 siRNA did not signiﬁcantly impact upon
new originﬁring (Fig. 2E). Following hydroxyurea, although
siORC1 did not impact upon the level of stalled forks, new
origin ﬁring was substantially diminished. These ﬁndings
strongly suggest that siORC1 diminishes replication restart
by new origin ﬁring after hydroxyurea while not affecting
new origin ﬁring in unperturbed cells.
Hypersensitivity of U20S to hydroxyurea following
depletion of additional licensing components
We next examined whether the sensitivity of U2OS cells
to hydroxyurea is impacted following depletion of additional
origin-licensing factors. We examined ORC6 and CDC6 as
they are also causal defects for MGS (22). A total of 0.6
nmol/L siORC6 or CDC6 substantially depleted ORC6 or
CDC6 but did not impede cellular proliferation (Fig. 3A;
data not shown). Viability assessment revealed a similar level
of hydroxyurea sensitivity following siORC6 or CDC6 to
that observed following siORC1 (Fig. 3B and C). However,
neither siORC6 nor siCDC6 affected hydroxyurea sensitiv-
ity in 1BR3hTERT (Supplementary Fig. S3).
siORC1 does not affect hydroxyurea sensitivity in
additional nontumor lines (BJhTERT, 48BR, andMRC-
5) but sensitizes additional tumor-derived lines (HeLa
and MDA-MB-231)
To extend our ﬁndings, we examined additional nontu-
mor ﬁbroblasts (BJhTERT, 48BR, andMRC-5) and tumor-
derived lines (HeLa andMDA-MB-231). 48BR andMRC5
represent primary ﬁbroblast lines to complement the analysis
of the hTERT-immortalized line. For all lines, we examined
the optimum siORC1 oligonucleotide concentration that
failed to impact upon viability (Supplementary Fig. S4).
BJhTERT cells showed slightly diminished viability above 5
nmol/L siORC1 similar to 1BR3hTERT cells; 5 nmol/Lwas
chosen for analysis (Supplementary Fig. S4A). HeLa cells
were resistant to high oligonucleotide concentrations; 0.6
nmol/L was chosen to allow comparison to U20S (Fig. 4A
and B, Supplementary Fig. S4D). 48BR, MDA-MB-231,
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and MRC-5 displayed diminished viability above 1 nmol/L
siORC1; 1 nmol/L was chosen for analysis (Supplementary
Fig. S4B, S4C, and S4E). The time of hydroxyurea treat-
ment required to achieve complete hydroxyurea -induced
S-phase damage was also assessed in each cell line (Supple-
mentary Fig. S5). The time indicated was used for subse-
quent viability experiments. Similar to 1BR3hTERT and
U20S cells, although ORC1 protein levels were greater in
siORC1-depleted HeLa andMDA-MB-231 cells compared
with BJhTERT, 48BR, or MRC-5 cells, siORC1 enhanced
hydroxyurea sensitivity of HeLa and MDA-MB-231 with-
out substantially impacting upon sensitivity of BJhTERT,
48BR, orMRC-5 cells (Fig. 4A, C–G). ForMRC-5, slightly
enhanced sensitivity was observed at high hydroxyurea doses
but there was no impact on the IC50 value.
siORC1 diminishes viability of tumor but not primary
cells to H202
Having shown that siORC1 hypersensitizes U20S and
HeLa but not 1BR3hTERT or BJhTERT cells to hydro-
xyurea, we used a similar approach to evaluate whether
recovery from oxidative damage, which can indirectly
B
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induce replication stress, might also involve differential
dormant origin usage. Strikingly, while siORC1 did not
affect sensitivity of 1BR3hTERT or BJhTERT to H202,
U20S and HeLa cells showed marked hypersensitivity (Fig.
5A–E). The slightly higher resistance of siORC1-treated
1BR3hTERT cells to H202 compared with siControl cells
likely reﬂects their slightly slower replication. Nonetheless,
the distinction between 1BR3hTERT/BJhTERT and
U20S/HeLa cells to combined siORC1 and H202 was
marked.
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sip53 mildly sensitizes 1BR3hTERT cells to siORC1
without exogenous DNA damage and causes marked
sensitivity to hydroxyurea
p53 loss abrogates the damage-induced G1–S checkpoint,
enhancing S-phase progression and replication stalling (37).
In addition, p53 is required for a licensing checkpoint which
prevents S-phase entry until sufﬁcient origins have been
licensed (38, 39). We examined whether sip53 in
1BR3hTERT affects viability and hydroxyurea sensitivity
following siORC1. 1BR3hTERT cells were transfected with
siControl, sip53, siORC1 or combined siORC1þsip53 for
48 hours, then viability assessed in untreated or hydroxyurea
-treated cells as described above. p53 was efﬁciently depleted
in 1BR3hTERT (Fig. 6A). As above, siORC1 did not affect
the viability of 1BR3hTERT cells (Fig. 6B). sip53 alone
slightly inhibited viability but combined sip53þsiORC1
diminished viability by approximately 1.7 (Fig. 6B). These
ﬁndings suggest that in undamaged cells, siORC1 more
markedly affects viability in the absence of p53. siORC1 did
not signiﬁcantly affect hydroxyurea sensitivity similar to the
ﬁndings in Fig. 1D; there was a modest but not statistically
signiﬁcant impact of sip53 on hydroxyurea sensitivity but a
marked decrease following sip53þsiORC1 (Fig. 6C andD).
Depletion of ORC1 confers sensitivity to Myc
overexpression
Myc overexpression, which enhances proliferation and
replication stress, is frequently observed during carcinogen-
esis (40–42). We examined whether Myc expression inﬂu-
ences the requirement for origin licensing capacity using a
BJhTERT derivative that expresses c-Myc fused to a tamox-
ifen-inducible estrogen receptor (40–42). First, anticipating
Figure 5. siORC1 speciﬁcally
enhances sensitivity of tumor-
derived cell lines to H2O2. A–E,
1BR3hTERT, BJhTERT, U20S or
HeLawere transfectedwith siRNAas
described in Figs. 1 and 4. 48 hours
later, cells were treated with H2O2,
with concentrations adjusted to
account for substantial differences in
sensitivity between cell lines. 24
hours later, H2O2 was removed and
viability assessed 4 days later. A–D,
representative viability plots. E,
estimated IC50 values.
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that tamoxifen concentration affects the level of c-Myc
expression, we estimated the tamoxifen concentration pro-
moting endogenous DNA damage (assessed by g-H2AX).
24 hours after 2 mmol/L tamoxifen, 30% of siControl-
transfected cells were g-H2AXþ, suggesting that Myc over-
expression induces replication stress (Fig. 7A). Following
siORC1, 60%of BJhTERT cells were g-H2AXþ, raising the
possibility that siORC1 causes enhanced or persistent c-
Myc–induced replication arrest. Next, assessment of viabil-
ity 5 days following exposure to different tamoxifen con-
centrations revealed substantial sensitivity following
siORC1 (Fig. 7B and C) suggesting that depletion of
origin-licensing capacity diminishes the ability to cope with
c-Myc–induced replication stress.
Discussion
We previously observed that MGS patient-derived cell
lines grow efﬁciently in culture despite 10-fold lower levels of
origin-licensing components (21, 22). This ability to sustain
substantial proliferation is consistent with ﬁndings that only
10% of licensed origins are used during unchallenged
replication (7–9). Recent studies have provided evidence
that dormant origins can be used to promote recovery from
replication fork stalling or collapse (11–15). Because tumor
cells show elevated oxidative and replicative stress, we pre-
dicted that they might have an enhanced reliance on origin-
licensing capacity compared with normal cells, raising the
possibility that targeting origin-licensing components could
speciﬁcally inhibit cancer cell growth. Here, we evaluate this
possibility.
Consistent with previous ﬁndings, we observed that 3
tumor-derived cell lines showed high ORC1 expression
compared with nontumor lines (24–27). In general, higher
ORC1 levels were required tomaintain viability in the tumor
lines (although MRC-5 cells also had a requirement for a
higherORC1 level). Nonetheless, the ability to detect higher
residual ORC1 in the tumor than nontumor cell lines shows
that our ﬁndings cannot simply be explained by more
efﬁcient ORC1 knockdown in the tumor versus nontumor
cells.
To enhance the applicability to exploit inhibition of origin
licensing for tumor therapy, we examined whether partial
ORC1 depletion affected the response to hydroxyurea, a
chemotherapeutic agent. Signiﬁcantly, we observed marked
sensitization of the tumor -derived lines to hydroxyurea (or
H202) compared with the nontumor cells. In addition, we
observed that ORC1 depletion enhanced hydroxyurea sen-
sitivity of p53-depleted nontumor cells and also conferred
sensitivity to Myc overexpression. This important result
suggests that enhancing the level of replication stress and/
or rate of proliferation, both of which arise following c-Myc
expression, increases the demand for origin-licensing
capacity.
Collectively, using our panel of 3 tumor and 4 primary or
hTERT-immortalized cell lines, our ﬁndings suggest that
tumor cells have a greater demand for origin-licensing
capacity following replication fork arrest compared with
nontumor lines and that loss of p53 or c-Myc expression
enhances this demand in nontumor cells. Our ﬁndings could
have several explanations. One possibility is that following
replication stress, stalled forksmore readily collapse in tumor
compared with nontumor cells and that dormant origin
ﬁring enhances recovery from replication fork collapse.
However, we are not aware of studies supporting this
suggestion. Alternatively, it is possible that fork collapse
occurs similarly in tumor and nontumor cells, but that
tumor cells more frequently exploit dormant origins for
recovery and are hence hypersensitive when this route is
unavailable. Although the original studies describing dor-
mant origin usage after replication stress used tumor cells, a
recent study involving primary MEFs showed that they also
exploit dormant origins for recovery from replicative stress
(15). However, it is difﬁcult to evaluate the comparative
usage of dormant origins in tumor versus nontumor cells
from these studies. An alternative and appealing possibility is
that tumor cells override the origin-licensing checkpoint to
enhance proliferation and, therefore, enter S-phase with
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diminished dormant origins. Indeed, the upregulation of
origin licensing proteins in tumor cells may reﬂect their need
to effect rapid origin licensing during their short G1 phase.
Thus, further reducing licensing capacity may provide a
situation where there are insufﬁcient dormant origins to
exploit following replication fork arrest. It should be noted
that our knockdown conditions were designed to prevent
any impact on unperturbed cell growth. This model is
consistent with the known function of p53 in enhancing
G1-phase progression and/or abolishing the G1–S check-
point. Importantly, in the present context, p53 is also
required for the origin-licensing checkpoint as codepletion
of p53 and CDC6, another licensing component, in normal
ﬁbroblasts permits S-phase entry with insufﬁcient origin
capacity (43). c-Myc also enhances G1-phase progression
and disrupts p53 activity (44, 45). However, both p53 loss
and c-Myc expression have multiple additional impacts
including an inﬂuence on replication (44–46). Thus,
although the latter explanation is appealing, further work
is required to deﬁne the basis underlying our observations. It
is likely,moreover, that there could bemultiple impacts.Our
ﬁndings to date are based on a restricted number of tumor or
nontumor cell lines. Nonetheless, the relationship seems
marked and further work will be required to examine the
extent to which this represents a phenotype of many tumor
cell lines. It should be noted that around 50% of tumor cell
lines show an upregulation of origin-licensing components
(24–27).
Our goal was to examine whether the origin-licensing
complex represents a suitable target to speciﬁcally sensitize
tumor cells. Importantly, we report that 3 tumor cells require
greater origin-licensing capacity following exposure to DNA
damaging agents than 4 nontumor cells. In addition, we
show that p53 loss (in the presence of hydroxyurea) or c-Myc
expression in nontumor cells enhances the reliance on
ORC1. Interestingly, the BAH domain of ORC1 was
recently reported to bind H4K20me2 with high speciﬁcity
and afﬁnity via an aromatic cage, which could provide a route
for drug targeting (47). In summary, we provide evidence
that the downregulation ofORC1 and other origin-licensing
proteins enhances the sensitivity of tumor but not nontumor
cell lines to replicative stress, providing a potential route for
speciﬁc sensitization of tumor cells.
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Supplementary Figure Legends 
Figure S1. Growth parameters of 1BR3hTERT and U2OS cells.  (A) 1BR3hTERT and 
U2OS cells were transfected with 5 or 0.6 nM siRNA oligonucleotides, respectively, and 
grown in normal growth medium. 7 days later, viability was assessed and normalized to that 
of siControl-transfected cells. Results represent the mean +/- SD from three independent 
experiments. (B) 1BR3hTERT and U2OS cells were transfected with indicated 
concentrations of siControl or a distinct siRNA oligonucleotide pool targeting ORC1 
(siORC1pool). 48 hours later, cells were lysed and ORC1 protein levels were assessed by 
immunoblotting. (C-D) 1BR3hTERT and U2OS cells were transfected with siControl, 
siORC1 (single), or siORC1pool, grown for 48 hours, and treated with HU for 24 hours. 
Viability was assessed 4 days later. (E) Exponentially growing cells were seeded at densities 
comparable to those used for the viability assay and grown in normal growth medium. Cells 
were harvested at the indicated time points, non-viable cells were labelled with trypan blue, 
and viable cells were manually scored. Cell number was then normalized to initial seeding 
density.  Results represent the mean +/- SD of from three experiments. (F) Cell doubling time 
was estimated from data in (E).  
 
Figure S2. Additional images of BrdU replication recovery and γH2AX staining in HU-
treated U2OS and/or 1BR3hTERT; description of DNA fibre assay.   (A) Experimental 
conditions were as described in the legend to Fig 2A-B. Images from FACS analysis showing 
BrdU vs. PI intensity for all time points tested in U2OS cells are depicted. Boxed regions 
containing blue data points indicate BrdU+ cells; adjacent numbers represent BrdU+ cell 
fraction. (B) Experimental conditions were as described in the legend to Fig 2C. 
Representative images of DAPI (blue), γH2AX (green), and CENPF (red) staining in 
1BR3hTERT and U2OS cells are presented. All three channels have been merged and images 
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have been cropped with identical settings. (C) Schematic of experimental setup for the DNA 
fibre assay. Briefly, U2OS cells were transfected with 0.6 nM siControl or siORC1. 48 hours 
later, cells were pulsed with CldU (red) for 20 minutes, washed, treated with 2 mM HU for 
24 hours, washed again, and labelled with IdU (green) for 1 hour. Acid treated fibre spreads 
were then stained and imaged using immunofluorescence methodology. (D) Representative 
images of labelled DNA fibres. CldU (red) and IdU (green)-labelled tracks represent 
ongoing/progressing forks. CldU-only (red) tracks represent fork stalling. IdU-only (green) 
tracks represent new origin firing. Levels of each were assessed as in Fig. 2E. 
 
Figure S3. Depletion of ORC6 and CDC6 does not affect HU sensitivity in 1BR3hTERT. 
(A) 1BR3hTERT cells were transfected with 5 nM indicated siRNA oligonucleotides. 48 
hours later, cells were lysed and ORC6 or CDC6 protein levels were assessed by 
immunoblotting. (B) Viability was assessed in siRNA-transfected cells treated with HU for 
24 hours as in Fig. 1D-E. 
 
Figure S4. Selected concentrations of siRNA oligonucleotides do not significantly impair 
viability in additional cell lines selected. Non-tumour BJhTERT, 48BR, and MRC-5 cells 
(A-C) or tumour-derived HeLa and MDA-MB-231 cells (D-E) were transfected with 
siControl or siORC1 oligonucleotides (0.1-20 nM) and viability assessed 7 days later as in 
Fig. 1A-B. Black arrows indicate the oligonucleotide concentration subsequently utilised. 
 
Figure S5. Assessment of HU treatment time required for complete HU-induced S phase 
damage induction. Non-tumour BJhTERT, 48BR, and MRC-5 cells (A-C) or tumour-
derived HeLa and MDA-MB-231 (D-E) were transfected with siControl or siORC1 
oligonucleotides indicated above. ORC1-P4hTERT cells (F) were grown in normal growth 
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medium for 48 hours. Cells were treated with 2 mM HU for indicated times, and HU-induced 
S phase damage was assessed by γH2AX analysis as in Fig. 1F-G.  
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